Trial Outcomes & Findings for Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19 (NCT NCT04403880)
NCT ID: NCT04403880
Last Updated: 2026-01-12
Results Overview
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and enrollment group
Recruitment status
COMPLETED
Target enrollment
760 participants
Primary outcome timeframe
Measured at Months 0, 2, 4
Results posted on
2026-01-12
Participant Flow
Participant milestones
| Measure |
Group 1A
1A: Asymptomatic, 18 - 55
|
Group 1B
1B: Asymptomatic, \> 55
|
Group 1C
1C: Symptomatic, 18 - 55
|
Group 1D
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
|---|---|---|---|---|---|---|---|
|
Overall Study
COMPLETED
|
81
|
24
|
98
|
32
|
68
|
44
|
67
|
|
Overall Study
NOT COMPLETED
|
48
|
27
|
84
|
45
|
54
|
30
|
58
|
|
Overall Study
STARTED
|
129
|
51
|
182
|
77
|
122
|
74
|
125
|
Reasons for withdrawal
| Measure |
Group 1A
1A: Asymptomatic, 18 - 55
|
Group 1B
1B: Asymptomatic, \> 55
|
Group 1C
1C: Symptomatic, 18 - 55
|
Group 1D
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
|---|---|---|---|---|---|---|---|
|
Overall Study
Death
|
1
|
0
|
2
|
0
|
0
|
0
|
0
|
|
Overall Study
Physician Decision
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
Overall Study
Lost to Follow-up
|
4
|
3
|
8
|
7
|
8
|
1
|
8
|
|
Overall Study
Withdrawal by Subject
|
8
|
9
|
22
|
16
|
16
|
8
|
11
|
|
Overall Study
Participant Unable to Adhere to Visit Schedule
|
6
|
5
|
12
|
2
|
8
|
1
|
2
|
|
Overall Study
Participant Unable to Comply with Study Procedure
|
7
|
1
|
7
|
9
|
8
|
8
|
19
|
|
Overall Study
Pregnancy
|
2
|
0
|
5
|
0
|
1
|
0
|
1
|
|
Overall Study
Sponsor Decision
|
2
|
0
|
14
|
1
|
1
|
0
|
2
|
|
Overall Study
Other
|
18
|
9
|
14
|
10
|
11
|
12
|
15
|
Baseline Characteristics
Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19
Baseline characteristics by cohort
| Measure |
Group 1A
n=129 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=51 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=182 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=77 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=122 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=74 Participants
2B: Hospitalized, \> 55
|
Group 3
n=125 Participants
3: Clinical spectrums
|
Total
n=760 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|
|
Age, Customized
46 - 55 years
|
21 Participants
n=210 Participants
|
0 Participants
n=19 Participants
|
35 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
42 Participants
n=5716 Participants
|
0 Participants
n=47026 Participants
|
27 Participants
n=66536 Participants
|
125 Participants
n=335 Participants
|
|
Age, Continuous
|
33 years
n=210 Participants
|
62 years
n=19 Participants
|
35 years
n=8 Participants
|
61 years
n=24 Participants
|
41 years
n=5716 Participants
|
62 years
n=47026 Participants
|
43 years
n=66536 Participants
|
44 years
n=335 Participants
|
|
Age, Customized
18 - 25 years
|
26 Participants
n=210 Participants
|
0 Participants
n=19 Participants
|
21 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
10 Participants
n=5716 Participants
|
0 Participants
n=47026 Participants
|
6 Participants
n=66536 Participants
|
63 Participants
n=335 Participants
|
|
Age, Customized
26 - 35 years
|
54 Participants
n=210 Participants
|
0 Participants
n=19 Participants
|
74 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
34 Participants
n=5716 Participants
|
0 Participants
n=47026 Participants
|
26 Participants
n=66536 Participants
|
188 Participants
n=335 Participants
|
|
Age, Customized
36 - 45 years
|
28 Participants
n=210 Participants
|
0 Participants
n=19 Participants
|
52 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
36 Participants
n=5716 Participants
|
0 Participants
n=47026 Participants
|
39 Participants
n=66536 Participants
|
155 Participants
n=335 Participants
|
|
Age, Customized
56 - 65 years
|
0 Participants
n=210 Participants
|
35 Participants
n=19 Participants
|
0 Participants
n=8 Participants
|
59 Participants
n=24 Participants
|
0 Participants
n=5716 Participants
|
54 Participants
n=47026 Participants
|
23 Participants
n=66536 Participants
|
171 Participants
n=335 Participants
|
|
Age, Customized
66 - 75 years
|
0 Participants
n=210 Participants
|
11 Participants
n=19 Participants
|
0 Participants
n=8 Participants
|
13 Participants
n=24 Participants
|
0 Participants
n=5716 Participants
|
13 Participants
n=47026 Participants
|
4 Participants
n=66536 Participants
|
41 Participants
n=335 Participants
|
|
Age, Customized
Over 75 years
|
0 Participants
n=210 Participants
|
5 Participants
n=19 Participants
|
0 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
0 Participants
n=5716 Participants
|
7 Participants
n=47026 Participants
|
0 Participants
n=66536 Participants
|
17 Participants
n=335 Participants
|
|
Age, Customized
Unknown or Not Reported
|
0 Participants
n=210 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=5716 Participants
|
0 Participants
n=47026 Participants
|
0 Participants
n=66536 Participants
|
0 Participants
n=335 Participants
|
|
Sex: Female, Male
Female
|
59 Participants
n=210 Participants
|
21 Participants
n=19 Participants
|
129 Participants
n=8 Participants
|
42 Participants
n=24 Participants
|
70 Participants
n=5716 Participants
|
33 Participants
n=47026 Participants
|
54 Participants
n=66536 Participants
|
408 Participants
n=335 Participants
|
|
Sex: Female, Male
Male
|
70 Participants
n=210 Participants
|
30 Participants
n=19 Participants
|
53 Participants
n=8 Participants
|
35 Participants
n=24 Participants
|
52 Participants
n=5716 Participants
|
41 Participants
n=47026 Participants
|
71 Participants
n=66536 Participants
|
352 Participants
n=335 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
28 Participants
n=210 Participants
|
19 Participants
n=19 Participants
|
28 Participants
n=8 Participants
|
28 Participants
n=24 Participants
|
30 Participants
n=5716 Participants
|
27 Participants
n=47026 Participants
|
52 Participants
n=66536 Participants
|
212 Participants
n=335 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
101 Participants
n=210 Participants
|
32 Participants
n=19 Participants
|
153 Participants
n=8 Participants
|
49 Participants
n=24 Participants
|
92 Participants
n=5716 Participants
|
47 Participants
n=47026 Participants
|
73 Participants
n=66536 Participants
|
547 Participants
n=335 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=210 Participants
|
0 Participants
n=19 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=5716 Participants
|
0 Participants
n=47026 Participants
|
0 Participants
n=66536 Participants
|
1 Participants
n=335 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=210 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=5716 Participants
|
0 Participants
n=47026 Participants
|
0 Participants
n=66536 Participants
|
1 Participants
n=335 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=210 Participants
|
1 Participants
n=19 Participants
|
8 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
5 Participants
n=5716 Participants
|
0 Participants
n=47026 Participants
|
5 Participants
n=66536 Participants
|
22 Participants
n=335 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=210 Participants
|
0 Participants
n=19 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=5716 Participants
|
0 Participants
n=47026 Participants
|
0 Participants
n=66536 Participants
|
0 Participants
n=335 Participants
|
|
Race (NIH/OMB)
Black or African American
|
83 Participants
n=210 Participants
|
17 Participants
n=19 Participants
|
87 Participants
n=8 Participants
|
20 Participants
n=24 Participants
|
68 Participants
n=5716 Participants
|
27 Participants
n=47026 Participants
|
27 Participants
n=66536 Participants
|
329 Participants
n=335 Participants
|
|
Race (NIH/OMB)
White
|
7 Participants
n=210 Participants
|
8 Participants
n=19 Participants
|
25 Participants
n=8 Participants
|
26 Participants
n=24 Participants
|
6 Participants
n=5716 Participants
|
21 Participants
n=47026 Participants
|
36 Participants
n=66536 Participants
|
129 Participants
n=335 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=210 Participants
|
2 Participants
n=19 Participants
|
2 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
1 Participants
n=5716 Participants
|
0 Participants
n=47026 Participants
|
1 Participants
n=66536 Participants
|
6 Participants
n=335 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
36 Participants
n=210 Participants
|
23 Participants
n=19 Participants
|
60 Participants
n=8 Participants
|
30 Participants
n=24 Participants
|
42 Participants
n=5716 Participants
|
26 Participants
n=47026 Participants
|
56 Participants
n=66536 Participants
|
273 Participants
n=335 Participants
|
|
Region of Enrollment
United States
|
25 Participants
n=210 Participants
|
18 Participants
n=19 Participants
|
28 Participants
n=8 Participants
|
26 Participants
n=24 Participants
|
24 Participants
n=5716 Participants
|
25 Participants
n=47026 Participants
|
51 Participants
n=66536 Participants
|
197 Participants
n=335 Participants
|
|
Region of Enrollment
Peru
|
25 Participants
n=210 Participants
|
16 Participants
n=19 Participants
|
25 Participants
n=8 Participants
|
25 Participants
n=24 Participants
|
25 Participants
n=5716 Participants
|
25 Participants
n=47026 Participants
|
50 Participants
n=66536 Participants
|
191 Participants
n=335 Participants
|
|
Region of Enrollment
South Africa
|
64 Participants
n=210 Participants
|
14 Participants
n=19 Participants
|
98 Participants
n=8 Participants
|
21 Participants
n=24 Participants
|
57 Participants
n=5716 Participants
|
19 Participants
n=47026 Participants
|
14 Participants
n=66536 Participants
|
287 Participants
n=335 Participants
|
|
Region of Enrollment
Non-RSA
|
15 Participants
n=210 Participants
|
3 Participants
n=19 Participants
|
31 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
16 Participants
n=5716 Participants
|
5 Participants
n=47026 Participants
|
10 Participants
n=66536 Participants
|
85 Participants
n=335 Participants
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and enrollment group
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-USA
|
10 Participants
|
6 Participants
|
18 Participants
|
21 Participants
|
10 Participants
|
17 Participants
|
36 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 4-Peru
|
22 Participants
|
2 Participants
|
16 Participants
|
12 Participants
|
18 Participants
|
16 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 4-Total
|
28 Participants
|
3 Participants
|
26 Participants
|
24 Participants
|
27 Participants
|
27 Participants
|
42 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 4-USA
|
6 Participants
|
1 Participants
|
10 Participants
|
12 Participants
|
9 Participants
|
11 Participants
|
23 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru
|
21 Participants
|
3 Participants
|
23 Participants
|
20 Participants
|
22 Participants
|
25 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
34 Participants
|
14 Participants
|
51 Participants
|
45 Participants
|
41 Participants
|
48 Participants
|
91 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA
|
13 Participants
|
11 Participants
|
28 Participants
|
25 Participants
|
19 Participants
|
23 Participants
|
42 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru
|
20 Participants
|
2 Participants
|
16 Participants
|
16 Participants
|
20 Participants
|
18 Participants
|
34 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
29 Participants
|
8 Participants
|
31 Participants
|
37 Participants
|
30 Participants
|
34 Participants
|
70 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA
|
9 Participants
|
6 Participants
|
15 Participants
|
21 Participants
|
10 Participants
|
16 Participants
|
36 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru
|
20 Participants
|
2 Participants
|
17 Participants
|
10 Participants
|
16 Participants
|
16 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total
|
26 Participants
|
3 Participants
|
25 Participants
|
22 Participants
|
25 Participants
|
26 Participants
|
37 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA
|
6 Participants
|
1 Participants
|
8 Participants
|
12 Participants
|
9 Participants
|
10 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru
|
12 Participants
|
3 Participants
|
16 Participants
|
16 Participants
|
19 Participants
|
23 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Peru
|
15 Participants
|
3 Participants
|
16 Participants
|
18 Participants
|
21 Participants
|
25 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
26 Participants
|
11 Participants
|
33 Participants
|
33 Participants
|
36 Participants
|
39 Participants
|
86 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-USA
|
11 Participants
|
8 Participants
|
17 Participants
|
15 Participants
|
15 Participants
|
14 Participants
|
37 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Peru
|
21 Participants
|
2 Participants
|
19 Participants
|
16 Participants
|
20 Participants
|
18 Participants
|
36 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
20 Participants
|
11 Participants
|
32 Participants
|
28 Participants
|
34 Participants
|
37 Participants
|
82 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA
|
8 Participants
|
8 Participants
|
16 Participants
|
12 Participants
|
15 Participants
|
14 Participants
|
35 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
30 Participants
|
8 Participants
|
36 Participants
|
37 Participants
|
32 Participants
|
36 Participants
|
71 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru
|
20 Participants
|
2 Participants
|
17 Participants
|
17 Participants
|
19 Participants
|
18 Participants
|
36 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-USA
|
9 Participants
|
6 Participants
|
17 Participants
|
21 Participants
|
12 Participants
|
18 Participants
|
35 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
31 Participants
|
8 Participants
|
34 Participants
|
38 Participants
|
29 Participants
|
36 Participants
|
73 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 4-Peru
|
22 Participants
|
2 Participants
|
17 Participants
|
13 Participants
|
18 Participants
|
16 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 4-Total
|
29 Participants
|
3 Participants
|
27 Participants
|
25 Participants
|
29 Participants
|
27 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 4-USA
|
7 Participants
|
1 Participants
|
10 Participants
|
12 Participants
|
11 Participants
|
11 Participants
|
24 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA
|
11 Participants
|
6 Participants
|
17 Participants
|
21 Participants
|
10 Participants
|
18 Participants
|
37 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Peru
|
21 Participants
|
3 Participants
|
23 Participants
|
20 Participants
|
22 Participants
|
25 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
34 Participants
|
13 Participants
|
51 Participants
|
45 Participants
|
43 Participants
|
47 Participants
|
93 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-USA
|
13 Participants
|
10 Participants
|
28 Participants
|
25 Participants
|
21 Participants
|
22 Participants
|
44 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Peru
|
20 Participants
|
2 Participants
|
17 Participants
|
16 Participants
|
20 Participants
|
18 Participants
|
36 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru
|
22 Participants
|
2 Participants
|
17 Participants
|
13 Participants
|
17 Participants
|
16 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
30 Participants
|
8 Participants
|
35 Participants
|
37 Participants
|
30 Participants
|
35 Participants
|
72 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total
|
29 Participants
|
3 Participants
|
27 Participants
|
25 Participants
|
27 Participants
|
27 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA
|
7 Participants
|
1 Participants
|
10 Participants
|
12 Participants
|
10 Participants
|
11 Participants
|
24 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Peru
|
19 Participants
|
3 Participants
|
24 Participants
|
20 Participants
|
20 Participants
|
25 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
31 Participants
|
13 Participants
|
51 Participants
|
43 Participants
|
40 Participants
|
47 Participants
|
92 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-USA
|
12 Participants
|
10 Participants
|
27 Participants
|
23 Participants
|
20 Participants
|
22 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Peru
|
20 Participants
|
2 Participants
|
18 Participants
|
17 Participants
|
20 Participants
|
18 Participants
|
36 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
31 Participants
|
8 Participants
|
36 Participants
|
38 Participants
|
30 Participants
|
35 Participants
|
71 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-USA
|
11 Participants
|
6 Participants
|
18 Participants
|
21 Participants
|
10 Participants
|
17 Participants
|
35 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 4-Peru
|
22 Participants
|
2 Participants
|
16 Participants
|
12 Participants
|
18 Participants
|
16 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 4-Total
|
29 Participants
|
3 Participants
|
26 Participants
|
24 Participants
|
27 Participants
|
27 Participants
|
42 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 4-USA
|
7 Participants
|
1 Participants
|
10 Participants
|
12 Participants
|
9 Participants
|
11 Participants
|
23 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru
|
21 Participants
|
3 Participants
|
23 Participants
|
20 Participants
|
22 Participants
|
25 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
36 Participants
|
16 Participants
|
51 Participants
|
45 Participants
|
42 Participants
|
49 Participants
|
92 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA
|
15 Participants
|
13 Participants
|
28 Participants
|
25 Participants
|
20 Participants
|
24 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru
|
19 Participants
|
2 Participants
|
18 Participants
|
17 Participants
|
20 Participants
|
17 Participants
|
35 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
28 Participants
|
8 Participants
|
35 Participants
|
38 Participants
|
31 Participants
|
35 Participants
|
71 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA
|
9 Participants
|
6 Participants
|
17 Participants
|
21 Participants
|
11 Participants
|
18 Participants
|
36 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru
|
23 Participants
|
2 Participants
|
15 Participants
|
11 Participants
|
16 Participants
|
16 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total
|
30 Participants
|
4 Participants
|
24 Participants
|
23 Participants
|
25 Participants
|
27 Participants
|
39 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA
|
7 Participants
|
2 Participants
|
9 Participants
|
12 Participants
|
9 Participants
|
11 Participants
|
22 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru
|
22 Participants
|
3 Participants
|
24 Participants
|
22 Participants
|
22 Participants
|
25 Participants
|
48 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
38 Participants
|
13 Participants
|
52 Participants
|
47 Participants
|
42 Participants
|
48 Participants
|
92 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA
|
16 Participants
|
10 Participants
|
28 Participants
|
25 Participants
|
20 Participants
|
23 Participants
|
44 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru
|
20 Participants
|
2 Participants
|
18 Participants
|
16 Participants
|
20 Participants
|
18 Participants
|
36 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
31 Participants
|
8 Participants
|
35 Participants
|
37 Participants
|
32 Participants
|
36 Participants
|
74 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA
|
11 Participants
|
6 Participants
|
17 Participants
|
21 Participants
|
12 Participants
|
18 Participants
|
38 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru
|
22 Participants
|
2 Participants
|
17 Participants
|
13 Participants
|
18 Participants
|
16 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total
|
29 Participants
|
3 Participants
|
27 Participants
|
25 Participants
|
29 Participants
|
27 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA
|
7 Participants
|
1 Participants
|
10 Participants
|
12 Participants
|
11 Participants
|
11 Participants
|
24 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru
|
12 Participants
|
3 Participants
|
16 Participants
|
16 Participants
|
19 Participants
|
24 Participants
|
48 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
22 Participants
|
11 Participants
|
32 Participants
|
29 Participants
|
33 Participants
|
38 Participants
|
82 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA
|
10 Participants
|
8 Participants
|
16 Participants
|
13 Participants
|
14 Participants
|
14 Participants
|
34 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru
|
20 Participants
|
2 Participants
|
17 Participants
|
17 Participants
|
20 Participants
|
17 Participants
|
36 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
30 Participants
|
7 Participants
|
35 Participants
|
38 Participants
|
30 Participants
|
33 Participants
|
68 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA
|
10 Participants
|
5 Participants
|
18 Participants
|
21 Participants
|
10 Participants
|
16 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru
|
22 Participants
|
2 Participants
|
17 Participants
|
14 Participants
|
18 Participants
|
16 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total
|
29 Participants
|
3 Participants
|
27 Participants
|
26 Participants
|
27 Participants
|
27 Participants
|
41 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA
|
7 Participants
|
1 Participants
|
10 Participants
|
12 Participants
|
9 Participants
|
11 Participants
|
22 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and enrollment group
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Peru
|
614.8 MFI
Interval 392.2 to 772.5
|
3533.1 MFI
Interval 2698.9 to 4367.3
|
938.9 MFI
Interval 287.9 to 2349.7
|
4508 MFI
Interval 1109.4 to 6349.9
|
5677.9 MFI
Interval 1321.9 to 18651.1
|
9158.1 MFI
Interval 4082.4 to 22000.0
|
3019.4 MFI
Interval 805.6 to 6961.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total
|
587.8 MFI
Interval 337.4 to 1037.4
|
743 MFI
Interval 90.9 to 1805.5
|
1485.5 MFI
Interval 520.5 to 3719.6
|
5276 MFI
Interval 1747.0 to 9449.2
|
5411.9 MFI
Interval 581.4 to 14784.2
|
8853.1 MFI
Interval 4646.4 to 14318.2
|
1755.5 MFI
Interval 569.2 to 4882.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-1000 at Month 0-Peru
|
10735 MFI
Interval 3712.8 to 14037.2
|
5225.2 MFI
Interval 3182.4 to 10215.2
|
22000 MFI
Interval 10914.1 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
22000 MFI
Interval 15797.8 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-1000 at Month 0-Total
|
7790.9 MFI
Interval 774.4 to 11902.2
|
3413.2 MFI
Interval 1.0 to 9553.6
|
13862.2 MFI
Interval 5081.0 to 22000.0
|
22000 MFI
Interval 8377.9 to 22000.0
|
22000 MFI
Interval 16996.2 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
16428.8 MFI
Interval 5858.1 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-1000 at Month 0-USA
|
958.8 MFI
Interval 1.0 to 7844.4
|
3013 MFI
Interval 1.0 to 9553.6
|
8418 MFI
Interval 2056.5 to 21876.8
|
9064.2 MFI
Interval 5341.4 to 22000.0
|
19159.8 MFI
Interval 6267.3 to 22000.0
|
22000 MFI
Interval 20962.2 to 22000.0
|
8637 MFI
Interval 2768.2 to 14335.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-1000 at Month 2-Peru
|
2149 MFI
Interval 1146.0 to 4407.1
|
14129.9 MFI
Interval 10194.8 to 18064.9
|
7039 MFI
Interval 2096.1 to 11836.4
|
14945 MFI
Interval 8318.5 to 20964.4
|
21771.9 MFI
Interval 9814.5 to 22000.0
|
22000 MFI
Interval 20542.2 to 22000.0
|
17594.6 MFI
Interval 8674.8 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-1000 at Month 2-Total
|
2090.9 MFI
Interval 955.2 to 4515.9
|
3946.9 MFI
Interval 83.3 to 8101.2
|
6997.9 MFI
Interval 2851.1 to 13690.4
|
12310.8 MFI
Interval 6517.0 to 19928.8
|
13478.1 MFI
Interval 5632.2 to 22000.0
|
22000 MFI
Interval 12489.0 to 22000.0
|
7604.6 MFI
Interval 2817.5 to 18727.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-1000 at Month 2-USA
|
2032.8 MFI
Interval 229.4 to 4360.1
|
1315.8 MFI
Interval 46.9 to 6980.1
|
5189.8 MFI
Interval 3272.8 to 14229.5
|
8462.9 MFI
Interval 6703.2 to 17697.0
|
7162 MFI
Interval 456.0 to 19814.4
|
16418.5 MFI
Interval 5184.5 to 22000.0
|
3124.1 MFI
Interval 615.6 to 7653.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-1000 at Month 4-Peru
|
1159.1 MFI
Interval 611.5 to 2272.9
|
12284.6 MFI
Interval 7426.9 to 17142.3
|
2039.4 MFI
Interval 722.3 to 5816.0
|
12227.4 MFI
Interval 1528.0 to 19363.6
|
11351.8 MFI
Interval 4295.6 to 17359.4
|
20226.2 MFI
Interval 12771.2 to 22000.0
|
11395.5 MFI
Interval 4846.1 to 19119.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-1000 at Month 4-Total
|
1159.1 MFI
Interval 611.5 to 2097.5
|
1027.8 MFI
Interval 180.7 to 2376.2
|
1917.6 MFI
Interval 638.8 to 5311.8
|
6339.8 MFI
Interval 1690.5 to 19297.5
|
8064.2 MFI
Interval 2891.2 to 15134.2
|
16315.5 MFI
Interval 7446.2 to 21740.8
|
4329.2 MFI
Interval 1293.8 to 13465.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-1000 at Month 4-USA
|
1182.9 MFI
Interval 680.1 to 1756.6
|
206.6 MFI
Interval 123.1 to 643.1
|
1867.5 MFI
Interval 816.7 to 4612.3
|
2586.8 MFI
Interval 1695.2 to 15358.5
|
5671.2 MFI
Interval 341.0 to 8064.2
|
11730.5 MFI
Interval 1608.5 to 16981.8
|
1706.6 MFI
Interval 993.1 to 4302.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 0-Peru
|
6075 MFI
Interval 4465.1 to 7750.2
|
8687.5 MFI
Interval 5760.1 to 10086.8
|
4655.5 MFI
Interval 4012.8 to 5647.9
|
9766.1 MFI
Interval 7655.8 to 13076.6
|
7667.2 MFI
Interval 4595.1 to 8742.5
|
8987 MFI
Interval 7051.7 to 11952.9
|
5536.8 MFI
Interval 4000.8 to 7704.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 2-USA
|
371.1 MFI
Interval 197.8 to 1902.9
|
282.5 MFI
Interval 80.2 to 944.2
|
3212.2 MFI
Interval 1006.8 to 10107.2
|
6872.9 MFI
Interval 2322.2 to 15478.2
|
4223.1 MFI
Interval 385.2 to 10834.0
|
7731.5 MFI
Interval 5068.4 to 13451.9
|
1301.5 MFI
Interval 303.2 to 3673.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 0-Total
|
4321.2 MFI
Interval 2266.5 to 6227.0
|
3656.5 MFI
Interval 1687.5 to 7638.4
|
4164 MFI
Interval 3314.8 to 5418.8
|
8399.5 MFI
Interval 6223.2 to 10962.0
|
5609 MFI
Interval 2988.0 to 7861.2
|
7848.9 MFI
Interval 5618.9 to 10069.6
|
4889.6 MFI
Interval 3536.6 to 7270.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 0-USA
|
2664.1 MFI
Interval 1670.3 to 4190.9
|
2398.2 MFI
Interval 1687.5 to 6818.2
|
3365.1 MFI
Interval 2633.3 to 4118.2
|
6920.4 MFI
Interval 3539.1 to 7853.8
|
3977.8 MFI
Interval 1847.7 to 7549.0
|
5114.9 MFI
Interval 3390.9 to 7718.6
|
4339.2 MFI
Interval 2300.5 to 5952.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Peru
|
179.9 MFI
Interval 128.4 to 363.2
|
1295.8 MFI
Interval 1124.0 to 1467.5
|
316 MFI
Interval 234.1 to 481.1
|
1731.8 MFI
Interval 398.8 to 2258.0
|
1442.9 MFI
Interval 320.6 to 3319.8
|
2589.5 MFI
Interval 834.2 to 4785.1
|
698.2 MFI
Interval 493.8 to 2218.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 2-Peru
|
5480.5 MFI
Interval 4087.0 to 7269.6
|
10204.8 MFI
Interval 8883.9 to 11525.6
|
5184.4 MFI
Interval 4430.1 to 6217.2
|
9299.8 MFI
Interval 7956.5 to 12819.2
|
6259.1 MFI
Interval 3543.9 to 7812.8
|
9592.9 MFI
Interval 8265.1 to 12218.4
|
6666.8 MFI
Interval 4642.2 to 8523.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 2-Total
|
4491 MFI
Interval 2831.5 to 6643.6
|
5538.9 MFI
Interval 3732.4 to 7727.1
|
4630.2 MFI
Interval 3039.0 to 5985.9
|
7680.6 MFI
Interval 4568.6 to 9781.8
|
4738.2 MFI
Interval 3038.9 to 7294.2
|
7152.1 MFI
Interval 4167.4 to 9633.8
|
4715.8 MFI
Interval 2662.9 to 7221.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total
|
185.8 MFI
Interval 128.4 to 363.2
|
647.2 MFI
Interval 267.4 to 1467.5
|
341 MFI
Interval 216.4 to 600.2
|
1779.8 MFI
Interval 452.7 to 4149.4
|
1122.5 MFI
Interval 287.9 to 2978.9
|
1776.8 MFI
Interval 507.5 to 4489.2
|
556.9 MFI
Interval 377.6 to 1292.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 2-USA
|
2676.5 MFI
Interval 1714.2 to 3997.5
|
4896 MFI
Interval 3052.1 to 7001.0
|
3227.9 MFI
Interval 2265.4 to 5141.9
|
5982 MFI
Interval 2890.2 to 7680.6
|
4185.8 MFI
Interval 2660.5 to 5522.2
|
4205.8 MFI
Interval 1024.2 to 5512.7
|
3671.8 MFI
Interval 2322.8 to 5293.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 4-USA
|
242.9 MFI
Interval 161.5 to 1067.7
|
292.4 MFI
Interval 215.8 to 815.1
|
443.9 MFI
Interval 161.5 to 1044.1
|
2524 MFI
Interval 659.2 to 4267.8
|
705 MFI
Interval 219.2 to 1810.2
|
833.4 MFI
Interval 386.3 to 3992.8
|
422.5 MFI
Interval 153.9 to 1011.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Peru
|
1226.9 MFI
Interval 769.1 to 3342.9
|
782 MFI
Interval 56.9 to 3556.8
|
4992.5 MFI
Interval 3063.4 to 12338.3
|
11573.2 MFI
Interval 5604.0 to 17840.2
|
18083.2 MFI
Interval 15367.6 to 21250.9
|
22000 MFI
Interval 14180.9 to 22000.0
|
14558.5 MFI
Interval 3418.0 to 21907.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 4-Peru
|
5674.4 MFI
Interval 3985.6 to 6540.4
|
12835.4 MFI
Interval 11581.9 to 14088.8
|
6628.8 MFI
Interval 5038.1 to 7600.2
|
10900.1 MFI
Interval 8523.8 to 13950.5
|
7793 MFI
Interval 6289.0 to 8675.0
|
11288.1 MFI
Interval 9721.0 to 12000.3
|
6895.5 MFI
Interval 5185.4 to 10066.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 4-Total
|
4769.4 MFI
Interval 3819.2 to 6273.0
|
7684.5 MFI
Interval 4887.2 to 9870.4
|
5758 MFI
Interval 3363.9 to 7464.1
|
8742.8 MFI
Interval 6231.1 to 13223.6
|
6800.8 MFI
Interval 4781.8 to 8223.5
|
9087.4 MFI
Interval 6173.9 to 11392.2
|
5392 MFI
Interval 3585.4 to 7818.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 4-USA
|
3782.9 MFI
Interval 2974.6 to 4094.6
|
5549.1 MFI
Interval 4096.2 to 7278.8
|
3770.2 MFI
Interval 1311.6 to 5784.1
|
6330 MFI
Interval 4810.5 to 9281.8
|
6125 MFI
Interval 3926.9 to 7413.3
|
6074.2 MFI
Interval 3362.9 to 7725.6
|
4619.6 MFI
Interval 2416.6 to 6273.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Peru
|
19899 MFI
Interval 15659.0 to 22000.0
|
14867.4 MFI
Interval 7324.9 to 22000.0
|
22000 MFI
Interval 18506.6 to 22000.0
|
14711 MFI
Interval 9667.2 to 20261.8
|
21350.2 MFI
Interval 13585.1 to 22000.0
|
14855.8 MFI
Interval 10743.0 to 20445.8
|
10342.2 MFI
Interval 7780.1 to 16512.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Total
|
17290.1 MFI
Interval 9474.8 to 22000.0
|
8322.4 MFI
Interval 5403.6 to 13950.9
|
21138.5 MFI
Interval 13965.0 to 22000.0
|
15478.8 MFI
Interval 9890.9 to 21045.4
|
15729 MFI
Interval 8237.5 to 22000.0
|
14555.8 MFI
Interval 7663.9 to 21172.6
|
10404 MFI
Interval 6037.0 to 14504.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total
|
792.2 MFI
Interval 1.0 to 1432.1
|
741.2 MFI
Interval 1.0 to 1349.2
|
3937.5 MFI
Interval 2489.8 to 8993.9
|
8441.2 MFI
Interval 4226.8 to 16106.0
|
12012 MFI
Interval 8091.1 to 20255.2
|
16904.5 MFI
Interval 9754.9 to 22000.0
|
3888 MFI
Interval 1467.2 to 15401.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-USA
|
13.4 MFI
Interval 1.0 to 978.0
|
741.2 MFI
Interval 1.0 to 1179.0
|
2803.5 MFI
Interval 458.7 to 5584.9
|
6295.4 MFI
Interval 2100.6 to 10299.3
|
5952.6 MFI
Interval 1129.8 to 11072.9
|
10463.5 MFI
Interval 5537.5 to 15002.4
|
1830 MFI
Interval 413.9 to 3857.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Peru
|
489.5 MFI
Interval 322.0 to 1176.9
|
7622.2 MFI
Interval 4443.2 to 10801.2
|
1177.2 MFI
Interval 289.9 to 2273.6
|
3506 MFI
Interval 1798.4 to 8417.8
|
7619.2 MFI
Interval 1618.0 to 9419.5
|
15530.8 MFI
Interval 10028.8 to 22000.0
|
4801.1 MFI
Interval 2781.6 to 8004.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-USA
|
10297.5 MFI
Interval 5067.8 to 21442.2
|
7937 MFI
Interval 4195.2 to 11355.8
|
19071.6 MFI
Interval 9260.4 to 22000.0
|
16298 MFI
Interval 10831.0 to 22000.0
|
11982.2 MFI
Interval 4528.8 to 20300.2
|
11300 MFI
Interval 4945.2 to 22000.0
|
10404 MFI
Interval 3929.2 to 13611.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total
|
434.6 MFI
Interval 229.0 to 1084.0
|
751.6 MFI
Interval 81.8 to 1607.1
|
1330.4 MFI
Interval 376.0 to 2229.9
|
3245.2 MFI
Interval 962.5 to 7709.2
|
3188.2 MFI
Interval 822.6 to 8989.9
|
9842.2 MFI
Interval 3396.5 to 16514.0
|
1820 MFI
Interval 569.8 to 4819.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Peru
|
15490 MFI
Interval 10239.5 to 21122.4
|
21984.2 MFI
Interval 21976.4 to 21992.1
|
13781.4 MFI
Interval 11054.8 to 16781.7
|
15861.8 MFI
Interval 9562.0 to 18270.5
|
12104.6 MFI
Interval 6711.9 to 16836.2
|
13485.8 MFI
Interval 8237.2 to 16891.2
|
7754 MFI
Interval 5060.9 to 13578.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-USA
|
362.2 MFI
Interval 85.5 to 1048.8
|
219.5 MFI
Interval 51.8 to 1465.0
|
1483.5 MFI
Interval 496.0 to 2111.2
|
1922.9 MFI
Interval 868.0 to 6178.5
|
1465.6 MFI
Interval 235.3 to 4535.2
|
4840.5 MFI
Interval 1480.0 to 9467.4
|
652.1 MFI
Interval 278.1 to 1644.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Total
|
13251.8 MFI
Interval 7342.4 to 18761.9
|
7710.4 MFI
Interval 5495.2 to 19288.2
|
12450.5 MFI
Interval 8284.1 to 16509.5
|
10741.6 MFI
Interval 8022.8 to 16222.2
|
10419.2 MFI
Interval 7264.8 to 15295.5
|
10632 MFI
Interval 5095.2 to 16246.6
|
6951 MFI
Interval 4356.9 to 11729.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-USA
|
7194.9 MFI
Interval 1959.9 to 9653.0
|
7437.2 MFI
Interval 5424.6 to 8784.2
|
8613.5 MFI
Interval 3376.6 to 14622.9
|
9110.2 MFI
Interval 6944.4 to 11406.2
|
9798 MFI
Interval 8471.5 to 13046.2
|
6805.5 MFI
Interval 1312.6 to 13434.1
|
6789.5 MFI
Interval 3251.5 to 9647.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 4-Peru
|
12664 MFI
Interval 8975.7 to 17440.9
|
21957.2 MFI
Interval 21935.9 to 21978.6
|
12504.6 MFI
Interval 7820.4 to 18872.4
|
13619.5 MFI
Interval 10011.1 to 16479.2
|
11718 MFI
Interval 7236.0 to 16642.8
|
11386.5 MFI
Interval 6412.5 to 14079.9
|
7465.9 MFI
Interval 5161.4 to 11797.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Peru
|
330.1 MFI
Interval 197.5 to 523.5
|
4673.1 MFI
Interval 2582.1 to 6764.2
|
353 MFI
Interval 235.3 to 1184.1
|
2770.9 MFI
Interval 320.4 to 4245.5
|
2815.2 MFI
Interval 743.5 to 5771.0
|
7131.1 MFI
Interval 3416.5 to 13282.6
|
3884.2 MFI
Interval 1348.5 to 5530.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 4-Total
|
10593.6 MFI
Interval 6351.4 to 15398.7
|
19506.5 MFI
Interval 10245.0 to 21978.6
|
9961.5 MFI
Interval 6591.2 to 19333.9
|
12133.1 MFI
Interval 8811.9 to 14841.1
|
11396 MFI
Interval 6578.0 to 14176.4
|
11556.8 MFI
Interval 6052.5 to 15732.1
|
7501.2 MFI
Interval 4611.0 to 12510.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total
|
301.8 MFI
Interval 182.9 to 485.0
|
230.4 MFI
Interval 72.4 to 443.1
|
384.2 MFI
Interval 228.8 to 1249.1
|
1359.2 MFI
Interval 318.5 to 4397.5
|
2078 MFI
Interval 494.9 to 5331.9
|
5453.2 MFI
Interval 2084.5 to 8042.8
|
997.2 MFI
Interval 322.2 to 3895.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-USA
|
272.8 MFI
Interval 139.7 to 434.1
|
102 MFI
Interval 39.5 to 195.8
|
427.8 MFI
Interval 240.4 to 1123.4
|
489 MFI
Interval 318.5 to 6099.5
|
1042.9 MFI
Interval 134.8 to 1957.4
|
3039 MFI
Interval 337.2 to 5453.2
|
382.8 MFI
Interval 200.1 to 985.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 4-USA
|
6045.6 MFI
Interval 4207.4 to 7005.4
|
12529.5 MFI
Interval 7219.9 to 18323.9
|
7846.5 MFI
Interval 4158.8 to 19113.9
|
9651.5 MFI
Interval 6913.8 to 12437.8
|
10991.1 MFI
Interval 5297.5 to 13288.2
|
11764.9 MFI
Interval 6239.4 to 16624.1
|
7501.2 MFI
Interval 2969.8 to 12632.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru
|
11668.8 MFI
Interval 5203.0 to 16714.0
|
15622.9 MFI
Interval 10535.9 to 20041.5
|
20251.9 MFI
Interval 11690.9 to 22000.0
|
22000 MFI
Interval 12186.2 to 22000.0
|
17805.8 MFI
Interval 10662.1 to 20763.2
|
19896.8 MFI
Interval 16454.0 to 22000.0
|
15293.1 MFI
Interval 9350.9 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total
|
10373.5 MFI
Interval 4227.2 to 17610.3
|
11830.1 MFI
Interval 7079.6 to 20054.6
|
20251.9 MFI
Interval 9224.1 to 22000.0
|
17539.9 MFI
Interval 12178.6 to 22000.0
|
14465 MFI
Interval 9054.0 to 20689.2
|
19475.8 MFI
Interval 14455.2 to 22000.0
|
14566.8 MFI
Interval 7623.0 to 21648.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA
|
7752.8 MFI
Interval 2475.0 to 20000.5
|
10792.8 MFI
Interval 4975.6 to 19968.2
|
20279.6 MFI
Interval 8633.2 to 22000.0
|
14482.8 MFI
Interval 10836.2 to 19693.2
|
13855.8 MFI
Interval 7185.0 to 19375.8
|
17473.6 MFI
Interval 11148.2 to 22000.0
|
13830.5 MFI
Interval 5683.2 to 20382.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru
|
10629 MFI
Interval 7875.9 to 15722.1
|
20287.9 MFI
Interval 19431.8 to 21143.9
|
11187 MFI
Interval 7741.8 to 22000.0
|
18858.8 MFI
Interval 7010.2 to 22000.0
|
14461.6 MFI
Interval 11335.4 to 20452.8
|
22000 MFI
Interval 21078.8 to 22000.0
|
14260.8 MFI
Interval 9801.1 to 19572.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 0-Peru
|
1450.6 MFI
Interval 774.5 to 3670.2
|
2351 MFI
Interval 153.7 to 8355.9
|
5647.5 MFI
Interval 563.8 to 12682.5
|
14945.9 MFI
Interval 6303.8 to 22000.0
|
22000 MFI
Interval 14979.6 to 22000.0
|
22000 MFI
Interval 21077.8 to 22000.0
|
16546 MFI
Interval 3766.2 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 0-Total
|
938.8 MFI
Interval 53.6 to 2176.2
|
654.9 MFI
Interval 34.0 to 2352.7
|
3900.2 MFI
Interval 563.6 to 7742.9
|
8602.8 MFI
Interval 2383.2 to 17571.2
|
14027.5 MFI
Interval 3387.9 to 22000.0
|
22000 MFI
Interval 8782.0 to 22000.0
|
4251 MFI
Interval 895.0 to 18275.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 0-USA
|
107.2 MFI
Interval 1.0 to 1106.9
|
654.9 MFI
Interval 5.4 to 1677.8
|
3034.5 MFI
Interval 954.6 to 6494.1
|
2889.5 MFI
Interval 1575.6 to 11238.9
|
7256.8 MFI
Interval 1109.3 to 14340.8
|
11397 MFI
Interval 5061.5 to 22000.0
|
1044.6 MFI
Interval 290.7 to 4973.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 2-Peru
|
607.5 MFI
Interval 239.2 to 1220.4
|
8367.4 MFI
Interval 4913.8 to 11820.9
|
1056.9 MFI
Interval 150.6 to 2012.8
|
5299.5 MFI
Interval 1063.6 to 8401.8
|
10770.6 MFI
Interval 1744.4 to 12486.9
|
16795.2 MFI
Interval 7519.1 to 22000.0
|
5463.8 MFI
Interval 1750.4 to 12009.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 2-Total
|
373.1 MFI
Interval 162.6 to 1122.8
|
527.5 MFI
Interval 42.1 to 1650.9
|
819.9 MFI
Interval 192.5 to 1990.2
|
2153.2 MFI
Interval 618.0 to 6854.0
|
3908 MFI
Interval 231.4 to 11546.8
|
8501.5 MFI
Interval 3085.5 to 17745.2
|
1748.8 MFI
Interval 368.8 to 5473.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 2-USA
|
214.5 MFI
Interval 86.5 to 771.2
|
220 MFI
Interval 33.2 to 1277.4
|
521.6 MFI
Interval 214.9 to 1875.2
|
1472.5 MFI
Interval 529.2 to 4961.9
|
1453.1 MFI
Interval 202.8 to 4516.6
|
4590 MFI
Interval 826.6 to 8820.5
|
476.8 MFI
Interval 172.5 to 1906.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 4-Peru
|
330.5 MFI
Interval 190.8 to 486.6
|
5505.8 MFI
Interval 3170.1 to 7841.4
|
585.1 MFI
Interval 131.8 to 719.4
|
4116.8 MFI
Interval 309.6 to 5886.4
|
3952.8 MFI
Interval 513.6 to 5890.4
|
7362.5 MFI
Interval 3965.2 to 12498.9
|
2819.8 MFI
Interval 1179.6 to 6570.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 4-Total
|
252.5 MFI
Interval 161.7 to 446.2
|
118.9 MFI
Interval 69.1 to 656.0
|
332.1 MFI
Interval 185.2 to 736.7
|
685.4 MFI
Interval 262.6 to 5740.9
|
1777.1 MFI
Interval 404.9 to 4717.2
|
5922.5 MFI
Interval 1578.0 to 8962.2
|
1062.8 MFI
Interval 235.8 to 3485.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total
|
12036.5 MFI
Interval 6845.0 to 17650.2
|
15556 MFI
Interval 11395.4 to 21613.9
|
12295.6 MFI
Interval 7485.9 to 20675.4
|
14119.9 MFI
Interval 7793.1 to 22000.0
|
13228.8 MFI
Interval 6242.9 to 18775.9
|
21639 MFI
Interval 11705.7 to 22000.0
|
13306.2 MFI
Interval 8014.2 to 18093.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA
|
15608.5 MFI
Interval 1507.5 to 19182.2
|
14067.4 MFI
Interval 10970.8 to 20364.4
|
13642.8 MFI
Interval 7470.8 to 17337.5
|
12119.5 MFI
Interval 8763.2 to 18655.6
|
8948.6 MFI
Interval 5130.1 to 16518.2
|
12770.5 MFI
Interval 7102.8 to 21470.5
|
11295.2 MFI
Interval 6278.9 to 16840.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Peru
|
8894.2 MFI
Interval 5556.9 to 14511.1
|
22000 MFI
Interval 22000.0 to 22000.0
|
10096.9 MFI
Interval 6855.2 to 15999.6
|
20468.8 MFI
Interval 8338.9 to 22000.0
|
15596.3 MFI
Interval 11027.1 to 19896.1
|
17215.8 MFI
Interval 12525.4 to 22000.0
|
15132.5 MFI
Interval 9262.5 to 20876.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 4-USA
|
155.1 MFI
Interval 110.4 to 261.3
|
85.1 MFI
Interval 46.2 to 118.1
|
299.1 MFI
Interval 243.1 to 648.5
|
432.8 MFI
Interval 268.0 to 4739.2
|
994.9 MFI
Interval 122.4 to 1886.6
|
1989 MFI
Interval 571.2 to 6985.5
|
349.8 MFI
Interval 140.0 to 1144.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total
|
8894.2 MFI
Interval 5115.9 to 16139.3
|
16623.1 MFI
Interval 9625.1 to 22000.0
|
10398.2 MFI
Interval 6761.2 to 16473.0
|
16420.5 MFI
Interval 8521.2 to 22000.0
|
15129 MFI
Interval 9183.8 to 20451.1
|
16627.8 MFI
Interval 10980.5 to 22000.0
|
12564.5 MFI
Interval 7646.8 to 20485.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-USA
|
11432.1 MFI
Interval 2214.0 to 21503.7
|
10165.5 MFI
Interval 7582.8 to 13934.7
|
10398.2 MFI
Interval 6660.2 to 18211.2
|
11051 MFI
Interval 8521.2 to 16683.5
|
11546.4 MFI
Interval 6935.4 to 20765.9
|
12100.8 MFI
Interval 9035.5 to 22000.0
|
12463.2 MFI
Interval 6857.5 to 18039.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru
|
1310.2 MFI
Interval 1019.5 to 2396.0
|
807.6 MFI
Interval 575.8 to 1401.6
|
1773.8 MFI
Interval 408.9 to 3607.5
|
771.4 MFI
Interval 1.0 to 1837.4
|
1 MFI
Interval 1.0 to 1759.4
|
1 MFI
Interval 1.0 to 692.8
|
920.5 MFI
Interval 1.0 to 2928.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Peru
|
1696.2 MFI
Interval 830.9 to 3348.9
|
998.9 MFI
Interval 476.2 to 4516.8
|
3486.2 MFI
Interval 1476.2 to 11336.0
|
15417.5 MFI
Interval 8476.2 to 22000.0
|
14651.5 MFI
Interval 9520.1 to 22000.0
|
22000 MFI
Interval 18660.2 to 22000.0
|
13939.8 MFI
Interval 6797.8 to 18247.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total
|
885 MFI
Interval 94.4 to 2685.0
|
656.2 MFI
Interval 29.2 to 4055.2
|
3887.5 MFI
Interval 1278.2 to 9165.5
|
6299.2 MFI
Interval 3413.0 to 17363.8
|
11095 MFI
Interval 4335.2 to 15640.6
|
20107.8 MFI
Interval 10867.4 to 22000.0
|
5338.2 MFI
Interval 1286.2 to 15321.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Total
|
1652.5 MFI
Interval 1033.6 to 2765.2
|
904 MFI
Interval 557.1 to 2311.6
|
2163.6 MFI
Interval 870.5 to 4423.7
|
1109 MFI
Interval 1.0 to 2274.0
|
1688.5 MFI
Interval 1.0 to 4138.2
|
1 MFI
Interval 1.0 to 1196.4
|
1302.1 MFI
Interval 63.3 to 2763.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-USA
|
2171 MFI
Interval 1100.5 to 2829.8
|
904 MFI
Interval 369.2 to 2565.6
|
2484.6 MFI
Interval 1145.6 to 4467.4
|
2048 MFI
Interval 94.0 to 3609.2
|
3091.2 MFI
Interval 422.2 to 4483.8
|
1 MFI
Interval 1.0 to 2562.0
|
1460.2 MFI
Interval 388.5 to 2677.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru
|
2241 MFI
Interval 1207.8 to 3753.8
|
5477.8 MFI
Interval 5477.8 to 5477.8
|
3263.6 MFI
Interval 1880.6 to 4896.8
|
1329.9 MFI
Interval 392.9 to 2680.5
|
576.6 MFI
Interval 6.5 to 2645.4
|
936.6 MFI
Interval 1.0 to 2939.8
|
658.8 MFI
Interval 25.4 to 1771.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Total
|
2431.2 MFI
Interval 1527.8 to 4081.8
|
1134 MFI
Interval 756.5 to 5441.8
|
3725.4 MFI
Interval 1644.0 to 4862.9
|
1474.8 MFI
Interval 358.2 to 3332.6
|
1825.9 MFI
Interval 480.2 to 4706.0
|
710.2 MFI
Interval 1.0 to 2920.0
|
1041.5 MFI
Interval 300.0 to 3206.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-USA
|
3289.9 MFI
Interval 2367.9 to 4426.8
|
1111.6 MFI
Interval 742.0 to 3619.8
|
4343.9 MFI
Interval 802.8 to 4765.3
|
2125.8 MFI
Interval 393.5 to 3722.8
|
4030.1 MFI
Interval 1939.8 to 6035.1
|
201 MFI
Interval 1.0 to 1266.2
|
1885.9 MFI
Interval 819.2 to 3440.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 4-Peru
|
1418.4 MFI
Interval 727.7 to 2977.8
|
2714.9 MFI
Interval 2714.2 to 2715.6
|
2002.9 MFI
Interval 944.4 to 3543.1
|
1314 MFI
Interval 470.6 to 2511.3
|
1372 MFI
Interval 677.8 to 1930.9
|
1213.1 MFI
Interval 588.2 to 1522.1
|
971.9 MFI
Interval 493.4 to 1970.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 0-USA
|
223.5 MFI
Interval 24.1 to 1728.4
|
578.5 MFI
Interval 25.1 to 4055.2
|
4259.2 MFI
Interval 1051.3 to 7644.1
|
5231.5 MFI
Interval 2196.2 to 7207.3
|
7229.5 MFI
Interval 2171.5 to 11993.9
|
12049 MFI
Interval 8752.8 to 22000.0
|
1919.4 MFI
Interval 489.0 to 4345.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 4-Total
|
1370.5 MFI
Interval 830.8 to 2874.6
|
1894.6 MFI
Interval 721.9 to 2715.6
|
2083.8 MFI
Interval 1126.1 to 3673.4
|
1526 MFI
Interval 275.3 to 2755.7
|
1561.9 MFI
Interval 802.5 to 3617.2
|
1099.9 MFI
Interval 343.7 to 2692.8
|
1570 MFI
Interval 727.1 to 2633.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Peru
|
494 MFI
Interval 238.5 to 909.2
|
10406.2 MFI
Interval 5576.9 to 15235.6
|
1474.2 MFI
Interval 249.5 to 4132.9
|
4938.2 MFI
Interval 2573.2 to 7135.8
|
7757.4 MFI
Interval 1805.2 to 13836.7
|
19485.8 MFI
Interval 9937.8 to 22000.0
|
5311.5 MFI
Interval 2412.4 to 9359.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 4-USA
|
1347.5 MFI
Interval 1134.4 to 2302.3
|
839.9 MFI
Interval 598.9 to 2860.3
|
2242.4 MFI
Interval 1261.2 to 4987.2
|
2158 MFI
Interval 78.8 to 3082.2
|
3185.5 MFI
Interval 968.4 to 4620.1
|
482.2 MFI
Interval 209.1 to 3879.1
|
2024.9 MFI
Interval 910.7 to 3238.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru
|
21654.8 MFI
Interval 16901.2 to 22000.0
|
20565.5 MFI
Interval 17515.8 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
22000 MFI
Interval 19747.2 to 22000.0
|
21985.4 MFI
Interval 18529.6 to 22000.0
|
22000 MFI
Interval 20590.8 to 22000.0
|
22000 MFI
Interval 20284.2 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Total
|
21228.5 MFI
Interval 11765.6 to 22000.0
|
22000 MFI
Interval 13884.7 to 22000.0
|
22000 MFI
Interval 18979.1 to 22000.0
|
22000 MFI
Interval 16712.6 to 22000.0
|
21717.8 MFI
Interval 16117.5 to 22000.0
|
22000 MFI
Interval 19735.2 to 22000.0
|
22000 MFI
Interval 17619.2 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-USA
|
20290.5 MFI
Interval 10726.8 to 22000.0
|
22000 MFI
Interval 12504.3 to 22000.0
|
22000 MFI
Interval 16110.6 to 22000.0
|
21400.2 MFI
Interval 14904.0 to 22000.0
|
20708.5 MFI
Interval 14630.8 to 22000.0
|
21808.2 MFI
Interval 19607.5 to 22000.0
|
22000 MFI
Interval 13638.5 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total
|
448 MFI
Interval 176.4 to 1371.9
|
307 MFI
Interval 99.8 to 3736.5
|
1524.2 MFI
Interval 258.9 to 3482.9
|
3972.8 MFI
Interval 1714.2 to 7157.5
|
3793.2 MFI
Interval 1557.4 to 11462.9
|
9353.9 MFI
Interval 4380.9 to 19869.0
|
2243.9 MFI
Interval 578.3 to 7630.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru
|
22000 MFI
Interval 13788.2 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
22000 MFI
Interval 18316.2 to 22000.0
|
22000 MFI
Interval 12123.0 to 22000.0
|
22000 MFI
Interval 19496.9 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
21939.4 MFI
Interval 17744.4 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 2-USA
|
345 MFI
Interval 102.0 to 1663.4
|
227 MFI
Interval 20.0 to 2668.0
|
2272.2 MFI
Interval 384.8 to 3335.0
|
3806.2 MFI
Interval 1321.6 to 7390.8
|
2130.5 MFI
Interval 282.0 to 6566.5
|
6990.8 MFI
Interval 2255.0 to 9507.0
|
686.5 MFI
Interval 262.8 to 2541.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Total
|
22000 MFI
Interval 12979.2 to 22000.0
|
22000 MFI
Interval 21736.1 to 22000.0
|
22000 MFI
Interval 17619.8 to 22000.0
|
22000 MFI
Interval 12700.5 to 22000.0
|
21747.2 MFI
Interval 14016.6 to 22000.0
|
22000 MFI
Interval 21492.6 to 22000.0
|
22000 MFI
Interval 15977.6 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-USA
|
22000 MFI
Interval 9940.5 to 22000.0
|
22000 MFI
Interval 21208.4 to 22000.0
|
22000 MFI
Interval 15400.6 to 22000.0
|
22000 MFI
Interval 13638.8 to 22000.0
|
14161.2 MFI
Interval 10428.8 to 22000.0
|
21857.8 MFI
Interval 16266.1 to 22000.0
|
22000 MFI
Interval 11849.1 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Peru
|
306.5 MFI
Interval 179.9 to 642.4
|
7358.9 MFI
Interval 4084.9 to 10632.8
|
457.8 MFI
Interval 114.6 to 1290.4
|
2838.8 MFI
Interval 515.0 to 5544.8
|
3457.9 MFI
Interval 771.6 to 5238.9
|
5575.5 MFI
Interval 3571.1 to 14695.4
|
2745.8 MFI
Interval 1451.2 to 7510.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 4-Peru
|
17605 MFI
Interval 12000.8 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
16831.6 MFI
Interval 13158.9 to 22000.0
|
22000 MFI
Interval 19771.0 to 22000.0
|
22000 MFI
Interval 19076.5 to 22000.0
|
22000 MFI
Interval 18506.9 to 22000.0
|
22000 MFI
Interval 16550.3 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 4-Total
|
18049.1 MFI
Interval 11269.3 to 22000.0
|
20167.9 MFI
Interval 10548.5 to 22000.0
|
16831.6 MFI
Interval 12711.1 to 22000.0
|
22000 MFI
Interval 17212.0 to 22000.0
|
22000 MFI
Interval 15154.6 to 22000.0
|
22000 MFI
Interval 17609.3 to 22000.0
|
22000 MFI
Interval 14835.4 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 4-USA
|
19733.5 MFI
Interval 7811.6 to 22000.0
|
13144.2 MFI
Interval 7889.9 to 19251.8
|
18198.8 MFI
Interval 12508.4 to 22000.0
|
18645.8 MFI
Interval 16707.2 to 22000.0
|
21096.9 MFI
Interval 12738.1 to 22000.0
|
22000 MFI
Interval 16967.2 to 22000.0
|
22000 MFI
Interval 14041.5 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 0-Peru
|
4680.8 MFI
Interval 3475.1 to 8266.1
|
5882.9 MFI
Interval 4273.1 to 8219.4
|
4182 MFI
Interval 3300.6 to 7167.7
|
6026.9 MFI
Interval 3761.6 to 8429.2
|
5722.8 MFI
Interval 4614.5 to 8720.2
|
6905.6 MFI
Interval 4252.9 to 11249.9
|
4614.2 MFI
Interval 2901.8 to 6242.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 0-Total
|
3685.9 MFI
Interval 2425.3 to 4976.2
|
2462.2 MFI
Interval 565.8 to 6050.5
|
4182 MFI
Interval 3004.1 to 6246.4
|
5345.4 MFI
Interval 2956.1 to 8354.8
|
5078.6 MFI
Interval 3295.9 to 7475.1
|
5831.5 MFI
Interval 3314.8 to 10451.2
|
4299 MFI
Interval 2765.1 to 5769.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 0-USA
|
2414.5 MFI
Interval 478.9 to 3875.4
|
967.2 MFI
Interval 153.1 to 4143.8
|
4038.2 MFI
Interval 2178.6 to 5600.7
|
3248.5 MFI
Interval 2614.1 to 5078.7
|
3224 MFI
Interval 1979.4 to 5239.5
|
3987.2 MFI
Interval 1161.2 to 6409.8
|
4159.8 MFI
Interval 2244.8 to 5272.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 2-Peru
|
4748.2 MFI
Interval 3258.1 to 5663.1
|
9305.6 MFI
Interval 7792.4 to 10818.8
|
4049.8 MFI
Interval 3332.4 to 5552.1
|
4465.2 MFI
Interval 1954.8 to 8036.0
|
5606.2 MFI
Interval 3029.4 to 6972.6
|
8100.4 MFI
Interval 6050.7 to 10273.3
|
4642.8 MFI
Interval 3140.2 to 5811.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 2-Total
|
4032 MFI
Interval 2750.6 to 5512.5
|
2888 MFI
Interval 850.9 to 4814.2
|
3940.1 MFI
Interval 2416.6 to 5373.0
|
4221.2 MFI
Interval 1945.1 to 5929.4
|
4755.5 MFI
Interval 2264.6 to 6572.6
|
5169 MFI
Interval 1606.1 to 8091.3
|
3674.4 MFI
Interval 1796.7 to 5306.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 2-USA
|
3937.5 MFI
Interval 782.2 to 5200.2
|
2740.8 MFI
Interval 803.0 to 3264.0
|
3319.1 MFI
Interval 1448.1 to 4993.1
|
2854.8 MFI
Interval 2050.1 to 4753.5
|
4335.5 MFI
Interval 1954.9 to 5833.6
|
1491 MFI
Interval 245.3 to 4634.9
|
3182 MFI
Interval 1526.2 to 4311.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 4-Peru
|
4390.2 MFI
Interval 2928.5 to 7017.4
|
13067 MFI
Interval 12782.0 to 13352.0
|
4000.2 MFI
Interval 2880.0 to 5417.9
|
5357.8 MFI
Interval 3623.2 to 10625.0
|
6637.8 MFI
Interval 5313.2 to 12187.3
|
8563.5 MFI
Interval 5879.8 to 9414.8
|
5364.6 MFI
Interval 3907.1 to 7440.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 4-Total
|
3976.5 MFI
Interval 2569.6 to 6837.5
|
6590.8 MFI
Interval 1939.2 to 11684.8
|
3957.6 MFI
Interval 2779.2 to 6059.6
|
5989.2 MFI
Interval 3841.5 to 10464.3
|
5765.2 MFI
Interval 4747.2 to 9501.9
|
6267 MFI
Interval 2413.2 to 8968.5
|
5670 MFI
Interval 3024.5 to 7187.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 4-USA
|
3915.6 MFI
Interval 1399.6 to 4973.2
|
2603.9 MFI
Interval 1152.1 to 5262.0
|
3812.2 MFI
Interval 601.2 to 7509.0
|
6620.8 MFI
Interval 4232.9 to 9818.0
|
5373 MFI
Interval 3729.4 to 6094.6
|
1736.2 MFI
Interval 1209.5 to 5977.9
|
5670 MFI
Interval 2819.4 to 6903.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 0-Peru
|
14484 MFI
Interval 10679.5 to 16088.0
|
13696.4 MFI
Interval 11150.8 to 15540.7
|
13275.8 MFI
Interval 10689.8 to 15579.8
|
10680.9 MFI
Interval 8479.9 to 17921.4
|
10645 MFI
Interval 8987.1 to 15443.4
|
11912.2 MFI
Interval 8342.7 to 15520.4
|
14069.2 MFI
Interval 10707.1 to 18166.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 0-Total
|
12764.2 MFI
Interval 10233.2 to 15747.9
|
9490.5 MFI
Interval 4515.8 to 15669.8
|
12702.1 MFI
Interval 10038.6 to 15158.8
|
11096.2 MFI
Interval 8436.5 to 16162.1
|
11885.5 MFI
Interval 8987.1 to 16305.9
|
11120.4 MFI
Interval 7035.6 to 14424.9
|
12568.1 MFI
Interval 8691.9 to 16769.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total
|
290.8 MFI
Interval 179.9 to 642.4
|
527.8 MFI
Interval 72.6 to 2350.4
|
475 MFI
Interval 129.8 to 1255.0
|
2359 MFI
Interval 740.4 to 5348.9
|
1877 MFI
Interval 376.6 to 4065.7
|
6120 MFI
Interval 2953.8 to 9433.5
|
1178 MFI
Interval 365.8 to 5440.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 0-USA
|
11552 MFI
Interval 9906.2 to 14993.9
|
9414.2 MFI
Interval 3832.9 to 14601.2
|
12460.1 MFI
Interval 9466.9 to 14499.1
|
14351.2 MFI
Interval 8396.5 to 15247.2
|
12491 MFI
Interval 9092.6 to 16777.2
|
8861.4 MFI
Interval 4558.1 to 10832.3
|
10617.9 MFI
Interval 7594.4 to 15042.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 4-USA
|
240.9 MFI
Interval 168.9 to 643.2
|
129.9 MFI
Interval 14.7 to 899.2
|
581.8 MFI
Interval 146.5 to 788.8
|
1288 MFI
Interval 911.2 to 4761.0
|
887.2 MFI
Interval 43.8 to 2504.4
|
6323.6 MFI
Interval 450.1 to 8479.2
|
468.8 MFI
Interval 165.2 to 1252.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 2-Peru
|
16886.5 MFI
Interval 14494.1 to 19482.5
|
19538.5 MFI
Interval 18307.8 to 20769.2
|
16900.9 MFI
Interval 14757.2 to 19905.1
|
13423.2 MFI
Interval 10413.0 to 16535.8
|
12332 MFI
Interval 9137.8 to 17829.5
|
14408.6 MFI
Interval 12356.5 to 18697.2
|
15272.5 MFI
Interval 10753.6 to 21236.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 2-Total
|
16187.4 MFI
Interval 13743.2 to 19997.6
|
15246.6 MFI
Interval 9385.9 to 18307.8
|
15328.8 MFI
Interval 11726.8 to 18709.9
|
12649.2 MFI
Interval 10162.9 to 16007.6
|
13769.6 MFI
Interval 9310.7 to 19473.3
|
11789.5 MFI
Interval 7024.7 to 14872.4
|
14403 MFI
Interval 9855.5 to 17739.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Peru
|
8176.2 MFI
Interval 4294.2 to 10606.5
|
5839.9 MFI
Interval 2648.2 to 11640.8
|
11742 MFI
Interval 6655.5 to 22000.0
|
22000 MFI
Interval 18757.0 to 22000.0
|
22000 MFI
Interval 20991.6 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
22000 MFI
Interval 13059.6 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 2-USA
|
15439 MFI
Interval 13683.2 to 20301.0
|
14859.6 MFI
Interval 6395.6 to 15680.6
|
11465.2 MFI
Interval 9249.9 to 17730.0
|
11990 MFI
Interval 9580.9 to 14540.6
|
14499.8 MFI
Interval 9550.0 to 20001.8
|
7331.5 MFI
Interval 4560.0 to 10097.0
|
13760 MFI
Interval 8139.9 to 16647.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 4-Peru
|
16414.2 MFI
Interval 14343.3 to 18427.4
|
21475.6 MFI
Interval 21213.4 to 21737.8
|
18752.8 MFI
Interval 14166.7 to 22000.0
|
17525 MFI
Interval 15082.4 to 19848.1
|
16948.2 MFI
Interval 13870.8 to 19255.8
|
15513.4 MFI
Interval 13387.0 to 18576.1
|
17003.2 MFI
Interval 15494.2 to 20300.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 4-Total
|
16414.2 MFI
Interval 14353.2 to 18465.1
|
16318 MFI
Interval 6564.5 to 21737.8
|
16138.9 MFI
Interval 13322.8 to 21966.8
|
16900.8 MFI
Interval 12282.1 to 19721.6
|
17029.5 MFI
Interval 13733.5 to 20776.2
|
14393.2 MFI
Interval 11098.4 to 17688.4
|
16313.8 MFI
Interval 12920.0 to 18796.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 4-USA
|
16102.8 MFI
Interval 15157.6 to 18760.1
|
8271.2 MFI
Interval 4730.7 to 14263.6
|
13724.9 MFI
Interval 9913.0 to 16349.1
|
13457.8 MFI
Interval 10843.2 to 18114.0
|
17576.5 MFI
Interval 12328.5 to 22000.0
|
12415 MFI
Interval 10593.8 to 16818.2
|
15684.8 MFI
Interval 11863.9 to 18141.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 0-Peru
|
2985.5 MFI
Interval 2566.6 to 4455.9
|
6679.5 MFI
Interval 5151.3 to 7903.9
|
3186.8 MFI
Interval 2262.6 to 6841.2
|
6486.6 MFI
Interval 4237.3 to 10093.1
|
6529.2 MFI
Interval 4211.5 to 9933.4
|
6453.1 MFI
Interval 3942.5 to 9665.8
|
4586.4 MFI
Interval 2770.2 to 6010.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 0-Total
|
2935.4 MFI
Interval 1285.6 to 4766.7
|
5071.2 MFI
Interval 2724.9 to 8088.6
|
3162 MFI
Interval 2009.2 to 5766.2
|
5100.2 MFI
Interval 3351.0 to 8183.0
|
4323.4 MFI
Interval 3443.5 to 8185.5
|
5370.1 MFI
Interval 2853.8 to 9246.1
|
4057.5 MFI
Interval 2167.2 to 5839.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 0-USA
|
1280 MFI
Interval 667.8 to 4596.9
|
4605.5 MFI
Interval 2724.9 to 7486.6
|
2889 MFI
Interval 1456.4 to 5263.1
|
3168.5 MFI
Interval 2747.2 to 3803.0
|
3926 MFI
Interval 1839.1 to 4282.2
|
3015.4 MFI
Interval 1672.7 to 8357.2
|
3453.2 MFI
Interval 1751.2 to 5351.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total
|
4511.2 MFI
Interval 217.2 to 9141.0
|
3607.8 MFI
Interval 74.1 to 9263.8
|
10723.5 MFI
Interval 6655.5 to 20231.5
|
18757 MFI
Interval 8573.1 to 22000.0
|
22000 MFI
Interval 13948.8 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
14302.8 MFI
Interval 4640.5 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-USA
|
716.8 MFI
Interval 89.8 to 6154.6
|
3377.6 MFI
Interval 50.3 to 9152.7
|
10606.9 MFI
Interval 6801.1 to 17332.1
|
9666.2 MFI
Interval 6437.3 to 20803.1
|
18665 MFI
Interval 5514.1 to 22000.0
|
22000 MFI
Interval 17777.8 to 22000.0
|
5977.8 MFI
Interval 2139.0 to 14994.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Peru
|
2497.5 MFI
Interval 1410.8 to 4421.1
|
13223.1 MFI
Interval 8834.7 to 17611.6
|
5731.5 MFI
Interval 1412.9 to 9827.2
|
12088.8 MFI
Interval 8519.5 to 21955.4
|
21598.4 MFI
Interval 7961.6 to 22000.0
|
22000 MFI
Interval 19496.1 to 22000.0
|
14899.1 MFI
Interval 8445.0 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 2-Peru
|
3673.2 MFI
Interval 2494.0 to 6038.0
|
8870.6 MFI
Interval 8101.7 to 9639.6
|
3561 MFI
Interval 1608.7 to 5501.9
|
6385 MFI
Interval 5289.5 to 10512.5
|
5122.2 MFI
Interval 3203.0 to 6494.8
|
7340 MFI
Interval 4637.5 to 12214.4
|
4977.5 MFI
Interval 3439.0 to 8033.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 2-Total
|
3474.9 MFI
Interval 2152.3 to 7595.8
|
7070.4 MFI
Interval 4944.4 to 10340.4
|
3520.8 MFI
Interval 1433.1 to 5827.1
|
5347.4 MFI
Interval 3705.7 to 8489.4
|
4034.8 MFI
Interval 3186.2 to 6998.0
|
5495.1 MFI
Interval 2247.9 to 10117.6
|
4046 MFI
Interval 2388.2 to 5986.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 2-USA
|
2449 MFI
Interval 867.5 to 8063.8
|
6665.1 MFI
Interval 4109.6 to 9791.8
|
3332 MFI
Interval 922.3 to 6568.1
|
3874.2 MFI
Interval 2698.1 to 6097.8
|
3852.1 MFI
Interval 1810.6 to 7122.4
|
2695.2 MFI
Interval 1087.6 to 5851.7
|
3108.5 MFI
Interval 1729.2 to 4968.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total
|
2468.5 MFI
Interval 1405.9 to 4912.9
|
2873.5 MFI
Interval 144.9 to 8252.7
|
6221.2 MFI
Interval 2360.1 to 11443.3
|
10721.8 MFI
Interval 5993.8 to 21405.5
|
15706.4 MFI
Interval 5884.6 to 22000.0
|
22000 MFI
Interval 11296.2 to 22000.0
|
7608.2 MFI
Interval 2573.4 to 16332.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 4-Peru
|
3639.8 MFI
Interval 2226.6 to 4428.2
|
12305.6 MFI
Interval 11062.2 to 13549.1
|
2662 MFI
Interval 1855.8 to 6446.2
|
7468 MFI
Interval 5363.2 to 11977.7
|
7015 MFI
Interval 4843.3 to 11032.9
|
8543.6 MFI
Interval 6634.9 to 11048.1
|
5337 MFI
Interval 4809.8 to 8129.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-USA
|
2439.5 MFI
Interval 328.2 to 5034.8
|
1141.6 MFI
Interval 89.8 to 7117.8
|
8299.5 MFI
Interval 2834.5 to 12296.0
|
8169.6 MFI
Interval 5845.6 to 17421.4
|
8241.1 MFI
Interval 532.2 to 16940.6
|
18872.8 MFI
Interval 6146.2 to 22000.0
|
3458 MFI
Interval 1286.9 to 7968.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Peru
|
1456.8 MFI
Interval 733.6 to 2466.3
|
11985.5 MFI
Interval 6978.2 to 16992.8
|
1741.6 MFI
Interval 759.3 to 5742.8
|
10768.9 MFI
Interval 1315.5 to 17353.1
|
11834.2 MFI
Interval 3807.0 to 14293.9
|
18837.4 MFI
Interval 11398.3 to 22000.0
|
9704 MFI
Interval 4758.2 to 15637.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 4-Total
|
3609.2 MFI
Interval 2161.1 to 4428.2
|
4994.5 MFI
Interval 3637.4 to 8680.9
|
2662 MFI
Interval 1454.8 to 5753.5
|
7003 MFI
Interval 4924.5 to 11003.5
|
6118 MFI
Interval 4052.6 to 9976.9
|
7069.8 MFI
Interval 4899.1 to 11790.6
|
5000.4 MFI
Interval 2824.2 to 7358.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total
|
1456.8 MFI
Interval 743.2 to 2466.3
|
1082.2 MFI
Interval 120.4 to 3005.2
|
1741.6 MFI
Interval 957.9 to 6495.4
|
7205 MFI
Interval 1833.8 to 17340.0
|
8435.5 MFI
Interval 3093.0 to 14028.0
|
15269 MFI
Interval 6482.0 to 20152.8
|
4275.5 MFI
Interval 1547.2 to 11311.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-USA
|
1367.2 MFI
Interval 794.6 to 2324.9
|
144.8 MFI
Interval 75.9 to 982.6
|
2163.5 MFI
Interval 1144.5 to 7376.4
|
2799.2 MFI
Interval 1952.0 to 16494.5
|
6531.5 MFI
Interval 446.8 to 8313.0
|
11779.2 MFI
Interval 1509.8 to 19080.0
|
2181.5 MFI
Interval 1027.4 to 4241.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Peru
|
876 MFI
Interval 555.5 to 3668.3
|
2067.1 MFI
Interval 1079.1 to 7522.2
|
5064.2 MFI
Interval 1398.3 to 10949.6
|
22000 MFI
Interval 4838.0 to 22000.0
|
22000 MFI
Interval 17183.5 to 22000.0
|
22000 MFI
Interval 17550.5 to 22000.0
|
17893.5 MFI
Interval 3567.6 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total
|
473.4 MFI
Interval 1.0 to 1547.2
|
140.8 MFI
Interval 2.0 to 914.5
|
2349 MFI
Interval 596.8 to 8934.9
|
11627.8 MFI
Interval 1568.9 to 22000.0
|
19478.5 MFI
Interval 6490.0 to 22000.0
|
20787.5 MFI
Interval 5290.9 to 22000.0
|
4985.5 MFI
Interval 1191.0 to 20774.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 4-USA
|
2245 MFI
Interval 2013.6 to 4268.0
|
3998.8 MFI
Interval 2895.9 to 4858.0
|
2509 MFI
Interval 1075.7 to 5299.2
|
6620 MFI
Interval 4530.0 to 7212.1
|
5568.2 MFI
Interval 2614.8 to 7064.0
|
6559.8 MFI
Interval 1678.5 to 12224.8
|
3969.9 MFI
Interval 2216.8 to 6878.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 0-Peru
|
2272.1 MFI
Interval 1064.8 to 5210.2
|
3001.1 MFI
Interval 242.5 to 8888.3
|
8110.5 MFI
Interval 1215.0 to 13445.2
|
12070.2 MFI
Interval 5880.1 to 21662.9
|
21820.8 MFI
Interval 13643.9 to 22000.0
|
22000 MFI
Interval 21660.5 to 22000.0
|
12744.2 MFI
Interval 4012.0 to 21697.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 0-Total
|
1172.4 MFI
Interval 92.1 to 3058.3
|
694.5 MFI
Interval 1.0 to 2723.8
|
4689.5 MFI
Interval 1215.0 to 10569.0
|
6640.5 MFI
Interval 2355.5 to 16510.0
|
13772.8 MFI
Interval 5428.8 to 22000.0
|
21909.8 MFI
Interval 10946.5 to 22000.0
|
4607.2 MFI
Interval 1268.8 to 14735.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 0-USA
|
162.8 MFI
Interval 1.0 to 1354.6
|
694.5 MFI
Interval 1.0 to 2000.9
|
3478.1 MFI
Interval 1517.6 to 6497.4
|
3557.4 MFI
Interval 1738.7 to 12147.0
|
7541.4 MFI
Interval 1296.2 to 13560.9
|
14427.5 MFI
Interval 4669.8 to 22000.0
|
1301.9 MFI
Interval 412.8 to 4977.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 2-Peru
|
705 MFI
Interval 467.2 to 1687.2
|
7273.9 MFI
Interval 4467.3 to 10080.4
|
1634.2 MFI
Interval 291.6 to 2563.8
|
5485.5 MFI
Interval 3341.5 to 9169.8
|
8686.4 MFI
Interval 1878.1 to 12229.2
|
14203.2 MFI
Interval 7380.3 to 22000.0
|
4075.5 MFI
Interval 2237.3 to 10192.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 2-Total
|
634.5 MFI
Interval 217.9 to 1528.3
|
676.6 MFI
Interval 69.6 to 1921.9
|
1088.8 MFI
Interval 373.8 to 2889.0
|
3341.5 MFI
Interval 1056.4 to 7316.1
|
4251.4 MFI
Interval 496.8 to 11344.0
|
6804.8 MFI
Interval 2819.2 to 15256.5
|
1694 MFI
Interval 553.7 to 4726.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 2-USA
|
292.5 MFI
Interval 112.0 to 1246.0
|
470.9 MFI
Interval 23.9 to 939.1
|
842.6 MFI
Interval 489.4 to 3606.4
|
1600.8 MFI
Interval 941.5 to 5260.6
|
1554.5 MFI
Interval 390.1 to 5356.8
|
3858.5 MFI
Interval 1356.9 to 7079.5
|
657.8 MFI
Interval 182.6 to 2197.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 4-Peru
|
401.9 MFI
Interval 291.2 to 694.9
|
4613.4 MFI
Interval 2861.3 to 6365.4
|
544.1 MFI
Interval 162.6 to 1050.5
|
3231 MFI
Interval 218.9 to 5238.8
|
3738.6 MFI
Interval 550.9 to 5867.6
|
5318.6 MFI
Interval 3252.5 to 11144.8
|
2636.5 MFI
Interval 1316.9 to 5056.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-USA
|
9.1 MFI
Interval 1.0 to 328.8
|
8.5 MFI
Interval 1.2 to 545.8
|
788 MFI
Interval 212.9 to 5181.0
|
3362.2 MFI
Interval 869.2 to 12886.8
|
8365.2 MFI
Interval 1114.6 to 17173.1
|
5221 MFI
Interval 3770.0 to 16935.6
|
1799.8 MFI
Interval 222.5 to 3423.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 4-Total
|
380 MFI
Interval 226.9 to 653.1
|
223.9 MFI
Interval 182.4 to 896.2
|
425.9 MFI
Interval 209.8 to 857.4
|
918.1 MFI
Interval 279.7 to 5238.5
|
2361.4 MFI
Interval 419.9 to 4192.9
|
4971.8 MFI
Interval 1490.8 to 7960.8
|
1322.5 MFI
Interval 444.0 to 3621.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 4-USA
|
236.1 MFI
Interval 154.6 to 386.2
|
185.1 MFI
Interval 135.1 to 207.2
|
415.8 MFI
Interval 322.5 to 597.0
|
764.8 MFI
Interval 280.8 to 4100.2
|
880.8 MFI
Interval 188.6 to 1731.3
|
1522.8 MFI
Interval 853.5 to 7447.2
|
536.9 MFI
Interval 201.3 to 1507.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Peru
|
102.2 MFI
Interval 56.6 to 429.0
|
7824.5 MFI
Interval 4566.2 to 11082.8
|
685.2 MFI
Interval 31.4 to 1508.8
|
3683 MFI
Interval 516.2 to 6296.1
|
6996.1 MFI
Interval 1120.9 to 15024.8
|
16491.5 MFI
Interval 11508.5 to 22000.0
|
3668.7 MFI
Interval 986.3 to 10759.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Peru
|
2329.5 MFI
Interval 1005.4 to 5028.4
|
1503.4 MFI
Interval 298.7 to 5402.8
|
8985.8 MFI
Interval 2113.8 to 21986.2
|
15238.5 MFI
Interval 6794.8 to 22000.0
|
22000 MFI
Interval 15314.7 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
8798.8 MFI
Interval 2016.5 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total
|
92.2 MFI
Interval 14.2 to 348.5
|
256.2 MFI
Interval 2.8 to 999.9
|
609.8 MFI
Interval 46.5 to 1413.8
|
1884.2 MFI
Interval 417.5 to 6870.8
|
2501.5 MFI
Interval 372.5 to 10071.8
|
7602.9 MFI
Interval 1896.7 to 16594.1
|
794.2 MFI
Interval 95.6 to 4681.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-USA
|
14.2 MFI
Interval 6.6 to 199.2
|
63.9 MFI
Interval 1.8 to 422.9
|
413.4 MFI
Interval 106.0 to 1092.7
|
1024.8 MFI
Interval 383.2 to 6003.1
|
740.5 MFI
Interval 8.2 to 2053.2
|
2081.8 MFI
Interval 564.8 to 5172.0
|
163.5 MFI
Interval 17.6 to 746.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total
|
1884 MFI
Interval 171.0 to 4922.2
|
455 MFI
Interval 37.4 to 3746.6
|
13842 MFI
Interval 2503.8 to 21986.2
|
18167.5 MFI
Interval 8253.2 to 22000.0
|
18282 MFI
Interval 9827.1 to 22000.0
|
22000 MFI
Interval 20043.4 to 22000.0
|
6321.5 MFI
Interval 1652.2 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Peru
|
44.7 MFI
Interval 20.8 to 130.9
|
2720.8 MFI
Interval 1644.2 to 3797.2
|
224.4 MFI
Interval 22.8 to 461.4
|
1209 MFI
Interval 53.9 to 2730.4
|
2275.2 MFI
Interval 183.4 to 3635.8
|
4180.9 MFI
Interval 2490.8 to 7229.2
|
1242 MFI
Interval 491.9 to 5010.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 0-USA
|
419 MFI
Interval 1.0 to 3479.5
|
454.6 MFI
Interval 4.4 to 3746.6
|
15998 MFI
Interval 3160.6 to 21518.5
|
18560 MFI
Interval 10265.1 to 22000.0
|
12634.5 MFI
Interval 2476.6 to 22000.0
|
22000 MFI
Interval 17478.2 to 22000.0
|
4664.8 MFI
Interval 768.9 to 20479.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total
|
44.4 MFI
Interval 20.0 to 129.5
|
162.6 MFI
Interval 1.1 to 506.8
|
183.2 MFI
Interval 17.6 to 380.3
|
458.8 MFI
Interval 69.8 to 2669.5
|
795.4 MFI
Interval 80.1 to 2955.9
|
2540.2 MFI
Interval 759.5 to 5222.0
|
371.5 MFI
Interval 46.0 to 1798.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-USA
|
34.9 MFI
Interval 14.1 to 93.1
|
1.1 MFI
Interval 1.0 to 81.9
|
101.9 MFI
Interval 14.2 to 191.7
|
245.2 MFI
Interval 94.0 to 2669.5
|
344.9 MFI
Interval 9.9 to 946.6
|
1035 MFI
Interval 99.5 to 2058.0
|
93.2 MFI
Interval 12.1 to 350.4
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarizedSARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and enrollment group among America Cohort
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Peru
|
22 Participants
|
3 Participants
|
22 Participants
|
21 Participants
|
23 Participants
|
25 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
37 Participants
|
13 Participants
|
50 Participants
|
46 Participants
|
44 Participants
|
47 Participants
|
93 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-USA
|
15 Participants
|
10 Participants
|
28 Participants
|
25 Participants
|
21 Participants
|
22 Participants
|
44 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
9 Participants
|
2 Participants
|
12 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
3 Participants
|
1 Participants
|
23 Participants
|
16 Participants
|
18 Participants
|
6 Participants
|
16 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-USA
|
3 Participants
|
1 Participants
|
14 Participants
|
14 Participants
|
6 Participants
|
4 Participants
|
15 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Peru
|
22 Participants
|
2 Participants
|
20 Participants
|
17 Participants
|
22 Participants
|
24 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
32 Participants
|
9 Participants
|
46 Participants
|
40 Participants
|
42 Participants
|
45 Participants
|
81 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-USA
|
10 Participants
|
7 Participants
|
26 Participants
|
23 Participants
|
20 Participants
|
21 Participants
|
34 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
8 Participants
|
1 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
2 Participants
|
0 Participants
|
12 Participants
|
8 Participants
|
13 Participants
|
2 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-USA
|
2 Participants
|
0 Participants
|
10 Participants
|
6 Participants
|
5 Participants
|
1 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru
|
23 Participants
|
3 Participants
|
23 Participants
|
20 Participants
|
22 Participants
|
25 Participants
|
50 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
41 Participants
|
13 Participants
|
51 Participants
|
44 Participants
|
43 Participants
|
47 Participants
|
96 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA
|
18 Participants
|
10 Participants
|
28 Participants
|
24 Participants
|
21 Participants
|
22 Participants
|
46 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
6 Participants
|
2 Participants
|
11 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
3 Participants
|
1 Participants
|
20 Participants
|
15 Participants
|
16 Participants
|
6 Participants
|
15 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA
|
3 Participants
|
1 Participants
|
14 Participants
|
13 Participants
|
5 Participants
|
4 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru
|
20 Participants
|
3 Participants
|
22 Participants
|
17 Participants
|
22 Participants
|
25 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
28 Participants
|
10 Participants
|
48 Participants
|
41 Participants
|
41 Participants
|
47 Participants
|
88 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA
|
8 Participants
|
7 Participants
|
26 Participants
|
24 Participants
|
19 Participants
|
22 Participants
|
39 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
10 Participants
|
1 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
3 Participants
|
0 Participants
|
14 Participants
|
11 Participants
|
15 Participants
|
5 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA
|
3 Participants
|
0 Participants
|
10 Participants
|
9 Participants
|
5 Participants
|
4 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Peru
|
22 Participants
|
3 Participants
|
19 Participants
|
19 Participants
|
22 Participants
|
25 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
33 Participants
|
11 Participants
|
46 Participants
|
42 Participants
|
42 Participants
|
47 Participants
|
86 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-USA
|
11 Participants
|
8 Participants
|
27 Participants
|
23 Participants
|
20 Participants
|
22 Participants
|
37 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
10 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
3 Participants
|
0 Participants
|
14 Participants
|
13 Participants
|
15 Participants
|
6 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-USA
|
3 Participants
|
0 Participants
|
10 Participants
|
11 Participants
|
5 Participants
|
4 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru
|
23 Participants
|
3 Participants
|
21 Participants
|
21 Participants
|
22 Participants
|
25 Participants
|
50 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
39 Participants
|
14 Participants
|
49 Participants
|
47 Participants
|
43 Participants
|
48 Participants
|
93 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA
|
16 Participants
|
11 Participants
|
28 Participants
|
26 Participants
|
21 Participants
|
23 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
10 Participants
|
2 Participants
|
14 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
3 Participants
|
1 Participants
|
26 Participants
|
16 Participants
|
19 Participants
|
6 Participants
|
18 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA
|
3 Participants
|
1 Participants
|
16 Participants
|
14 Participants
|
5 Participants
|
4 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru
|
22 Participants
|
3 Participants
|
23 Participants
|
21 Participants
|
23 Participants
|
25 Participants
|
50 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
36 Participants
|
13 Participants
|
51 Participants
|
46 Participants
|
44 Participants
|
47 Participants
|
94 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA
|
14 Participants
|
10 Participants
|
28 Participants
|
25 Participants
|
21 Participants
|
22 Participants
|
44 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
7 Participants
|
2 Participants
|
13 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
3 Participants
|
1 Participants
|
21 Participants
|
16 Participants
|
19 Participants
|
6 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA
|
3 Participants
|
1 Participants
|
14 Participants
|
14 Participants
|
6 Participants
|
4 Participants
|
13 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru
|
22 Participants
|
3 Participants
|
20 Participants
|
19 Participants
|
22 Participants
|
25 Participants
|
50 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
33 Participants
|
11 Participants
|
47 Participants
|
42 Participants
|
42 Participants
|
46 Participants
|
89 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA
|
11 Participants
|
8 Participants
|
27 Participants
|
23 Participants
|
20 Participants
|
21 Participants
|
39 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
8 Participants
|
2 Participants
|
12 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
3 Participants
|
1 Participants
|
21 Participants
|
15 Participants
|
18 Participants
|
6 Participants
|
12 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA
|
3 Participants
|
1 Participants
|
13 Participants
|
13 Participants
|
6 Participants
|
4 Participants
|
11 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarizedSARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and enrollment group among America Cohort
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 0-Peru
|
288.8 MFI
Interval 38.4 to 480.1
|
497.6 MFI
Interval 363.2 to 818.6
|
132.8 MFI
Interval 32.6 to 315.4
|
157.1 MFI
Interval 1.0 to 504.4
|
275.5 MFI
Interval 80.2 to 505.2
|
243.8 MFI
Interval 85.0 to 413.2
|
194.6 MFI
Interval 51.4 to 392.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Peru
|
4377 MFI
Interval 2471.8 to 8394.2
|
7774.2 MFI
Interval 5560.0 to 10312.6
|
6265.9 MFI
Interval 2470.4 to 10721.7
|
5985.4 MFI
Interval 2062.8 to 11245.5
|
9181.5 MFI
Interval 5618.2 to 12658.5
|
12261.8 MFI
Interval 8197.5 to 17973.0
|
6745.2 MFI
Interval 4181.8 to 15152.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
2775.6 MFI
Interval 406.1 to 6192.9
|
2438.5 MFI
Interval 8.6 to 7641.0
|
6082.5 MFI
Interval 3354.8 to 9443.8
|
6652.8 MFI
Interval 3177.3 to 12608.7
|
10695.2 MFI
Interval 5466.9 to 18239.3
|
11434 MFI
Interval 6861.5 to 16712.8
|
5657.4 MFI
Interval 3352.8 to 11538.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-USA
|
1045.5 MFI
Interval 207.8 to 2955.5
|
991.6 MFI
Interval 8.6 to 5058.5
|
6082.5 MFI
Interval 3561.6 to 8754.6
|
7411.9 MFI
Interval 4118.8 to 12608.7
|
14983.4 MFI
Interval 5466.9 to 21413.5
|
9738.9 MFI
Interval 6336.3 to 13702.1
|
5248 MFI
Interval 2353.5 to 8077.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Peru
|
—
|
—
|
622.8 MFI
Interval 377.8 to 1412.0
|
7904.8 MFI
Interval 3952.9 to 12097.2
|
2597 MFI
Interval 1484.2 to 3392.2
|
2632.5 MFI
Interval 2031.9 to 3233.1
|
4400.5 MFI
Interval 4400.5 to 4400.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
3472.5 MFI
Interval 2581.5 to 3573.2
|
11872.5 MFI
Interval 11872.5 to 11872.5
|
3146.2 MFI
Interval 595.0 to 4352.5
|
3713 MFI
Interval 1790.4 to 7475.8
|
2880 MFI
Interval 1484.2 to 4996.9
|
3717.9 MFI
Interval 3572.0 to 4421.4
|
1836.4 MFI
Interval 648.1 to 4331.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-USA
|
3472.5 MFI
Interval 2581.5 to 3573.2
|
11872.5 MFI
Interval 11872.5 to 11872.5
|
3563.6 MFI
Interval 2836.3 to 5393.4
|
3415 MFI
Interval 1913.2 to 5502.5
|
5908.8 MFI
Interval 2160.2 to 8574.5
|
4109.6 MFI
Interval 3592.0 to 5001.0
|
1737.2 MFI
Interval 581.1 to 4073.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 0-Peru
|
343 MFI
Interval 131.0 to 408.2
|
357.8 MFI
Interval 179.4 to 544.4
|
262.5 MFI
Interval 115.0 to 438.2
|
204.9 MFI
Interval 2.1 to 430.8
|
233.6 MFI
Interval 87.8 to 403.2
|
221 MFI
Interval 81.5 to 428.0
|
322.6 MFI
Interval 1.0 to 606.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 0-Total
|
207.5 MFI
Interval 12.6 to 384.5
|
49 MFI
Interval 1.0 to 451.1
|
262.5 MFI
Interval 84.8 to 456.2
|
224.2 MFI
Interval 65.5 to 558.0
|
256.8 MFI
Interval 50.9 to 628.9
|
245 MFI
Interval 44.4 to 524.8
|
273.5 MFI
Interval 40.2 to 586.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 0-USA
|
71.1 MFI
Interval 1.0 to 227.0
|
1 MFI
Interval 1.0 to 290.8
|
244.2 MFI
Interval 72.9 to 463.4
|
268.2 MFI
Interval 134.2 to 696.2
|
360.9 MFI
Interval 18.3 to 688.8
|
336.2 MFI
Interval 41.1 to 531.2
|
230.8 MFI
Interval 98.2 to 513.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 2-Peru
|
—
|
—
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 3.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
181 MFI
Interval 181.0 to 181.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 2-Total
|
16.8 MFI
Interval 8.9 to 31.9
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 61.8
|
1 MFI
Interval 1.0 to 6.0
|
1 MFI
Interval 1.0 to 10.4
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 34.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 2-USA
|
16.8 MFI
Interval 8.9 to 31.9
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 182.0
|
1 MFI
Interval 1.0 to 292.9
|
1 MFI
Interval 1.0 to 267.9
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 10.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Peru
|
21.2 MFI
Interval 1.0 to 61.8
|
335.9 MFI
Interval 215.7 to 425.6
|
41.8 MFI
Interval 13.8 to 116.8
|
1 MFI
Interval 1.0 to 12.9
|
21.1 MFI
Interval 1.0 to 58.8
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 120.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Total
|
28.2 MFI
Interval 1.0 to 74.5
|
61 MFI
Interval 1.0 to 330.2
|
47.5 MFI
Interval 1.0 to 148.0
|
1 MFI
Interval 1.0 to 66.7
|
22.8 MFI
Interval 1.0 to 64.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 98.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-USA
|
33.5 MFI
Interval 1.0 to 75.5
|
42 MFI
Interval 1.0 to 159.2
|
68.9 MFI
Interval 1.0 to 158.9
|
16.6 MFI
Interval 1.0 to 446.1
|
22.8 MFI
Interval 1.0 to 119.6
|
1 MFI
Interval 1.0 to 2.1
|
9 MFI
Interval 1.0 to 69.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Peru
|
—
|
—
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Total
|
147.2 MFI
Interval 74.1 to 388.8
|
4066.5 MFI
Interval 4066.5 to 4066.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 8.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-USA
|
147.2 MFI
Interval 74.1 to 388.8
|
4066.5 MFI
Interval 4066.5 to 4066.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 420.0
|
1 MFI
Interval 1.0 to 15.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru
|
202.8 MFI
Interval 102.2 to 358.8
|
742.8 MFI
Interval 371.9 to 2045.8
|
397.5 MFI
Interval 156.0 to 499.0
|
183 MFI
Interval 3.8 to 350.2
|
323.9 MFI
Interval 221.2 to 611.8
|
232 MFI
Interval 113.5 to 485.5
|
403.5 MFI
Interval 1.0 to 1390.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total
|
268.5 MFI
Interval 110.8 to 448.4
|
217 MFI
Interval 52.2 to 819.5
|
435.2 MFI
Interval 158.2 to 723.2
|
340.5 MFI
Interval 146.8 to 1542.7
|
594.5 MFI
Interval 274.6 to 1778.0
|
273 MFI
Interval 121.6 to 984.4
|
500.8 MFI
Interval 62.5 to 1538.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA
|
300.5 MFI
Interval 143.8 to 718.8
|
171.2 MFI
Interval 52.5 to 726.4
|
463.9 MFI
Interval 182.2 to 2537.8
|
918.6 MFI
Interval 244.7 to 3551.6
|
1468.8 MFI
Interval 602.1 to 2759.2
|
557.2 MFI
Interval 150.1 to 1658.5
|
546.5 MFI
Interval 147.2 to 1578.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru
|
—
|
—
|
160.2 MFI
Interval 29.0 to 306.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 105.1
|
612.5 MFI
Interval 377.4 to 847.6
|
562.2 MFI
Interval 562.2 to 562.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total
|
406.8 MFI
Interval 276.8 to 626.8
|
8733.2 MFI
Interval 8733.2 to 8733.2
|
273.5 MFI
Interval 29.0 to 652.8
|
18.4 MFI
Interval 1.0 to 242.8
|
100.5 MFI
Interval 1.0 to 738.2
|
102.6 MFI
Interval 16.5 to 163.2
|
453.1 MFI
Interval 127.1 to 1195.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA
|
406.8 MFI
Interval 276.8 to 626.8
|
8733.2 MFI
Interval 8733.2 to 8733.2
|
481.5 MFI
Interval 22.0 to 2138.9
|
73.8 MFI
Interval 1.0 to 755.2
|
1350.6 MFI
Interval 274.0 to 3450.6
|
32 MFI
Interval 1.0 to 89.8
|
403.5 MFI
Interval 104.1 to 1205.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru
|
4.5 MFI
Interval 1.0 to 38.0
|
73.6 MFI
Interval 1.0 to 447.8
|
21.2 MFI
Interval 1.0 to 41.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 33.4
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 59.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Total
|
5.8 MFI
Interval 1.0 to 42.9
|
19.9 MFI
Interval 1.0 to 54.1
|
21.2 MFI
Interval 1.0 to 74.5
|
1 MFI
Interval 1.0 to 48.3
|
1 MFI
Interval 1.0 to 98.2
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 50.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-USA
|
7.2 MFI
Interval 1.0 to 63.2
|
19.9 MFI
Interval 1.0 to 50.2
|
20.6 MFI
Interval 1.0 to 83.3
|
1.2 MFI
Interval 1.0 to 302.6
|
32 MFI
Interval 1.0 to 281.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 29.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru
|
—
|
—
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Total
|
1 MFI
Interval 1.0 to 15.4
|
3743.2 MFI
Interval 3743.2 to 3743.2
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-USA
|
1 MFI
Interval 1.0 to 15.4
|
3743.2 MFI
Interval 3743.2 to 3743.2
|
1 MFI
Interval 1.0 to 50.1
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 33.8
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru
|
331 MFI
Interval 185.8 to 821.8
|
519.8 MFI
Interval 260.4 to 3885.5
|
410.8 MFI
Interval 249.5 to 714.0
|
121.9 MFI
Interval 1.0 to 355.3
|
370.6 MFI
Interval 211.7 to 1060.1
|
113.2 MFI
Interval 1.0 to 653.0
|
364.5 MFI
Interval 1.0 to 1230.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Total
|
553.5 MFI
Interval 188.1 to 1425.4
|
921.5 MFI
Interval 93.0 to 2026.2
|
581 MFI
Interval 249.5 to 1802.2
|
259.8 MFI
Interval 72.1 to 2326.0
|
887 MFI
Interval 266.2 to 1540.6
|
359.9 MFI
Interval 98.2 to 1018.8
|
485.2 MFI
Interval 1.0 to 2040.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-USA
|
618.2 MFI
Interval 221.5 to 1736.8
|
932.8 MFI
Interval 96.0 to 1914.9
|
1089.2 MFI
Interval 266.4 to 3798.4
|
787 MFI
Interval 168.7 to 6205.8
|
1264.2 MFI
Interval 604.5 to 7354.4
|
616 MFI
Interval 225.0 to 4806.2
|
967 MFI
Interval 131.0 to 3628.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru
|
—
|
—
|
124.5 MFI
Interval 3.8 to 269.2
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
519.8 MFI
Interval 519.8 to 519.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Total
|
577.5 MFI
Interval 552.9 to 802.8
|
22000 MFI
Interval 22000.0 to 22000.0
|
124.5 MFI
Interval 1.0 to 423.8
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 255.2
|
1 MFI
Interval 1.0 to 1.0
|
534.5 MFI
Interval 7.9 to 1205.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-USA
|
577.5 MFI
Interval 552.9 to 802.8
|
22000 MFI
Interval 22000.0 to 22000.0
|
132.5 MFI
Interval 1.0 to 2458.5
|
1 MFI
Interval 1.0 to 41.2
|
272.5 MFI
Interval 251.4 to 5251.8
|
1 MFI
Interval 1.0 to 32.6
|
549.2 MFI
Interval 5.6 to 1431.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 0-Peru
|
214.2 MFI
Interval 75.0 to 390.2
|
312.8 MFI
Interval 156.9 to 366.8
|
212.8 MFI
Interval 131.9 to 247.9
|
93.4 MFI
Interval 10.6 to 280.9
|
180.8 MFI
Interval 104.3 to 372.0
|
177.8 MFI
Interval 1.0 to 311.5
|
278 MFI
Interval 1.0 to 553.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 0-Total
|
146 MFI
Interval 42.6 to 305.9
|
39 MFI
Interval 1.0 to 420.8
|
205 MFI
Interval 114.1 to 295.8
|
176.2 MFI
Interval 40.5 to 328.9
|
188.2 MFI
Interval 63.2 to 462.5
|
204 MFI
Interval 28.8 to 365.0
|
230.5 MFI
Interval 56.6 to 525.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 0-USA
|
121.8 MFI
Interval 30.0 to 267.2
|
20 MFI
Interval 1.0 to 458.2
|
156.6 MFI
Interval 99.9 to 420.0
|
188 MFI
Interval 153.7 to 420.4
|
203.8 MFI
Interval 33.2 to 513.8
|
255.2 MFI
Interval 41.9 to 387.1
|
207.4 MFI
Interval 112.9 to 315.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 2-Peru
|
—
|
—
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 49.6
|
1 MFI
Interval 1.0 to 1.0
|
103 MFI
Interval 103.0 to 103.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 2-Total
|
131.8 MFI
Interval 66.4 to 167.9
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 55.8
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 87.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 108.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 2-USA
|
131.8 MFI
Interval 66.4 to 167.9
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 106.9
|
1 MFI
Interval 1.0 to 283.0
|
8.1 MFI
Interval 1.0 to 385.4
|
1 MFI
Interval 1.0 to 48.8
|
1 MFI
Interval 1.0 to 62.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 0-Total
|
250.1 MFI
Interval 3.2 to 386.8
|
14.9 MFI
Interval 1.0 to 406.9
|
178.2 MFI
Interval 35.2 to 401.2
|
216.8 MFI
Interval 22.4 to 540.8
|
257 MFI
Interval 33.9 to 518.4
|
263 MFI
Interval 34.8 to 423.1
|
203.8 MFI
Interval 24.2 to 408.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 0-USA
|
154.2 MFI
Interval 1.0 to 377.5
|
1 MFI
Interval 1.0 to 188.0
|
313 MFI
Interval 119.4 to 538.0
|
279.1 MFI
Interval 144.7 to 583.3
|
179.8 MFI
Interval 1.0 to 590.0
|
304.9 MFI
Interval 13.5 to 522.8
|
246.5 MFI
Interval 21.8 to 497.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 2-Peru
|
—
|
—
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
81.8 MFI
Interval 81.8 to 81.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 2-Total
|
122.5 MFI
Interval 61.8 to 137.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 76.2
|
1 MFI
Interval 1.0 to 161.3
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 12.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 2-USA
|
122.5 MFI
Interval 61.8 to 137.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 111.1
|
1 MFI
Interval 1.0 to 269.1
|
1 MFI
Interval 1.0 to 125.0
|
1 MFI
Interval 1.0 to 207.1
|
1 MFI
Interval 1.0 to 6.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 0-Peru
|
167 MFI
Interval 27.5 to 359.5
|
240 MFI
Interval 120.5 to 281.8
|
181 MFI
Interval 32.0 to 302.0
|
132.1 MFI
Interval 34.6 to 226.4
|
190.4 MFI
Interval 10.8 to 299.6
|
159.8 MFI
Interval 60.3 to 437.9
|
156 MFI
Interval 1.0 to 461.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 0-Total
|
110.2 MFI
Interval 1.0 to 254.5
|
101.5 MFI
Interval 1.0 to 323.5
|
157 MFI
Interval 1.0 to 298.8
|
132.1 MFI
Interval 24.6 to 311.9
|
149.8 MFI
Interval 1.0 to 478.1
|
189 MFI
Interval 35.3 to 379.9
|
154.1 MFI
Interval 1.2 to 465.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 0-USA
|
81.4 MFI
Interval 1.0 to 212.6
|
100 MFI
Interval 6.2 to 573.8
|
75 MFI
Interval 1.0 to 234.9
|
136.2 MFI
Interval 19.9 to 457.1
|
103 MFI
Interval 1.0 to 568.8
|
223.2 MFI
Interval 9.4 to 348.5
|
147 MFI
Interval 8.6 to 467.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 2-Peru
|
—
|
—
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
64.5 MFI
Interval 64.5 to 64.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 2-Total
|
4.5 MFI
Interval 2.8 to 27.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 10.0
|
1 MFI
Interval 1.0 to 107.5
|
1 MFI
Interval 1.0 to 8.9
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 36.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 2-USA
|
4.5 MFI
Interval 2.8 to 27.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 20.8
|
1 MFI
Interval 1.0 to 162.1
|
1 MFI
Interval 1.0 to 67.0
|
1 MFI
Interval 1.0 to 12.9
|
1 MFI
Interval 1.0 to 23.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Peru
|
1247.8 MFI
Interval 659.8 to 2080.0
|
2987.2 MFI
Interval 1494.1 to 4597.2
|
1896.2 MFI
Interval 905.2 to 3023.5
|
2111.2 MFI
Interval 574.0 to 4108.2
|
3152.4 MFI
Interval 1396.4 to 4115.6
|
3438.8 MFI
Interval 1941.0 to 5054.5
|
2317.4 MFI
Interval 1096.1 to 4969.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
764.4 MFI
Interval 252.4 to 1785.1
|
108.2 MFI
Interval 1.0 to 1962.5
|
1896.2 MFI
Interval 912.2 to 3081.2
|
2111.2 MFI
Interval 865.8 to 3609.8
|
3284.6 MFI
Interval 1267.8 to 5261.2
|
3438.8 MFI
Interval 1941.0 to 5054.5
|
1580 MFI
Interval 624.9 to 4279.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-USA
|
290 MFI
Interval 58.2 to 869.0
|
96 MFI
Interval 1.0 to 1342.1
|
1883.4 MFI
Interval 1010.7 to 3113.5
|
1893.5 MFI
Interval 1162.8 to 2980.1
|
4810.2 MFI
Interval 1267.8 to 7371.3
|
3307 MFI
Interval 2054.8 to 4990.4
|
872.8 MFI
Interval 275.0 to 2740.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Peru
|
—
|
—
|
46.5 MFI
Interval 16.5 to 171.2
|
3266.5 MFI
Interval 1633.8 to 4457.9
|
494.2 MFI
Interval 10.2 to 1133.9
|
465.5 MFI
Interval 249.5 to 681.5
|
496.8 MFI
Interval 496.8 to 496.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
514.2 MFI
Interval 413.9 to 954.0
|
346.5 MFI
Interval 346.5 to 346.5
|
171.2 MFI
Interval 3.8 to 717.8
|
312.8 MFI
Interval 6.0 to 1494.4
|
645.2 MFI
Interval 10.2 to 1524.4
|
17.2 MFI
Interval 1.0 to 681.5
|
15.4 MFI
Interval 1.0 to 676.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-USA
|
514.2 MFI
Interval 413.9 to 954.0
|
346.5 MFI
Interval 346.5 to 346.5
|
697.2 MFI
Interval 3.1 to 1342.4
|
205.8 MFI
Interval 11.0 to 1201.1
|
1351 MFI
Interval 43.4 to 2304.1
|
1 MFI
Interval 1.0 to 341.3
|
9.2 MFI
Interval 1.0 to 696.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru
|
4540 MFI
Interval 1557.0 to 8570.2
|
8121.9 MFI
Interval 5061.2 to 9750.1
|
6731.5 MFI
Interval 1961.8 to 11736.8
|
5331.8 MFI
Interval 2050.6 to 6125.0
|
10606.9 MFI
Interval 6633.0 to 17674.9
|
12610.5 MFI
Interval 8540.8 to 20633.8
|
8297.1 MFI
Interval 3853.0 to 14525.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
3345.2 MFI
Interval 604.8 to 8570.2
|
3968.6 MFI
Interval 82.0 to 9199.1
|
7088.5 MFI
Interval 3108.5 to 12626.8
|
7420 MFI
Interval 5062.5 to 15174.8
|
12102.8 MFI
Interval 6388.2 to 22000.0
|
13097.5 MFI
Interval 7045.8 to 20633.8
|
6348.5 MFI
Interval 3134.8 to 11790.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA
|
1013.5 MFI
Interval 351.1 to 8565.4
|
2257.6 MFI
Interval 82.0 to 8092.4
|
7385.8 MFI
Interval 4077.6 to 14141.1
|
10450.8 MFI
Interval 8539.1 to 20967.1
|
13650.9 MFI
Interval 4723.1 to 22000.0
|
13518.8 MFI
Interval 5902.8 to 19489.2
|
4659 MFI
Interval 2641.2 to 9487.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru
|
—
|
—
|
288.5 MFI
Interval 207.2 to 1246.8
|
4660 MFI
Interval 2330.5 to 13330.0
|
1506 MFI
Interval 403.9 to 2825.5
|
757.8 MFI
Interval 742.1 to 773.4
|
2547.2 MFI
Interval 2547.2 to 2547.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
1482.5 MFI
Interval 1187.4 to 5246.1
|
7057.8 MFI
Interval 7057.8 to 7057.8
|
1269.5 MFI
Interval 274.8 to 3284.2
|
3317.9 MFI
Interval 1500.3 to 4612.6
|
1506 MFI
Interval 165.9 to 3244.4
|
2865.2 MFI
Interval 973.1 to 4958.6
|
1260.2 MFI
Interval 336.9 to 2759.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA
|
1482.5 MFI
Interval 1187.4 to 5246.1
|
7057.8 MFI
Interval 7057.8 to 7057.8
|
2885.2 MFI
Interval 1281.4 to 5245.7
|
3037.5 MFI
Interval 1596.1 to 4345.5
|
1932.1 MFI
Interval 1.0 to 3230.2
|
4707.4 MFI
Interval 3535.1 to 5445.4
|
1135 MFI
Interval 306.6 to 2956.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru
|
799.2 MFI
Interval 448.3 to 1883.4
|
2001.1 MFI
Interval 1428.2 to 3307.8
|
1523.2 MFI
Interval 579.2 to 2439.8
|
1568.4 MFI
Interval 269.6 to 5099.3
|
2848.6 MFI
Interval 1612.4 to 4861.2
|
4569 MFI
Interval 2166.5 to 6604.8
|
2606.2 MFI
Interval 982.4 to 5748.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
499.6 MFI
Interval 114.2 to 1122.8
|
76.5 MFI
Interval 4.2 to 1948.2
|
1421.2 MFI
Interval 712.0 to 2314.8
|
2088.5 MFI
Interval 579.0 to 4415.8
|
3197 MFI
Interval 1477.4 to 5996.5
|
4066.8 MFI
Interval 2331.8 to 6157.2
|
1472.2 MFI
Interval 555.9 to 4452.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA
|
128.6 MFI
Interval 88.1 to 804.4
|
58.5 MFI
Interval 4.2 to 1496.1
|
1406 MFI
Interval 720.2 to 1990.6
|
2262.2 MFI
Interval 880.2 to 3596.2
|
3871.9 MFI
Interval 1314.5 to 6343.0
|
3179.2 MFI
Interval 2387.8 to 5427.3
|
780.5 MFI
Interval 302.0 to 2039.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru
|
—
|
—
|
45.2 MFI
Interval 1.0 to 246.5
|
1562 MFI
Interval 781.5 to 2860.5
|
441.8 MFI
Interval 51.2 to 1069.8
|
672.8 MFI
Interval 432.6 to 912.9
|
1590 MFI
Interval 1590.0 to 1590.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
610.2 MFI
Interval 551.0 to 700.1
|
134 MFI
Interval 134.0 to 134.0
|
149 MFI
Interval 1.0 to 565.0
|
980.5 MFI
Interval 120.0 to 2519.4
|
441.8 MFI
Interval 1.0 to 1290.2
|
869 MFI
Interval 420.2 to 1019.3
|
173 MFI
Interval 1.0 to 989.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA
|
610.2 MFI
Interval 551.0 to 700.1
|
134 MFI
Interval 134.0 to 134.0
|
431.6 MFI
Interval 1.0 to 826.2
|
959 MFI
Interval 131.5 to 1959.9
|
822.4 MFI
Interval 1.0 to 2244.6
|
869 MFI
Interval 654.6 to 983.9
|
143.2 MFI
Interval 1.0 to 760.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Peru
|
1190.8 MFI
Interval 693.5 to 1905.8
|
2553.5 MFI
Interval 1776.8 to 4001.2
|
1480.2 MFI
Interval 578.0 to 3166.2
|
2077.6 MFI
Interval 327.2 to 5539.8
|
3030 MFI
Interval 1712.8 to 4956.4
|
4704.8 MFI
Interval 2374.2 to 7462.5
|
2987.1 MFI
Interval 1258.6 to 6831.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
644.6 MFI
Interval 170.6 to 1385.9
|
195.2 MFI
Interval 3.0 to 1890.2
|
1595.8 MFI
Interval 710.0 to 2696.0
|
1709.9 MFI
Interval 769.2 to 4666.6
|
3347.6 MFI
Interval 1284.1 to 6429.8
|
4140.5 MFI
Interval 2164.5 to 6077.8
|
1960.5 MFI
Interval 680.0 to 4877.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-USA
|
206.2 MFI
Interval 98.8 to 580.8
|
107.6 MFI
Interval 3.0 to 770.5
|
1621.8 MFI
Interval 754.8 to 2662.4
|
1439.8 MFI
Interval 867.5 to 3042.4
|
4387.2 MFI
Interval 1139.0 to 8450.7
|
3513.9 MFI
Interval 2124.4 to 5082.6
|
886 MFI
Interval 239.2 to 2624.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Peru
|
—
|
—
|
112.5 MFI
Interval 27.5 to 274.2
|
3691 MFI
Interval 1846.0 to 4663.1
|
781.2 MFI
Interval 14.5 to 1423.4
|
1147.1 MFI
Interval 780.7 to 1513.6
|
1553.8 MFI
Interval 1553.8 to 1553.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
489.8 MFI
Interval 421.1 to 984.6
|
28.8 MFI
Interval 28.8 to 28.8
|
205.2 MFI
Interval 56.0 to 957.0
|
825.1 MFI
Interval 136.5 to 1760.3
|
781.2 MFI
Interval 14.5 to 1783.6
|
936.4 MFI
Interval 669.9 to 1531.7
|
197.2 MFI
Interval 1.0 to 1189.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-USA
|
489.8 MFI
Interval 421.1 to 984.6
|
28.8 MFI
Interval 28.8 to 28.8
|
843.5 MFI
Interval 146.9 to 1256.4
|
616 MFI
Interval 166.8 to 1363.1
|
1355.4 MFI
Interval 58.8 to 3433.0
|
936.4 MFI
Interval 703.8 to 1278.6
|
177 MFI
Interval 1.0 to 1161.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru
|
6430.5 MFI
Interval 3013.2 to 11019.5
|
10084.8 MFI
Interval 4316.9 to 16310.5
|
5864 MFI
Interval 3558.8 to 12139.2
|
8299 MFI
Interval 3134.2 to 22000.0
|
9396.2 MFI
Interval 5386.7 to 17049.7
|
18159 MFI
Interval 11974.5 to 21673.8
|
10162.9 MFI
Interval 5466.2 to 21283.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
4036.2 MFI
Interval 1105.4 to 9311.7
|
6061.8 MFI
Interval 109.8 to 10656.9
|
6036.2 MFI
Interval 3810.0 to 10591.0
|
8299 MFI
Interval 3412.7 to 22000.0
|
14250.9 MFI
Interval 6001.6 to 22000.0
|
16390 MFI
Interval 7880.5 to 22000.0
|
8674.1 MFI
Interval 4608.1 to 19279.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA
|
1902.2 MFI
Interval 410.0 to 4706.2
|
4475.5 MFI
Interval 109.8 to 10595.1
|
6749.1 MFI
Interval 3941.9 to 10170.9
|
8291.6 MFI
Interval 4321.6 to 21521.4
|
20010.5 MFI
Interval 8572.8 to 22000.0
|
9598.5 MFI
Interval 6330.3 to 22000.0
|
7004.2 MFI
Interval 3149.2 to 15619.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru
|
—
|
—
|
2205 MFI
Interval 731.5 to 3424.2
|
5818.5 MFI
Interval 2909.8 to 12104.4
|
2566.2 MFI
Interval 1860.1 to 5217.4
|
6808.2 MFI
Interval 5886.2 to 7730.2
|
16761 MFI
Interval 16761.0 to 16761.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
2903.8 MFI
Interval 2420.8 to 6799.9
|
22000 MFI
Interval 22000.0 to 22000.0
|
4254.2 MFI
Interval 2074.0 to 8559.2
|
4811.6 MFI
Interval 2823.2 to 13714.5
|
4119.8 MFI
Interval 1673.6 to 8207.9
|
6705 MFI
Interval 4218.0 to 8600.6
|
3609.4 MFI
Interval 1900.9 to 12713.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA
|
2903.8 MFI
Interval 2420.8 to 6799.9
|
22000 MFI
Interval 22000.0 to 22000.0
|
7544.4 MFI
Interval 4787.2 to 9652.3
|
4610 MFI
Interval 2910.0 to 13500.2
|
9226 MFI
Interval 402.8 to 15873.3
|
6207.5 MFI
Interval 3321.6 to 8959.0
|
3503.5 MFI
Interval 1849.2 to 12111.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru
|
3074.5 MFI
Interval 1752.8 to 6132.0
|
5450.2 MFI
Interval 3614.9 to 7521.1
|
3757.2 MFI
Interval 1824.5 to 7062.0
|
4377.2 MFI
Interval 1549.8 to 7839.9
|
5785.1 MFI
Interval 3959.2 to 8580.8
|
8264.2 MFI
Interval 5681.2 to 10629.8
|
6218.5 MFI
Interval 3751.0 to 13401.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
2129 MFI
Interval 351.1 to 4434.1
|
2121.8 MFI
Interval 12.1 to 5765.6
|
3877.5 MFI
Interval 2449.8 to 6245.0
|
4657 MFI
Interval 2207.6 to 8233.1
|
7018.5 MFI
Interval 3255.6 to 11673.8
|
7882 MFI
Interval 4650.5 to 10555.5
|
4350 MFI
Interval 2516.2 to 10204.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA
|
741.8 MFI
Interval 310.8 to 2310.2
|
1220.1 MFI
Interval 12.1 to 4265.7
|
3970.1 MFI
Interval 2488.4 to 5625.9
|
4713.8 MFI
Interval 2569.2 to 8528.8
|
9034.8 MFI
Interval 3255.6 to 13397.9
|
6215.9 MFI
Interval 4113.8 to 9481.1
|
3454 MFI
Interval 1593.5 to 5449.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru
|
—
|
—
|
547.8 MFI
Interval 153.2 to 958.0
|
5159.2 MFI
Interval 2580.1 to 7608.6
|
1699.2 MFI
Interval 1082.0 to 2201.1
|
1634.8 MFI
Interval 1171.1 to 2098.4
|
3405.5 MFI
Interval 3405.5 to 3405.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
2345.2 MFI
Interval 1799.2 to 2365.4
|
4631.5 MFI
Interval 4631.5 to 4631.5
|
1728.5 MFI
Interval 345.2 to 2753.0
|
2320.2 MFI
Interval 946.4 to 4908.1
|
1891 MFI
Interval 1042.1 to 2935.9
|
2551.6 MFI
Interval 2437.0 to 3225.2
|
1573.1 MFI
Interval 283.2 to 2905.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA
|
2345.2 MFI
Interval 1799.2 to 2365.4
|
4631.5 MFI
Interval 4631.5 to 4631.5
|
2346.6 MFI
Interval 1622.2 to 3395.2
|
2211 MFI
Interval 946.8 to 4139.2
|
3902.8 MFI
Interval 1159.2 to 4859.9
|
2993.8 MFI
Interval 2506.5 to 3776.0
|
1415.2 MFI
Interval 189.4 to 2565.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru
|
1367.2 MFI
Interval 411.0 to 2780.2
|
4262.8 MFI
Interval 3097.8 to 7194.0
|
2059.8 MFI
Interval 310.0 to 6002.8
|
3125.8 MFI
Interval 806.8 to 9861.4
|
7868.5 MFI
Interval 3332.9 to 9858.1
|
9611.8 MFI
Interval 5616.5 to 12570.0
|
3746.2 MFI
Interval 1709.6 to 9411.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
488.8 MFI
Interval 9.2 to 2020.1
|
91.2 MFI
Interval 1.0 to 2734.8
|
2059.8 MFI
Interval 562.8 to 5227.5
|
3125.8 MFI
Interval 913.5 to 9593.2
|
7271.1 MFI
Interval 2195.8 to 11250.9
|
7521.5 MFI
Interval 3017.8 to 11929.5
|
2698.2 MFI
Interval 520.1 to 7149.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA
|
19.8 MFI
Interval 2.2 to 568.5
|
13.4 MFI
Interval 1.0 to 709.4
|
2001.6 MFI
Interval 997.4 to 4191.4
|
2984.2 MFI
Interval 1184.4 to 8780.8
|
6749.1 MFI
Interval 1390.9 to 14595.4
|
4729.4 MFI
Interval 2768.4 to 7843.6
|
630.5 MFI
Interval 137.8 to 4620.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru
|
—
|
—
|
175.2 MFI
Interval 1.0 to 422.8
|
5091.8 MFI
Interval 2548.1 to 6470.5
|
686.5 MFI
Interval 246.9 to 1175.1
|
1202.9 MFI
Interval 1052.9 to 1352.8
|
849.2 MFI
Interval 849.2 to 849.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
393 MFI
Interval 296.0 to 940.1
|
260.5 MFI
Interval 260.5 to 260.5
|
243 MFI
Interval 12.5 to 999.0
|
1788.8 MFI
Interval 408.7 to 3230.5
|
747.5 MFI
Interval 246.9 to 1774.1
|
1269.1 MFI
Interval 1029.6 to 1497.4
|
130.9 MFI
Interval 2.8 to 1055.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA
|
393 MFI
Interval 296.0 to 940.1
|
260.5 MFI
Interval 260.5 to 260.5
|
721.6 MFI
Interval 127.1 to 1071.1
|
1470.5 MFI
Interval 466.4 to 2808.1
|
1845.2 MFI
Interval 391.3 to 3901.2
|
1269.1 MFI
Interval 1047.7 to 1539.4
|
126.8 MFI
Interval 2.8 to 949.4
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and enrollment group among America Cohort
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Peru
|
23 Participants
|
3 Participants
|
22 Participants
|
22 Participants
|
22 Participants
|
25 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
36 Participants
|
13 Participants
|
48 Participants
|
46 Participants
|
42 Participants
|
47 Participants
|
90 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-USA
|
13 Participants
|
10 Participants
|
26 Participants
|
24 Participants
|
20 Participants
|
22 Participants
|
41 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
8 Participants
|
2 Participants
|
14 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
3 Participants
|
1 Participants
|
20 Participants
|
17 Participants
|
19 Participants
|
6 Participants
|
15 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Peru
|
22 Participants
|
3 Participants
|
23 Participants
|
23 Participants
|
22 Participants
|
25 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
38 Participants
|
13 Participants
|
49 Participants
|
48 Participants
|
42 Participants
|
47 Participants
|
92 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-USA
|
16 Participants
|
10 Participants
|
26 Participants
|
25 Participants
|
20 Participants
|
22 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
9 Participants
|
2 Participants
|
14 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
3 Participants
|
1 Participants
|
23 Participants
|
17 Participants
|
19 Participants
|
6 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-USA
|
3 Participants
|
1 Participants
|
14 Participants
|
15 Participants
|
5 Participants
|
4 Participants
|
16 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Peru
|
18 Participants
|
3 Participants
|
21 Participants
|
21 Participants
|
22 Participants
|
25 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
27 Participants
|
12 Participants
|
38 Participants
|
41 Participants
|
40 Participants
|
45 Participants
|
80 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-USA
|
9 Participants
|
9 Participants
|
17 Participants
|
20 Participants
|
18 Participants
|
20 Participants
|
33 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
6 Participants
|
2 Participants
|
12 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
2 Participants
|
1 Participants
|
15 Participants
|
14 Participants
|
17 Participants
|
5 Participants
|
11 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-USA
|
2 Participants
|
1 Participants
|
9 Participants
|
12 Participants
|
5 Participants
|
3 Participants
|
10 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru
|
23 Participants
|
3 Participants
|
23 Participants
|
23 Participants
|
24 Participants
|
25 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
39 Participants
|
15 Participants
|
47 Participants
|
47 Participants
|
45 Participants
|
47 Participants
|
82 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA
|
16 Participants
|
12 Participants
|
24 Participants
|
24 Participants
|
21 Participants
|
22 Participants
|
39 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
9 Participants
|
3 Participants
|
15 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
2 Participants
|
1 Participants
|
21 Participants
|
16 Participants
|
20 Participants
|
5 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA
|
2 Participants
|
1 Participants
|
12 Participants
|
13 Participants
|
5 Participants
|
3 Participants
|
13 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru
|
23 Participants
|
3 Participants
|
23 Participants
|
23 Participants
|
22 Participants
|
25 Participants
|
50 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
39 Participants
|
13 Participants
|
50 Participants
|
48 Participants
|
42 Participants
|
47 Participants
|
94 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA
|
16 Participants
|
10 Participants
|
27 Participants
|
25 Participants
|
20 Participants
|
22 Participants
|
44 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
11 Participants
|
2 Participants
|
14 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
3 Participants
|
1 Participants
|
26 Participants
|
17 Participants
|
19 Participants
|
6 Participants
|
16 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA
|
3 Participants
|
1 Participants
|
15 Participants
|
15 Participants
|
5 Participants
|
4 Participants
|
15 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-USA
|
3 Participants
|
1 Participants
|
12 Participants
|
15 Participants
|
5 Participants
|
4 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru
|
4 Participants
|
1 Participants
|
12 Participants
|
16 Participants
|
19 Participants
|
20 Participants
|
35 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
7 Participants
|
4 Participants
|
15 Participants
|
29 Participants
|
32 Participants
|
33 Participants
|
48 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA
|
3 Participants
|
3 Participants
|
3 Participants
|
13 Participants
|
13 Participants
|
13 Participants
|
13 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
5 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
0 Participants
|
1 Participants
|
4 Participants
|
9 Participants
|
9 Participants
|
2 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA
|
0 Participants
|
1 Participants
|
2 Participants
|
8 Participants
|
4 Participants
|
0 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru
|
22 Participants
|
3 Participants
|
21 Participants
|
22 Participants
|
22 Participants
|
25 Participants
|
48 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
36 Participants
|
13 Participants
|
44 Participants
|
45 Participants
|
41 Participants
|
47 Participants
|
89 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA
|
14 Participants
|
10 Participants
|
23 Participants
|
23 Participants
|
19 Participants
|
22 Participants
|
41 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
6 Participants
|
2 Participants
|
13 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
3 Participants
|
1 Participants
|
19 Participants
|
16 Participants
|
18 Participants
|
6 Participants
|
16 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA
|
3 Participants
|
1 Participants
|
13 Participants
|
14 Participants
|
5 Participants
|
4 Participants
|
15 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru
|
15 Participants
|
2 Participants
|
8 Participants
|
20 Participants
|
14 Participants
|
21 Participants
|
44 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
22 Participants
|
7 Participants
|
13 Participants
|
29 Participants
|
27 Participants
|
38 Participants
|
71 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA
|
7 Participants
|
5 Participants
|
5 Participants
|
9 Participants
|
13 Participants
|
17 Participants
|
27 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru
|
0 Participants
|
0 Participants
|
5 Participants
|
2 Participants
|
13 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
1 Participants
|
0 Participants
|
16 Participants
|
12 Participants
|
18 Participants
|
4 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA
|
1 Participants
|
0 Participants
|
11 Participants
|
10 Participants
|
5 Participants
|
2 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and enrollment group among America Cohort
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-USA
|
1962.8 MFI
Interval 184.0 to 3639.8
|
1705.6 MFI
Interval 139.2 to 7828.9
|
3735.2 MFI
Interval 2226.3 to 6124.2
|
6235.1 MFI
Interval 2679.1 to 11670.9
|
8299.6 MFI
Interval 3850.7 to 12724.4
|
7566.8 MFI
Interval 4263.2 to 8878.8
|
4570 MFI
Interval 1625.2 to 8088.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Peru
|
—
|
—
|
1324.5 MFI
Interval 449.5 to 2601.8
|
3951.5 MFI
Interval 2089.6 to 6816.8
|
6588 MFI
Interval 4829.2 to 8250.1
|
12474.9 MFI
Interval 12384.4 to 12565.3
|
19584.8 MFI
Interval 19584.8 to 19584.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
6468.8 MFI
Interval 4381.6 to 9069.8
|
11144 MFI
Interval 11144.0 to 11144.0
|
2494.2 MFI
Interval 1072.2 to 3137.0
|
6919.2 MFI
Interval 3324.1 to 9006.8
|
6300 MFI
Interval 1769.1 to 7385.5
|
5126.8 MFI
Interval 3915.5 to 10686.9
|
2111.5 MFI
Interval 1495.4 to 4591.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-USA
|
6468.8 MFI
Interval 4381.6 to 9069.8
|
11144 MFI
Interval 11144.0 to 11144.0
|
2749.2 MFI
Interval 2013.0 to 3516.9
|
6952.2 MFI
Interval 3493.5 to 8426.4
|
4303.1 MFI
Interval 217.0 to 7231.9
|
4073 MFI
Interval 3688.0 to 4757.4
|
2093.5 MFI
Interval 1463.5 to 3573.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-250 at Month 0-Peru
|
125.2 MFI
Interval 89.8 to 244.2
|
450 MFI
Interval 251.6 to 697.9
|
119.2 MFI
Interval 75.8 to 178.0
|
194.5 MFI
Interval 83.8 to 320.0
|
161.5 MFI
Interval 109.3 to 220.4
|
308.8 MFI
Interval 209.5 to 491.0
|
175.6 MFI
Interval 99.2 to 277.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-250 at Month 0-Total
|
94.9 MFI
Interval 72.6 to 158.2
|
145 MFI
Interval 83.2 to 276.5
|
94.5 MFI
Interval 43.8 to 169.0
|
177 MFI
Interval 89.2 to 337.2
|
152.4 MFI
Interval 99.8 to 235.9
|
236.2 MFI
Interval 112.7 to 451.1
|
132.5 MFI
Interval 67.5 to 252.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-250 at Month 0-USA
|
82.2 MFI
Interval 55.2 to 121.5
|
134.8 MFI
Interval 79.1 to 184.4
|
76 MFI
Interval 33.1 to 124.6
|
159.6 MFI
Interval 104.0 to 353.1
|
139 MFI
Interval 96.4 to 235.9
|
119.8 MFI
Interval 76.2 to 247.5
|
103.2 MFI
Interval 60.8 to 242.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-250 at Month 2-Peru
|
—
|
—
|
68.8 MFI
Interval 25.8 to 97.0
|
179 MFI
Interval 117.8 to 197.1
|
75.5 MFI
Interval 52.9 to 91.2
|
346.2 MFI
Interval 278.0 to 414.5
|
113.2 MFI
Interval 113.2 to 113.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-250 at Month 2-Total
|
83 MFI
Interval 62.9 to 84.2
|
105 MFI
Interval 105.0 to 105.0
|
66.2 MFI
Interval 28.0 to 97.0
|
143.2 MFI
Interval 108.1 to 234.2
|
90.8 MFI
Interval 68.9 to 177.5
|
258.1 MFI
Interval 154.8 to 328.8
|
99.8 MFI
Interval 57.7 to 179.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-250 at Month 2-USA
|
83 MFI
Interval 62.9 to 84.2
|
105 MFI
Interval 105.0 to 105.0
|
66.1 MFI
Interval 41.9 to 117.0
|
135 MFI
Interval 109.1 to 264.8
|
177.5 MFI
Interval 136.3 to 669.8
|
221.5 MFI
Interval 115.1 to 313.9
|
99.5 MFI
Interval 56.9 to 186.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 0-Peru
|
481.5 MFI
Interval 359.0 to 974.8
|
2143 MFI
Interval 971.4 to 3283.1
|
487 MFI
Interval 344.0 to 785.0
|
772.2 MFI
Interval 347.2 to 983.0
|
599.9 MFI
Interval 407.9 to 840.6
|
1119.2 MFI
Interval 796.8 to 1808.8
|
654.9 MFI
Interval 380.0 to 1075.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 0-Total
|
414.6 MFI
Interval 267.4 to 620.8
|
595.2 MFI
Interval 356.2 to 1040.5
|
417 MFI
Interval 205.5 to 644.8
|
678.8 MFI
Interval 352.1 to 1130.4
|
598 MFI
Interval 376.7 to 822.5
|
831.2 MFI
Interval 461.3 to 1628.0
|
504 MFI
Interval 279.2 to 1013.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 0-USA
|
340.5 MFI
Interval 240.8 to 520.5
|
495.1 MFI
Interval 333.2 to 869.4
|
297.5 MFI
Interval 154.6 to 516.0
|
643.5 MFI
Interval 367.3 to 1172.5
|
464.9 MFI
Interval 336.6 to 799.4
|
476 MFI
Interval 288.8 to 925.0
|
409.5 MFI
Interval 225.8 to 984.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 2-Peru
|
—
|
—
|
321 MFI
Interval 124.8 to 388.8
|
700 MFI
Interval 425.9 to 756.0
|
295.8 MFI
Interval 204.8 to 323.1
|
1148.2 MFI
Interval 891.9 to 1404.6
|
268.2 MFI
Interval 268.2 to 268.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 2-Total
|
299.2 MFI
Interval 224.5 to 332.9
|
382.2 MFI
Interval 382.2 to 382.2
|
282.8 MFI
Interval 124.8 to 388.8
|
527.9 MFI
Interval 365.5 to 885.3
|
332.5 MFI
Interval 234.8 to 699.9
|
786.8 MFI
Interval 540.4 to 1137.9
|
362.6 MFI
Interval 205.9 to 662.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
229E-RBD-50 at Month 2-USA
|
299.2 MFI
Interval 224.5 to 332.9
|
382.2 MFI
Interval 382.2 to 382.2
|
260.4 MFI
Interval 135.6 to 430.4
|
518.8 MFI
Interval 371.2 to 972.2
|
699.9 MFI
Interval 447.5 to 1730.8
|
723.4 MFI
Interval 434.7 to 1004.6
|
445 MFI
Interval 202.5 to 687.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-250 at Month 0-Peru
|
130 MFI
Interval 101.2 to 370.5
|
328.1 MFI
Interval 160.4 to 552.9
|
157.2 MFI
Interval 83.5 to 221.5
|
147 MFI
Interval 74.0 to 290.0
|
104.6 MFI
Interval 52.1 to 253.6
|
157.5 MFI
Interval 83.5 to 258.8
|
129.1 MFI
Interval 66.1 to 264.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-250 at Month 0-Total
|
115.1 MFI
Interval 69.8 to 251.8
|
121.1 MFI
Interval 80.6 to 219.2
|
86.8 MFI
Interval 30.0 to 191.0
|
128.5 MFI
Interval 62.9 to 285.8
|
105.9 MFI
Interval 58.8 to 222.3
|
126.5 MFI
Interval 66.9 to 236.0
|
106.8 MFI
Interval 47.0 to 236.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-250 at Month 0-USA
|
109.2 MFI
Interval 34.5 to 194.0
|
103.5 MFI
Interval 78.9 to 204.6
|
43.8 MFI
Interval 18.3 to 109.8
|
104.8 MFI
Interval 49.8 to 229.1
|
105.9 MFI
Interval 66.8 to 205.4
|
116.8 MFI
Interval 41.0 to 227.0
|
83.8 MFI
Interval 30.8 to 208.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-250 at Month 2-Peru
|
—
|
—
|
194.5 MFI
Interval 102.8 to 252.5
|
238.2 MFI
Interval 172.5 to 343.5
|
128 MFI
Interval 66.9 to 170.1
|
379.5 MFI
Interval 268.1 to 490.9
|
17 MFI
Interval 17.0 to 17.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-250 at Month 2-Total
|
65.2 MFI
Interval 46.4 to 141.9
|
126.2 MFI
Interval 126.2 to 126.2
|
109 MFI
Interval 43.0 to 224.0
|
163.8 MFI
Interval 85.5 to 315.5
|
166.5 MFI
Interval 70.4 to 359.5
|
135.9 MFI
Interval 93.6 to 271.3
|
99.1 MFI
Interval 40.7 to 314.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-250 at Month 2-USA
|
65.2 MFI
Interval 46.4 to 141.9
|
126.2 MFI
Interval 126.2 to 126.2
|
71.9 MFI
Interval 39.5 to 155.0
|
137 MFI
Interval 75.6 to 284.9
|
359.5 MFI
Interval 253.1 to 460.4
|
100.8 MFI
Interval 70.7 to 163.6
|
111.8 MFI
Interval 44.2 to 333.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Peru
|
579.2 MFI
Interval 346.5 to 1431.8
|
1333 MFI
Interval 715.9 to 2160.4
|
593.5 MFI
Interval 315.5 to 954.5
|
656.2 MFI
Interval 299.5 to 1341.5
|
440.1 MFI
Interval 217.8 to 1022.3
|
659.2 MFI
Interval 384.0 to 1027.5
|
480.1 MFI
Interval 238.1 to 1053.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Total
|
487.2 MFI
Interval 276.8 to 998.8
|
548.1 MFI
Interval 334.9 to 975.6
|
329 MFI
Interval 123.2 to 743.5
|
552.8 MFI
Interval 290.1 to 1066.2
|
424.2 MFI
Interval 243.6 to 912.2
|
542.1 MFI
Interval 241.3 to 1008.4
|
420 MFI
Interval 183.8 to 1053.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-250 at Month 0-USA
|
518.8 MFI
Interval 37.0 to 1083.8
|
361.2 MFI
Interval 33.6 to 2436.8
|
999.9 MFI
Interval 600.4 to 1651.0
|
1868.4 MFI
Interval 850.3 to 5626.9
|
2831.6 MFI
Interval 890.1 to 4766.2
|
2407.5 MFI
Interval 1336.8 to 3196.2
|
1292.8 MFI
Interval 390.8 to 2564.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-250 at Month 2-Peru
|
—
|
—
|
457.2 MFI
Interval 117.2 to 646.8
|
1272.2 MFI
Interval 663.4 to 2134.2
|
2037.5 MFI
Interval 1378.2 to 3073.2
|
4681.6 MFI
Interval 4323.3 to 5039.9
|
8920.8 MFI
Interval 8920.8 to 8920.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-250 at Month 2-Total
|
1902.2 MFI
Interval 1230.0 to 3130.4
|
4086.5 MFI
Interval 4086.5 to 4086.5
|
642.8 MFI
Interval 277.2 to 875.5
|
2688.1 MFI
Interval 831.2 to 3771.1
|
1765 MFI
Interval 397.8 to 2616.5
|
1630.2 MFI
Interval 1159.2 to 3438.9
|
465 MFI
Interval 361.5 to 1775.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-250 at Month 2-USA
|
1902.2 MFI
Interval 1230.0 to 3130.4
|
4086.5 MFI
Interval 4086.5 to 4086.5
|
712 MFI
Interval 519.7 to 916.8
|
2761.2 MFI
Interval 917.0 to 4261.1
|
1148.9 MFI
Interval 78.1 to 2202.4
|
1239.4 MFI
Interval 1014.1 to 1515.0
|
460.8 MFI
Interval 360.8 to 1166.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Peru
|
4666 MFI
Interval 2600.2 to 10206.8
|
6144.8 MFI
Interval 4454.9 to 10284.4
|
8446.2 MFI
Interval 4770.0 to 16894.5
|
9177.5 MFI
Interval 5253.2 to 18415.2
|
17476.5 MFI
Interval 11429.7 to 22000.0
|
22000 MFI
Interval 14734.0 to 22000.0
|
11884.5 MFI
Interval 6291.9 to 16184.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-250 at Month 0-Peru
|
1386.2 MFI
Interval 588.0 to 3401.8
|
1661.2 MFI
Interval 1043.5 to 3932.1
|
2782.8 MFI
Interval 1240.0 to 6458.0
|
3824.5 MFI
Interval 2088.0 to 7100.5
|
8149.6 MFI
Interval 3577.0 to 11434.5
|
9913.8 MFI
Interval 5485.0 to 16653.5
|
3818.9 MFI
Interval 2128.9 to 7245.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-250 at Month 0-Total
|
732 MFI
Interval 214.1 to 1944.8
|
517.5 MFI
Interval 33.6 to 2436.8
|
1493 MFI
Interval 701.8 to 3198.0
|
2831 MFI
Interval 1075.0 to 6386.8
|
3937.5 MFI
Interval 2108.6 to 8818.0
|
3256.9 MFI
Interval 2269.5 to 9825.4
|
2177.2 MFI
Interval 703.6 to 5355.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
3158.5 MFI
Interval 853.7 to 7593.0
|
2428 MFI
Interval 139.2 to 7828.9
|
5461.2 MFI
Interval 2735.8 to 10318.2
|
8326.5 MFI
Interval 3622.2 to 15899.6
|
11991.2 MFI
Interval 5031.8 to 18433.8
|
9468.2 MFI
Interval 6621.1 to 22000.0
|
7086 MFI
Interval 2970.6 to 13692.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-USA
|
465.5 MFI
Interval 135.2 to 849.0
|
493 MFI
Interval 302.9 to 901.8
|
178.4 MFI
Interval 94.3 to 459.4
|
445.6 MFI
Interval 234.7 to 822.0
|
421.5 MFI
Interval 282.6 to 878.1
|
466.8 MFI
Interval 162.5 to 931.5
|
364.8 MFI
Interval 119.8 to 906.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Peru
|
—
|
—
|
698 MFI
Interval 374.8 to 1095.0
|
843.5 MFI
Interval 562.9 to 1271.6
|
387 MFI
Interval 212.5 to 699.5
|
1399.4 MFI
Interval 941.2 to 1857.6
|
82.8 MFI
Interval 82.8 to 82.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Total
|
278.2 MFI
Interval 177.8 to 619.0
|
448.8 MFI
Interval 448.8 to 448.8
|
447 MFI
Interval 160.2 to 918.5
|
642.4 MFI
Interval 285.2 to 1201.1
|
685.8 MFI
Interval 239.0 to 1155.0
|
418.1 MFI
Interval 314.8 to 1002.4
|
405.2 MFI
Interval 153.7 to 976.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-USA
|
278.2 MFI
Interval 177.8 to 619.0
|
448.8 MFI
Interval 448.8 to 448.8
|
273.5 MFI
Interval 135.5 to 654.8
|
614.2 MFI
Interval 276.8 to 1026.4
|
1155 MFI
Interval 885.2 to 1664.0
|
327.6 MFI
Interval 248.9 to 558.8
|
482.8 MFI
Interval 162.5 to 1067.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Peru
|
149 MFI
Interval 114.0 to 192.0
|
124.8 MFI
Interval 98.9 to 899.9
|
200.8 MFI
Interval 81.8 to 380.8
|
598 MFI
Interval 253.0 to 897.0
|
357.8 MFI
Interval 217.4 to 988.1
|
599.2 MFI
Interval 329.5 to 1111.2
|
289.4 MFI
Interval 180.2 to 945.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total
|
153.9 MFI
Interval 111.4 to 312.6
|
328.8 MFI
Interval 142.2 to 1374.1
|
200.8 MFI
Interval 82.5 to 380.8
|
680.8 MFI
Interval 268.0 to 1413.8
|
483.6 MFI
Interval 241.3 to 1503.0
|
634.6 MFI
Interval 339.8 to 1276.1
|
304.8 MFI
Interval 139.0 to 777.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-USA
|
194.5 MFI
Interval 109.8 to 354.5
|
448.6 MFI
Interval 208.6 to 1374.1
|
186.9 MFI
Interval 106.4 to 379.6
|
744.2 MFI
Interval 316.0 to 2270.9
|
650.2 MFI
Interval 271.0 to 2067.2
|
875.8 MFI
Interval 370.8 to 1435.0
|
319.2 MFI
Interval 115.0 to 686.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Peru
|
—
|
—
|
142 MFI
Interval 88.0 to 309.5
|
135.5 MFI
Interval 98.6 to 351.4
|
342.8 MFI
Interval 162.6 to 872.5
|
540.2 MFI
Interval 485.0 to 595.5
|
2519 MFI
Interval 2519.0 to 2519.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total
|
663 MFI
Interval 484.9 to 983.2
|
242.8 MFI
Interval 242.8 to 242.8
|
210.2 MFI
Interval 134.2 to 484.5
|
749 MFI
Interval 375.6 to 1974.3
|
379.8 MFI
Interval 162.6 to 897.4
|
400.6 MFI
Interval 302.1 to 595.5
|
269.1 MFI
Interval 120.4 to 1054.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-USA
|
663 MFI
Interval 484.9 to 983.2
|
242.8 MFI
Interval 242.8 to 242.8
|
240.2 MFI
Interval 176.5 to 539.6
|
1333.8 MFI
Interval 392.6 to 2461.4
|
530.9 MFI
Interval 207.3 to 1055.9
|
325.2 MFI
Interval 272.9 to 850.1
|
254 MFI
Interval 116.2 to 878.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru
|
620.8 MFI
Interval 490.2 to 765.2
|
583.6 MFI
Interval 488.8 to 2825.3
|
802.5 MFI
Interval 335.8 to 1463.0
|
2467 MFI
Interval 1054.8 to 3207.8
|
1471.4 MFI
Interval 969.4 to 4263.3
|
2385.5 MFI
Interval 1418.5 to 4160.8
|
1273.9 MFI
Interval 704.9 to 2929.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total
|
656.5 MFI
Interval 500.4 to 1360.0
|
1423.4 MFI
Interval 644.2 to 4740.1
|
802.5 MFI
Interval 389.8 to 1556.8
|
2643.2 MFI
Interval 1129.2 to 4805.4
|
1848.1 MFI
Interval 1018.6 to 5324.2
|
2405.5 MFI
Interval 1392.2 to 4271.4
|
1280.8 MFI
Interval 568.0 to 2663.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA
|
809.2 MFI
Interval 530.0 to 1496.5
|
1936.9 MFI
Interval 865.7 to 4740.1
|
882.1 MFI
Interval 467.4 to 1597.8
|
2800.2 MFI
Interval 1232.7 to 6306.3
|
2481.6 MFI
Interval 1100.4 to 6433.5
|
3168.5 MFI
Interval 1383.5 to 4673.8
|
1310 MFI
Interval 467.8 to 2440.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru
|
—
|
—
|
649.5 MFI
Interval 280.0 to 1220.5
|
405 MFI
Interval 345.4 to 1146.6
|
1766.2 MFI
Interval 530.0 to 3200.4
|
1904.2 MFI
Interval 1518.1 to 2290.4
|
6969 MFI
Interval 6969.0 to 6969.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total
|
2649.2 MFI
Interval 1952.2 to 3733.0
|
947 MFI
Interval 947.0 to 947.0
|
844.8 MFI
Interval 459.5 to 1714.2
|
2519.5 MFI
Interval 1349.1 to 5729.1
|
1766.2 MFI
Interval 602.4 to 3365.8
|
1364.4 MFI
Interval 1165.6 to 2372.9
|
1057.4 MFI
Interval 513.4 to 3326.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA
|
2649.2 MFI
Interval 1952.2 to 3733.0
|
947 MFI
Interval 947.0 to 947.0
|
933.6 MFI
Interval 647.6 to 1851.3
|
4018.8 MFI
Interval 1544.8 to 7106.6
|
1723.5 MFI
Interval 842.8 to 3663.9
|
1364.4 MFI
Interval 1161.8 to 2458.0
|
888.2 MFI
Interval 493.6 to 2804.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-250 at Month 0-Peru
|
16 MFI
Interval 10.5 to 36.8
|
15.8 MFI
Interval 8.9 to 22.6
|
19 MFI
Interval 9.5 to 30.5
|
21.2 MFI
Interval 7.2 to 37.2
|
24.5 MFI
Interval 7.8 to 38.6
|
15.5 MFI
Interval 1.0 to 38.2
|
19.6 MFI
Interval 8.4 to 45.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-250 at Month 0-Total
|
16.1 MFI
Interval 10.1 to 42.0
|
25.9 MFI
Interval 12.7 to 58.6
|
12.5 MFI
Interval 6.0 to 26.8
|
18 MFI
Interval 7.4 to 43.8
|
31.6 MFI
Interval 15.3 to 59.9
|
29.1 MFI
Interval 5.4 to 55.1
|
19.8 MFI
Interval 8.9 to 38.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-250 at Month 0-USA
|
24.5 MFI
Interval 9.5 to 49.5
|
32.9 MFI
Interval 16.7 to 66.6
|
9.2 MFI
Interval 3.7 to 20.1
|
16.4 MFI
Interval 7.7 to 44.6
|
51.6 MFI
Interval 23.4 to 67.3
|
39.5 MFI
Interval 24.2 to 79.0
|
19.8 MFI
Interval 9.5 to 37.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-250 at Month 2-Peru
|
—
|
—
|
15.5 MFI
Interval 10.0 to 50.5
|
18.5 MFI
Interval 11.8 to 23.8
|
16 MFI
Interval 8.6 to 20.5
|
98 MFI
Interval 62.5 to 133.5
|
1 MFI
Interval 1.0 to 1.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-250 at Month 2-Total
|
26.2 MFI
Interval 23.1 to 43.2
|
6.2 MFI
Interval 6.2 to 6.2
|
20.8 MFI
Interval 8.8 to 38.2
|
18.4 MFI
Interval 9.8 to 39.5
|
18.2 MFI
Interval 11.2 to 49.4
|
25.2 MFI
Interval 12.4 to 37.5
|
36.4 MFI
Interval 18.2 to 57.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-250 at Month 2-USA
|
26.2 MFI
Interval 23.1 to 43.2
|
6.2 MFI
Interval 6.2 to 6.2
|
21.9 MFI
Interval 8.3 to 32.4
|
18.2 MFI
Interval 10.5 to 41.1
|
49.4 MFI
Interval 37.7 to 104.3
|
16.1 MFI
Interval 6.8 to 27.9
|
39.5 MFI
Interval 21.9 to 64.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru
|
58 MFI
Interval 38.8 to 134.8
|
71.9 MFI
Interval 43.2 to 101.1
|
78.2 MFI
Interval 41.8 to 167.0
|
61.2 MFI
Interval 30.0 to 166.5
|
88.9 MFI
Interval 26.6 to 153.0
|
21.8 MFI
Interval 1.0 to 150.2
|
70.5 MFI
Interval 33.1 to 220.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Total
|
73 MFI
Interval 25.8 to 184.9
|
106.4 MFI
Interval 56.1 to 208.1
|
65.2 MFI
Interval 28.5 to 115.8
|
67.2 MFI
Interval 30.0 to 173.6
|
133.4 MFI
Interval 60.0 to 230.2
|
123.9 MFI
Interval 14.6 to 221.2
|
81.8 MFI
Interval 34.1 to 174.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-USA
|
96.2 MFI
Interval 23.0 to 219.5
|
150.8 MFI
Interval 72.8 to 279.4
|
41.6 MFI
Interval 20.7 to 108.2
|
72 MFI
Interval 23.0 to 183.2
|
198.4 MFI
Interval 99.2 to 313.1
|
186 MFI
Interval 70.8 to 305.8
|
90.2 MFI
Interval 36.0 to 145.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru
|
—
|
—
|
74.2 MFI
Interval 38.0 to 189.0
|
82 MFI
Interval 45.4 to 85.5
|
67.2 MFI
Interval 38.4 to 89.2
|
594.2 MFI
Interval 444.0 to 744.5
|
1 MFI
Interval 1.0 to 1.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Total
|
147.5 MFI
Interval 119.8 to 199.4
|
36.5 MFI
Interval 36.5 to 36.5
|
81.8 MFI
Interval 32.5 to 165.2
|
80 MFI
Interval 37.1 to 152.1
|
87.2 MFI
Interval 50.0 to 156.6
|
99.2 MFI
Interval 26.6 to 252.9
|
98 MFI
Interval 64.6 to 222.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-USA
|
147.5 MFI
Interval 119.8 to 199.4
|
36.5 MFI
Interval 36.5 to 36.5
|
92.6 MFI
Interval 21.2 to 147.8
|
78 MFI
Interval 38.6 to 171.6
|
163.5 MFI
Interval 128.6 to 455.4
|
40.5 MFI
Interval 9.8 to 83.8
|
122.4 MFI
Interval 79.9 to 222.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-250 at Month 0-Peru
|
421.8 MFI
Interval 305.8 to 619.0
|
571.1 MFI
Interval 262.7 to 2215.8
|
621.2 MFI
Interval 278.2 to 1361.0
|
1187.5 MFI
Interval 456.5 to 1905.2
|
989.1 MFI
Interval 345.4 to 1559.0
|
1213.2 MFI
Interval 623.2 to 2450.8
|
591.9 MFI
Interval 356.3 to 1670.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-250 at Month 0-Total
|
481.6 MFI
Interval 322.9 to 797.3
|
884.2 MFI
Interval 425.2 to 2295.5
|
541 MFI
Interval 233.8 to 1199.2
|
1386.2 MFI
Interval 518.5 to 3339.2
|
1181 MFI
Interval 478.1 to 2433.1
|
1302.4 MFI
Interval 608.6 to 2482.6
|
735.8 MFI
Interval 306.2 to 1776.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-250 at Month 0-USA
|
504.5 MFI
Interval 353.2 to 1403.5
|
954 MFI
Interval 600.9 to 2295.5
|
509.1 MFI
Interval 229.8 to 852.9
|
2208 MFI
Interval 619.8 to 4864.6
|
1362.6 MFI
Interval 603.7 to 4023.8
|
1391.5 MFI
Interval 603.8 to 2605.8
|
772.2 MFI
Interval 215.2 to 1808.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-250 at Month 2-Peru
|
—
|
—
|
346 MFI
Interval 210.5 to 993.5
|
220.8 MFI
Interval 164.5 to 726.0
|
717 MFI
Interval 282.9 to 1365.6
|
805.1 MFI
Interval 759.1 to 851.2
|
4030.2 MFI
Interval 4030.2 to 4030.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-250 at Month 2-Total
|
832.8 MFI
Interval 736.9 to 1024.4
|
612.2 MFI
Interval 612.2 to 612.2
|
606.5 MFI
Interval 288.5 to 1015.2
|
1748.9 MFI
Interval 392.1 to 5996.4
|
921 MFI
Interval 348.5 to 1765.2
|
583.2 MFI
Interval 450.7 to 851.2
|
1088.1 MFI
Interval 278.6 to 3229.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-250 at Month 2-USA
|
832.8 MFI
Interval 736.9 to 1024.4
|
612.2 MFI
Interval 612.2 to 612.2
|
700.9 MFI
Interval 295.6 to 1045.2
|
2575.5 MFI
Interval 561.5 to 6913.4
|
1412.8 MFI
Interval 849.5 to 1937.1
|
451.6 MFI
Interval 432.9 to 653.8
|
1055.2 MFI
Interval 276.6 to 2821.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru
|
1669.2 MFI
Interval 1243.5 to 2515.0
|
2364.9 MFI
Interval 1164.8 to 6805.2
|
2410.2 MFI
Interval 1124.5 to 4152.5
|
4462.8 MFI
Interval 1807.8 to 6591.2
|
3525.2 MFI
Interval 1489.9 to 6133.6
|
5101.8 MFI
Interval 2537.5 to 7638.5
|
2568.4 MFI
Interval 1635.9 to 4584.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Total
|
2032.4 MFI
Interval 1340.1 to 2943.3
|
3540 MFI
Interval 1821.3 to 8140.1
|
2171.5 MFI
Interval 1044.2 to 4024.5
|
5032.2 MFI
Interval 2204.9 to 8806.0
|
4103.4 MFI
Interval 1941.1 to 8606.4
|
5020.8 MFI
Interval 2513.9 to 7627.4
|
2708.8 MFI
Interval 1175.9 to 5926.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-USA
|
2120.5 MFI
Interval 1627.0 to 5052.2
|
3772.1 MFI
Interval 2476.2 to 8140.1
|
1986.2 MFI
Interval 983.3 to 3146.6
|
7532.8 MFI
Interval 2586.9 to 11554.1
|
5224.1 MFI
Interval 2340.1 to 9621.4
|
4939.8 MFI
Interval 2506.0 to 7594.0
|
3052.8 MFI
Interval 1043.8 to 6111.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru
|
—
|
—
|
1234.2 MFI
Interval 1066.5 to 3223.5
|
639.5 MFI
Interval 519.1 to 2434.5
|
1990 MFI
Interval 870.6 to 5109.4
|
2501.9 MFI
Interval 2137.8 to 2865.9
|
9763 MFI
Interval 9763.0 to 9763.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Total
|
3461.5 MFI
Interval 2964.2 to 3968.6
|
2148 MFI
Interval 2148.0 to 2148.0
|
2316.8 MFI
Interval 1071.2 to 3237.0
|
5426.5 MFI
Interval 1512.4 to 14248.9
|
3481 MFI
Interval 1041.5 to 5940.8
|
1759.1 MFI
Interval 1720.3 to 2865.9
|
4846.5 MFI
Interval 1150.4 to 7468.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-USA
|
3461.5 MFI
Interval 2964.2 to 3968.6
|
2148 MFI
Interval 2148.0 to 2148.0
|
2475.2 MFI
Interval 1325.9 to 3286.7
|
7931.2 MFI
Interval 2113.1 to 15247.9
|
4800.1 MFI
Interval 2334.5 to 6707.9
|
1728.4 MFI
Interval 1614.9 to 2384.9
|
3977.8 MFI
Interval 1141.2 to 7037.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-250 at Month 0-Peru
|
97.5 MFI
Interval 60.8 to 148.8
|
208.1 MFI
Interval 163.2 to 310.8
|
99 MFI
Interval 62.0 to 125.2
|
113.2 MFI
Interval 75.5 to 186.5
|
169 MFI
Interval 121.8 to 497.1
|
223.5 MFI
Interval 136.5 to 356.2
|
134.4 MFI
Interval 79.7 to 231.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-250 at Month 0-Total
|
94.9 MFI
Interval 60.8 to 140.8
|
120.5 MFI
Interval 65.8 to 518.0
|
64.2 MFI
Interval 44.0 to 125.2
|
150.5 MFI
Interval 91.8 to 221.1
|
156.9 MFI
Interval 105.5 to 299.0
|
160.5 MFI
Interval 106.8 to 317.2
|
130 MFI
Interval 57.9 to 231.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-250 at Month 0-USA
|
89 MFI
Interval 61.8 to 136.5
|
115.2 MFI
Interval 49.5 to 518.0
|
54 MFI
Interval 35.8 to 108.4
|
186.4 MFI
Interval 106.8 to 320.2
|
135.5 MFI
Interval 85.1 to 237.8
|
116.5 MFI
Interval 86.8 to 173.8
|
98.2 MFI
Interval 49.0 to 214.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-250 at Month 2-Peru
|
—
|
—
|
52.8 MFI
Interval 27.5 to 87.2
|
112.8 MFI
Interval 96.0 to 158.2
|
95.2 MFI
Interval 73.2 to 340.6
|
244.5 MFI
Interval 222.0 to 267.0
|
157.2 MFI
Interval 157.2 to 157.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-250 at Month 2-Total
|
92 MFI
Interval 85.1 to 681.6
|
83.2 MFI
Interval 83.2 to 83.2
|
53.2 MFI
Interval 34.8 to 110.0
|
155.6 MFI
Interval 102.4 to 246.8
|
112.5 MFI
Interval 80.2 to 292.0
|
204.8 MFI
Interval 108.8 to 269.6
|
122.9 MFI
Interval 53.6 to 162.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-250 at Month 2-USA
|
92 MFI
Interval 85.1 to 681.6
|
83.2 MFI
Interval 83.2 to 83.2
|
55.1 MFI
Interval 41.5 to 131.4
|
157.5 MFI
Interval 106.6 to 292.4
|
132.9 MFI
Interval 101.5 to 266.9
|
144.2 MFI
Interval 74.7 to 268.0
|
108.8 MFI
Interval 51.4 to 166.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 0-Peru
|
410.5 MFI
Interval 258.8 to 598.2
|
815.9 MFI
Interval 628.9 to 1468.0
|
337.2 MFI
Interval 273.5 to 515.2
|
410.8 MFI
Interval 313.0 to 582.0
|
629 MFI
Interval 476.5 to 2169.0
|
771.2 MFI
Interval 508.5 to 1253.0
|
527 MFI
Interval 349.7 to 845.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 0-Total
|
375.9 MFI
Interval 268.2 to 582.1
|
514.2 MFI
Interval 301.8 to 1740.8
|
311 MFI
Interval 185.5 to 515.2
|
568 MFI
Interval 355.1 to 847.5
|
555 MFI
Interval 396.2 to 1160.1
|
559.2 MFI
Interval 374.8 to 1105.2
|
447.2 MFI
Interval 237.8 to 862.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 0-USA
|
373.5 MFI
Interval 291.0 to 577.0
|
453 MFI
Interval 233.0 to 1740.8
|
243.6 MFI
Interval 147.4 to 449.6
|
686.2 MFI
Interval 420.2 to 1316.8
|
452.9 MFI
Interval 370.1 to 917.4
|
395.8 MFI
Interval 308.0 to 673.5
|
333.5 MFI
Interval 186.2 to 884.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 2-Peru
|
—
|
—
|
172.8 MFI
Interval 150.8 to 355.0
|
491.2 MFI
Interval 373.2 to 610.2
|
364.8 MFI
Interval 321.2 to 1068.6
|
735 MFI
Interval 715.2 to 754.8
|
376.2 MFI
Interval 376.2 to 376.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 2-Total
|
432.2 MFI
Interval 362.9 to 2247.5
|
324.2 MFI
Interval 324.2 to 324.2
|
236 MFI
Interval 150.8 to 448.5
|
549 MFI
Interval 403.6 to 834.7
|
397.5 MFI
Interval 341.5 to 1051.5
|
731.5 MFI
Interval 392.5 to 772.8
|
424.6 MFI
Interval 201.3 to 732.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
HKU1-RBD-50 at Month 2-USA
|
432.2 MFI
Interval 362.9 to 2247.5
|
324.2 MFI
Interval 324.2 to 324.2
|
239.9 MFI
Interval 150.9 to 500.6
|
561.8 MFI
Interval 403.9 to 1024.5
|
510 MFI
Interval 386.2 to 825.4
|
529.5 MFI
Interval 267.4 to 1016.8
|
427.5 MFI
Interval 179.1 to 748.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-250 at Month 0-Peru
|
334 MFI
Interval 210.8 to 448.2
|
481.8 MFI
Interval 307.8 to 627.6
|
266.8 MFI
Interval 181.0 to 463.2
|
276.8 MFI
Interval 193.2 to 422.0
|
340.6 MFI
Interval 254.0 to 708.0
|
399 MFI
Interval 244.8 to 723.0
|
224.4 MFI
Interval 128.8 to 313.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-250 at Month 0-Total
|
262.8 MFI
Interval 162.6 to 437.7
|
406.5 MFI
Interval 193.8 to 688.9
|
232.5 MFI
Interval 125.8 to 386.8
|
300 MFI
Interval 160.1 to 505.8
|
402.8 MFI
Interval 255.4 to 963.6
|
419.1 MFI
Interval 215.6 to 873.1
|
285.5 MFI
Interval 153.2 to 622.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-250 at Month 0-USA
|
213.8 MFI
Interval 140.5 to 342.5
|
406.5 MFI
Interval 193.8 to 806.3
|
163.2 MFI
Interval 90.4 to 321.8
|
355.8 MFI
Interval 141.1 to 584.6
|
747.4 MFI
Interval 256.4 to 1195.7
|
652.5 MFI
Interval 200.2 to 1035.2
|
433.2 MFI
Interval 169.8 to 833.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-250 at Month 2-Peru
|
—
|
—
|
301.2 MFI
Interval 159.8 to 460.0
|
312 MFI
Interval 268.6 to 389.2
|
232.8 MFI
Interval 139.9 to 395.8
|
424.6 MFI
Interval 399.7 to 449.6
|
150.2 MFI
Interval 150.2 to 150.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-250 at Month 2-Total
|
176 MFI
Interval 166.6 to 217.4
|
192 MFI
Interval 192.0 to 192.0
|
180.5 MFI
Interval 115.0 to 421.0
|
375 MFI
Interval 227.1 to 468.9
|
332.2 MFI
Interval 180.4 to 1064.1
|
300.8 MFI
Interval 183.1 to 449.6
|
431.6 MFI
Interval 261.6 to 1074.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-250 at Month 2-USA
|
176 MFI
Interval 166.6 to 217.4
|
192 MFI
Interval 192.0 to 192.0
|
166.2 MFI
Interval 90.8 to 289.0
|
405.8 MFI
Interval 186.5 to 594.9
|
1064.1 MFI
Interval 794.1 to 1494.8
|
197.6 MFI
Interval 159.9 to 376.9
|
455 MFI
Interval 319.0 to 1096.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 0-Peru
|
1297.8 MFI
Interval 898.2 to 1782.0
|
1837.9 MFI
Interval 1173.8 to 2635.2
|
1098.8 MFI
Interval 745.8 to 1894.2
|
1158.5 MFI
Interval 806.8 to 1773.2
|
1375.9 MFI
Interval 955.4 to 2272.4
|
1543 MFI
Interval 912.5 to 2466.5
|
955.1 MFI
Interval 531.1 to 1364.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 0-Total
|
1133 MFI
Interval 668.0 to 1771.5
|
1747.6 MFI
Interval 855.1 to 3276.6
|
862 MFI
Interval 545.2 to 1582.5
|
1160.8 MFI
Interval 673.5 to 2169.0
|
1706.6 MFI
Interval 968.9 to 3644.6
|
1683.9 MFI
Interval 873.7 to 3427.7
|
1166.5 MFI
Interval 588.8 to 2450.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 0-USA
|
877.2 MFI
Interval 638.8 to 1707.8
|
1747.6 MFI
Interval 855.1 to 3473.1
|
659.6 MFI
Interval 394.1 to 1305.4
|
1478 MFI
Interval 618.4 to 2458.9
|
2868 MFI
Interval 1116.1 to 4143.1
|
2510.8 MFI
Interval 839.2 to 4327.2
|
1751.5 MFI
Interval 721.8 to 3389.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 2-Peru
|
—
|
—
|
1289.2 MFI
Interval 648.2 to 1866.5
|
1186.8 MFI
Interval 957.0 to 1565.1
|
942.5 MFI
Interval 595.5 to 1471.5
|
1347.6 MFI
Interval 1198.2 to 1497.1
|
423.8 MFI
Interval 423.8 to 423.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 2-Total
|
712.2 MFI
Interval 658.1 to 873.0
|
774.8 MFI
Interval 774.8 to 774.8
|
766 MFI
Interval 439.0 to 1800.0
|
1368.5 MFI
Interval 779.4 to 2033.7
|
1185.8 MFI
Interval 756.1 to 3509.8
|
959.2 MFI
Interval 739.2 to 1497.1
|
1793.6 MFI
Interval 1094.2 to 3507.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
NL63-RBD-50 at Month 2-USA
|
712.2 MFI
Interval 658.1 to 873.0
|
774.8 MFI
Interval 774.8 to 774.8
|
642 MFI
Interval 385.8 to 1201.1
|
1467.5 MFI
Interval 699.4 to 2217.4
|
3509.8 MFI
Interval 2735.2 to 4470.2
|
782.8 MFI
Interval 678.4 to 1388.8
|
1932.8 MFI
Interval 1292.1 to 3567.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-250 at Month 0-Peru
|
89 MFI
Interval 56.0 to 162.0
|
431.6 MFI
Interval 303.3 to 671.7
|
73.2 MFI
Interval 59.0 to 150.0
|
103.8 MFI
Interval 68.0 to 166.0
|
138.4 MFI
Interval 78.4 to 254.2
|
223.2 MFI
Interval 125.2 to 272.0
|
165.8 MFI
Interval 89.6 to 230.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-250 at Month 0-Total
|
108 MFI
Interval 65.2 to 211.5
|
182.4 MFI
Interval 101.6 to 399.7
|
73.2 MFI
Interval 45.5 to 152.5
|
142.8 MFI
Interval 85.6 to 254.4
|
161.9 MFI
Interval 82.9 to 301.8
|
160.4 MFI
Interval 81.9 to 266.4
|
108.2 MFI
Interval 68.5 to 252.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-250 at Month 0-USA
|
146.2 MFI
Interval 67.0 to 248.0
|
163.5 MFI
Interval 91.5 to 322.7
|
80.6 MFI
Interval 43.8 to 217.6
|
162.9 MFI
Interval 99.3 to 318.1
|
204 MFI
Interval 122.9 to 330.1
|
123.2 MFI
Interval 78.0 to 195.5
|
100.8 MFI
Interval 51.5 to 282.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-250 at Month 2-Peru
|
—
|
—
|
57.2 MFI
Interval 47.0 to 91.5
|
123.2 MFI
Interval 102.0 to 128.0
|
76.8 MFI
Interval 59.4 to 148.5
|
476.6 MFI
Interval 319.1 to 634.2
|
166.8 MFI
Interval 166.8 to 166.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-250 at Month 2-Total
|
237.5 MFI
Interval 152.4 to 303.2
|
55.8 MFI
Interval 55.8 to 55.8
|
83.8 MFI
Interval 52.5 to 250.8
|
173.5 MFI
Interval 116.7 to 335.8
|
139.8 MFI
Interval 67.0 to 207.6
|
311.5 MFI
Interval 157.9 to 497.7
|
151.2 MFI
Interval 65.6 to 248.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-250 at Month 2-USA
|
237.5 MFI
Interval 152.4 to 303.2
|
55.8 MFI
Interval 55.8 to 55.8
|
98.1 MFI
Interval 71.4 to 264.9
|
239 MFI
Interval 119.6 to 404.0
|
189.1 MFI
Interval 130.9 to 223.9
|
309.1 MFI
Interval 135.4 to 473.6
|
135.8 MFI
Interval 59.9 to 249.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 0-Peru
|
343.5 MFI
Interval 233.0 to 566.8
|
2130.2 MFI
Interval 1226.1 to 3186.4
|
323.5 MFI
Interval 214.0 to 654.5
|
413 MFI
Interval 270.8 to 730.0
|
469.9 MFI
Interval 300.9 to 939.2
|
776.2 MFI
Interval 396.8 to 1088.2
|
571 MFI
Interval 332.8 to 865.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 0-Total
|
472.4 MFI
Interval 265.7 to 945.4
|
793.9 MFI
Interval 448.9 to 1747.9
|
326.2 MFI
Interval 193.5 to 671.8
|
524.5 MFI
Interval 302.4 to 1055.1
|
605 MFI
Interval 344.2 to 1110.3
|
606.8 MFI
Interval 337.8 to 1015.2
|
431.5 MFI
Interval 289.5 to 885.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 0-USA
|
596.8 MFI
Interval 322.2 to 1037.8
|
671.8 MFI
Interval 383.1 to 1202.5
|
329.2 MFI
Interval 190.0 to 836.1
|
698.2 MFI
Interval 388.6 to 1385.8
|
786.1 MFI
Interval 479.4 to 1173.1
|
476 MFI
Interval 300.2 to 829.0
|
388 MFI
Interval 225.2 to 1152.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 2-Peru
|
—
|
—
|
276.8 MFI
Interval 183.0 to 432.2
|
477.8 MFI
Interval 380.8 to 597.9
|
299 MFI
Interval 249.9 to 668.0
|
2104.2 MFI
Interval 1277.8 to 2930.8
|
588 MFI
Interval 588.0 to 588.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 2-Total
|
1043.5 MFI
Interval 644.2 to 1307.5
|
225.2 MFI
Interval 225.2 to 225.2
|
328.2 MFI
Interval 228.2 to 1016.8
|
745.4 MFI
Interval 481.1 to 1251.4
|
552.2 MFI
Interval 269.4 to 715.2
|
1226.1 MFI
Interval 528.1 to 1982.5
|
594.4 MFI
Interval 259.8 to 1013.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
OC43-RBD-50 at Month 2-USA
|
1043.5 MFI
Interval 644.2 to 1307.5
|
225.2 MFI
Interval 225.2 to 225.2
|
387.6 MFI
Interval 288.1 to 1080.4
|
914.5 MFI
Interval 491.5 to 1575.2
|
653.8 MFI
Interval 531.9 to 765.4
|
1226.1 MFI
Interval 617.6 to 1790.0
|
600.8 MFI
Interval 240.0 to 1039.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-250 at Month 0-Peru
|
543 MFI
Interval 240.8 to 1479.8
|
910.1 MFI
Interval 620.4 to 1934.7
|
1318.8 MFI
Interval 588.0 to 2936.0
|
1897.5 MFI
Interval 993.0 to 3614.8
|
3860.9 MFI
Interval 1681.3 to 5231.6
|
4564.5 MFI
Interval 2671.0 to 7601.2
|
2018.4 MFI
Interval 909.0 to 4491.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-250 at Month 0-Total
|
303.1 MFI
Interval 97.4 to 782.1
|
258.5 MFI
Interval 45.3 to 1047.9
|
588 MFI
Interval 256.5 to 1764.5
|
1140.5 MFI
Interval 382.9 to 2695.8
|
1701.8 MFI
Interval 634.2 to 4165.8
|
1595.6 MFI
Interval 646.2 to 4467.4
|
868.8 MFI
Interval 334.9 to 2732.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-250 at Month 0-USA
|
149.8 MFI
Interval 35.2 to 459.8
|
180.8 MFI
Interval 45.3 to 1040.4
|
440 MFI
Interval 133.5 to 651.7
|
630.4 MFI
Interval 324.4 to 1885.5
|
1050.4 MFI
Interval 230.1 to 1778.2
|
637.8 MFI
Interval 287.0 to 1144.8
|
425.8 MFI
Interval 133.2 to 809.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-250 at Month 2-Peru
|
—
|
—
|
161.2 MFI
Interval 58.2 to 517.2
|
617.2 MFI
Interval 370.4 to 1068.1
|
1100.5 MFI
Interval 695.5 to 2026.2
|
2382.8 MFI
Interval 2142.9 to 2622.6
|
1853.8 MFI
Interval 1853.8 to 1853.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-250 at Month 2-Total
|
280.8 MFI
Interval 227.4 to 521.4
|
2368.8 MFI
Interval 2368.8 to 2368.8
|
260 MFI
Interval 99.0 to 517.2
|
809.8 MFI
Interval 427.2 to 1970.7
|
994.2 MFI
Interval 279.2 to 1886.9
|
1104 MFI
Interval 500.2 to 1821.6
|
245.6 MFI
Interval 126.7 to 444.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-250 at Month 2-USA
|
280.8 MFI
Interval 227.4 to 521.4
|
2368.8 MFI
Interval 2368.8 to 2368.8
|
290 MFI
Interval 112.5 to 480.6
|
1002.2 MFI
Interval 432.5 to 2279.8
|
654 MFI
Interval 98.3 to 1554.2
|
543.6 MFI
Interval 380.2 to 867.2
|
211.5 MFI
Interval 125.6 to 409.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Peru
|
2304.8 MFI
Interval 767.8 to 5899.5
|
3538 MFI
Interval 1690.7 to 7010.9
|
4670 MFI
Interval 2052.0 to 8169.8
|
4758 MFI
Interval 2425.0 to 8798.2
|
8992.6 MFI
Interval 5308.0 to 13508.6
|
12178.5 MFI
Interval 7477.2 to 16828.0
|
6193.8 MFI
Interval 2862.4 to 12000.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
1250.9 MFI
Interval 372.0 to 2932.6
|
1150.9 MFI
Interval 178.3 to 4541.8
|
2052 MFI
Interval 736.5 to 4930.2
|
3225.2 MFI
Interval 1563.9 to 7628.8
|
5402.9 MFI
Interval 2225.8 to 9744.4
|
5477.4 MFI
Interval 1864.6 to 12046.4
|
2882.5 MFI
Interval 1257.5 to 7792.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-USA
|
620 MFI
Interval 151.8 to 1902.0
|
871.2 MFI
Interval 152.0 to 3467.7
|
1672.4 MFI
Interval 640.9 to 2139.8
|
1991.4 MFI
Interval 1343.7 to 4912.1
|
3021.2 MFI
Interval 849.7 to 5527.8
|
1765.2 MFI
Interval 1092.8 to 3799.0
|
1591.2 MFI
Interval 498.2 to 2882.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Peru
|
—
|
—
|
692 MFI
Interval 222.5 to 1916.8
|
1909.5 MFI
Interval 1261.4 to 3380.4
|
3837.5 MFI
Interval 2585.0 to 6053.1
|
6267.4 MFI
Interval 5638.1 to 6896.7
|
7420.2 MFI
Interval 7420.2 to 7420.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
1194.8 MFI
Interval 912.8 to 2107.6
|
6779.5 MFI
Interval 6779.5 to 6779.5
|
1022.2 MFI
Interval 366.2 to 1916.8
|
2117.6 MFI
Interval 1493.3 to 5386.8
|
3611.5 MFI
Interval 938.2 to 5729.2
|
3749 MFI
Interval 2084.6 to 5080.6
|
884.2 MFI
Interval 531.9 to 2100.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-USA
|
1194.8 MFI
Interval 912.8 to 2107.6
|
6779.5 MFI
Interval 6779.5 to 6779.5
|
1055.1 MFI
Interval 388.4 to 1864.8
|
2325.8 MFI
Interval 1541.4 to 5556.0
|
2308.2 MFI
Interval 269.8 to 5089.8
|
2219.5 MFI
Interval 1586.8 to 3143.1
|
858.2 MFI
Interval 504.1 to 1718.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-250 at Month 0-Peru
|
234.8 MFI
Interval 100.8 to 483.8
|
457.4 MFI
Interval 336.5 to 554.4
|
506 MFI
Interval 166.0 to 1150.0
|
1170.8 MFI
Interval 528.5 to 4269.2
|
1406.2 MFI
Interval 892.3 to 6171.4
|
3855.2 MFI
Interval 2199.8 to 6346.8
|
569 MFI
Interval 285.2 to 1947.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total
|
128.9 MFI
Interval 78.9 to 398.9
|
86.1 MFI
Interval 55.8 to 413.8
|
335.8 MFI
Interval 143.5 to 920.5
|
769 MFI
Interval 221.4 to 2239.2
|
1041 MFI
Interval 354.1 to 2154.2
|
2402 MFI
Interval 568.1 to 5530.1
|
361.8 MFI
Interval 125.6 to 1214.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-250 at Month 0-USA
|
84.2 MFI
Interval 45.8 to 215.0
|
81.2 MFI
Interval 55.8 to 249.2
|
253.1 MFI
Interval 131.4 to 554.4
|
483.6 MFI
Interval 210.8 to 1744.6
|
634.5 MFI
Interval 174.2 to 1612.4
|
1066.2 MFI
Interval 366.2 to 2604.2
|
239.2 MFI
Interval 107.5 to 497.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-250 at Month 2-Peru
|
—
|
—
|
108.2 MFI
Interval 54.8 to 217.0
|
651 MFI
Interval 383.8 to 1409.1
|
256.5 MFI
Interval 159.0 to 749.6
|
1382.6 MFI
Interval 1265.2 to 1500.1
|
303.2 MFI
Interval 303.2 to 303.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total
|
162.5 MFI
Interval 113.5 to 762.2
|
348.8 MFI
Interval 348.8 to 348.8
|
109.2 MFI
Interval 68.2 to 222.8
|
344.1 MFI
Interval 157.7 to 726.1
|
256.5 MFI
Interval 141.1 to 836.1
|
809.5 MFI
Interval 274.0 to 1500.1
|
164.4 MFI
Interval 81.8 to 315.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-250 at Month 2-USA
|
162.5 MFI
Interval 113.5 to 762.2
|
348.8 MFI
Interval 348.8 to 348.8
|
111.2 MFI
Interval 81.4 to 292.2
|
323.2 MFI
Interval 163.1 to 717.4
|
265.2 MFI
Interval 99.9 to 835.1
|
339.8 MFI
Interval 176.9 to 967.2
|
129.5 MFI
Interval 74.9 to 307.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru
|
1028.8 MFI
Interval 457.0 to 2128.2
|
2256.1 MFI
Interval 1397.9 to 2856.5
|
2037.2 MFI
Interval 797.5 to 4537.0
|
4512.5 MFI
Interval 2344.5 to 8401.2
|
5091.6 MFI
Interval 3741.6 to 16792.0
|
12226 MFI
Interval 7813.5 to 15799.2
|
2402 MFI
Interval 1168.5 to 6867.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
542.1 MFI
Interval 318.9 to 1765.8
|
395.2 MFI
Interval 227.8 to 1723.1
|
1603.2 MFI
Interval 650.2 to 3705.2
|
3119.5 MFI
Interval 910.2 to 7749.6
|
3996.6 MFI
Interval 1441.1 to 7093.4
|
8303.8 MFI
Interval 2277.8 to 15231.6
|
1466.8 MFI
Interval 555.9 to 4147.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA
|
357.5 MFI
Interval 204.8 to 783.2
|
352.5 MFI
Interval 227.8 to 1284.9
|
1095.6 MFI
Interval 511.4 to 2274.6
|
1966 MFI
Interval 841.0 to 6227.4
|
2289 MFI
Interval 771.1 to 5483.6
|
3912.8 MFI
Interval 1297.8 to 9189.0
|
1033.8 MFI
Interval 425.8 to 1992.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru
|
—
|
—
|
653 MFI
Interval 278.8 to 870.2
|
2536.5 MFI
Interval 1546.8 to 4367.0
|
971.2 MFI
Interval 682.1 to 2768.1
|
3870.6 MFI
Interval 3818.4 to 3922.8
|
1310.2 MFI
Interval 1310.2 to 1310.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
713 MFI
Interval 461.1 to 2752.8
|
1427.5 MFI
Interval 1427.5 to 1427.5
|
434 MFI
Interval 292.2 to 876.2
|
1435.9 MFI
Interval 634.8 to 2686.3
|
971.2 MFI
Interval 546.2 to 3163.5
|
3049.4 MFI
Interval 1163.2 to 3922.8
|
684.6 MFI
Interval 244.6 to 1340.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA
|
713 MFI
Interval 461.1 to 2752.8
|
1427.5 MFI
Interval 1427.5 to 1427.5
|
433.1 MFI
Interval 302.0 to 1145.2
|
1380 MFI
Interval 701.8 to 2458.5
|
965.9 MFI
Interval 271.1 to 3252.9
|
1553 MFI
Interval 641.3 to 3857.6
|
590.8 MFI
Interval 239.8 to 1346.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Peru
|
510.8 MFI
Interval 180.0 to 1516.8
|
812.8 MFI
Interval 455.9 to 1843.9
|
1166.8 MFI
Interval 350.5 to 2918.5
|
1742.2 MFI
Interval 625.8 to 3278.5
|
3140.5 MFI
Interval 1594.0 to 4530.1
|
4241.2 MFI
Interval 2460.5 to 8315.0
|
1891.2 MFI
Interval 1024.6 to 4645.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total
|
256.2 MFI
Interval 84.8 to 702.6
|
218.6 MFI
Interval 6.4 to 1063.3
|
430 MFI
Interval 234.5 to 1174.2
|
1299 MFI
Interval 328.0 to 2634.8
|
1764.9 MFI
Interval 503.6 to 3227.9
|
1754.2 MFI
Interval 544.5 to 4328.8
|
1069.8 MFI
Interval 293.1 to 2767.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-USA
|
105.8 MFI
Interval 12.8 to 273.0
|
179.6 MFI
Interval 6.4 to 928.2
|
370.5 MFI
Interval 208.3 to 502.1
|
559.2 MFI
Interval 276.3 to 2048.8
|
910.2 MFI
Interval 255.4 to 1809.3
|
536 MFI
Interval 294.0 to 1368.8
|
435 MFI
Interval 124.2 to 1076.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Peru
|
—
|
—
|
119.2 MFI
Interval 56.2 to 359.5
|
556 MFI
Interval 287.5 to 891.1
|
1057.5 MFI
Interval 792.5 to 1489.2
|
2268.9 MFI
Interval 2013.2 to 2524.6
|
5367.8 MFI
Interval 5367.8 to 5367.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total
|
651.5 MFI
Interval 484.1 to 875.8
|
3036 MFI
Interval 3036.0 to 3036.0
|
238.8 MFI
Interval 84.0 to 382.8
|
1083.2 MFI
Interval 271.9 to 1416.2
|
846.5 MFI
Interval 162.5 to 1401.0
|
628.9 MFI
Interval 304.4 to 1506.1
|
176 MFI
Interval 133.8 to 544.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-USA
|
651.5 MFI
Interval 484.1 to 875.8
|
3036 MFI
Interval 3036.0 to 3036.0
|
277.6 MFI
Interval 179.4 to 384.1
|
1146 MFI
Interval 279.5 to 1504.0
|
347.9 MFI
Interval 17.5 to 770.9
|
371.5 MFI
Interval 237.2 to 567.3
|
169.5 MFI
Interval 129.8 to 378.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru
|
2082.8 MFI
Interval 1030.2 to 5188.5
|
3215.4 MFI
Interval 2375.1 to 5986.1
|
3899.2 MFI
Interval 1348.0 to 8463.0
|
4311.2 MFI
Interval 2194.8 to 8428.8
|
8338.5 MFI
Interval 4221.9 to 11994.6
|
12204.2 MFI
Interval 6914.2 to 16983.8
|
6274.6 MFI
Interval 3227.6 to 10836.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
1067.5 MFI
Interval 366.2 to 2900.6
|
1054.1 MFI
Interval 35.4 to 3684.1
|
1916.8 MFI
Interval 1067.0 to 4190.5
|
3689 MFI
Interval 1292.8 to 6751.8
|
4588.2 MFI
Interval 2000.0 to 8662.9
|
4657.1 MFI
Interval 1730.1 to 12233.3
|
3352.5 MFI
Interval 1296.4 to 8296.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA
|
524.2 MFI
Interval 43.5 to 1166.0
|
882.6 MFI
Interval 28.4 to 3411.5
|
1471.2 MFI
Interval 842.5 to 2083.1
|
2267.5 MFI
Interval 961.9 to 4534.2
|
3400.2 MFI
Interval 1085.6 to 5620.3
|
1804 MFI
Interval 1160.2 to 4016.8
|
1629.2 MFI
Interval 495.2 to 3443.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru
|
—
|
—
|
593 MFI
Interval 232.0 to 1460.2
|
1977.2 MFI
Interval 1042.5 to 3139.4
|
3117.2 MFI
Interval 2803.5 to 5018.5
|
6224.2 MFI
Interval 5663.6 to 6784.9
|
14234.2 MFI
Interval 14234.2 to 14234.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
2534.8 MFI
Interval 2007.8 to 3078.8
|
9878 MFI
Interval 9878.0 to 9878.0
|
988.8 MFI
Interval 332.2 to 1574.2
|
2346.5 MFI
Interval 1269.6 to 4247.1
|
2881.5 MFI
Interval 742.8 to 4497.8
|
2239.6 MFI
Interval 1177.1 to 4512.1
|
850.8 MFI
Interval 619.5 to 1840.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA
|
2534.8 MFI
Interval 2007.8 to 3078.8
|
9878 MFI
Interval 9878.0 to 9878.0
|
1068.1 MFI
Interval 839.1 to 1611.7
|
2715.8 MFI
Interval 1293.5 to 4572.1
|
1429.5 MFI
Interval 37.9 to 2831.7
|
1364.6 MFI
Interval 945.9 to 1989.7
|
841.2 MFI
Interval 591.8 to 1195.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-250 at Month 0-Peru
|
365.8 MFI
Interval 130.2 to 1226.8
|
507.2 MFI
Interval 296.6 to 1384.8
|
883.5 MFI
Interval 385.0 to 3011.5
|
1819.2 MFI
Interval 791.0 to 3136.8
|
3305.6 MFI
Interval 1119.6 to 5415.2
|
4220.8 MFI
Interval 1798.5 to 8442.0
|
1587 MFI
Interval 553.6 to 3450.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-250 at Month 0-Total
|
151.5 MFI
Interval 32.2 to 495.8
|
117.2 MFI
Interval 14.8 to 744.3
|
412 MFI
Interval 152.0 to 977.8
|
970.5 MFI
Interval 238.6 to 2283.6
|
1273.2 MFI
Interval 387.6 to 3416.2
|
1327 MFI
Interval 338.4 to 4201.5
|
644.5 MFI
Interval 223.6 to 2004.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-250 at Month 0-USA
|
54.2 MFI
Interval 4.5 to 203.2
|
106.9 MFI
Interval 14.8 to 744.3
|
299.8 MFI
Interval 100.4 to 430.4
|
401.2 MFI
Interval 176.9 to 1677.7
|
612 MFI
Interval 101.3 to 1486.4
|
334.2 MFI
Interval 210.5 to 886.8
|
276.8 MFI
Interval 67.5 to 665.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-250 at Month 2-Peru
|
—
|
—
|
90.8 MFI
Interval 16.2 to 170.8
|
328.5 MFI
Interval 182.4 to 651.4
|
734.2 MFI
Interval 307.6 to 1303.2
|
1439.1 MFI
Interval 1285.2 to 1593.1
|
1564.5 MFI
Interval 1564.5 to 1564.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-250 at Month 2-Total
|
140.5 MFI
Interval 108.1 to 323.0
|
639.2 MFI
Interval 639.2 to 639.2
|
119.8 MFI
Interval 40.2 to 261.2
|
564.4 MFI
Interval 142.7 to 974.2
|
496.2 MFI
Interval 121.0 to 1055.2
|
497.4 MFI
Interval 282.9 to 1006.6
|
115.5 MFI
Interval 44.0 to 206.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-250 at Month 2-USA
|
140.5 MFI
Interval 108.1 to 323.0
|
639.2 MFI
Interval 639.2 to 639.2
|
162.6 MFI
Interval 45.9 to 278.2
|
800.2 MFI
Interval 151.1 to 1051.8
|
288 MFI
Interval 33.5 to 527.0
|
309.4 MFI
Interval 209.3 to 429.8
|
104.2 MFI
Interval 40.0 to 192.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Peru
|
1579.5 MFI
Interval 367.5 to 4783.5
|
2320.9 MFI
Interval 1088.8 to 5366.1
|
3205.2 MFI
Interval 1713.8 to 9341.0
|
5855.5 MFI
Interval 1946.0 to 9810.2
|
9250.4 MFI
Interval 4361.8 to 13217.6
|
11542.8 MFI
Interval 6017.0 to 17961.5
|
5657.2 MFI
Interval 2255.9 to 10684.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
826.1 MFI
Interval 163.9 to 2260.2
|
578.2 MFI
Interval 50.9 to 3341.9
|
1713.8 MFI
Interval 635.8 to 4561.5
|
2875.8 MFI
Interval 928.6 to 6921.5
|
4361.5 MFI
Interval 1375.6 to 10423.9
|
4292.2 MFI
Interval 1470.4 to 11388.4
|
2317.8 MFI
Interval 793.9 to 6852.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-USA
|
264.8 MFI
Interval 44.5 to 902.2
|
506.1 MFI
Interval 49.1 to 3294.1
|
1481.5 MFI
Interval 452.0 to 1939.3
|
1652.4 MFI
Interval 648.5 to 5173.1
|
2609.6 MFI
Interval 530.0 to 4407.4
|
1475.5 MFI
Interval 915.2 to 3036.5
|
1080 MFI
Interval 328.0 to 2317.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Peru
|
—
|
—
|
429.5 MFI
Interval 71.0 to 760.5
|
1005.5 MFI
Interval 593.5 to 2221.4
|
2455.5 MFI
Interval 1007.6 to 4413.8
|
4198.9 MFI
Interval 3810.4 to 4587.3
|
6491 MFI
Interval 6491.0 to 6491.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
587 MFI
Interval 464.9 to 1346.8
|
2490 MFI
Interval 2490.0 to 2490.0
|
544 MFI
Interval 125.5 to 1029.2
|
1655.2 MFI
Interval 562.1 to 3330.9
|
1840.8 MFI
Interval 469.1 to 3324.5
|
2145.2 MFI
Interval 1365.1 to 3141.9
|
541.8 MFI
Interval 202.8 to 791.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-USA
|
587 MFI
Interval 464.9 to 1346.8
|
2490 MFI
Interval 2490.0 to 2490.0
|
610.2 MFI
Interval 181.5 to 1081.2
|
2212 MFI
Interval 605.4 to 3273.0
|
1178.2 MFI
Interval 101.3 to 2022.9
|
1573 MFI
Interval 930.1 to 2067.0
|
519.8 MFI
Interval 193.8 to 681.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-250 at Month 0-Peru
|
451.5 MFI
Interval 277.2 to 982.0
|
834.8 MFI
Interval 519.5 to 1513.0
|
850.5 MFI
Interval 547.8 to 1614.0
|
1633.8 MFI
Interval 773.2 to 3279.0
|
2386.4 MFI
Interval 1448.7 to 3207.9
|
2742.8 MFI
Interval 1663.2 to 6081.2
|
1843.9 MFI
Interval 1082.8 to 3064.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total
|
307.8 MFI
Interval 131.7 to 903.5
|
462.2 MFI
Interval 175.5 to 1159.6
|
733.2 MFI
Interval 319.8 to 1361.8
|
1427 MFI
Interval 481.4 to 2937.4
|
1636.8 MFI
Interval 850.0 to 2998.5
|
1672.2 MFI
Interval 783.1 to 4268.8
|
1109.8 MFI
Interval 383.2 to 2421.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-250 at Month 0-USA
|
189.8 MFI
Interval 30.2 to 637.2
|
352.6 MFI
Interval 80.6 to 1159.6
|
621.5 MFI
Interval 251.6 to 941.8
|
1116 MFI
Interval 469.8 to 2145.4
|
1168 MFI
Interval 568.0 to 2376.1
|
1290 MFI
Interval 394.2 to 2213.8
|
439.2 MFI
Interval 222.8 to 1428.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-250 at Month 2-Peru
|
—
|
—
|
346 MFI
Interval 215.2 to 1155.5
|
900.8 MFI
Interval 508.0 to 2845.0
|
1152 MFI
Interval 798.8 to 1370.6
|
5372.2 MFI
Interval 4912.4 to 5832.1
|
3516.2 MFI
Interval 3516.2 to 3516.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total
|
906.2 MFI
Interval 685.5 to 991.2
|
1324.5 MFI
Interval 1324.5 to 1324.5
|
709.8 MFI
Interval 294.2 to 1155.5
|
1549.9 MFI
Interval 685.8 to 3743.4
|
1152 MFI
Interval 491.8 to 1459.5
|
1364.5 MFI
Interval 825.2 to 3743.8
|
1102 MFI
Interval 320.8 to 1512.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-250 at Month 2-USA
|
906.2 MFI
Interval 685.5 to 991.2
|
1324.5 MFI
Interval 1324.5 to 1324.5
|
769.1 MFI
Interval 336.8 to 1141.8
|
1958.5 MFI
Interval 747.2 to 3740.2
|
1008.9 MFI
Interval 161.6 to 1693.8
|
920.6 MFI
Interval 688.2 to 1238.0
|
1041.2 MFI
Interval 311.1 to 1348.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru
|
2012.8 MFI
Interval 1248.0 to 3929.2
|
3682.1 MFI
Interval 2565.7 to 5712.9
|
3802.2 MFI
Interval 2311.5 to 6288.8
|
6633.5 MFI
Interval 3774.8 to 11760.2
|
8764.4 MFI
Interval 5625.3 to 11090.9
|
10069.8 MFI
Interval 6482.2 to 17653.5
|
6459.8 MFI
Interval 4079.4 to 9182.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
1355.5 MFI
Interval 524.2 to 3653.7
|
1732.8 MFI
Interval 624.4 to 4565.5
|
3250.2 MFI
Interval 1414.5 to 5353.8
|
5355.2 MFI
Interval 2139.2 to 10999.1
|
6353.6 MFI
Interval 3592.3 to 10081.1
|
6586.8 MFI
Interval 3121.6 to 12902.6
|
4322.5 MFI
Interval 1640.0 to 7954.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA
|
859.2 MFI
Interval 147.2 to 2892.8
|
1559 MFI
Interval 290.8 to 4565.5
|
2830.9 MFI
Interval 1219.4 to 3997.7
|
4557.2 MFI
Interval 2090.8 to 8041.7
|
5069.8 MFI
Interval 2413.9 to 6825.4
|
5087.2 MFI
Interval 1700.2 to 8646.5
|
1926 MFI
Interval 955.8 to 5027.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru
|
—
|
—
|
1443.8 MFI
Interval 722.5 to 4231.0
|
2952 MFI
Interval 1700.6 to 8363.9
|
4357.2 MFI
Interval 2989.8 to 5413.9
|
12948.8 MFI
Interval 12857.4 to 13040.1
|
9814.5 MFI
Interval 9814.5 to 9814.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
3765.8 MFI
Interval 2861.2 to 3985.6
|
4734.8 MFI
Interval 4734.8 to 4734.8
|
2989 MFI
Interval 1174.2 to 4159.5
|
4578.6 MFI
Interval 2529.6 to 11753.1
|
4357.2 MFI
Interval 2178.8 to 5596.4
|
4247.4 MFI
Interval 3708.1 to 10668.9
|
3859.6 MFI
Interval 1524.5 to 4881.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA
|
3765.8 MFI
Interval 2861.2 to 3985.6
|
4734.8 MFI
Interval 4734.8 to 4734.8
|
3106 MFI
Interval 1327.9 to 3862.1
|
4780.2 MFI
Interval 2942.1 to 11726.4
|
3620.9 MFI
Interval 554.1 to 6178.8
|
3844.5 MFI
Interval 3154.2 to 4182.3
|
3751.8 MFI
Interval 1315.0 to 4706.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Peru
|
940.5 MFI
Interval 386.5 to 2845.5
|
1380.5 MFI
Interval 940.1 to 2492.4
|
1504.5 MFI
Interval 656.2 to 3795.2
|
2827.2 MFI
Interval 1783.0 to 4365.5
|
5367.2 MFI
Interval 2407.3 to 7182.3
|
6622 MFI
Interval 3348.2 to 10889.0
|
4030.1 MFI
Interval 2057.6 to 6474.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total
|
655.8 MFI
Interval 207.1 to 1392.2
|
483.2 MFI
Interval 41.4 to 2353.8
|
1066.2 MFI
Interval 426.5 to 2060.8
|
2359 MFI
Interval 753.5 to 4325.0
|
3228.4 MFI
Interval 1526.6 to 5999.6
|
3018.9 MFI
Interval 1434.8 to 7059.8
|
2002.8 MFI
Interval 642.4 to 5018.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-USA
|
429.5 MFI
Interval 48.5 to 660.5
|
363.1 MFI
Interval 41.4 to 2353.8
|
682 MFI
Interval 409.3 to 1345.4
|
1591.2 MFI
Interval 534.7 to 3476.8
|
2092.8 MFI
Interval 762.6 to 4682.0
|
1435.8 MFI
Interval 762.0 to 2754.8
|
949.2 MFI
Interval 350.0 to 2002.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Peru
|
—
|
—
|
341.2 MFI
Interval 114.8 to 621.2
|
983 MFI
Interval 531.2 to 1642.9
|
1913 MFI
Interval 1103.6 to 2892.4
|
3588.2 MFI
Interval 3150.0 to 4026.5
|
12174 MFI
Interval 12174.0 to 12174.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total
|
1405.5 MFI
Interval 1058.5 to 3207.1
|
3051.2 MFI
Interval 3051.2 to 3051.2
|
510.8 MFI
Interval 205.0 to 918.0
|
1791.1 MFI
Interval 710.8 to 3240.8
|
1777.5 MFI
Interval 430.5 to 2505.9
|
2252.1 MFI
Interval 959.1 to 3027.7
|
473.6 MFI
Interval 340.9 to 1544.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-USA
|
1405.5 MFI
Interval 1058.5 to 3207.1
|
3051.2 MFI
Interval 3051.2 to 3051.2
|
868.9 MFI
Interval 452.7 to 955.2
|
1886.5 MFI
Interval 812.9 to 3299.4
|
1139 MFI
Interval 65.8 to 1802.1
|
1236.9 MFI
Interval 663.4 to 2127.6
|
409.5 MFI
Interval 336.6 to 1017.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru
|
3373.2 MFI
Interval 1536.2 to 7157.8
|
5532.8 MFI
Interval 2943.7 to 9198.6
|
5187.2 MFI
Interval 2515.5 to 11161.0
|
7723.8 MFI
Interval 4711.2 to 13375.0
|
11580.9 MFI
Interval 7287.9 to 17208.5
|
17681.5 MFI
Interval 10206.2 to 22000.0
|
11726.9 MFI
Interval 6183.8 to 16206.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
2696.9 MFI
Interval 852.4 to 5018.1
|
2161.9 MFI
Interval 159.9 to 9057.2
|
3981.8 MFI
Interval 1759.2 to 6511.5
|
7053.5 MFI
Interval 2527.9 to 11267.1
|
9034.9 MFI
Interval 4407.8 to 14598.1
|
8970 MFI
Interval 4342.2 to 17536.8
|
6778.2 MFI
Interval 2671.5 to 13436.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA
|
1917.2 MFI
Interval 184.0 to 3080.2
|
1679 MFI
Interval 159.9 to 9057.2
|
2949.5 MFI
Interval 1690.0 to 4343.1
|
5716.9 MFI
Interval 1983.2 to 8939.8
|
6613.6 MFI
Interval 2719.8 to 12047.6
|
4108.2 MFI
Interval 2701.2 to 7600.0
|
3418.8 MFI
Interval 1545.5 to 6778.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru
|
—
|
—
|
1039.8 MFI
Interval 582.2 to 2282.8
|
3087.5 MFI
Interval 1707.0 to 5127.6
|
5526.5 MFI
Interval 3651.4 to 7994.2
|
8850.6 MFI
Interval 7892.6 to 9808.7
|
22000 MFI
Interval 22000.0 to 22000.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
5119.8 MFI
Interval 3968.1 to 8922.5
|
9059.5 MFI
Interval 9059.5 to 9059.5
|
2231.5 MFI
Interval 928.0 to 3058.8
|
5186.1 MFI
Interval 2661.5 to 7748.6
|
5463 MFI
Interval 1833.9 to 7410.1
|
6261.1 MFI
Interval 3649.4 to 7180.7
|
2042.5 MFI
Interval 1388.1 to 4885.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA
|
5119.8 MFI
Interval 3968.1 to 8922.5
|
9059.5 MFI
Interval 9059.5 to 9059.5
|
2792.8 MFI
Interval 1781.0 to 3846.6
|
5510.2 MFI
Interval 2964.2 to 8096.2
|
3929.5 MFI
Interval 183.2 to 6048.1
|
4295.5 MFI
Interval 2871.5 to 6006.5
|
1991.5 MFI
Interval 1382.0 to 3244.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Peru
|
219.4 MFI
Interval 64.0 to 482.5
|
166.8 MFI
Interval 87.5 to 232.0
|
248.8 MFI
Interval 42.2 to 645.5
|
735 MFI
Interval 185.6 to 1681.5
|
1408 MFI
Interval 825.8 to 6131.5
|
2562 MFI
Interval 1195.0 to 4096.5
|
1141.8 MFI
Interval 401.2 to 2333.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total
|
82.9 MFI
Interval 13.1 to 297.1
|
30.8 MFI
Interval 6.7 to 148.8
|
144.2 MFI
Interval 43.8 to 556.8
|
424.6 MFI
Interval 62.1 to 1128.5
|
825.8 MFI
Interval 148.3 to 1768.2
|
993.9 MFI
Interval 322.2 to 2676.0
|
479 MFI
Interval 119.0 to 1701.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-USA
|
16.8 MFI
Interval 7.7 to 117.4
|
26.5 MFI
Interval 5.8 to 91.8
|
69.5 MFI
Interval 46.2 to 210.6
|
157.2 MFI
Interval 46.5 to 410.0
|
275.5 MFI
Interval 79.0 to 885.5
|
331 MFI
Interval 96.2 to 629.2
|
182.9 MFI
Interval 23.1 to 500.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Peru
|
—
|
—
|
37.2 MFI
Interval 11.8 to 66.8
|
165.5 MFI
Interval 86.2 to 1830.4
|
355.2 MFI
Interval 88.6 to 1011.6
|
1065.4 MFI
Interval 943.6 to 1187.2
|
774.2 MFI
Interval 774.2 to 774.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total
|
46.5 MFI
Interval 46.2 to 88.5
|
43.8 MFI
Interval 43.8 to 43.8
|
58.8 MFI
Interval 26.8 to 84.0
|
248.1 MFI
Interval 47.4 to 559.9
|
248.8 MFI
Interval 79.0 to 597.2
|
164.4 MFI
Interval 72.5 to 666.3
|
41.5 MFI
Interval 16.1 to 226.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-USA
|
46.5 MFI
Interval 46.2 to 88.5
|
43.8 MFI
Interval 43.8 to 43.8
|
62.1 MFI
Interval 43.9 to 93.2
|
330.8 MFI
Interval 47.8 to 557.9
|
171.9 MFI
Interval 26.5 to 261.6
|
91.2 MFI
Interval 51.1 to 146.6
|
38.5 MFI
Interval 14.1 to 89.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru
|
981 MFI
Interval 278.1 to 2451.1
|
981.8 MFI
Interval 517.1 to 1186.8
|
1302.2 MFI
Interval 241.9 to 3154.0
|
3766.2 MFI
Interval 791.0 to 6982.5
|
6168.2 MFI
Interval 3710.9 to 16496.9
|
9308.2 MFI
Interval 4772.2 to 14115.0
|
5188.8 MFI
Interval 1739.6 to 9367.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
383.8 MFI
Interval 65.6 to 1308.9
|
136.6 MFI
Interval 33.3 to 701.0
|
680.4 MFI
Interval 210.2 to 2929.4
|
1853.9 MFI
Interval 310.2 to 5121.7
|
3545.8 MFI
Interval 688.2 to 7389.3
|
3956.8 MFI
Interval 1477.6 to 9763.5
|
2181.8 MFI
Interval 512.0 to 7634.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA
|
83.1 MFI
Interval 40.0 to 541.0
|
94.2 MFI
Interval 22.2 to 451.0
|
431.8 MFI
Interval 231.0 to 1048.4
|
917 MFI
Interval 213.8 to 1827.2
|
1256.2 MFI
Interval 360.5 to 3764.8
|
1590.5 MFI
Interval 446.5 to 2773.2
|
836.2 MFI
Interval 123.1 to 2368.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru
|
—
|
—
|
189 MFI
Interval 44.8 to 435.2
|
579.8 MFI
Interval 302.5 to 5607.9
|
1510.8 MFI
Interval 431.6 to 3538.4
|
3434.4 MFI
Interval 3247.3 to 3621.4
|
3687.2 MFI
Interval 3687.2 to 3687.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
214.8 MFI
Interval 212.8 to 383.6
|
176.2 MFI
Interval 176.2 to 176.2
|
254.5 MFI
Interval 145.5 to 435.2
|
1045.5 MFI
Interval 219.2 to 2319.1
|
1118.8 MFI
Interval 407.9 to 2273.8
|
776.4 MFI
Interval 290.6 to 2512.9
|
141.9 MFI
Interval 63.4 to 960.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA
|
214.8 MFI
Interval 212.8 to 383.6
|
176.2 MFI
Interval 176.2 to 176.2
|
265.5 MFI
Interval 147.9 to 398.1
|
1357.2 MFI
Interval 220.0 to 2245.4
|
704.1 MFI
Interval 64.2 to 1122.1
|
421 MFI
Interval 158.7 to 729.1
|
139.8 MFI
Interval 59.4 to 430.4
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and enrollment group among America Cohort (USA and Peru only)
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 0-Peru
|
22 Participants
|
3 Participants
|
23 Participants
|
22 Participants
|
23 Participants
|
25 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 0-Total
|
37 Participants
|
15 Participants
|
51 Participants
|
47 Participants
|
43 Participants
|
49 Participants
|
93 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 0-USA
|
15 Participants
|
12 Participants
|
28 Participants
|
25 Participants
|
20 Participants
|
24 Participants
|
44 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 12-Peru
|
—
|
—
|
1 Participants
|
—
|
—
|
—
|
6 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 12-Total
|
—
|
1 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 12-USA
|
—
|
1 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
3 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 2-Peru
|
13 Participants
|
2 Participants
|
17 Participants
|
11 Participants
|
20 Participants
|
17 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 2-Total
|
22 Participants
|
6 Participants
|
33 Participants
|
29 Participants
|
30 Participants
|
30 Participants
|
41 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 2-USA
|
9 Participants
|
4 Participants
|
16 Participants
|
18 Participants
|
10 Participants
|
13 Participants
|
27 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 4-Peru
|
1 Participants
|
—
|
1 Participants
|
—
|
—
|
—
|
7 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 4-Total
|
1 Participants
|
1 Participants
|
2 Participants
|
—
|
2 Participants
|
2 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614 at Month 4-USA
|
—
|
1 Participants
|
1 Participants
|
—
|
2 Participants
|
2 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3,4, overall and by region and enrollment group among America Cohort (USA and Peru only)
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 0-Peru
|
179.3 Titer
Interval 68.2 to 399.8
|
684.8 Titer
Interval 83.9 to 1352.6
|
328.7 Titer
Interval 142.5 to 1377.7
|
1140.6 Titer
Interval 712.2 to 2224.6
|
3636.2 Titer
Interval 962.4 to 8836.3
|
2907.6 Titer
Interval 1731.0 to 9196.0
|
910.9 Titer
Interval 350.2 to 3607.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 0-Total
|
81.8 Titer
Interval 10.0 to 267.5
|
83.2 Titer
Interval 5.0 to 401.3
|
315.9 Titer
Interval 101.6 to 1078.9
|
743.7 Titer
Interval 225.1 to 1974.4
|
984.6 Titer
Interval 252.4 to 4078.2
|
1801.9 Titer
Interval 664.0 to 5198.6
|
518.2 Titer
Interval 84.6 to 1916.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 0-USA
|
40.1 Titer
Interval 5.0 to 105.9
|
62.2 Titer
Interval 5.0 to 210.0
|
235.6 Titer
Interval 101.5 to 1002.7
|
392.2 Titer
Interval 186.6 to 1569.3
|
316.8 Titer
Interval 100.8 to 1147.9
|
1232.5 Titer
Interval 350.7 to 2627.8
|
130.2 Titer
Interval 45.7 to 588.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 12-Peru
|
—
|
—
|
866.7 Titer
Interval 866.7 to 866.7
|
—
|
—
|
—
|
204.9 Titer
Interval 78.9 to 440.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 12-Total
|
—
|
346.4 Titer
Interval 346.4 to 346.4
|
737.7 Titer
Interval 673.2 to 802.2
|
1034.5 Titer
Interval 1034.5 to 1034.5
|
117.8 Titer
Interval 117.8 to 117.8
|
430.5 Titer
Interval 271.8 to 578.4
|
232.2 Titer
Interval 62.7 to 350.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 12-USA
|
—
|
346.4 Titer
Interval 346.4 to 346.4
|
608.8 Titer
Interval 608.8 to 608.8
|
1034.5 Titer
Interval 1034.5 to 1034.5
|
117.8 Titer
Interval 117.8 to 117.8
|
430.5 Titer
Interval 271.8 to 578.4
|
232.2 Titer
Interval 60.3 to 281.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 2-Peru
|
30.6 Titer
Interval 10.0 to 48.3
|
167.6 Titer
Interval 106.9 to 228.4
|
56.8 Titer
Interval 10.0 to 99.6
|
154.5 Titer
Interval 54.4 to 428.2
|
336.5 Titer
Interval 202.3 to 650.4
|
951.8 Titer
Interval 335.2 to 1387.5
|
301.5 Titer
Interval 193.6 to 653.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 2-Total
|
35.1 Titer
Interval 10.0 to 56.2
|
48.6 Titer
Interval 35.9 to 186.1
|
70.8 Titer
Interval 10.0 to 137.9
|
204 Titer
Interval 63.5 to 555.9
|
268.3 Titer
Interval 65.0 to 703.7
|
458.1 Titer
Interval 289.2 to 1173.5
|
139.8 Titer
Interval 40.7 to 340.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 2-USA
|
38.3 Titer
Interval 26.1 to 78.2
|
48.6 Titer
Interval 15.6 to 126.4
|
89.9 Titer
Interval 44.9 to 149.6
|
282.8 Titer
Interval 112.4 to 653.9
|
148.3 Titer
Interval 23.9 to 802.2
|
358 Titer
Interval 176.8 to 479.9
|
61.2 Titer
Interval 24.4 to 225.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 4-Peru
|
113.2 Titer
Interval 113.2 to 113.2
|
—
|
29.4 Titer
Interval 29.4 to 29.4
|
—
|
—
|
—
|
232.2 Titer
Interval 118.2 to 328.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 4-Total
|
113.2 Titer
Interval 113.2 to 113.2
|
253.3 Titer
Interval 253.3 to 253.3
|
239.8 Titer
Interval 134.6 to 345.0
|
—
|
120.2 Titer
Interval 62.6 to 419.6
|
690.4 Titer
Interval 518.4 to 862.5
|
187.1 Titer
Interval 89.5 to 346.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID50 at Month 4-USA
|
—
|
253.3 Titer
Interval 253.3 to 253.3
|
450.2 Titer
Interval 450.2 to 450.2
|
—
|
120.2 Titer
Interval 62.6 to 419.6
|
690.4 Titer
Interval 518.4 to 862.5
|
152.4 Titer
Interval 85.5 to 323.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 0-Peru
|
42.5 Titer
Interval 25.5 to 120.2
|
103.3 Titer
Interval 26.4 to 187.3
|
80.4 Titer
Interval 39.2 to 225.3
|
209 Titer
Interval 105.6 to 565.1
|
587.9 Titer
Interval 226.1 to 962.0
|
622.4 Titer
Interval 531.4 to 1101.3
|
215.5 Titer
Interval 99.1 to 842.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 0-Total
|
29.1 Titer
Interval 10.0 to 68.8
|
26.8 Titer
Interval 5.0 to 110.9
|
56.7 Titer
Interval 29.1 to 179.8
|
144.4 Titer
Interval 53.5 to 517.4
|
225.8 Titer
Interval 77.9 to 648.9
|
554.4 Titer
Interval 172.3 to 948.7
|
130.2 Titer
Interval 27.8 to 454.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 0-USA
|
10 Titer
Interval 5.0 to 34.7
|
22.1 Titer
Interval 5.0 to 50.1
|
44.1 Titer
Interval 27.9 to 145.7
|
110 Titer
Interval 43.8 to 310.0
|
121.4 Titer
Interval 31.9 to 217.4
|
240.9 Titer
Interval 105.7 to 615.5
|
36.6 Titer
Interval 10.0 to 148.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 12-Peru
|
—
|
—
|
259.2 Titer
Interval 259.2 to 259.2
|
—
|
—
|
—
|
75.5 Titer
Interval 46.2 to 127.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 12-Total
|
—
|
120.4 Titer
Interval 120.4 to 120.4
|
220.7 Titer
Interval 201.4 to 239.9
|
334 Titer
Interval 334.0 to 334.0
|
44.1 Titer
Interval 44.1 to 44.1
|
128.3 Titer
Interval 82.8 to 157.0
|
73.5 Titer
Interval 27.5 to 123.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 12-USA
|
—
|
120.4 Titer
Interval 120.4 to 120.4
|
182.2 Titer
Interval 182.2 to 182.2
|
334 Titer
Interval 334.0 to 334.0
|
44.1 Titer
Interval 44.1 to 44.1
|
128.3 Titer
Interval 82.8 to 157.0
|
73.5 Titer
Interval 24.4 to 111.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 2-Peru
|
10 Titer
Interval 10.0 to 20.3
|
84.6 Titer
Interval 53.6 to 115.5
|
25.5 Titer
Interval 10.0 to 35.3
|
39.6 Titer
Interval 23.5 to 130.4
|
129.9 Titer
Interval 56.6 to 187.6
|
302.5 Titer
Interval 116.0 to 518.7
|
124.2 Titer
Interval 58.5 to 175.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 2-Total
|
10 Titer
Interval 10.0 to 23.9
|
22.6 Titer
Interval 16.6 to 69.8
|
25.7 Titer
Interval 10.0 to 36.9
|
48.7 Titer
Interval 28.5 to 171.2
|
107.5 Titer
Interval 26.4 to 188.1
|
159.3 Titer
Interval 62.4 to 338.3
|
47.6 Titer
Interval 10.0 to 126.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 2-USA
|
10 Titer
Interval 10.0 to 27.4
|
21.4 Titer
Interval 8.9 to 43.3
|
26.5 Titer
Interval 10.0 to 43.1
|
51 Titer
Interval 35.4 to 182.7
|
50.6 Titer
Interval 10.0 to 191.8
|
82.1 Titer
Interval 44.8 to 172.8
|
22.9 Titer
Interval 10.0 to 69.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 4-Peru
|
37.3 Titer
Interval 37.3 to 37.3
|
—
|
13.7 Titer
Interval 13.7 to 13.7
|
—
|
—
|
—
|
73.5 Titer
Interval 43.2 to 122.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 4-Total
|
37.3 Titer
Interval 37.3 to 37.3
|
80.7 Titer
Interval 80.7 to 80.7
|
76 Titer
Interval 44.8 to 107.1
|
—
|
46.6 Titer
Interval 25.8 to 111.8
|
227.2 Titer
Interval 173.8 to 280.6
|
62.6 Titer
Interval 30.6 to 119.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
VRC7480_G614-ID80 at Month 4-USA
|
—
|
80.7 Titer
Interval 80.7 to 80.7
|
138.2 Titer
Interval 138.2 to 138.2
|
—
|
46.6 Titer
Interval 25.8 to 111.8
|
227.2 Titer
Interval 173.8 to 280.6
|
53.4 Titer
Interval 29.1 to 115.6
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and enrollment group among Africa Cohort
Outcome measures
| Measure |
Group 1A
n=79 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=17 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=129 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=26 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=73 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=24 Participants
2B: Hospitalized, \> 55
|
Group 3
n=24 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 0-RSA
|
48 Participants
|
11 Participants
|
87 Participants
|
17 Participants
|
37 Participants
|
13 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 0-Total
|
59 Participants
|
14 Participants
|
110 Participants
|
22 Participants
|
51 Participants
|
18 Participants
|
18 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 0-non-RSA
|
11 Participants
|
3 Participants
|
23 Participants
|
5 Participants
|
14 Participants
|
5 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 12-RSA
|
31 Participants
|
2 Participants
|
41 Participants
|
4 Participants
|
23 Participants
|
6 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 12-Total
|
44 Participants
|
5 Participants
|
68 Participants
|
7 Participants
|
33 Participants
|
9 Participants
|
10 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 12-non-RSA
|
13 Participants
|
3 Participants
|
27 Participants
|
3 Participants
|
10 Participants
|
3 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 2-RSA
|
32 Participants
|
4 Participants
|
60 Participants
|
10 Participants
|
27 Participants
|
8 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 2-Total
|
43 Participants
|
7 Participants
|
80 Participants
|
13 Participants
|
43 Participants
|
12 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 2-non-RSA
|
11 Participants
|
3 Participants
|
20 Participants
|
3 Participants
|
16 Participants
|
4 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 4-RSA
|
34 Participants
|
3 Participants
|
58 Participants
|
10 Participants
|
27 Participants
|
6 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 4-Total
|
46 Participants
|
6 Participants
|
79 Participants
|
13 Participants
|
40 Participants
|
11 Participants
|
13 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G at Month 4-non-RSA
|
12 Participants
|
3 Participants
|
21 Participants
|
3 Participants
|
13 Participants
|
5 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and enrollment group among Africa Cohort
Outcome measures
| Measure |
Group 1A
n=79 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=17 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=129 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=26 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=73 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=24 Participants
2B: Hospitalized, \> 55
|
Group 3
n=24 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 0-RSA
|
169 Titer
Interval 45.7 to 350.5
|
358.7 Titer
Interval 212.6 to 1295.5
|
303.2 Titer
Interval 126.7 to 1449.2
|
478.7 Titer
Interval 190.5 to 1039.8
|
501.5 Titer
Interval 172.5 to 1157.5
|
1570.3 Titer
Interval 947.6 to 2243.8
|
1950.5 Titer
Interval 320.3 to 2365.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 0-Total
|
169.6 Titer
Interval 34.2 to 309.4
|
239.3 Titer
Interval 153.0 to 723.5
|
288.3 Titer
Interval 77.5 to 1183.3
|
761.8 Titer
Interval 226.6 to 1071.6
|
543.4 Titer
Interval 135.0 to 1560.6
|
1645.9 Titer
Interval 994.1 to 2637.6
|
1141.3 Titer
Interval 331.1 to 2336.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 0-non-RSA
|
183.5 Titer
Interval 6.6 to 232.5
|
59.5 Titer
Interval 33.9 to 74.2
|
155.4 Titer
Interval 7.5 to 418.9
|
1149 Titer
Interval 909.9 to 1860.1
|
971 Titer
Interval 129.4 to 1685.7
|
2610.3 Titer
Interval 1535.3 to 3762.0
|
637.8 Titer
Interval 363.3 to 2012.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 12-RSA
|
312.6 Titer
Interval 99.3 to 2118.2
|
7946.9 Titer
Interval 7215.5 to 8678.4
|
2071.9 Titer
Interval 405.6 to 9058.9
|
18743.3 Titer
Interval 4428.6 to 86976.3
|
2700 Titer
Interval 1307.3 to 11734.9
|
13387 Titer
Interval 5435.6 to 23224.6
|
296.8 Titer
Interval 248.8 to 2950.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 12-Total
|
451.6 Titer
Interval 175.0 to 2191.2
|
6268.4 Titer
Interval 612.4 to 6484.0
|
796.8 Titer
Interval 286.6 to 7428.8
|
5616.2 Titer
Interval 814.7 to 19901.6
|
2443.4 Titer
Interval 654.1 to 7211.4
|
11384.1 Titer
Interval 3452.8 to 25836.3
|
600.5 Titer
Interval 277.5 to 13651.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 12-non-RSA
|
1305.9 Titer
Interval 342.3 to 2191.2
|
612.4 Titer
Interval 362.0 to 3440.4
|
426.7 Titer
Interval 225.0 to 1844.7
|
763.5 Titer
Interval 595.0 to 4348.2
|
1657.7 Titer
Interval 382.1 to 5252.7
|
3743.2 Titer
Interval 1976.1 to 28947.3
|
4857.5 Titer
Interval 283.5 to 21796.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 2-RSA
|
82.3 Titer
Interval 10.0 to 208.0
|
156.4 Titer
Interval 76.1 to 276.7
|
121 Titer
Interval 57.8 to 518.5
|
377.4 Titer
Interval 193.0 to 805.4
|
270.7 Titer
Interval 76.7 to 823.3
|
783.2 Titer
Interval 432.4 to 1058.8
|
627.8 Titer
Interval 317.6 to 1373.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 2-Total
|
68.3 Titer
Interval 10.0 to 197.6
|
71.4 Titer
Interval 53.5 to 156.4
|
95.3 Titer
Interval 30.9 to 320.4
|
356.5 Titer
Interval 238.6 to 726.4
|
244.6 Titer
Interval 64.1 to 621.5
|
852.9 Titer
Interval 477.7 to 1354.0
|
422 Titer
Interval 122.5 to 1104.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 2-non-RSA
|
50.9 Titer
Interval 7.5 to 179.6
|
52.8 Titer
Interval 30.5 to 62.1
|
43.2 Titer
Interval 5.0 to 141.6
|
356.5 Titer
Interval 297.5 to 410.8
|
218.7 Titer
Interval 49.4 to 404.2
|
1698.5 Titer
Interval 769.6 to 4066.8
|
122.5 Titer
Interval 43.3 to 946.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 4-RSA
|
211.1 Titer
Interval 47.2 to 636.3
|
142.7 Titer
Interval 109.5 to 191.7
|
323.3 Titer
Interval 79.8 to 971.3
|
396.2 Titer
Interval 208.6 to 900.2
|
446.4 Titer
Interval 105.3 to 1347.6
|
772.5 Titer
Interval 356.5 to 1276.4
|
720.4 Titer
Interval 492.5 to 1095.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 4-Total
|
163 Titer
Interval 51.4 to 383.1
|
130.7 Titer
Interval 86.9 to 147.1
|
252.1 Titer
Interval 62.2 to 869.3
|
458.3 Titer
Interval 261.0 to 569.4
|
450.3 Titer
Interval 97.2 to 1132.0
|
954.2 Titer
Interval 519.4 to 2129.6
|
633.8 Titer
Interval 267.7 to 1152.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 4-non-RSA
|
135.2 Titer
Interval 76.8 to 185.4
|
118.7 Titer
Interval 63.5 to 133.6
|
99.2 Titer
Interval 10.0 to 276.5
|
520.5 Titer
Interval 416.5 to 538.9
|
538 Titer
Interval 77.4 to 1126.2
|
2671.3 Titer
Interval 954.2 to 4229.0
|
537.5 Titer
Interval 172.5 to 1314.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 0-RSA
|
40.2 Titer
Interval 10.0 to 117.1
|
82.2 Titer
Interval 52.2 to 229.0
|
78.3 Titer
Interval 34.4 to 340.5
|
181.5 Titer
Interval 51.7 to 207.5
|
131.6 Titer
Interval 37.3 to 394.4
|
572.9 Titer
Interval 258.7 to 605.8
|
399.5 Titer
Interval 117.0 to 680.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 0-Total
|
38.7 Titer
Interval 10.0 to 95.8
|
58.2 Titer
Interval 34.5 to 212.8
|
62.8 Titer
Interval 27.5 to 214.1
|
190.8 Titer
Interval 59.5 to 309.7
|
138.1 Titer
Interval 36.7 to 394.4
|
573.5 Titer
Interval 275.7 to 609.3
|
283.5 Titer
Interval 101.8 to 664.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 0-non-RSA
|
36.7 Titer
Interval 6.3 to 49.6
|
24.7 Titer
Interval 16.1 to 27.1
|
31.9 Titer
Interval 7.5 to 117.6
|
274.7 Titer
Interval 182.1 to 612.6
|
237.2 Titer
Interval 35.3 to 438.9
|
610.4 Titer
Interval 326.9 to 1009.9
|
167.5 Titer
Interval 101.4 to 615.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 12-RSA
|
103.4 Titer
Interval 35.4 to 719.6
|
2108.9 Titer
Interval 1594.0 to 2623.7
|
605.6 Titer
Interval 114.7 to 2737.1
|
4870.3 Titer
Interval 990.6 to 26125.8
|
698.9 Titer
Interval 270.0 to 3349.1
|
3519.1 Titer
Interval 1372.1 to 5869.0
|
62.8 Titer
Interval 59.0 to 720.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 12-Total
|
135.6 Titer
Interval 39.0 to 708.1
|
945.6 Titer
Interval 161.2 to 1079.1
|
217.2 Titer
Interval 103.5 to 1729.5
|
1237.1 Titer
Interval 212.0 to 5302.0
|
694.1 Titer
Interval 224.0 to 2500.0
|
3310.6 Titer
Interval 725.9 to 6582.8
|
190.8 Titer
Interval 81.4 to 3046.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 12-non-RSA
|
431.1 Titer
Interval 100.5 to 673.1
|
161.2 Titer
Interval 96.5 to 553.4
|
137.4 Titer
Interval 65.5 to 600.9
|
173.2 Titer
Interval 144.4 to 1136.9
|
437.3 Titer
Interval 161.7 to 1717.0
|
971.6 Titer
Interval 517.2 to 8470.0
|
1389.2 Titer
Interval 117.0 to 5979.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 2-RSA
|
31.7 Titer
Interval 10.0 to 47.1
|
35.1 Titer
Interval 24.9 to 52.1
|
36.4 Titer
Interval 10.0 to 139.5
|
125.7 Titer
Interval 44.2 to 191.7
|
92.5 Titer
Interval 31.0 to 228.2
|
184.8 Titer
Interval 155.4 to 199.6
|
173.5 Titer
Interval 87.3 to 408.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 2-Total
|
20.9 Titer
Interval 10.0 to 41.2
|
23.6 Titer
Interval 16.2 to 35.1
|
34 Titer
Interval 10.0 to 91.8
|
122.2 Titer
Interval 43.6 to 182.3
|
89.2 Titer
Interval 26.6 to 167.3
|
188.6 Titer
Interval 155.4 to 224.0
|
105 Titer
Interval 31.3 to 302.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 2-non-RSA
|
10 Titer
Interval 6.3 to 29.6
|
22.5 Titer
Interval 15.0 to 23.1
|
10 Titer
Interval 5.0 to 37.8
|
122.2 Titer
Interval 82.9 to 136.6
|
74.1 Titer
Interval 12.2 to 119.7
|
351.7 Titer
Interval 162.8 to 797.0
|
31.3 Titer
Interval 21.4 to 259.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 4-RSA
|
51.9 Titer
Interval 10.0 to 163.8
|
31.9 Titer
Interval 27.3 to 32.9
|
100.9 Titer
Interval 26.1 to 236.5
|
101 Titer
Interval 40.4 to 214.2
|
121.9 Titer
Interval 37.6 to 408.7
|
190.4 Titer
Interval 92.3 to 441.3
|
164.2 Titer
Interval 141.4 to 251.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 4-Total
|
42.1 Titer
Interval 10.0 to 130.8
|
32.9 Titer
Interval 25.0 to 33.8
|
66.6 Titer
Interval 21.8 to 206.1
|
116.4 Titer
Interval 55.4 to 182.5
|
124 Titer
Interval 33.7 to 288.9
|
234.7 Titer
Interval 151.2 to 674.6
|
164.2 Titer
Interval 65.9 to 286.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 4-non-RSA
|
34.2 Titer
Interval 26.6 to 43.3
|
33.8 Titer
Interval 20.7 to 36.3
|
36.4 Titer
Interval 10.0 to 89.2
|
147.3 Titer
Interval 133.3 to 168.1
|
163.9 Titer
Interval 29.8 to 276.1
|
717.7 Titer
Interval 234.7 to 749.6
|
144.5 Titer
Interval 45.6 to 386.7
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population (USA and Peru only), all available data at each visit
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and enrollment group among America Cohort (USA and Peru only)
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=81 Participants
3: Clinical spectrums
|
Group 8
n=20 Participants
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru
|
8 Participants
|
2 Participants
|
11 Participants
|
13 Participants
|
17 Participants
|
17 Participants
|
19 Participants
|
5 Participants
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total
|
10 Participants
|
4 Participants
|
14 Participants
|
22 Participants
|
28 Participants
|
33 Participants
|
29 Participants
|
12 Participants
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA
|
2 Participants
|
2 Participants
|
3 Participants
|
9 Participants
|
11 Participants
|
16 Participants
|
10 Participants
|
7 Participants
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru
|
7 Participants
|
3 Participants
|
13 Participants
|
13 Participants
|
18 Participants
|
16 Participants
|
19 Participants
|
6 Participants
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total
|
9 Participants
|
6 Participants
|
20 Participants
|
21 Participants
|
27 Participants
|
27 Participants
|
30 Participants
|
13 Participants
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA
|
2 Participants
|
3 Participants
|
7 Participants
|
8 Participants
|
9 Participants
|
11 Participants
|
11 Participants
|
7 Participants
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population (USA and Peru only), all available data at each visit
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and enrollment group among America Cohort
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=81 Participants
3: Clinical spectrums
|
Group 8
n=20 Participants
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru
|
1.5 Percent CD107a+ NK Cells
Interval 0.5 to 4.4
|
3.7 Percent CD107a+ NK Cells
Interval 1.1 to 6.3
|
5 Percent CD107a+ NK Cells
Interval 1.9 to 13.8
|
8.8 Percent CD107a+ NK Cells
Interval 4.5 to 15.1
|
12.6 Percent CD107a+ NK Cells
Interval 6.5 to 14.9
|
13.6 Percent CD107a+ NK Cells
Interval 12.4 to 20.9
|
8.9 Percent CD107a+ NK Cells
Interval 5.3 to 17.3
|
15.5 Percent CD107a+ NK Cells
Interval 11.6 to 22.4
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total
|
1.2 Percent CD107a+ NK Cells
Interval 0.0 to 4.1
|
0.8 Percent CD107a+ NK Cells
Interval 0.0 to 2.6
|
3.4 Percent CD107a+ NK Cells
Interval 1.0 to 9.4
|
6.5 Percent CD107a+ NK Cells
Interval 3.5 to 11.8
|
10.8 Percent CD107a+ NK Cells
Interval 4.6 to 14.8
|
14.1 Percent CD107a+ NK Cells
Interval 11.6 to 18.8
|
6.3 Percent CD107a+ NK Cells
Interval 2.1 to 14.0
|
10.8 Percent CD107a+ NK Cells
Interval 2.0 to 16.0
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA
|
1 Percent CD107a+ NK Cells
Interval 0.0 to 2.1
|
0.3 Percent CD107a+ NK Cells
Interval 0.0 to 2.0
|
1.4 Percent CD107a+ NK Cells
Interval 0.3 to 3.9
|
4.6 Percent CD107a+ NK Cells
Interval 3.5 to 7.8
|
7.7 Percent CD107a+ NK Cells
Interval 4.3 to 13.3
|
15.3 Percent CD107a+ NK Cells
Interval 10.0 to 18.1
|
3.3 Percent CD107a+ NK Cells
Interval 1.1 to 7.5
|
6.7 Percent CD107a+ NK Cells
Interval 1.6 to 12.9
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru
|
4.5 Percent CD107a+ NK Cells
Interval 2.2 to 8.0
|
8.3 Percent CD107a+ NK Cells
Interval 4.3 to 11.8
|
8 Percent CD107a+ NK Cells
Interval 3.6 to 12.3
|
8.6 Percent CD107a+ NK Cells
Interval 5.3 to 11.3
|
15.7 Percent CD107a+ NK Cells
Interval 11.4 to 18.0
|
15.2 Percent CD107a+ NK Cells
Interval 12.6 to 18.7
|
9.8 Percent CD107a+ NK Cells
Interval 6.6 to 14.3
|
16.5 Percent CD107a+ NK Cells
Interval 15.1 to 16.8
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total
|
3.4 Percent CD107a+ NK Cells
Interval 0.5 to 5.3
|
2.8 Percent CD107a+ NK Cells
Interval 0.0 to 5.9
|
6.7 Percent CD107a+ NK Cells
Interval 4.1 to 12.4
|
6.8 Percent CD107a+ NK Cells
Interval 3.8 to 10.2
|
13.1 Percent CD107a+ NK Cells
Interval 7.2 to 16.9
|
12.5 Percent CD107a+ NK Cells
Interval 5.8 to 15.6
|
6.8 Percent CD107a+ NK Cells
Interval 3.6 to 11.2
|
8.8 Percent CD107a+ NK Cells
Interval 4.7 to 15.2
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA
|
1.4 Percent CD107a+ NK Cells
Interval 0.0 to 4.3
|
1.4 Percent CD107a+ NK Cells
Interval 0.0 to 4.7
|
5.6 Percent CD107a+ NK Cells
Interval 4.2 to 9.9
|
5.8 Percent CD107a+ NK Cells
Interval 2.7 to 8.8
|
9.4 Percent CD107a+ NK Cells
Interval 3.3 to 13.0
|
7.7 Percent CD107a+ NK Cells
Interval 2.8 to 12.3
|
4.5 Percent CD107a+ NK Cells
Interval 2.8 to 8.2
|
5.8 Percent CD107a+ NK Cells
Interval 3.5 to 8.6
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population (USA and Peru only), all available data at each visit
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1 , overall and by region and enrollment group among America Cohort (USA and Peru only)
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Any COV2 at Month 0-Total
|
21 Participants
|
11 Participants
|
31 Participants
|
46 Participants
|
37 Participants
|
47 Participants
|
79 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Any COV2 at Month 0-USA
|
9 Participants
|
8 Participants
|
18 Participants
|
23 Participants
|
17 Participants
|
22 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-E M at Month 0-Peru
|
5 Participants
|
2 Participants
|
9 Participants
|
20 Participants
|
17 Participants
|
22 Participants
|
40 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-E M at Month 0-Total
|
10 Participants
|
5 Participants
|
20 Participants
|
40 Participants
|
32 Participants
|
39 Participants
|
57 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-E M at Month 0-USA
|
5 Participants
|
3 Participants
|
11 Participants
|
20 Participants
|
15 Participants
|
17 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF3a6 at Month 0-Total
|
3 Participants
|
5 Participants
|
7 Participants
|
29 Participants
|
22 Participants
|
29 Participants
|
31 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF3a6 at Month 0-USA
|
2 Participants
|
3 Participants
|
4 Participants
|
12 Participants
|
13 Participants
|
17 Participants
|
10 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-Total
|
3 Participants
|
5 Participants
|
8 Participants
|
30 Participants
|
21 Participants
|
32 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-USA
|
0 Participants
|
3 Participants
|
4 Participants
|
13 Participants
|
9 Participants
|
13 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S1 at Month 0-Peru
|
8 Participants
|
2 Participants
|
12 Participants
|
20 Participants
|
19 Participants
|
24 Participants
|
41 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S1 at Month 0-Total
|
12 Participants
|
7 Participants
|
25 Participants
|
41 Participants
|
35 Participants
|
45 Participants
|
66 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-N at Month 0-Peru
|
9 Participants
|
2 Participants
|
10 Participants
|
21 Participants
|
16 Participants
|
21 Participants
|
37 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-N at Month 0-Total
|
14 Participants
|
5 Participants
|
24 Participants
|
44 Participants
|
30 Participants
|
43 Participants
|
61 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-N at Month 0-USA
|
5 Participants
|
3 Participants
|
14 Participants
|
23 Participants
|
14 Participants
|
22 Participants
|
24 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF3a6 at Month 0-Peru
|
1 Participants
|
2 Participants
|
3 Participants
|
17 Participants
|
9 Participants
|
12 Participants
|
21 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S1 at Month 0-USA
|
4 Participants
|
5 Participants
|
13 Participants
|
21 Participants
|
16 Participants
|
21 Participants
|
25 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Any COV2 at Month 0-Peru
|
12 Participants
|
3 Participants
|
13 Participants
|
23 Participants
|
20 Participants
|
25 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S2 at Month 0-Peru
|
10 Participants
|
2 Participants
|
7 Participants
|
18 Participants
|
16 Participants
|
24 Participants
|
39 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-Peru
|
3 Participants
|
2 Participants
|
4 Participants
|
17 Participants
|
12 Participants
|
19 Participants
|
29 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S2 at Month 0-Total
|
13 Participants
|
8 Participants
|
19 Participants
|
37 Participants
|
32 Participants
|
45 Participants
|
65 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S2 at Month 0-USA
|
3 Participants
|
6 Participants
|
12 Participants
|
19 Participants
|
16 Participants
|
21 Participants
|
26 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Spike at Month 0-Peru
|
11 Participants
|
2 Participants
|
12 Participants
|
20 Participants
|
20 Participants
|
25 Participants
|
45 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Spike at Month 0-Total
|
16 Participants
|
8 Participants
|
27 Participants
|
43 Participants
|
37 Participants
|
46 Participants
|
75 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Spike at Month 0-USA
|
5 Participants
|
6 Participants
|
15 Participants
|
23 Participants
|
17 Participants
|
21 Participants
|
30 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Any COV2 at Month 0-Peru
|
13 Participants
|
1 Participants
|
17 Participants
|
18 Participants
|
19 Participants
|
19 Participants
|
35 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Any COV2 at Month 0-Total
|
23 Participants
|
8 Participants
|
33 Participants
|
37 Participants
|
35 Participants
|
33 Participants
|
63 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Any COV2 at Month 0-USA
|
10 Participants
|
7 Participants
|
16 Participants
|
19 Participants
|
16 Participants
|
14 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-E M at Month 0-Peru
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-E M at Month 0-Total
|
1 Participants
|
1 Participants
|
3 Participants
|
5 Participants
|
3 Participants
|
7 Participants
|
10 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-E M at Month 0-USA
|
1 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
1 Participants
|
4 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-N at Month 0-Peru
|
10 Participants
|
1 Participants
|
15 Participants
|
18 Participants
|
17 Participants
|
16 Participants
|
31 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-N at Month 0-Total
|
19 Participants
|
7 Participants
|
26 Participants
|
36 Participants
|
31 Participants
|
26 Participants
|
55 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-N at Month 0-USA
|
9 Participants
|
6 Participants
|
11 Participants
|
18 Participants
|
14 Participants
|
10 Participants
|
24 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF3a6 at Month 0-Peru
|
4 Participants
|
0 Participants
|
6 Participants
|
8 Participants
|
11 Participants
|
7 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF3a6 at Month 0-Total
|
6 Participants
|
2 Participants
|
8 Participants
|
14 Participants
|
15 Participants
|
13 Participants
|
22 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF3a6 at Month 0-USA
|
2 Participants
|
2 Participants
|
2 Participants
|
6 Participants
|
4 Participants
|
6 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-Peru
|
3 Participants
|
0 Participants
|
6 Participants
|
9 Participants
|
11 Participants
|
8 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-Total
|
5 Participants
|
0 Participants
|
6 Participants
|
14 Participants
|
15 Participants
|
11 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-USA
|
2 Participants
|
0 Participants
|
0 Participants
|
5 Participants
|
4 Participants
|
3 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S1 at Month 0-Peru
|
1 Participants
|
0 Participants
|
5 Participants
|
8 Participants
|
7 Participants
|
6 Participants
|
15 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S1 at Month 0-Total
|
1 Participants
|
0 Participants
|
13 Participants
|
15 Participants
|
11 Participants
|
10 Participants
|
21 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S1 at Month 0-USA
|
0 Participants
|
0 Participants
|
8 Participants
|
7 Participants
|
4 Participants
|
4 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S2 at Month 0-Peru
|
3 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S2 at Month 0-Total
|
4 Participants
|
0 Participants
|
4 Participants
|
5 Participants
|
6 Participants
|
3 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S2 at Month 0-USA
|
1 Participants
|
0 Participants
|
3 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Spike at Month 0-Peru
|
4 Participants
|
0 Participants
|
5 Participants
|
9 Participants
|
7 Participants
|
6 Participants
|
16 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Spike at Month 0-Total
|
5 Participants
|
0 Participants
|
15 Participants
|
17 Participants
|
12 Participants
|
10 Participants
|
23 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Spike at Month 0-USA
|
1 Participants
|
0 Participants
|
10 Participants
|
8 Participants
|
5 Participants
|
4 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population among positive responders (USA and Peru only), all available data at each visit
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and enrollment group among America Cohort positive responders (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Any COV2 at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-E M at Month 0-Peru
|
—
|
—
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-E M at Month 0-Total
|
2.3 % T cells expressing IFN-g/IL-2
Interval 2.3 to 2.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-E M at Month 0-USA
|
2.3 % T cells expressing IFN-g/IL-2
Interval 2.3 to 2.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.7 to 0.7
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-N at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.1 to 1.0
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 3.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-N at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.9
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 1.0
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-N at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Any COV2 at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.5
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.6
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF3a6 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF3a6 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.9
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF3a6 at Month 0-USA
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
1 % T cells expressing IFN-g/IL-2
Interval 0.5 to 2.0
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-USA
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
—
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S1 at Month 0-Peru
|
0 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.0
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S1 at Month 0-Total
|
0 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.0
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S1 at Month 0-USA
|
—
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S2 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.4 to 0.4
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.9
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S2 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.9
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-S2 at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.4 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Spike at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Spike at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Spike at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Any COV2 at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.6
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.4
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.1
|
1 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.5
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Any COV2 at Month 0-Total
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.6
|
0.8 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.2
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.1
|
1 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.5
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Any COV2 at Month 0-USA
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.0
|
1 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.4
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-E M at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-E M at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-E M at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-N at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF3a6 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF3a6 at Month 0-Total
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.9
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF3a6 at Month 0-USA
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.7 to 1.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-USA
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S1 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S1 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S1 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S2 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S2 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-S2 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Spike at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Spike at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD4+-Spike at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
CD8+-Any COV2 at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.3
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 2.0
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.7
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.2 to 3.8
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0.Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). There is no positivity call for B cell phenotypic data. The magnitude is B cell subset frequency. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and enrollment group among America Cohort (USA and Peru only)
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-Peru
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.03
|
0 percentage of cells
Interval 0.0 to 0.02
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.03 percentage of cells
Interval 0.01 to 0.08
|
0 percentage of cells
Interval 0.0 to 0.03
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-Total
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.02 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.05
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-USA
|
0 percentage of cells
Interval 0.0 to 0.07
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.05
|
0 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-Peru
|
0.08 percentage of cells
Interval 0.04 to 0.15
|
0.23 percentage of cells
Interval 0.04 to 0.41
|
0.1 percentage of cells
Interval 0.04 to 0.17
|
0.25 percentage of cells
Interval 0.1 to 0.75
|
0.14 percentage of cells
Interval 0.08 to 0.29
|
0.28 percentage of cells
Interval 0.13 to 0.45
|
0.18 percentage of cells
Interval 0.12 to 0.32
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-Total
|
0.07 percentage of cells
Interval 0.01 to 0.15
|
0.09 percentage of cells
Interval 0.0 to 0.28
|
0.12 percentage of cells
Interval 0.05 to 0.2
|
0.24 percentage of cells
Interval 0.09 to 0.49
|
0.16 percentage of cells
Interval 0.08 to 0.33
|
0.28 percentage of cells
Interval 0.12 to 0.41
|
0.16 percentage of cells
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-USA
|
0.06 percentage of cells
Interval 0.0 to 0.16
|
0.09 percentage of cells
Interval 0.0 to 0.26
|
0.15 percentage of cells
Interval 0.06 to 0.22
|
0.21 percentage of cells
Interval 0.08 to 0.4
|
0.21 percentage of cells
Interval 0.08 to 0.42
|
0.25 percentage of cells
Interval 0.1 to 0.37
|
0.12 percentage of cells
Interval 0.05 to 0.23
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-Peru
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.0
|
0.02 percentage of cells
Interval 0.0 to 0.11
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-Total
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.03
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.04
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-USA
|
0 percentage of cells
Interval 0.0 to 0.04
|
0 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.02
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ of Total B Cells-Peru
|
0.05 percentage of cells
Interval 0.04 to 0.07
|
0.05 percentage of cells
Interval 0.01 to 0.13
|
0.06 percentage of cells
Interval 0.04 to 0.08
|
0.14 percentage of cells
Interval 0.07 to 0.65
|
0.06 percentage of cells
Interval 0.04 to 0.1
|
0.11 percentage of cells
Interval 0.07 to 0.19
|
0.1 percentage of cells
Interval 0.07 to 0.14
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ of Total B Cells-Total
|
0.05 percentage of cells
Interval 0.02 to 0.1
|
0.07 percentage of cells
Interval 0.03 to 0.12
|
0.05 percentage of cells
Interval 0.04 to 0.08
|
0.1 percentage of cells
Interval 0.04 to 0.14
|
0.07 percentage of cells
Interval 0.04 to 0.11
|
0.07 percentage of cells
Interval 0.05 to 0.12
|
0.07 percentage of cells
Interval 0.04 to 0.12
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%RBD+ of Total B Cells-USA
|
0.04 percentage of cells
Interval 0.01 to 0.21
|
0.07 percentage of cells
Interval 0.04 to 0.12
|
0.05 percentage of cells
Interval 0.04 to 0.06
|
0.07 percentage of cells
Interval 0.04 to 0.1
|
0.09 percentage of cells
Interval 0.02 to 0.17
|
0.06 percentage of cells
Interval 0.03 to 0.07
|
0.04 percentage of cells
Interval 0.03 to 0.06
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgA+ of Memory B Cells-Peru
|
0.06 percentage of cells
Interval 0.03 to 0.1
|
0.05 percentage of cells
Interval 0.02 to 0.08
|
0.08 percentage of cells
Interval 0.03 to 0.11
|
0.08 percentage of cells
Interval 0.05 to 0.12
|
0.05 percentage of cells
Interval 0.03 to 0.12
|
0.11 percentage of cells
Interval 0.05 to 0.38
|
0.07 percentage of cells
Interval 0.03 to 0.12
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgA+ of Memory B Cells-Total
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
0.04 percentage of cells
Interval 0.01 to 0.07
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.07 percentage of cells
Interval 0.03 to 0.12
|
0.06 percentage of cells
Interval 0.03 to 0.1
|
0.07 percentage of cells
Interval 0.02 to 0.16
|
0.08 percentage of cells
Interval 0.04 to 0.12
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgA+ of Memory B Cells-USA
|
0.04 percentage of cells
Interval 0.02 to 0.1
|
0.04 percentage of cells
Interval 0.0 to 0.05
|
0.04 percentage of cells
Interval 0.03 to 0.1
|
0.06 percentage of cells
Interval 0.02 to 0.08
|
0.07 percentage of cells
Interval 0.04 to 0.09
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.08 percentage of cells
Interval 0.06 to 0.12
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgA+ of Total B Cells-Peru
|
0.02 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.04 percentage of cells
Interval 0.02 to 0.06
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgA+ of Total B Cells-Total
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.02 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.01 to 0.03
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgA+ of Total B Cells-USA
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.02 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgG+ of Memory B Cells-Peru
|
0.4 percentage of cells
Interval 0.2 to 0.6
|
0.38 percentage of cells
Interval 0.27 to 0.69
|
0.43 percentage of cells
Interval 0.19 to 0.99
|
0.81 percentage of cells
Interval 0.49 to 1.12
|
0.88 percentage of cells
Interval 0.44 to 1.23
|
1.21 percentage of cells
Interval 0.85 to 1.58
|
0.83 percentage of cells
Interval 0.61 to 1.28
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgG+ of Memory B Cells-Total
|
0.32 percentage of cells
Interval 0.1 to 0.52
|
0.35 percentage of cells
Interval 0.04 to 0.98
|
0.49 percentage of cells
Interval 0.24 to 0.93
|
0.93 percentage of cells
Interval 0.49 to 1.55
|
0.94 percentage of cells
Interval 0.42 to 1.29
|
1.21 percentage of cells
Interval 0.71 to 1.73
|
0.7 percentage of cells
Interval 0.5 to 1.14
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgG+ of Memory B Cells-USA
|
0.18 percentage of cells
Interval 0.05 to 0.44
|
0.33 percentage of cells
Interval 0.04 to 0.98
|
0.69 percentage of cells
Interval 0.3 to 0.81
|
0.99 percentage of cells
Interval 0.52 to 1.69
|
1.01 percentage of cells
Interval 0.33 to 1.44
|
1.25 percentage of cells
Interval 0.62 to 1.9
|
0.58 percentage of cells
Interval 0.34 to 0.97
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgG+ of Total B Cells-Peru
|
0.09 percentage of cells
Interval 0.05 to 0.15
|
0.04 percentage of cells
Interval 0.03 to 0.09
|
0.1 percentage of cells
Interval 0.05 to 0.21
|
0.23 percentage of cells
Interval 0.1 to 0.3
|
0.18 percentage of cells
Interval 0.1 to 0.25
|
0.26 percentage of cells
Interval 0.17 to 0.41
|
0.22 percentage of cells
Interval 0.16 to 0.29
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgG+ of Total B Cells-Total
|
0.06 percentage of cells
Interval 0.02 to 0.13
|
0.05 percentage of cells
Interval 0.01 to 0.15
|
0.1 percentage of cells
Interval 0.06 to 0.19
|
0.22 percentage of cells
Interval 0.1 to 0.27
|
0.19 percentage of cells
Interval 0.09 to 0.25
|
0.19 percentage of cells
Interval 0.12 to 0.27
|
0.16 percentage of cells
Interval 0.08 to 0.24
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgG+ of Total B Cells-USA
|
0.04 percentage of cells
Interval 0.01 to 0.11
|
0.11 percentage of cells
Interval 0.0 to 0.15
|
0.1 percentage of cells
Interval 0.07 to 0.14
|
0.18 percentage of cells
Interval 0.11 to 0.26
|
0.22 percentage of cells
Interval 0.09 to 0.26
|
0.18 percentage of cells
Interval 0.09 to 0.21
|
0.1 percentage of cells
Interval 0.05 to 0.14
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-Peru
|
0.12 percentage of cells
Interval 0.09 to 0.14
|
0.06 percentage of cells
Interval 0.04 to 0.09
|
0.13 percentage of cells
Interval 0.1 to 0.18
|
0.14 percentage of cells
Interval 0.11 to 0.17
|
0.11 percentage of cells
Interval 0.08 to 0.14
|
0.09 percentage of cells
Interval 0.08 to 0.14
|
0.1 percentage of cells
Interval 0.08 to 0.15
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-Total
|
0.1 percentage of cells
Interval 0.06 to 0.13
|
0.07 percentage of cells
Interval 0.05 to 0.1
|
0.12 percentage of cells
Interval 0.09 to 0.16
|
0.13 percentage of cells
Interval 0.07 to 0.16
|
0.11 percentage of cells
Interval 0.08 to 0.15
|
0.09 percentage of cells
Interval 0.07 to 0.14
|
0.1 percentage of cells
Interval 0.07 to 0.15
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-USA
|
0.08 percentage of cells
Interval 0.05 to 0.1
|
0.07 percentage of cells
Interval 0.05 to 0.1
|
0.1 percentage of cells
Interval 0.08 to 0.11
|
0.08 percentage of cells
Interval 0.07 to 0.13
|
0.12 percentage of cells
Interval 0.08 to 0.17
|
0.09 percentage of cells
Interval 0.05 to 0.15
|
0.09 percentage of cells
Interval 0.07 to 0.12
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgM+ of Memory B Cells-Peru
|
0.03 percentage of cells
Interval 0.0 to 0.08
|
0.03 percentage of cells
Interval 0.01 to 0.06
|
0.04 percentage of cells
Interval 0.02 to 0.11
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.04 percentage of cells
Interval 0.02 to 0.06
|
0.05 percentage of cells
Interval 0.02 to 0.07
|
0.04 percentage of cells
Interval 0.0 to 0.06
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgM+ of Memory B Cells-Total
|
0.03 percentage of cells
Interval 0.0 to 0.09
|
0.01 percentage of cells
Interval 0.0 to 0.06
|
0.05 percentage of cells
Interval 0.02 to 0.08
|
0.05 percentage of cells
Interval 0.03 to 0.11
|
0.04 percentage of cells
Interval 0.01 to 0.06
|
0.05 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgM+ of Memory B Cells-USA
|
0.04 percentage of cells
Interval 0.01 to 0.09
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.05 percentage of cells
Interval 0.03 to 0.06
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.02 percentage of cells
Interval 0.0 to 0.06
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.05 percentage of cells
Interval 0.02 to 0.08
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgM+ of Total B Cells-Peru
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgM+ of Total B Cells-Total
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ IgM+ of Total B Cells-USA
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ of Total B Cells-Peru
|
0.3 percentage of cells
Interval 0.18 to 0.37
|
0.17 percentage of cells
Interval 0.09 to 0.27
|
0.33 percentage of cells
Interval 0.24 to 0.55
|
0.51 percentage of cells
Interval 0.3 to 0.65
|
0.37 percentage of cells
Interval 0.31 to 0.52
|
0.47 percentage of cells
Interval 0.4 to 0.7
|
0.43 percentage of cells
Interval 0.32 to 0.53
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ of Total B Cells-Total
|
0.21 percentage of cells
Interval 0.16 to 0.33
|
0.23 percentage of cells
Interval 0.1 to 0.34
|
0.28 percentage of cells
Interval 0.21 to 0.49
|
0.43 percentage of cells
Interval 0.25 to 0.57
|
0.39 percentage of cells
Interval 0.3 to 0.54
|
0.4 percentage of cells
Interval 0.28 to 0.51
|
0.35 percentage of cells
Interval 0.24 to 0.49
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
%S+ of Total B Cells-USA
|
0.21 percentage of cells
Interval 0.11 to 0.32
|
0.24 percentage of cells
Interval 0.1 to 0.34
|
0.26 percentage of cells
Interval 0.19 to 0.34
|
0.34 percentage of cells
Interval 0.23 to 0.49
|
0.42 percentage of cells
Interval 0.3 to 0.58
|
0.3 percentage of cells
Interval 0.23 to 0.41
|
0.25 percentage of cells
Interval 0.2 to 0.35
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3 , overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-USA
|
25 Participants
|
83 Participants
|
6 Participants
|
29 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Peru
|
22 Participants
|
41 Participants
|
15 Participants
|
31 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
39 Participants
|
106 Participants
|
19 Participants
|
51 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-USA
|
17 Participants
|
65 Participants
|
4 Participants
|
20 Participants
|
12 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 4-Peru
|
24 Participants
|
31 Participants
|
14 Participants
|
22 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 4-Total
|
31 Participants
|
70 Participants
|
16 Participants
|
37 Participants
|
23 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 4-USA
|
7 Participants
|
39 Participants
|
2 Participants
|
15 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru
|
24 Participants
|
55 Participants
|
16 Participants
|
41 Participants
|
27 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
50 Participants
|
137 Participants
|
21 Participants
|
69 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA
|
26 Participants
|
82 Participants
|
5 Participants
|
28 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru
|
22 Participants
|
40 Participants
|
15 Participants
|
29 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
38 Participants
|
103 Participants
|
19 Participants
|
48 Participants
|
31 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA
|
16 Participants
|
63 Participants
|
4 Participants
|
19 Participants
|
11 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru
|
22 Participants
|
30 Participants
|
14 Participants
|
20 Participants
|
12 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total
|
29 Participants
|
65 Participants
|
16 Participants
|
34 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru
|
22 Participants
|
42 Participants
|
14 Participants
|
31 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 0-Peru
|
18 Participants
|
46 Participants
|
15 Participants
|
41 Participants
|
27 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
39 Participants
|
103 Participants
|
19 Participants
|
60 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 0-USA
|
21 Participants
|
57 Participants
|
4 Participants
|
19 Participants
|
16 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 2-Peru
|
23 Participants
|
43 Participants
|
15 Participants
|
31 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
39 Participants
|
106 Participants
|
19 Participants
|
52 Participants
|
34 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 2-USA
|
16 Participants
|
63 Participants
|
4 Participants
|
21 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 4-Peru
|
24 Participants
|
33 Participants
|
14 Participants
|
22 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 4-Total
|
32 Participants
|
73 Participants
|
16 Participants
|
38 Participants
|
24 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 4-USA
|
8 Participants
|
40 Participants
|
2 Participants
|
16 Participants
|
10 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Peru
|
24 Participants
|
55 Participants
|
16 Participants
|
41 Participants
|
27 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
49 Participants
|
138 Participants
|
22 Participants
|
70 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
38 Participants
|
103 Participants
|
18 Participants
|
50 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA
|
7 Participants
|
35 Participants
|
2 Participants
|
14 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru
|
15 Participants
|
43 Participants
|
14 Participants
|
38 Participants
|
26 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
33 Participants
|
95 Participants
|
18 Participants
|
56 Participants
|
42 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA
|
18 Participants
|
52 Participants
|
4 Participants
|
18 Participants
|
16 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru
|
22 Participants
|
42 Participants
|
14 Participants
|
31 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
40 Participants
|
107 Participants
|
18 Participants
|
51 Participants
|
33 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA
|
18 Participants
|
65 Participants
|
4 Participants
|
20 Participants
|
13 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru
|
24 Participants
|
33 Participants
|
14 Participants
|
21 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total
|
32 Participants
|
73 Participants
|
16 Participants
|
36 Participants
|
24 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA
|
8 Participants
|
40 Participants
|
2 Participants
|
15 Participants
|
10 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Peru
|
22 Participants
|
56 Participants
|
15 Participants
|
40 Participants
|
27 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
46 Participants
|
136 Participants
|
21 Participants
|
68 Participants
|
46 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-USA
|
24 Participants
|
80 Participants
|
6 Participants
|
28 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Peru
|
22 Participants
|
43 Participants
|
15 Participants
|
31 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
40 Participants
|
107 Participants
|
19 Participants
|
51 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-USA
|
18 Participants
|
64 Participants
|
4 Participants
|
20 Participants
|
12 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 4-Peru
|
24 Participants
|
31 Participants
|
14 Participants
|
22 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 4-Total
|
32 Participants
|
70 Participants
|
16 Participants
|
37 Participants
|
23 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 4-USA
|
8 Participants
|
39 Participants
|
2 Participants
|
15 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru
|
24 Participants
|
55 Participants
|
16 Participants
|
41 Participants
|
27 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
54 Participants
|
138 Participants
|
22 Participants
|
70 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA
|
30 Participants
|
83 Participants
|
6 Participants
|
29 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru
|
21 Participants
|
43 Participants
|
14 Participants
|
30 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
36 Participants
|
108 Participants
|
18 Participants
|
50 Participants
|
34 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA
|
15 Participants
|
65 Participants
|
4 Participants
|
20 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru
|
25 Participants
|
29 Participants
|
13 Participants
|
21 Participants
|
12 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total
|
34 Participants
|
66 Participants
|
15 Participants
|
37 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA
|
9 Participants
|
37 Participants
|
2 Participants
|
16 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru
|
25 Participants
|
58 Participants
|
16 Participants
|
41 Participants
|
26 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
53 Participants
|
141 Participants
|
22 Participants
|
69 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA
|
28 Participants
|
83 Participants
|
6 Participants
|
28 Participants
|
21 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru
|
22 Participants
|
42 Participants
|
15 Participants
|
31 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
40 Participants
|
108 Participants
|
19 Participants
|
52 Participants
|
34 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA
|
18 Participants
|
66 Participants
|
4 Participants
|
21 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru
|
24 Participants
|
33 Participants
|
14 Participants
|
22 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total
|
32 Participants
|
73 Participants
|
16 Participants
|
38 Participants
|
24 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA
|
8 Participants
|
40 Participants
|
2 Participants
|
16 Participants
|
10 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru
|
15 Participants
|
44 Participants
|
14 Participants
|
39 Participants
|
26 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
35 Participants
|
96 Participants
|
18 Participants
|
57 Participants
|
41 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA
|
16 Participants
|
61 Participants
|
4 Participants
|
19 Participants
|
12 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA
|
20 Participants
|
52 Participants
|
4 Participants
|
18 Participants
|
15 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru
|
24 Participants
|
34 Participants
|
14 Participants
|
22 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total
|
32 Participants
|
72 Participants
|
16 Participants
|
37 Participants
|
23 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA
|
8 Participants
|
38 Participants
|
2 Participants
|
15 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
OC43-RBD-50 at Month 4-Total
|
3639.8 MFI
Interval 2183.8 to 5068.2
|
4952.2 MFI
Interval 2098.1 to 7392.9
|
6118 MFI
Interval 4052.6 to 9482.8
|
7069.8 MFI
Interval 5100.8 to 10583.5
|
6074.8 MFI
Interval 3952.9 to 9225.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-1000 at Month 0-Total
|
1172.4 MFI
Interval 4.9 to 3036.6
|
3808 MFI
Interval 949.2 to 10571.0
|
13049.5 MFI
Interval 7157.2 to 22000.0
|
20453.6 MFI
Interval 6304.2 to 22000.0
|
15945.2 MFI
Interval 5574.2 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-1000 at Month 2-Total
|
676.2 MFI
Interval 196.5 to 1679.2
|
1196 MFI
Interval 348.6 to 3746.6
|
5149 MFI
Interval 1728.2 to 10064.0
|
5809 MFI
Interval 1712.8 to 15047.1
|
4720 MFI
Interval 2789.8 to 11054.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-1000 at Month 4-Total
|
363.6 MFI
Interval 192.8 to 658.4
|
526.5 MFI
Interval 222.4 to 2206.1
|
1479.2 MFI
Interval 453.1 to 4343.0
|
2783 MFI
Interval 1316.9 to 7014.1
|
3621 MFI
Interval 1590.0 to 5098.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-1000 at Month 0-Total
|
5989.2 MFI
Interval 90.5 to 11296.8
|
11935.2 MFI
Interval 4328.6 to 22000.0
|
22000 MFI
Interval 16117.8 to 22000.0
|
22000 MFI
Interval 22000.0 to 22000.0
|
22000 MFI
Interval 16040.6 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-1000 at Month 2-Total
|
2149 MFI
Interval 892.8 to 5544.1
|
6736.9 MFI
Interval 2053.1 to 14929.9
|
16940.5 MFI
Interval 7339.0 to 22000.0
|
19418 MFI
Interval 9154.0 to 22000.0
|
15764.8 MFI
Interval 10970.8 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-1000 at Month 4-Total
|
1159.1 MFI
Interval 469.4 to 2136.5
|
2032.6 MFI
Interval 957.7 to 8274.9
|
7015.6 MFI
Interval 2425.8 to 15008.7
|
11395.5 MFI
Interval 4827.0 to 19747.2
|
13465.2 MFI
Interval 5921.2 to 20349.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
229E-RBD-50 at Month 0-Total
|
4100.9 MFI
Interval 1900.8 to 7294.5
|
5351.8 MFI
Interval 3432.4 to 8184.1
|
6758.9 MFI
Interval 3951.3 to 8605.0
|
7487.5 MFI
Interval 4141.0 to 9716.0
|
5035.8 MFI
Interval 3682.0 to 6589.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
229E-RBD-50 at Month 2-Total
|
4701.2 MFI
Interval 2838.5 to 6825.5
|
4798 MFI
Interval 2842.5 to 7790.1
|
7490.1 MFI
Interval 4311.1 to 8744.1
|
5405.2 MFI
Interval 3093.4 to 8470.2
|
5567.6 MFI
Interval 4189.1 to 7235.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
229E-RBD-50 at Month 4-Total
|
5162.5 MFI
Interval 3855.9 to 7221.9
|
6192.8 MFI
Interval 3392.0 to 9030.2
|
8425.6 MFI
Interval 6552.2 to 10927.2
|
7296.2 MFI
Interval 5270.8 to 9552.1
|
6106.1 MFI
Interval 5264.1 to 8204.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Total
|
14002.2 MFI
Interval 6702.2 to 21425.9
|
14944.4 MFI
Interval 9753.9 to 22000.0
|
18253.1 MFI
Interval 12441.3 to 21369.4
|
13857.6 MFI
Interval 7431.0 to 21445.4
|
10321.2 MFI
Interval 5614.9 to 15196.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Total
|
10239.5 MFI
Interval 7166.4 to 18628.6
|
9586.8 MFI
Interval 6383.6 to 15287.4
|
15170.5 MFI
Interval 9241.1 to 18084.6
|
8577.8 MFI
Interval 5176.2 to 14077.9
|
6796.5 MFI
Interval 4171.5 to 12932.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 4-Total
|
10870.5 MFI
Interval 6480.4 to 17301.9
|
9447.5 MFI
Interval 6667.2 to 14856.6
|
11755.5 MFI
Interval 8332.2 to 14752.1
|
9325.8 MFI
Interval 5152.5 to 14824.0
|
9645.5 MFI
Interval 4611.0 to 13284.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total
|
11218.4 MFI
Interval 4227.2 to 17991.8
|
15650.4 MFI
Interval 10267.8 to 22000.0
|
18108.8 MFI
Interval 7185.0 to 20531.0
|
17008.2 MFI
Interval 10572.9 to 22000.0
|
14307.9 MFI
Interval 7145.9 to 21912.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total
|
12434.8 MFI
Interval 7962.8 to 18575.8
|
12646.1 MFI
Interval 7867.9 to 19532.1
|
14461.6 MFI
Interval 7353.3 to 21226.6
|
16030 MFI
Interval 6863.0 to 22000.0
|
14744.2 MFI
Interval 9894.9 to 20172.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total
|
9754 MFI
Interval 5536.6 to 18087.8
|
13201.2 MFI
Interval 6891.8 to 20931.6
|
15596.3 MFI
Interval 8533.3 to 19332.8
|
16039.8 MFI
Interval 9555.5 to 22000.0
|
12057.8 MFI
Interval 7646.8 to 18609.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Total
|
1328.1 MFI
Interval 740.6 to 2715.1
|
1890.5 MFI
Interval 421.0 to 3400.5
|
787.2 MFI
Interval 1.0 to 2116.8
|
128.8 MFI
Interval 1.0 to 2817.5
|
384.8 MFI
Interval 1.0 to 1827.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Total
|
2430 MFI
Interval 1111.6 to 4146.8
|
2124.8 MFI
Interval 887.6 to 4072.9
|
1430 MFI
Interval 125.5 to 3789.6
|
863 MFI
Interval 1.0 to 3723.5
|
196 MFI
Interval 1.0 to 1349.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 4-Total
|
1370.5 MFI
Interval 793.9 to 2813.2
|
1990.5 MFI
Interval 791.8 to 3077.6
|
1411 MFI
Interval 866.5 to 1976.8
|
1123 MFI
Interval 497.8 to 3821.2
|
947.2 MFI
Interval 326.8 to 2567.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Total
|
21718.6 MFI
Interval 11765.6 to 22000.0
|
22000 MFI
Interval 17471.2 to 22000.0
|
20677.4 MFI
Interval 15975.0 to 22000.0
|
21907.4 MFI
Interval 19535.0 to 22000.0
|
22000 MFI
Interval 17563.7 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Total
|
22000 MFI
Interval 14469.5 to 22000.0
|
22000 MFI
Interval 14622.4 to 22000.0
|
21644.5 MFI
Interval 12189.4 to 22000.0
|
22000 MFI
Interval 16390.9 to 22000.0
|
22000 MFI
Interval 18397.4 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 4-Total
|
18483.5 MFI
Interval 10544.5 to 22000.0
|
22000 MFI
Interval 13327.5 to 22000.0
|
21513.2 MFI
Interval 13513.9 to 22000.0
|
22000 MFI
Interval 17186.5 to 22000.0
|
22000 MFI
Interval 16949.7 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HKU1-RBD-50 at Month 0-Total
|
3326.8 MFI
Interval 955.4 to 4966.1
|
4487.5 MFI
Interval 2979.8 to 6232.0
|
5480.8 MFI
Interval 3668.6 to 7159.3
|
5309.2 MFI
Interval 3624.6 to 8638.2
|
3714.6 MFI
Interval 2070.3 to 5822.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HKU1-RBD-50 at Month 2-Total
|
3843 MFI
Interval 2609.4 to 5512.5
|
3835.9 MFI
Interval 1945.1 to 5303.4
|
5927.4 MFI
Interval 3782.1 to 8082.2
|
4881.2 MFI
Interval 1952.2 to 7723.0
|
3902.6 MFI
Interval 1972.3 to 5690.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
HKU1-RBD-50 at Month 4-Total
|
3976.5 MFI
Interval 2390.0 to 7096.8
|
4933.5 MFI
Interval 2869.3 to 7746.8
|
7185.2 MFI
Interval 4821.9 to 12208.1
|
6354.1 MFI
Interval 4134.8 to 8926.9
|
5575.8 MFI
Interval 3624.0 to 6671.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
NL63-RBD-50 at Month 0-Total
|
11577 MFI
Interval 9062.4 to 15938.8
|
12831.8 MFI
Interval 9340.0 to 16679.6
|
10709.4 MFI
Interval 8215.4 to 13102.1
|
12869.4 MFI
Interval 8782.1 to 16942.2
|
10772.1 MFI
Interval 7934.6 to 13885.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
NL63-RBD-50 at Month 2-Total
|
15942.5 MFI
Interval 13683.2 to 20130.5
|
14045 MFI
Interval 10306.9 to 17711.2
|
16062.2 MFI
Interval 11906.2 to 20001.2
|
13088.2 MFI
Interval 8506.8 to 19241.6
|
11879.5 MFI
Interval 8520.2 to 15218.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
NL63-RBD-50 at Month 4-Total
|
16414.2 MFI
Interval 14140.4 to 19850.0
|
16559.2 MFI
Interval 12559.5 to 19641.5
|
17690.1 MFI
Interval 15662.1 to 21231.3
|
15559.8 MFI
Interval 11989.5 to 20530.5
|
15900.2 MFI
Interval 12375.8 to 18128.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
OC43-RBD-50 at Month 0-Total
|
3364.8 MFI
Interval 1423.4 to 5812.4
|
4057.5 MFI
Interval 2340.8 to 6578.6
|
3836.9 MFI
Interval 2239.9 to 6492.2
|
4979.5 MFI
Interval 3344.9 to 8658.0
|
3653.9 MFI
Interval 2134.6 to 6225.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
OC43-RBD-50 at Month 2-Total
|
4004.2 MFI
Interval 2449.0 to 8214.0
|
4138.5 MFI
Interval 2234.2 to 6051.5
|
6048 MFI
Interval 2454.2 to 9758.5
|
4726.5 MFI
Interval 2750.0 to 9097.6
|
4209.2 MFI
Interval 2684.0 to 6779.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total
|
1591.8 MFI
Interval 113.0 to 4922.2
|
10582 MFI
Interval 2114.2 to 22000.0
|
22000 MFI
Interval 11571.4 to 22000.0
|
22000 MFI
Interval 14010.6 to 22000.0
|
16037.8 MFI
Interval 3105.0 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total
|
614.8 MFI
Interval 287.9 to 1356.0
|
1910.8 MFI
Interval 554.2 to 5501.4
|
6201.5 MFI
Interval 2773.5 to 13504.8
|
6099.5 MFI
Interval 2365.7 to 12367.8
|
4573.9 MFI
Interval 1131.8 to 8607.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 0-Total
|
837.1 MFI
Interval 53.6 to 2356.2
|
3224.8 MFI
Interval 566.9 to 8992.8
|
11397 MFI
Interval 5598.4 to 22000.0
|
20747.2 MFI
Interval 6541.8 to 22000.0
|
18275.8 MFI
Interval 7261.0 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total
|
218.9 MFI
Interval 135.8 to 434.1
|
465 MFI
Interval 237.4 to 1591.2
|
1442.9 MFI
Interval 233.9 to 3319.8
|
1442.5 MFI
Interval 452.5 to 4576.2
|
801.5 MFI
Interval 432.8 to 1695.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total
|
838.5 MFI
Interval 1.0 to 1488.5
|
3318.9 MFI
Interval 1198.0 to 8993.9
|
13555.6 MFI
Interval 8042.8 to 20075.0
|
15429.4 MFI
Interval 9351.4 to 22000.0
|
14558.5 MFI
Interval 3989.8 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total
|
434.8 MFI
Interval 211.5 to 1337.2
|
1093.4 MFI
Interval 401.2 to 3314.4
|
4634.2 MFI
Interval 1322.6 to 10511.0
|
6504.2 MFI
Interval 1883.8 to 11889.5
|
4875 MFI
Interval 2939.5 to 12514.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total
|
292 MFI
Interval 151.3 to 487.3
|
436.5 MFI
Interval 239.4 to 1852.6
|
1634.2 MFI
Interval 382.5 to 4709.4
|
2848 MFI
Interval 1081.5 to 6415.8
|
3884.2 MFI
Interval 1477.5 to 6633.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 2-Total
|
375.5 MFI
Interval 156.8 to 1260.5
|
879.5 MFI
Interval 226.8 to 3227.0
|
3926.5 MFI
Interval 1530.8 to 12636.0
|
5654.2 MFI
Interval 1635.5 to 16795.2
|
4787.5 MFI
Interval 2606.9 to 13220.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 4-Total
|
228 MFI
Interval 124.6 to 463.1
|
383.8 MFI
Interval 193.2 to 2039.6
|
1493.2 MFI
Interval 418.3 to 5506.1
|
2603.9 MFI
Interval 1040.0 to 7404.1
|
3391.8 MFI
Interval 1766.5 to 6985.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total
|
839.2 MFI
Interval 62.8 to 3136.2
|
3872.8 MFI
Interval 1031.1 to 10614.9
|
10200 MFI
Interval 3868.4 to 18939.6
|
15822 MFI
Interval 9604.5 to 22000.0
|
14078.2 MFI
Interval 9060.0 to 18504.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total
|
402 MFI
Interval 169.1 to 1450.5
|
1496.5 MFI
Interval 355.8 to 4277.1
|
6103.8 MFI
Interval 1693.4 to 10371.4
|
6823.5 MFI
Interval 2420.5 to 14742.1
|
8218.5 MFI
Interval 2871.2 to 12878.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total
|
290.8 MFI
Interval 179.1 to 690.0
|
710.2 MFI
Interval 164.7 to 2857.7
|
1147 MFI
Interval 463.2 to 4076.8
|
3203.2 MFI
Interval 1156.2 to 7891.5
|
4619.9 MFI
Interval 1360.0 to 7799.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total
|
4511.2 MFI
Interval 182.0 to 9507.8
|
10463.4 MFI
Interval 4513.8 to 21974.2
|
21026.6 MFI
Interval 14574.4 to 22000.0
|
22000 MFI
Interval 19015.4 to 22000.0
|
22000 MFI
Interval 18083.9 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total
|
2497.5 MFI
Interval 1173.0 to 5380.2
|
5993.8 MFI
Interval 2335.8 to 12505.5
|
16653.5 MFI
Interval 5921.5 to 22000.0
|
17261.2 MFI
Interval 8244.2 to 22000.0
|
17681.8 MFI
Interval 9882.0 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total
|
1456.8 MFI
Interval 642.3 to 2659.9
|
2203.4 MFI
Interval 1047.7 to 8793.9
|
7099.9 MFI
Interval 2271.6 to 13897.5
|
11311.2 MFI
Interval 5053.0 to 18428.2
|
11779.2 MFI
Interval 5739.0 to 19179.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total
|
325.8 MFI
Interval 1.0 to 1308.5
|
2031.2 MFI
Interval 326.8 to 10576.4
|
5595.2 MFI
Interval 3346.0 to 22000.0
|
22000 MFI
Interval 9695.6 to 22000.0
|
15796.8 MFI
Interval 4864.1 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total
|
99.6 MFI
Interval 9.4 to 405.8
|
472 MFI
Interval 46.9 to 2230.9
|
3360.2 MFI
Interval 538.0 to 14750.2
|
4301 MFI
Interval 1118.8 to 11382.8
|
3229.6 MFI
Interval 1033.2 to 11824.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total
|
44.4 MFI
Interval 18.7 to 145.8
|
165 MFI
Interval 19.1 to 581.1
|
583.4 MFI
Interval 92.5 to 3312.4
|
1914.2 MFI
Interval 403.9 to 4041.2
|
1798.5 MFI
Interval 515.5 to 4191.5
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 0-Peru
|
25 Participants
|
54 Participants
|
17 Participants
|
41 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
52 Participants
|
136 Participants
|
23 Participants
|
71 Participants
|
48 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 0-USA
|
27 Participants
|
82 Participants
|
6 Participants
|
30 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 2-Peru
|
0 Participants
|
11 Participants
|
6 Participants
|
7 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
4 Participants
|
50 Participants
|
7 Participants
|
16 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 2-USA
|
4 Participants
|
39 Participants
|
1 Participants
|
9 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Peru
|
24 Participants
|
48 Participants
|
15 Participants
|
41 Participants
|
26 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
42 Participants
|
117 Participants
|
21 Participants
|
70 Participants
|
45 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-USA
|
18 Participants
|
69 Participants
|
6 Participants
|
29 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Peru
|
0 Participants
|
4 Participants
|
4 Participants
|
4 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
2 Participants
|
23 Participants
|
5 Participants
|
10 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-USA
|
2 Participants
|
19 Participants
|
1 Participants
|
6 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru
|
26 Participants
|
55 Participants
|
16 Participants
|
41 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
56 Participants
|
138 Participants
|
22 Participants
|
71 Participants
|
48 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA
|
30 Participants
|
83 Participants
|
6 Participants
|
30 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru
|
0 Participants
|
8 Participants
|
6 Participants
|
6 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
4 Participants
|
46 Participants
|
7 Participants
|
13 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA
|
4 Participants
|
38 Participants
|
1 Participants
|
7 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru
|
23 Participants
|
51 Participants
|
16 Participants
|
40 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
39 Participants
|
126 Participants
|
22 Participants
|
68 Participants
|
48 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA
|
16 Participants
|
75 Participants
|
6 Participants
|
28 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru
|
0 Participants
|
6 Participants
|
4 Participants
|
6 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
3 Participants
|
29 Participants
|
5 Participants
|
14 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA
|
3 Participants
|
23 Participants
|
1 Participants
|
8 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Peru
|
25 Participants
|
50 Participants
|
16 Participants
|
40 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
45 Participants
|
123 Participants
|
22 Participants
|
69 Participants
|
48 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-USA
|
20 Participants
|
73 Participants
|
6 Participants
|
29 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Peru
|
0 Participants
|
6 Participants
|
5 Participants
|
6 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
3 Participants
|
31 Participants
|
6 Participants
|
14 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-USA
|
3 Participants
|
25 Participants
|
1 Participants
|
8 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru
|
26 Participants
|
54 Participants
|
16 Participants
|
41 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
55 Participants
|
136 Participants
|
22 Participants
|
72 Participants
|
48 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA
|
29 Participants
|
82 Participants
|
6 Participants
|
31 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru
|
0 Participants
|
12 Participants
|
7 Participants
|
8 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
4 Participants
|
55 Participants
|
8 Participants
|
16 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA
|
4 Participants
|
43 Participants
|
1 Participants
|
8 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru
|
25 Participants
|
56 Participants
|
17 Participants
|
41 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
51 Participants
|
138 Participants
|
23 Participants
|
71 Participants
|
48 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA
|
26 Participants
|
82 Participants
|
6 Participants
|
30 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru
|
0 Participants
|
9 Participants
|
7 Participants
|
7 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
4 Participants
|
46 Participants
|
8 Participants
|
16 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA
|
4 Participants
|
37 Participants
|
1 Participants
|
9 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru
|
25 Participants
|
51 Participants
|
16 Participants
|
41 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
45 Participants
|
127 Participants
|
22 Participants
|
69 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA
|
20 Participants
|
76 Participants
|
6 Participants
|
28 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru
|
0 Participants
|
10 Participants
|
6 Participants
|
7 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
4 Participants
|
44 Participants
|
7 Participants
|
15 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA
|
4 Participants
|
34 Participants
|
1 Participants
|
8 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point.SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
2775.6 MFI
Interval 226.4 to 7398.3
|
5366.5 MFI
Interval 3056.1 to 9837.5
|
5835.1 MFI
Interval 3507.9 to 10801.1
|
11878.2 MFI
Interval 7048.9 to 17857.1
|
10388.5 MFI
Interval 5691.6 to 18870.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
3573.2 MFI
Interval 3027.0 to 5723.6
|
2217.9 MFI
Interval 628.8 to 4404.2
|
2597 MFI
Interval 738.2 to 3307.0
|
3720.4 MFI
Interval 2910.6 to 5906.6
|
3562 MFI
Interval 2814.6 to 5474.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
229E-RBD-50 at Month 0-Total
|
131 MFI
Interval 1.0 to 377.5
|
235.2 MFI
Interval 82.4 to 474.7
|
143 MFI
Interval 29.7 to 254.1
|
329 MFI
Interval 75.9 to 626.8
|
374 MFI
Interval 1.0 to 660.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
229E-RBD-50 at Month 2-Total
|
8.9 MFI
Interval 1.0 to 24.3
|
1 MFI
Interval 1.0 to 61.8
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 10.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Total
|
32 MFI
Interval 1.0 to 127.2
|
29.2 MFI
Interval 1.0 to 136.5
|
7.6 MFI
Interval 1.0 to 57.2
|
1 MFI
Interval 1.0 to 51.9
|
1 MFI
Interval 1.0 to 17.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Total
|
388.8 MFI
Interval 110.7 to 1489.3
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 15.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total
|
268.2 MFI
Interval 66.5 to 718.8
|
459.5 MFI
Interval 163.0 to 1213.2
|
328.5 MFI
Interval 196.2 to 776.4
|
518.8 MFI
Interval 176.0 to 1390.2
|
383 MFI
Interval 1.0 to 1697.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total
|
626.8 MFI
Interval 341.8 to 2818.4
|
189.6 MFI
Interval 1.0 to 714.8
|
142.2 MFI
Interval 1.0 to 318.2
|
97.2 MFI
Interval 1.0 to 416.1
|
562.2 MFI
Interval 160.1 to 1378.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Total
|
7.1 MFI
Interval 1.0 to 54.1
|
9.8 MFI
Interval 1.0 to 69.5
|
1 MFI
Interval 1.0 to 33.4
|
1 MFI
Interval 1.0 to 54.1
|
1 MFI
Interval 1.0 to 1.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Total
|
15.4 MFI
Interval 1.0 to 958.1
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Total
|
562.8 MFI
Interval 158.8 to 1637.0
|
611.5 MFI
Interval 164.2 to 2449.0
|
424.5 MFI
Interval 100.9 to 943.8
|
485.2 MFI
Interval 132.0 to 1650.5
|
131 MFI
Interval 1.0 to 1264.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Total
|
802.8 MFI
Interval 565.2 to 6271.0
|
10.2 MFI
Interval 1.0 to 570.0
|
1 MFI
Interval 1.0 to 32.2
|
1 MFI
Interval 1.0 to 255.2
|
371.1 MFI
Interval 56.4 to 1543.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
HKU1-RBD-50 at Month 0-Total
|
122.6 MFI
Interval 1.0 to 328.4
|
196.8 MFI
Interval 97.5 to 312.8
|
132.9 MFI
Interval 37.5 to 254.9
|
250.8 MFI
Interval 59.8 to 446.8
|
270.8 MFI
Interval 1.0 to 546.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
HKU1-RBD-50 at Month 2-Total
|
66.4 MFI
Interval 1.0 to 149.8
|
1 MFI
Interval 1.0 to 1.9
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 167.2
|
1 MFI
Interval 1.0 to 59.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
NL63-RBD-50 at Month 0-Total
|
191.5 MFI
Interval 1.0 to 386.4
|
215.2 MFI
Interval 35.2 to 453.0
|
206.6 MFI
Interval 70.1 to 400.2
|
275.5 MFI
Interval 74.5 to 518.4
|
195.8 MFI
Interval 1.0 to 439.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
NL63-RBD-50 at Month 2-Total
|
61.8 MFI
Interval 1.0 to 130.0
|
1 MFI
Interval 1.0 to 37.7
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 41.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
OC43-RBD-50 at Month 0-Total
|
102.2 MFI
Interval 1.0 to 261.1
|
151.9 MFI
Interval 12.1 to 313.6
|
122.9 MFI
Interval 1.0 to 260.3
|
198 MFI
Interval 42.6 to 453.5
|
154.1 MFI
Interval 1.0 to 449.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
OC43-RBD-50 at Month 2-Total
|
2.8 MFI
Interval 1.0 to 16.0
|
1 MFI
Interval 1.0 to 16.8
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 40.6
|
1 MFI
Interval 1.0 to 29.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
549 MFI
Interval 61.5 to 1848.5
|
1472.5 MFI
Interval 570.2 to 2942.9
|
1848.9 MFI
Interval 796.4 to 3564.9
|
3532.5 MFI
Interval 1978.6 to 5226.4
|
3818.5 MFI
Interval 1378.9 to 5591.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
430.4 MFI
Interval 338.2 to 734.1
|
111.8 MFI
Interval 1.0 to 790.6
|
494.2 MFI
Interval 19.5 to 897.5
|
691.5 MFI
Interval 9.6 to 1343.6
|
655.5 MFI
Interval 248.9 to 1001.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
3858.8 MFI
Interval 408.8 to 8570.2
|
6125 MFI
Interval 3010.0 to 11582.6
|
8722.4 MFI
Interval 4573.3 to 12243.4
|
13805.6 MFI
Interval 6730.1 to 20791.1
|
11790.8 MFI
Interval 4678.7 to 18578.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
4270.1 MFI
Interval 1334.9 to 7545.8
|
1596.1 MFI
Interval 308.2 to 3591.9
|
726.5 MFI
Interval 521.0 to 1330.8
|
2358.2 MFI
Interval 583.1 to 4394.3
|
3132.5 MFI
Interval 1966.4 to 4286.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
466.6 MFI
Interval 55.1 to 1777.4
|
1235.5 MFI
Interval 474.1 to 2423.0
|
1634.1 MFI
Interval 1044.4 to 3244.7
|
4180.4 MFI
Interval 2199.1 to 6351.9
|
4158.9 MFI
Interval 1424.2 to 6264.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
551 MFI
Interval 402.3 to 655.2
|
178.6 MFI
Interval 1.0 to 991.2
|
241.2 MFI
Interval 101.5 to 1153.0
|
681.2 MFI
Interval 276.2 to 1079.2
|
966.2 MFI
Interval 755.1 to 1617.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
542.2 MFI
Interval 83.8 to 1428.8
|
1394.8 MFI
Interval 354.0 to 2617.2
|
1690.2 MFI
Interval 870.9 to 3543.7
|
4453.4 MFI
Interval 2463.8 to 6519.8
|
4152.1 MFI
Interval 2270.4 to 7842.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
421.1 MFI
Interval 271.6 to 737.2
|
222.4 MFI
Interval 18.9 to 1120.9
|
781.2 MFI
Interval 28.0 to 1880.0
|
1168.6 MFI
Interval 377.0 to 1630.4
|
1200.5 MFI
Interval 768.0 to 1534.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
4162.8 MFI
Interval 799.6 to 10622.6
|
6037.8 MFI
Interval 3290.1 to 14853.2
|
7290.6 MFI
Interval 5033.0 to 17937.1
|
15804.8 MFI
Interval 7974.9 to 22000.0
|
15218.4 MFI
Interval 8344.4 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
6799.9 MFI
Interval 2662.2 to 13522.0
|
3986.6 MFI
Interval 1958.4 to 9672.4
|
2566.2 MFI
Interval 1660.2 to 5027.2
|
5121.6 MFI
Interval 2066.5 to 10043.6
|
8445.8 MFI
Interval 5726.5 to 17144.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
2129 MFI
Interval 311.9 to 4773.1
|
3914.5 MFI
Interval 2186.5 to 6376.5
|
3562.6 MFI
Interval 2272.2 to 6921.2
|
8685.9 MFI
Interval 5554.5 to 11434.8
|
7397.4 MFI
Interval 4187.8 to 13306.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
2365.4 MFI
Interval 2072.2 to 2947.0
|
1729.8 MFI
Interval 403.1 to 2896.8
|
1699.2 MFI
Interval 539.0 to 2524.5
|
2640.1 MFI
Interval 1741.9 to 3770.8
|
2402.2 MFI
Interval 2008.0 to 3440.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
430.8 MFI
Interval 2.9 to 2020.1
|
1814.2 MFI
Interval 314.4 to 5209.5
|
3141.2 MFI
Interval 1434.1 to 8485.8
|
7721.8 MFI
Interval 3836.0 to 11832.4
|
5454 MFI
Interval 2733.5 to 11251.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
326.8 MFI
Interval 245.1 to 666.6
|
234.8 MFI
Interval 6.5 to 1381.2
|
903 MFI
Interval 144.8 to 1502.8
|
997.2 MFI
Interval 562.6 to 1721.0
|
1713 MFI
Interval 749.8 to 1865.8
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 0-Peru
|
25 Participants
|
57 Participants
|
16 Participants
|
41 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
53 Participants
|
137 Participants
|
22 Participants
|
70 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 0-USA
|
28 Participants
|
80 Participants
|
6 Participants
|
29 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 2-Peru
|
0 Participants
|
11 Participants
|
7 Participants
|
8 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
4 Participants
|
52 Participants
|
8 Participants
|
16 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 2-USA
|
4 Participants
|
41 Participants
|
1 Participants
|
8 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Peru
|
21 Participants
|
51 Participants
|
16 Participants
|
41 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
41 Participants
|
109 Participants
|
22 Participants
|
66 Participants
|
45 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-USA
|
20 Participants
|
58 Participants
|
6 Participants
|
25 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Peru
|
0 Participants
|
8 Participants
|
6 Participants
|
7 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
3 Participants
|
37 Participants
|
7 Participants
|
12 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-USA
|
3 Participants
|
29 Participants
|
1 Participants
|
5 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru
|
26 Participants
|
54 Participants
|
18 Participants
|
39 Participants
|
27 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
56 Participants
|
127 Participants
|
24 Participants
|
68 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA
|
30 Participants
|
73 Participants
|
6 Participants
|
29 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru
|
0 Participants
|
12 Participants
|
8 Participants
|
8 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
3 Participants
|
47 Participants
|
9 Participants
|
14 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA
|
3 Participants
|
35 Participants
|
1 Participants
|
6 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru
|
26 Participants
|
58 Participants
|
16 Participants
|
41 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
54 Participants
|
140 Participants
|
22 Participants
|
70 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA
|
28 Participants
|
82 Participants
|
6 Participants
|
29 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru
|
0 Participants
|
13 Participants
|
7 Participants
|
8 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
4 Participants
|
55 Participants
|
8 Participants
|
15 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA
|
4 Participants
|
42 Participants
|
1 Participants
|
7 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Peru
|
26 Participants
|
55 Participants
|
16 Participants
|
41 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
51 Participants
|
132 Participants
|
22 Participants
|
70 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-USA
|
25 Participants
|
77 Participants
|
6 Participants
|
29 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Peru
|
0 Participants
|
10 Participants
|
7 Participants
|
8 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
4 Participants
|
48 Participants
|
8 Participants
|
15 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-USA
|
4 Participants
|
38 Participants
|
1 Participants
|
7 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru
|
5 Participants
|
32 Participants
|
12 Participants
|
33 Participants
|
25 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
11 Participants
|
54 Participants
|
15 Participants
|
51 Participants
|
37 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA
|
6 Participants
|
22 Participants
|
3 Participants
|
18 Participants
|
12 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru
|
0 Participants
|
3 Participants
|
2 Participants
|
5 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
1 Participants
|
16 Participants
|
3 Participants
|
7 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA
|
1 Participants
|
13 Participants
|
1 Participants
|
2 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru
|
25 Participants
|
53 Participants
|
16 Participants
|
41 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
51 Participants
|
127 Participants
|
22 Participants
|
68 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA
|
26 Participants
|
74 Participants
|
6 Participants
|
27 Participants
|
19 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru
|
0 Participants
|
8 Participants
|
6 Participants
|
8 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
4 Participants
|
47 Participants
|
7 Participants
|
15 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA
|
4 Participants
|
39 Participants
|
1 Participants
|
7 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru
|
17 Participants
|
37 Participants
|
10 Participants
|
35 Participants
|
25 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
31 Participants
|
66 Participants
|
14 Participants
|
57 Participants
|
39 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA
|
14 Participants
|
29 Participants
|
4 Participants
|
22 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru
|
0 Participants
|
7 Participants
|
6 Participants
|
8 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
1 Participants
|
33 Participants
|
7 Participants
|
14 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA
|
1 Participants
|
26 Participants
|
1 Participants
|
6 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-250 at Month 0-Total
|
712.6 MFI
Interval 84.3 to 2433.4
|
1591.4 MFI
Interval 535.4 to 4673.6
|
6170 MFI
Interval 2483.8 to 10780.6
|
3396.5 MFI
Interval 2324.1 to 9464.5
|
3914.4 MFI
Interval 2241.7 to 6653.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-250 at Month 2-Total
|
2994.4 MFI
Interval 1566.1 to 4154.5
|
650.6 MFI
Interval 368.1 to 1486.9
|
2644.8 MFI
Interval 1731.2 to 3965.0
|
1280.2 MFI
Interval 402.6 to 2513.9
|
2037.5 MFI
Interval 1812.9 to 4390.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
3018.9 MFI
Interval 355.2 to 7725.2
|
5220.1 MFI
Interval 2267.2 to 11085.5
|
13988.5 MFI
Interval 7764.6 to 22000.0
|
10462 MFI
Interval 5808.1 to 20569.1
|
11893.9 MFI
Interval 7800.2 to 15405.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
8806.4 MFI
Interval 5425.2 to 11275.7
|
2630 MFI
Interval 1486.0 to 4731.1
|
7052 MFI
Interval 5451.2 to 9517.5
|
4473.9 MFI
Interval 1626.4 to 7328.2
|
6588 MFI
Interval 6082.8 to 11702.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
229E-RBD-250 at Month 0-Total
|
104 MFI
Interval 73.2 to 190.6
|
115 MFI
Interval 57.6 to 214.9
|
173.2 MFI
Interval 103.1 to 303.9
|
170.5 MFI
Interval 111.9 to 342.6
|
162.8 MFI
Interval 97.8 to 317.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
229E-RBD-250 at Month 2-Total
|
84.2 MFI
Interval 72.9 to 90.4
|
85.5 MFI
Interval 56.6 to 177.2
|
87.8 MFI
Interval 72.5 to 209.8
|
129 MFI
Interval 60.3 to 178.8
|
305.2 MFI
Interval 99.2 to 451.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
229E-RBD-50 at Month 0-Total
|
460.8 MFI
Interval 300.1 to 766.3
|
443.9 MFI
Interval 223.1 to 859.8
|
644.4 MFI
Interval 407.9 to 1120.8
|
642.2 MFI
Interval 420.2 to 1264.8
|
603.1 MFI
Interval 357.1 to 1162.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
229E-RBD-50 at Month 2-Total
|
332.9 MFI
Interval 261.9 to 370.4
|
334.1 MFI
Interval 204.4 to 687.4
|
308 MFI
Interval 250.2 to 635.5
|
452.1 MFI
Interval 238.4 to 704.3
|
938 MFI
Interval 300.4 to 1191.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-229E S1S2 ECD His-250 at Month 0-Total
|
118 MFI
Interval 74.4 to 245.9
|
99.4 MFI
Interval 40.8 to 211.4
|
116.4 MFI
Interval 64.4 to 217.6
|
135.2 MFI
Interval 64.6 to 287.0
|
107.6 MFI
Interval 60.9 to 234.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-229E S1S2 ECD His-250 at Month 2-Total
|
95.8 MFI
Interval 55.8 to 149.3
|
110.4 MFI
Interval 47.0 to 235.8
|
156.8 MFI
Interval 128.0 to 173.8
|
174.6 MFI
Interval 68.5 to 372.7
|
345 MFI
Interval 87.2 to 373.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Total
|
498.9 MFI
Interval 294.7 to 977.8
|
408.2 MFI
Interval 161.1 to 884.2
|
466.4 MFI
Interval 279.6 to 894.1
|
575 MFI
Interval 243.9 to 1077.5
|
401.2 MFI
Interval 227.3 to 890.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Total
|
363.5 MFI
Interval 228.0 to 576.5
|
464.9 MFI
Interval 163.2 to 891.3
|
585.8 MFI
Interval 387.0 to 713.2
|
681.4 MFI
Interval 225.4 to 1414.2
|
913 MFI
Interval 261.6 to 1305.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total
|
178.6 MFI
Interval 114.9 to 431.7
|
320.8 MFI
Interval 127.3 to 726.9
|
516.6 MFI
Interval 212.5 to 1008.7
|
533 MFI
Interval 286.6 to 1169.5
|
482 MFI
Interval 165.5 to 1415.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total
|
484.9 MFI
Interval 290.8 to 823.1
|
278 MFI
Interval 134.6 to 828.6
|
650.8 MFI
Interval 251.5 to 907.8
|
362.5 MFI
Interval 181.4 to 756.4
|
379.8 MFI
Interval 224.9 to 1769.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total
|
744.9 MFI
Interval 524.9 to 1694.9
|
1302.8 MFI
Interval 560.1 to 2915.9
|
2011.9 MFI
Interval 883.1 to 3873.5
|
2137.2 MFI
Interval 1164.5 to 4296.5
|
1911.2 MFI
Interval 691.1 to 4071.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total
|
1952.2 MFI
Interval 1178.2 to 3191.1
|
1115.2 MFI
Interval 477.5 to 2850.4
|
2676.5 MFI
Interval 718.0 to 4025.5
|
1755 MFI
Interval 758.9 to 2820.9
|
1009.5 MFI
Interval 718.2 to 5220.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-NL63 S1S2 ECD His-250 at Month 0-Total
|
22.5 MFI
Interval 10.6 to 46.0
|
18 MFI
Interval 7.6 to 37.1
|
25.1 MFI
Interval 11.4 to 66.2
|
32.8 MFI
Interval 9.8 to 63.5
|
15.6 MFI
Interval 8.1 to 34.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-NL63 S1S2 ECD His-250 at Month 2-Total
|
23.1 MFI
Interval 16.6 to 34.8
|
21.1 MFI
Interval 9.2 to 40.9
|
27 MFI
Interval 14.5 to 169.0
|
20.9 MFI
Interval 11.5 to 44.6
|
22.5 MFI
Interval 3.2 to 41.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Total
|
89 MFI
Interval 39.5 to 208.1
|
76.6 MFI
Interval 31.5 to 162.8
|
96.4 MFI
Interval 22.2 to 186.6
|
136.2 MFI
Interval 31.1 to 249.8
|
70.5 MFI
Interval 25.3 to 133.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Total
|
119.8 MFI
Interval 78.1 to 173.4
|
85.9 MFI
Interval 39.5 to 174.1
|
219.5 MFI
Interval 87.8 to 852.5
|
77.6 MFI
Interval 55.0 to 156.6
|
31.8 MFI
Interval 1.0 to 98.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-OC43 S1S2 ECD His-250 at Month 0-Total
|
535.6 MFI
Interval 354.1 to 1191.9
|
800.9 MFI
Interval 296.2 to 1898.2
|
1031.4 MFI
Interval 437.4 to 1811.7
|
1124.2 MFI
Interval 534.1 to 2245.1
|
879.1 MFI
Interval 354.9 to 2375.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-OC43 S1S2 ECD His-250 at Month 2-Total
|
736.9 MFI
Interval 633.8 to 928.6
|
745.4 MFI
Interval 290.9 to 1811.0
|
897.2 MFI
Interval 713.0 to 1340.5
|
876.5 MFI
Interval 400.8 to 1654.6
|
1083 MFI
Interval 377.8 to 3124.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Total
|
2260 MFI
Interval 1354.8 to 4344.1
|
3069.2 MFI
Interval 1200.4 to 6140.9
|
3915.4 MFI
Interval 1775.8 to 6449.9
|
4348 MFI
Interval 2009.9 to 7600.6
|
3272.5 MFI
Interval 1648.2 to 7296.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Total
|
2964.2 MFI
Interval 2387.2 to 3715.1
|
2630.5 MFI
Interval 1146.8 to 6272.0
|
3230 MFI
Interval 1773.8 to 4732.0
|
3524.8 MFI
Interval 1720.3 to 5816.1
|
2436 MFI
Interval 1223.0 to 8469.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HKU1-RBD-250 at Month 0-Total
|
98 MFI
Interval 60.8 to 190.0
|
102 MFI
Interval 52.8 to 192.8
|
159.5 MFI
Interval 106.3 to 223.6
|
173.8 MFI
Interval 107.4 to 328.9
|
132.2 MFI
Interval 81.4 to 218.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HKU1-RBD-250 at Month 2-Total
|
87.6 MFI
Interval 82.0 to 386.8
|
88.2 MFI
Interval 44.1 to 157.1
|
95.2 MFI
Interval 84.0 to 289.5
|
144.1 MFI
Interval 80.7 to 275.6
|
157.2 MFI
Interval 120.6 to 271.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HKU1-RBD-50 at Month 0-Total
|
410.5 MFI
Interval 269.0 to 832.5
|
389.2 MFI
Interval 224.2 to 736.3
|
589.5 MFI
Interval 378.2 to 855.4
|
618.5 MFI
Interval 381.0 to 1212.4
|
445.4 MFI
Interval 309.2 to 817.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
HKU1-RBD-50 at Month 2-Total
|
378.2 MFI
Interval 316.6 to 1339.9
|
376.6 MFI
Interval 155.5 to 614.6
|
364.8 MFI
Interval 333.0 to 774.5
|
605 MFI
Interval 360.1 to 1031.8
|
536.2 MFI
Interval 386.9 to 859.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
NL63-RBD-250 at Month 0-Total
|
307.4 MFI
Interval 178.4 to 592.9
|
276.6 MFI
Interval 139.7 to 491.9
|
411 MFI
Interval 202.4 to 877.5
|
366 MFI
Interval 201.8 to 936.5
|
302.8 MFI
Interval 192.6 to 612.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
NL63-RBD-250 at Month 2-Total
|
184 MFI
Interval 171.3 to 208.7
|
328.1 MFI
Interval 152.5 to 530.3
|
374.8 MFI
Interval 232.8 to 1210.0
|
332.6 MFI
Interval 139.2 to 937.8
|
226.8 MFI
Interval 169.5 to 1207.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
NL63-RBD-50 at Month 0-Total
|
1208.5 MFI
Interval 775.6 to 2311.5
|
1093.5 MFI
Interval 584.3 to 2096.1
|
1686 MFI
Interval 888.0 to 3298.7
|
1405.8 MFI
Interval 798.8 to 3598.0
|
1192.4 MFI
Interval 842.6 to 2416.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
NL63-RBD-50 at Month 2-Total
|
743.5 MFI
Interval 685.2 to 839.5
|
1279.4 MFI
Interval 590.0 to 2185.1
|
1185.8 MFI
Interval 942.5 to 3301.2
|
1183.9 MFI
Interval 629.3 to 3318.1
|
869.8 MFI
Interval 566.4 to 3704.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
OC43-RBD-250 at Month 0-Total
|
126.5 MFI
Interval 67.9 to 257.8
|
100.4 MFI
Interval 59.4 to 225.1
|
139.1 MFI
Interval 78.8 to 257.6
|
168 MFI
Interval 84.2 to 326.6
|
143.2 MFI
Interval 89.6 to 223.7
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
OC43-RBD-250 at Month 2-Total
|
152.4 MFI
Interval 64.4 to 270.4
|
105.2 MFI
Interval 57.4 to 258.2
|
69.5 MFI
Interval 54.0 to 791.8
|
154.6 MFI
Interval 123.8 to 247.1
|
202.5 MFI
Interval 153.2 to 234.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
OC43-RBD-50 at Month 0-Total
|
531.5 MFI
Interval 300.8 to 1094.1
|
405 MFI
Interval 238.8 to 827.1
|
502 MFI
Interval 297.8 to 1111.4
|
664.5 MFI
Interval 387.2 to 1143.9
|
534.1 MFI
Interval 332.8 to 870.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
OC43-RBD-50 at Month 2-Total
|
644.2 MFI
Interval 240.1 to 1175.5
|
442.6 MFI
Interval 256.7 to 1026.9
|
262.8 MFI
Interval 209.5 to 2457.0
|
668 MFI
Interval 491.3 to 975.8
|
708.8 MFI
Interval 505.8 to 850.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-250 at Month 0-Total
|
309 MFI
Interval 64.8 to 950.7
|
569 MFI
Interval 185.1 to 1769.8
|
2676.2 MFI
Interval 766.7 to 5780.2
|
1974.8 MFI
Interval 654.8 to 4493.0
|
1454.8 MFI
Interval 770.2 to 3669.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-250 at Month 2-Total
|
521.4 MFI
Interval 254.1 to 1163.7
|
324.9 MFI
Interval 119.4 to 602.3
|
1810.2 MFI
Interval 706.5 to 2307.2
|
657.5 MFI
Interval 140.2 to 1681.8
|
1577.5 MFI
Interval 984.0 to 2064.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
1296.4 MFI
Interval 279.2 to 3206.4
|
2033.8 MFI
Interval 738.4 to 4901.8
|
8428.4 MFI
Interval 2794.6 to 14028.2
|
5319.8 MFI
Interval 1964.0 to 11542.6
|
5062.2 MFI
Interval 2705.7 to 10498.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
2107.6 MFI
Interval 1053.8 to 3960.2
|
1126.4 MFI
Interval 479.2 to 2168.9
|
5008.8 MFI
Interval 2829.2 to 6104.8
|
2415 MFI
Interval 536.4 to 5368.4
|
3611.5 MFI
Interval 3383.2 to 6262.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total
|
121.2 MFI
Interval 67.4 to 398.9
|
348.6 MFI
Interval 118.9 to 1087.1
|
1093.2 MFI
Interval 619.8 to 2442.6
|
1485.8 MFI
Interval 515.9 to 4719.9
|
569 MFI
Interval 290.5 to 2004.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total
|
255.6 MFI
Interval 138.0 to 602.1
|
163.1 MFI
Interval 86.5 to 372.9
|
470.2 MFI
Interval 161.0 to 1147.8
|
192.8 MFI
Interval 118.4 to 743.3
|
352.5 MFI
Interval 279.9 to 1082.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
542.1 MFI
Interval 311.1 to 1765.8
|
1537 MFI
Interval 531.3 to 4386.6
|
4777.8 MFI
Interval 2256.8 to 9205.6
|
5562.5 MFI
Interval 2107.0 to 13340.1
|
2238.2 MFI
Interval 1168.5 to 7081.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
1070.2 MFI
Interval 587.1 to 2268.8
|
654.1 MFI
Interval 321.8 to 1547.6
|
1543 MFI
Interval 641.8 to 3766.2
|
843.9 MFI
Interval 444.6 to 2901.4
|
1432 MFI
Interval 1016.4 to 3680.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total
|
256.2 MFI
Interval 16.3 to 1063.3
|
532.2 MFI
Interval 181.1 to 1631.9
|
1957.4 MFI
Interval 807.6 to 4744.6
|
1807.8 MFI
Interval 470.1 to 4193.9
|
1579.6 MFI
Interval 862.4 to 3270.7
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total
|
875.8 MFI
Interval 567.8 to 1584.0
|
254.2 MFI
Interval 133.4 to 546.2
|
1378.5 MFI
Interval 799.5 to 1757.5
|
495.2 MFI
Interval 177.2 to 1190.0
|
961.2 MFI
Interval 690.8 to 1517.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
1065.6 MFI
Interval 78.1 to 3402.7
|
1990.8 MFI
Interval 834.2 to 4490.6
|
4846 MFI
Interval 2976.8 to 12278.4
|
5485 MFI
Interval 1807.1 to 11671.9
|
5390.4 MFI
Interval 3056.2 to 9709.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
3078.8 MFI
Interval 2271.2 to 5186.6
|
1027.6 MFI
Interval 604.2 to 1952.6
|
4093.8 MFI
Interval 2869.2 to 5135.2
|
1839.9 MFI
Interval 736.3 to 3652.6
|
3416.2 MFI
Interval 2612.9 to 3548.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-250 at Month 0-Total
|
151.5 MFI
Interval 28.1 to 669.1
|
408.2 MFI
Interval 111.2 to 1447.3
|
1963.8 MFI
Interval 513.2 to 4579.1
|
1399 MFI
Interval 342.6 to 3522.9
|
1221.5 MFI
Interval 513.7 to 3367.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-250 at Month 2-Total
|
323 MFI
Interval 124.3 to 538.9
|
142.5 MFI
Interval 48.1 to 319.6
|
924.2 MFI
Interval 147.0 to 1186.2
|
392.6 MFI
Interval 74.6 to 763.8
|
734.2 MFI
Interval 547.9 to 1390.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
826.1 MFI
Interval 99.6 to 2747.2
|
1619 MFI
Interval 490.0 to 4896.8
|
6613.9 MFI
Interval 2168.0 to 13021.4
|
4902.5 MFI
Interval 1350.9 to 10810.8
|
4784.8 MFI
Interval 2080.9 to 9906.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
1346.8 MFI
Interval 525.9 to 2202.4
|
652.2 MFI
Interval 224.8 to 1182.7
|
2569.5 MFI
Interval 679.2 to 3422.0
|
1502.9 MFI
Interval 287.5 to 3502.3
|
2455.5 MFI
Interval 2061.9 to 4340.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total
|
352.6 MFI
Interval 133.1 to 981.5
|
765.4 MFI
Interval 330.4 to 1609.5
|
1606.1 MFI
Interval 848.2 to 3024.8
|
1695.2 MFI
Interval 862.9 to 3009.8
|
2312.9 MFI
Interval 1082.8 to 4092.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total
|
991.2 MFI
Interval 795.9 to 1138.3
|
885.5 MFI
Interval 330.3 to 1514.1
|
1287.2 MFI
Interval 1047.0 to 3310.8
|
989.9 MFI
Interval 563.9 to 1424.7
|
1465.5 MFI
Interval 1358.0 to 2566.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
1499.1 MFI
Interval 552.9 to 3896.9
|
3341.1 MFI
Interval 1419.6 to 6273.8
|
6263.9 MFI
Interval 3477.1 to 10531.8
|
6482.2 MFI
Interval 3425.2 to 10429.2
|
7607.4 MFI
Interval 4498.7 to 12773.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
3985.6 MFI
Interval 3313.5 to 4337.8
|
3409 MFI
Interval 1285.3 to 4751.1
|
4357.2 MFI
Interval 3539.0 to 9127.8
|
4217.1 MFI
Interval 2144.5 to 5614.4
|
4748.8 MFI
Interval 4172.8 to 7596.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total
|
647 MFI
Interval 59.8 to 1854.2
|
1215.1 MFI
Interval 431.2 to 3214.7
|
4612.6 MFI
Interval 1456.4 to 6742.9
|
3062.2 MFI
Interval 1600.2 to 6567.4
|
3139 MFI
Interval 1691.9 to 6339.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total
|
2228.4 MFI
Interval 1232.0 to 3540.6
|
622.6 MFI
Interval 342.2 to 1149.2
|
2653.5 MFI
Interval 1369.5 to 3131.2
|
1266.5 MFI
Interval 555.8 to 2246.9
|
1792.5 MFI
Interval 1722.0 to 3725.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
2660 MFI
Interval 278.9 to 6524.4
|
4547.9 MFI
Interval 1704.7 to 8595.2
|
10962.8 MFI
Interval 5416.1 to 16444.4
|
9146.2 MFI
Interval 4922.6 to 17148.5
|
10017.5 MFI
Interval 6068.2 to 15630.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
7089.6 MFI
Interval 4543.9 to 9975.9
|
2410 MFI
Interval 1375.9 to 4038.2
|
6934.5 MFI
Interval 4572.8 to 8524.5
|
3716.6 MFI
Interval 2169.1 to 7332.9
|
5988.8 MFI
Interval 5557.1 to 8848.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total
|
51 MFI
Interval 8.8 to 287.7
|
180.2 MFI
Interval 41.6 to 551.8
|
1466.5 MFI
Interval 411.2 to 4669.2
|
994.2 MFI
Interval 322.2 to 2063.4
|
1004.5 MFI
Interval 444.9 to 2333.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total
|
46.2 MFI
Interval 45.4 to 67.5
|
59.6 MFI
Interval 22.4 to 158.1
|
353.8 MFI
Interval 71.8 to 821.8
|
202.1 MFI
Interval 92.1 to 347.4
|
774.2 MFI
Interval 151.2 to 896.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
229.9 MFI
Interval 46.7 to 1288.2
|
846.2 MFI
Interval 192.2 to 2530.2
|
6049.8 MFI
Interval 1836.8 to 12734.1
|
4312 MFI
Interval 1477.6 to 8403.2
|
3966.5 MFI
Interval 2065.0 to 9188.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
212.8 MFI
Interval 202.1 to 299.2
|
255.6 MFI
Interval 97.4 to 704.9
|
1390 MFI
Interval 406.8 to 3060.2
|
825.1 MFI
Interval 446.4 to 1427.5
|
2855.2 MFI
Interval 646.1 to 3468.9
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and COVID-19 severity
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 0-Peru
|
25 Participants
|
56 Participants
|
17 Participants
|
41 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 0-Total
|
54 Participants
|
139 Participants
|
23 Participants
|
70 Participants
|
49 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 0-USA
|
29 Participants
|
83 Participants
|
6 Participants
|
29 Participants
|
21 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 12-Peru
|
—
|
3 Participants
|
—
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 12-Total
|
2 Participants
|
9 Participants
|
1 Participants
|
7 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 12-USA
|
2 Participants
|
6 Participants
|
1 Participants
|
3 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 2-Peru
|
15 Participants
|
30 Participants
|
13 Participants
|
30 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 2-Total
|
29 Participants
|
84 Participants
|
16 Participants
|
45 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 2-USA
|
14 Participants
|
54 Participants
|
3 Participants
|
15 Participants
|
11 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 4-Peru
|
1 Participants
|
3 Participants
|
—
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 4-Total
|
3 Participants
|
9 Participants
|
1 Participants
|
7 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614 at Month 4-USA
|
2 Participants
|
6 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3,4, overall and by region and COVID-19 severity among America Cohort
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 4-Total
|
253.3 Titer
Interval 183.2 to 489.8
|
117.8 Titer
Interval 60.3 to 232.2
|
1034.5 Titer
Interval 1034.5 to 1034.5
|
198.7 Titer
Interval 111.4 to 461.1
|
281.8 Titer
Interval 143.4 to 314.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 4-USA
|
489.8 Titer
Interval 371.5 to 608.0
|
152.4 Titer
Interval 100.2 to 382.5
|
1034.5 Titer
Interval 1034.5 to 1034.5
|
120.2 Titer
Interval 62.6 to 419.6
|
281.8 Titer
Interval 143.4 to 314.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 0-Peru
|
42.50 Titer
Interval 25.5 to 132.4
|
117.6 Titer
Interval 39.2 to 354.1
|
459.3 Titer
Interval 159.2 to 799.7
|
601.8 Titer
Interval 244.5 to 1101.3
|
675.6 Titer
Interval 205.0 to 1113.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 0-Total
|
27.90 Titer
Interval 5.0 to 70.0
|
60.10 Titer
Interval 27.5 to 209.0
|
321.5 Titer
Interval 161.2 to 729.1
|
262.4 Titer
Interval 135.6 to 821.4
|
293.9 Titer
Interval 136.2 to 890.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 0-USA
|
20.20 Titer
Interval 5.0 to 51.2
|
41.40 Titer
Interval 21.6 to 144.8
|
227.0 Titer
Interval 185.8 to 537.5
|
127.3 Titer
Interval 62.6 to 266.1
|
169.2 Titer
Interval 108.0 to 343.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 12-Peru
|
—
|
104.3 Titer
Interval 75.2 to 181.7
|
—
|
91.00 Titer
Interval 36.8 to 198.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 12-Total
|
75.50 Titer
Interval 53.1 to 98.0
|
107.9 Titer
Interval 29.8 to 187.6
|
185.8 Titer
Interval 185.8 to 185.8
|
128.3 Titer
Interval 45.4 to 146.9
|
73.50 Titer
Interval 55.4 to 80.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 12-USA
|
75.50 Titer
Interval 53.1 to 98.0
|
111.5 Titer
Interval 15.9 to 185.8
|
185.8 Titer
Interval 185.8 to 185.8
|
128.3 Titer
Interval 86.2 to 143.4
|
73.50 Titer
Interval 55.4 to 80.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 2-Peru
|
10.00 Titer
Interval 10.0 to 25.1
|
28.50 Titer
Interval 10.0 to 56.1
|
103.4 Titer
Interval 27.1 to 173.0
|
190.3 Titer
Interval 113.3 to 310.5
|
124.3 Titer
Interval 73.0 to 141.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 2-Total
|
10.00 Titer
Interval 10.0 to 31.4
|
28.50 Titer
Interval 10.0 to 57.2
|
109.7 Titer
Interval 26.4 to 232.8
|
127.8 Titer
Interval 62.0 to 237.9
|
120.6 Titer
Interval 55.7 to 172.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 2-USA
|
13.70 Titer
Interval 10.0 to 38.4
|
29.00 Titer
Interval 10.0 to 56.4
|
246.1 Titer
Interval 134.1 to 296.1
|
54.10 Titer
Interval 10.0 to 82.1
|
120.4 Titer
Interval 45.1 to 223.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 4-Peru
|
37.30 Titer
Interval 37.3 to 37.3
|
13.70 Titer
Interval 10.6 to 50.5
|
—
|
73.50 Titer
Interval 55.7 to 158.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 4-Total
|
80.70 Titer
Interval 59.0 to 133.2
|
44.10 Titer
Interval 24.4 to 87.3
|
334.0 Titer
Interval 334.0 to 334.0
|
64.60 Titer
Interval 42.6 to 163.1
|
111.5 Titer
Interval 58.3 to 116.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID80 at Month 4-USA
|
133.2 Titer
Interval 107.0 to 159.5
|
53.40 Titer
Interval 34.0 to 111.5
|
334.0 Titer
Interval 334.0 to 334.0
|
46.60 Titer
Interval 25.8 to 111.8
|
111.5 Titer
Interval 58.3 to 116.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 0-Peru
|
179.3 Titer
Interval 68.2 to 544.4
|
527.7 Titer
Interval 142.5 to 1636.1
|
2180 Titer
Interval 635.6 to 4978.0
|
2826 Titer
Interval 962.8 to 9093.1
|
2599 Titer
Interval 750.0 to 5664.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 0-Total
|
87.60 Titer
Interval 5.0 to 340.0
|
284.8 Titer
Interval 83.7 to 1078.9
|
1778 Titer
Interval 702.2 to 4876.1
|
1497 Titer
Interval 426.5 to 4781.4
|
1341 Titer
Interval 524.2 to 4367.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 0-USA
|
53.00 Titer
Interval 5.0 to 195.0
|
211.0 Titer
Interval 66.1 to 627.0
|
1121 Titer
Interval 875.7 to 3416.2
|
357.2 Titer
Interval 190.8 to 1492.6
|
627.4 Titer
Interval 373.5 to 1547.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 12-Peru
|
—
|
289.6 Titer
Interval 177.4 to 578.1
|
—
|
305.6 Titer
Interval 97.2 to 609.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 12-Total
|
220.4 Titer
Interval 157.3 to 283.4
|
285.7 Titer
Interval 61.5 to 682.6
|
726.3 Titer
Interval 726.3 to 726.3
|
411.9 Titer
Interval 119.0 to 460.7
|
232.2 Titer
Interval 172.7 to 239.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 12-USA
|
220.4 Titer
Interval 157.3 to 283.4
|
281.8 Titer
Interval 59.6 to 658.0
|
726.3 Titer
Interval 726.3 to 726.3
|
411.9 Titer
Interval 264.9 to 421.2
|
232.2 Titer
Interval 172.7 to 239.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 2-Peru
|
35.10 Titer
Interval 10.0 to 56.2
|
81.00 Titer
Interval 10.0 to 189.2
|
335.2 Titer
Interval 74.7 to 643.1
|
663.0 Titer
Interval 281.9 to 1059.3
|
281.9 Titer
Interval 222.4 to 367.7
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 2-Total
|
38.30 Titer
Interval 10.0 to 82.0
|
85.40 Titer
Interval 35.8 to 202.9
|
338.8 Titer
Interval 65.0 to 832.1
|
358.0 Titer
Interval 205.1 to 843.3
|
325.7 Titer
Interval 165.2 to 564.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 2-USA
|
47.30 Titer
Interval 25.1 to 106.7
|
89.90 Titer
Interval 37.5 to 214.7
|
890.3 Titer
Interval 471.8 to 1046.2
|
176.8 Titer
Interval 28.6 to 358.0
|
436.3 Titer
Interval 121.5 to 872.7
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
VRC7480_G614-ID50 at Month 4-Peru
|
113.2 Titer
Interval 113.2 to 113.2
|
60.30 Titer
Interval 44.8 to 146.2
|
—
|
245.7 Titer
Interval 151.7 to 411.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and COVID-19 severity
Outcome measures
| Measure |
Group 1A
n=96 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=161 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=26 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=67 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=21 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=1 Participants
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 0-RSA
|
59 Participants
|
107 Participants
|
19 Participants
|
28 Participants
|
8 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 0-Total
|
73 Participants
|
137 Participants
|
22 Participants
|
44 Participants
|
15 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 0-non-RSA
|
14 Participants
|
30 Participants
|
3 Participants
|
16 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 12-RSA
|
33 Participants
|
46 Participants
|
12 Participants
|
14 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 12-Total
|
49 Participants
|
78 Participants
|
14 Participants
|
27 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 12-non-RSA
|
16 Participants
|
32 Participants
|
2 Participants
|
13 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 2-RSA
|
36 Participants
|
72 Participants
|
15 Participants
|
18 Participants
|
6 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 2-Total
|
50 Participants
|
97 Participants
|
19 Participants
|
35 Participants
|
10 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 2-non-RSA
|
14 Participants
|
25 Participants
|
4 Participants
|
17 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 4-RSA
|
37 Participants
|
70 Participants
|
15 Participants
|
16 Participants
|
5 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 4-Total
|
52 Participants
|
96 Participants
|
18 Participants
|
31 Participants
|
10 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G at Month 4-non-RSA
|
15 Participants
|
26 Participants
|
3 Participants
|
15 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and COVID-19 severity among Africa Cohort
Outcome measures
| Measure |
Group 1A
n=96 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=161 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=26 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=67 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=21 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=1 Participants
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 0-RSA
|
189.0 Titer
Interval 49.2 to 474.5
|
344.8 Titer
Interval 132.7 to 1342.9
|
422.3 Titer
Interval 172.5 to 932.1
|
1136 Titer
Interval 283.4 to 2206.3
|
1594 Titer
Interval 464.4 to 3441.6
|
2658.5 Titer
Interval 2658.5 to 2658.5
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 0-Total
|
183.5 Titer
Interval 40.7 to 361.5
|
327.3 Titer
Interval 101.2 to 1157.5
|
397.0 Titer
Interval 112.5 to 851.1
|
1304 Titer
Interval 227.8 to 2076.4
|
1672 Titer
Interval 575.1 to 3064.0
|
2658.5 Titer
Interval 2658.5 to 2658.5
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 0-non-RSA
|
74.20 Titer
Interval 8.2 to 216.8
|
265.1 Titer
Interval 19.3 to 714.1
|
80.60 Titer
Interval 37.7 to 243.9
|
1328 Titer
Interval 144.8 to 1786.8
|
1672 Titer
Interval 1086.5 to 2746.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 12-RSA
|
374.2 Titer
Interval 120.2 to 3956.1
|
2543 Titer
Interval 425.3 to 9673.3
|
1558 Titer
Interval 361.6 to 4887.3
|
12337 Titer
Interval 4219.0 to 37945.2
|
2700 Titer
Interval 1430.6 to 5603.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 12-Total
|
559.2 Titer
Interval 177.1 to 2693.7
|
997.3 Titer
Interval 291.7 to 7868.9
|
1558 Titer
Interval 442.0 to 5741.1
|
5130 Titer
Interval 430.3 to 19363.0
|
2065 Titer
Interval 1131.6 to 6481.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 12-non-RSA
|
1160 Titer
Interval 337.0 to 2281.9
|
478.9 Titer
Interval 239.6 to 3393.2
|
3521 Titer
Interval 2196.6 to 4845.7
|
1522 Titer
Interval 306.6 to 6278.1
|
265.6 Titer
Interval 237.3 to 4690.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 2-RSA
|
86.30 Titer
Interval 10.0 to 231.2
|
165.4 Titer
Interval 59.9 to 586.1
|
224.8 Titer
Interval 76.7 to 535.8
|
540.6 Titer
Interval 185.2 to 1287.9
|
827.2 Titer
Interval 337.9 to 1283.4
|
1925.3 Titer
Interval 1925.3 to 1925.3
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 2-Total
|
68.40 Titer
Interval 10.0 to 198.0
|
125.3 Titer
Interval 43.5 to 413.3
|
211.4 Titer
Interval 67.7 to 451.1
|
490.0 Titer
Interval 110.6 to 963.2
|
494.6 Titer
Interval 115.5 to 884.7
|
1925.3 Titer
Interval 1925.3 to 1925.3
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 2-non-RSA
|
51.90 Titer
Interval 8.7 to 139.6
|
52.40 Titer
Interval 5.0 to 192.2
|
130.2 Titer
Interval 48.1 to 211.4
|
427.5 Titer
Interval 50.8 to 834.3
|
157.3 Titer
Interval 80.1 to 385.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 4-RSA
|
203.6 Titer
Interval 48.5 to 552.1
|
356.5 Titer
Interval 83.7 to 932.5
|
382.2 Titer
Interval 101.8 to 619.6
|
657.1 Titer
Interval 214.5 to 1422.1
|
738.7 Titer
Interval 239.1 to 1161.9
|
2231.7 Titer
Interval 2231.7 to 2231.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 4-Total
|
148.5 Titer
Interval 54.3 to 314.9
|
276.5 Titer
Interval 71.8 to 880.5
|
251.2 Titer
Interval 93.2 to 531.6
|
713.2 Titer
Interval 220.9 to 1403.5
|
659.8 Titer
Interval 267.7 to 1110.0
|
2231.7 Titer
Interval 2231.7 to 2231.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 4-non-RSA
|
130.8 Titer
Interval 71.1 to 168.6
|
174.1 Titer
Interval 42.5 to 392.4
|
95.10 Titer
Interval 83.3 to 165.0
|
1114 Titer
Interval 333.2 to 1310.4
|
580.8 Titer
Interval 353.6 to 954.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 0-RSA
|
42.50 Titer
Interval 10.0 to 130.6
|
88.50 Titer
Interval 35.1 to 314.8
|
100.9 Titer
Interval 37.3 to 238.5
|
303.0 Titer
Interval 83.1 to 573.9
|
328.1 Titer
Interval 129.5 to 571.4
|
813.8 Titer
Interval 813.8 to 813.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 0-Total
|
40.40 Titer
Interval 10.0 to 111.3
|
80.40 Titer
Interval 31.7 to 240.8
|
83.20 Titer
Interval 30.9 to 202.6
|
347.3 Titer
Interval 65.3 to 605.8
|
399.5 Titer
Interval 149.6 to 715.7
|
813.8 Titer
Interval 813.8 to 813.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 0-non-RSA
|
27.10 Titer
Interval 7.5 to 46.6
|
45.70 Titer
Interval 10.0 to 181.3
|
27.50 Titer
Interval 19.1 to 65.1
|
361.0 Titer
Interval 43.1 to 615.2
|
614.9 Titer
Interval 247.2 to 836.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 12-RSA
|
122.4 Titer
Interval 36.0 to 894.2
|
634.9 Titer
Interval 116.7 to 2755.0
|
391.2 Titer
Interval 126.8 to 1189.4
|
3390 Titer
Interval 1041.9 to 5450.3
|
452.5 Titer
Interval 389.6 to 1378.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 12-Total
|
161.2 Titer
Interval 41.9 to 776.1
|
240.7 Titer
Interval 104.8 to 2149.5
|
391.2 Titer
Interval 154.3 to 1287.7
|
1914 Titer
Interval 170.0 to 4128.4
|
421.0 Titer
Interval 242.0 to 1681.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 12-non-RSA
|
381.6 Titer
Interval 92.4 to 712.6
|
161.8 Titer
Interval 70.6 to 793.1
|
797.9 Titer
Interval 518.3 to 1077.5
|
413.3 Titer
Interval 131.4 to 2113.3
|
100.0 Titer
Interval 81.4 to 1343.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 2-RSA
|
31.70 Titer
Interval 10.0 to 47.1
|
43.10 Titer
Interval 20.7 to 173.5
|
65.00 Titer
Interval 31.0 to 166.6
|
142.4 Titer
Interval 63.7 to 230.7
|
203.1 Titer
Interval 97.5 to 320.8
|
678.1 Titer
Interval 678.1 to 678.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 2-Total
|
22.70 Titer
Interval 10.0 to 40.9
|
36.10 Titer
Interval 10.0 to 122.0
|
53.00 Titer
Interval 29.6 to 118.7
|
137.1 Titer
Interval 37.0 to 207.6
|
146.1 Titer
Interval 36.7 to 204.8
|
678.1 Titer
Interval 678.1 to 678.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 2-non-RSA
|
10.00 Titer
Interval 7.5 to 24.3
|
22.30 Titer
Interval 5.0 to 42.7
|
31.50 Titer
Interval 10.0 to 53.0
|
114.1 Titer
Interval 16.3 to 196.7
|
65.20 Titer
Interval 27.1 to 124.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 4-RSA
|
42.30 Titer
Interval 10.0 to 152.9
|
102.1 Titer
Interval 28.8 to 226.0
|
101.1 Titer
Interval 33.8 to 167.5
|
169.7 Titer
Interval 63.4 to 562.3
|
209.9 Titer
Interval 60.9 to 274.8
|
643.1 Titer
Interval 643.1 to 643.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 4-Total
|
36.50 Titer
Interval 10.0 to 120.5
|
85.60 Titer
Interval 24.1 to 202.1
|
64.80 Titer
Interval 33.0 to 152.5
|
179.1 Titer
Interval 70.7 to 552.4
|
193.5 Titer
Interval 65.9 to 264.7
|
643.1 Titer
Interval 643.1 to 643.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 4-non-RSA
|
34.00 Titer
Interval 22.4 to 41.0
|
46.10 Titer
Interval 13.5 to 140.2
|
32.50 Titer
Interval 30.7 to 43.9
|
239.3 Titer
Interval 118.0 to 353.5
|
177.1 Titer
Interval 80.8 to 234.7
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population (USA and Peru only), all available data at each visit
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru
|
10 Participants
|
32 Participants
|
8 Participants
|
31 Participants
|
11 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total
|
15 Participants
|
53 Participants
|
11 Participants
|
49 Participants
|
24 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA
|
5 Participants
|
21 Participants
|
3 Participants
|
18 Participants
|
13 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru
|
10 Participants
|
34 Participants
|
10 Participants
|
31 Participants
|
10 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total
|
17 Participants
|
59 Participants
|
13 Participants
|
46 Participants
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA
|
7 Participants
|
25 Participants
|
3 Participants
|
15 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population (USA and Peru only), all available data at each visit
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru
|
1.6 Percent CD107a+ NK Cells
Interval 0.5 to 4.6
|
7.7 Percent CD107a+ NK Cells
Interval 3.3 to 13.8
|
11.3 Percent CD107a+ NK Cells
Interval 2.8 to 21.1
|
13.6 Percent CD107a+ NK Cells
Interval 9.5 to 15.7
|
17.9 Percent CD107a+ NK Cells
Interval 11.7 to 26.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total
|
1.1 Percent CD107a+ NK Cells
Interval 0.0 to 4.0
|
4.6 Percent CD107a+ NK Cells
Interval 1.4 to 9.0
|
10.8 Percent CD107a+ NK Cells
Interval 3.8 to 17.1
|
13.3 Percent CD107a+ NK Cells
Interval 6.6 to 15.9
|
17.6 Percent CD107a+ NK Cells
Interval 11.6 to 22.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA
|
0.7 Percent CD107a+ NK Cells
Interval 0.0 to 2.3
|
3.4 Percent CD107a+ NK Cells
Interval 1.1 to 6.7
|
9.5 Percent CD107a+ NK Cells
Interval 5.9 to 13.3
|
10.8 Percent CD107a+ NK Cells
Interval 5.6 to 16.6
|
17.5 Percent CD107a+ NK Cells
Interval 11.7 to 20.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru
|
4.8 Percent CD107a+ NK Cells
Interval 2.2 to 11.0
|
8.6 Percent CD107a+ NK Cells
Interval 4.1 to 12.3
|
12.9 Percent CD107a+ NK Cells
Interval 8.3 to 15.0
|
15.9 Percent CD107a+ NK Cells
Interval 12.3 to 18.3
|
11.8 Percent CD107a+ NK Cells
Interval 9.2 to 16.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total
|
3.8 Percent CD107a+ NK Cells
Interval 0.2 to 6.0
|
6 Percent CD107a+ NK Cells
Interval 3.5 to 11.2
|
12 Percent CD107a+ NK Cells
Interval 6.6 to 13.8
|
13.1 Percent CD107a+ NK Cells
Interval 7.6 to 16.7
|
9.5 Percent CD107a+ NK Cells
Interval 3.5 to 14.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA
|
1.6 Percent CD107a+ NK Cells
Interval 0.0 to 5.1
|
5.2 Percent CD107a+ NK Cells
Interval 3.0 to 7.5
|
7 Percent CD107a+ NK Cells
Interval 5.1 to 9.5
|
9.4 Percent CD107a+ NK Cells
Interval 3.0 to 12.7
|
5.9 Percent CD107a+ NK Cells
Interval 2.2 to 12.2
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population (USA and Peru only), all available data at each visit
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S1 at Month 0-Peru
|
1 Participants
|
14 Participants
|
5 Participants
|
12 Participants
|
10 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S1 at Month 0-USA
|
0 Participants
|
19 Participants
|
3 Participants
|
3 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S2 at Month 0-Peru
|
3 Participants
|
4 Participants
|
2 Participants
|
4 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-N at Month 0-Total
|
20 Participants
|
87 Participants
|
16 Participants
|
56 Participants
|
42 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-N at Month 0-USA
|
9 Participants
|
50 Participants
|
4 Participants
|
25 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Any COV2 at Month 0-Peru
|
15 Participants
|
46 Participants
|
14 Participants
|
40 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Any COV2 at Month 0-Total
|
33 Participants
|
107 Participants
|
19 Participants
|
67 Participants
|
46 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Any COV2 at Month 0-USA
|
18 Participants
|
61 Participants
|
5 Participants
|
27 Participants
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-E M at Month 0-Peru
|
7 Participants
|
35 Participants
|
12 Participants
|
34 Participants
|
27 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-E M at Month 0-Total
|
16 Participants
|
72 Participants
|
14 Participants
|
58 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-E M at Month 0-USA
|
9 Participants
|
37 Participants
|
2 Participants
|
24 Participants
|
16 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-N at Month 0-Peru
|
11 Participants
|
37 Participants
|
12 Participants
|
31 Participants
|
25 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF3a6 at Month 0-Peru
|
3 Participants
|
22 Participants
|
5 Participants
|
20 Participants
|
15 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF3a6 at Month 0-Total
|
8 Participants
|
42 Participants
|
8 Participants
|
42 Participants
|
26 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF3a6 at Month 0-USA
|
5 Participants
|
20 Participants
|
3 Participants
|
22 Participants
|
11 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF7a7b8 at Month 0-Peru
|
5 Participants
|
23 Participants
|
7 Participants
|
30 Participants
|
21 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF7a7b8 at Month 0-Total
|
9 Participants
|
45 Participants
|
10 Participants
|
46 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF7a7b8 at Month 0-USA
|
4 Participants
|
22 Participants
|
3 Participants
|
16 Participants
|
11 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S1 at Month 0-Peru
|
10 Participants
|
37 Participants
|
14 Participants
|
38 Participants
|
27 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S1 at Month 0-Total
|
20 Participants
|
84 Participants
|
19 Participants
|
64 Participants
|
44 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S1 at Month 0-USA
|
10 Participants
|
47 Participants
|
5 Participants
|
26 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S2 at Month 0-Peru
|
12 Participants
|
32 Participants
|
11 Participants
|
34 Participants
|
27 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S2 at Month 0-Total
|
21 Participants
|
78 Participants
|
16 Participants
|
59 Participants
|
45 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S2 at Month 0-USA
|
9 Participants
|
46 Participants
|
5 Participants
|
25 Participants
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Spike at Month 0-Peru
|
13 Participants
|
40 Participants
|
14 Participants
|
40 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Spike at Month 0-Total
|
25 Participants
|
96 Participants
|
19 Participants
|
66 Participants
|
46 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Spike at Month 0-USA
|
12 Participants
|
56 Participants
|
5 Participants
|
26 Participants
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Any COV2 at Month 0-Peru
|
14 Participants
|
41 Participants
|
10 Participants
|
34 Participants
|
23 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Any COV2 at Month 0-Total
|
33 Participants
|
93 Participants
|
16 Participants
|
54 Participants
|
36 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Any COV2 at Month 0-USA
|
19 Participants
|
52 Participants
|
6 Participants
|
20 Participants
|
13 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-E M at Month 0-Peru
|
0 Participants
|
1 Participants
|
0 Participants
|
7 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-E M at Month 0-Total
|
3 Participants
|
8 Participants
|
2 Participants
|
10 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-E M at Month 0-USA
|
3 Participants
|
7 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-N at Month 0-Peru
|
11 Participants
|
39 Participants
|
8 Participants
|
30 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-N at Month 0-Total
|
27 Participants
|
84 Participants
|
13 Participants
|
46 Participants
|
30 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-N at Month 0-USA
|
16 Participants
|
45 Participants
|
5 Participants
|
16 Participants
|
10 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF3a6 at Month 0-Peru
|
4 Participants
|
16 Participants
|
3 Participants
|
18 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF3a6 at Month 0-Total
|
8 Participants
|
29 Participants
|
6 Participants
|
25 Participants
|
12 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF3a6 at Month 0-USA
|
4 Participants
|
13 Participants
|
3 Participants
|
7 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF7a7b8 at Month 0-Peru
|
3 Participants
|
17 Participants
|
3 Participants
|
17 Participants
|
11 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF7a7b8 at Month 0-Total
|
6 Participants
|
23 Participants
|
5 Participants
|
22 Participants
|
15 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF7a7b8 at Month 0-USA
|
3 Participants
|
6 Participants
|
2 Participants
|
5 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S1 at Month 0-Total
|
1 Participants
|
33 Participants
|
8 Participants
|
15 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S2 at Month 0-Total
|
4 Participants
|
11 Participants
|
3 Participants
|
5 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S2 at Month 0-USA
|
1 Participants
|
7 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Spike at Month 0-Peru
|
4 Participants
|
15 Participants
|
5 Participants
|
12 Participants
|
11 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Spike at Month 0-Total
|
5 Participants
|
38 Participants
|
8 Participants
|
15 Participants
|
16 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Spike at Month 0-USA
|
1 Participants
|
23 Participants
|
3 Participants
|
3 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population with positive responders (USA and Peru only), all available data at each visit
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and COVID-19 severity among America Cohort
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Any COV2 at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.4 to 0.7
|
1.1 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.6
|
1.1 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Any COV2 at Month 0-Total
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.9
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.4 to 0.7
|
1 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.4
|
1 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Any COV2 at Month 0-USA
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.6
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.8
|
0.8 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.1
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-E M at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-E M at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-E M at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-N at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF3a6 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF3a6 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF7a7b8 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF3a6 at Month 0-USA
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF7a7b8 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S1 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-ORF7a7b8 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S1 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S1 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S2 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S2 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-S2 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Spike at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Spike at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.7
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD4+-Spike at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Any COV2 at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.0
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.3 to 2.2
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Any COV2 at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.0
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.6
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Any COV2 at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-E M at Month 0-Peru
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-E M at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 1.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-E M at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 1.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-N at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.9
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 1.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF3a6 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF3a6 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF3a6 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF7a7b8 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF7a7b8 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-ORF7a7b8 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S1 at Month 0-Peru
|
0 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.0
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S1 at Month 0-Total
|
0 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.0
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S1 at Month 0-USA
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 1.0
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S2 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S2 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-S2 at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Spike at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Spike at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
CD8+-Spike at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 1.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). The sample will be included in the analysis only if the number of IgD- B cells is equal or greater than 1000 for that sample. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=86 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=150 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=25 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=76 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=51 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ of Total B Cells-Total
|
0.22 percentage of cells
Interval 0.12 to 0.33
|
0.31 percentage of cells
Interval 0.22 to 0.5
|
0.36 percentage of cells
Interval 0.3 to 0.52
|
0.42 percentage of cells
Interval 0.29 to 0.55
|
0.4 percentage of cells
Interval 0.3 to 0.48
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ IgA+ of Memory B Cells-Peru
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.02 percentage of cells
Interval 0.0 to 0.04
|
0.02 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.05
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ IgA+ of Memory B Cells-USA
|
0 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.02 percentage of cells
Interval 0.02 to 0.05
|
0 percentage of cells
Interval 0.0 to 0.05
|
0 percentage of cells
Interval 0.0 to 0.01
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ IgG+ of Memory B Cells-Peru
|
0.08 percentage of cells
Interval 0.04 to 0.15
|
0.14 percentage of cells
Interval 0.06 to 0.3
|
0.13 percentage of cells
Interval 0.04 to 0.31
|
0.23 percentage of cells
Interval 0.11 to 0.35
|
0.23 percentage of cells
Interval 0.13 to 0.36
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ IgA+ of Memory B Cells-Total
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.02 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0 percentage of cells
Interval 0.0 to 0.03
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ IgG+ of Memory B Cells-Total
|
0.09 percentage of cells
Interval 0.01 to 0.18
|
0.14 percentage of cells
Interval 0.05 to 0.28
|
0.15 percentage of cells
Interval 0.08 to 0.31
|
0.25 percentage of cells
Interval 0.11 to 0.35
|
0.23 percentage of cells
Interval 0.13 to 0.36
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ IgG+ of Memory B Cells-USA
|
0.1 percentage of cells
Interval 0.0 to 0.23
|
0.13 percentage of cells
Interval 0.05 to 0.25
|
0.24 percentage of cells
Interval 0.19 to 0.32
|
0.27 percentage of cells
Interval 0.08 to 0.41
|
0.23 percentage of cells
Interval 0.1 to 0.38
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ IgM+ of Memory B Cells-Peru
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ IgM+ of Memory B Cells-Total
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ IgM+ of Memory B Cells-USA
|
0 percentage of cells
Interval 0.0 to 0.03
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.03 percentage of cells
Interval 0.0 to 0.07
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ of Total B Cells-Peru
|
0.05 percentage of cells
Interval 0.03 to 0.09
|
0.08 percentage of cells
Interval 0.05 to 0.14
|
0.08 percentage of cells
Interval 0.05 to 0.11
|
0.1 percentage of cells
Interval 0.05 to 0.14
|
0.09 percentage of cells
Interval 0.07 to 0.13
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ of Total B Cells-Total
|
0.05 percentage of cells
Interval 0.03 to 0.12
|
0.06 percentage of cells
Interval 0.04 to 0.11
|
0.08 percentage of cells
Interval 0.05 to 0.11
|
0.08 percentage of cells
Interval 0.05 to 0.14
|
0.07 percentage of cells
Interval 0.05 to 0.12
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%RBD+ of Total B Cells-USA
|
0.06 percentage of cells
Interval 0.02 to 0.16
|
0.04 percentage of cells
Interval 0.03 to 0.07
|
0.08 percentage of cells
Interval 0.06 to 0.2
|
0.07 percentage of cells
Interval 0.04 to 0.12
|
0.05 percentage of cells
Interval 0.02 to 0.07
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgA+ of Memory B Cells-Peru
|
0.06 percentage of cells
Interval 0.03 to 0.09
|
0.08 percentage of cells
Interval 0.04 to 0.12
|
0.09 percentage of cells
Interval 0.04 to 0.21
|
0.07 percentage of cells
Interval 0.03 to 0.15
|
0.08 percentage of cells
Interval 0.04 to 0.15
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgA+ of Memory B Cells-Total
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.08 percentage of cells
Interval 0.03 to 0.12
|
0.07 percentage of cells
Interval 0.04 to 0.15
|
0.07 percentage of cells
Interval 0.03 to 0.12
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgA+ of Memory B Cells-USA
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.07 percentage of cells
Interval 0.03 to 0.11
|
0.04 percentage of cells
Interval 0.04 to 0.07
|
0.07 percentage of cells
Interval 0.03 to 0.1
|
0.04 percentage of cells
Interval 0.0 to 0.08
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgA+ of Total B Cells-Peru
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.06
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgA+ of Total B Cells-Total
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.02 percentage of cells
Interval 0.01 to 0.06
|
0.01 percentage of cells
Interval 0.01 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgA+ of Total B Cells-USA
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgG+ of Memory B Cells-Peru
|
0.39 percentage of cells
Interval 0.2 to 0.6
|
0.63 percentage of cells
Interval 0.38 to 1.07
|
0.78 percentage of cells
Interval 0.32 to 1.32
|
1.02 percentage of cells
Interval 0.6 to 1.26
|
1.09 percentage of cells
Interval 0.63 to 1.4
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgG+ of Memory B Cells-Total
|
0.33 percentage of cells
Interval 0.07 to 0.61
|
0.63 percentage of cells
Interval 0.38 to 1.02
|
0.95 percentage of cells
Interval 0.33 to 1.32
|
1.07 percentage of cells
Interval 0.55 to 1.43
|
1.08 percentage of cells
Interval 0.61 to 1.43
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgG+ of Memory B Cells-USA
|
0.28 percentage of cells
Interval 0.05 to 0.61
|
0.63 percentage of cells
Interval 0.36 to 1.0
|
0.98 percentage of cells
Interval 0.75 to 1.38
|
1.13 percentage of cells
Interval 0.46 to 1.73
|
1.07 percentage of cells
Interval 0.44 to 1.6
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgG+ of Total B Cells-Peru
|
0.07 percentage of cells
Interval 0.04 to 0.15
|
0.17 percentage of cells
Interval 0.08 to 0.26
|
0.2 percentage of cells
Interval 0.12 to 0.26
|
0.2 percentage of cells
Interval 0.14 to 0.33
|
0.24 percentage of cells
Interval 0.2 to 0.29
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgG+ of Total B Cells-Total
|
0.06 percentage of cells
Interval 0.01 to 0.14
|
0.11 percentage of cells
Interval 0.06 to 0.23
|
0.2 percentage of cells
Interval 0.12 to 0.23
|
0.2 percentage of cells
Interval 0.12 to 0.29
|
0.21 percentage of cells
Interval 0.1 to 0.26
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgG+ of Total B Cells-USA
|
0.05 percentage of cells
Interval 0.01 to 0.14
|
0.1 percentage of cells
Interval 0.06 to 0.17
|
0.17 percentage of cells
Interval 0.12 to 0.22
|
0.2 percentage of cells
Interval 0.11 to 0.25
|
0.16 percentage of cells
Interval 0.05 to 0.22
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-Peru
|
0.11 percentage of cells
Interval 0.08 to 0.13
|
0.14 percentage of cells
Interval 0.1 to 0.18
|
0.11 percentage of cells
Interval 0.09 to 0.15
|
0.09 percentage of cells
Interval 0.08 to 0.13
|
0.11 percentage of cells
Interval 0.08 to 0.14
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-Total
|
0.08 percentage of cells
Interval 0.06 to 0.12
|
0.11 percentage of cells
Interval 0.08 to 0.16
|
0.1 percentage of cells
Interval 0.09 to 0.15
|
0.1 percentage of cells
Interval 0.08 to 0.14
|
0.1 percentage of cells
Interval 0.06 to 0.14
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-USA
|
0.08 percentage of cells
Interval 0.05 to 0.1
|
0.09 percentage of cells
Interval 0.07 to 0.12
|
0.1 percentage of cells
Interval 0.07 to 0.13
|
0.11 percentage of cells
Interval 0.07 to 0.17
|
0.1 percentage of cells
Interval 0.06 to 0.14
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgM+ of Memory B Cells-Peru
|
0.03 percentage of cells
Interval 0.0 to 0.06
|
0.04 percentage of cells
Interval 0.02 to 0.09
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.06
|
0.04 percentage of cells
Interval 0.02 to 0.09
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgM+ of Memory B Cells-Total
|
0.03 percentage of cells
Interval 0.0 to 0.07
|
0.05 percentage of cells
Interval 0.03 to 0.09
|
0.04 percentage of cells
Interval 0.02 to 0.09
|
0.04 percentage of cells
Interval 0.01 to 0.06
|
0.03 percentage of cells
Interval 0.0 to 0.07
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgM+ of Memory B Cells-USA
|
0.03 percentage of cells
Interval 0.0 to 0.07
|
0.06 percentage of cells
Interval 0.03 to 0.09
|
0.07 percentage of cells
Interval 0.02 to 0.12
|
0.04 percentage of cells
Interval 0.0 to 0.07
|
0.02 percentage of cells
Interval 0.0 to 0.05
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgM+ of Total B Cells-Peru
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.01 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgM+ of Total B Cells-Total
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.02
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ IgM+ of Total B Cells-USA
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ of Total B Cells-Peru
|
0.29 percentage of cells
Interval 0.16 to 0.37
|
0.43 percentage of cells
Interval 0.26 to 0.59
|
0.43 percentage of cells
Interval 0.27 to 0.59
|
0.43 percentage of cells
Interval 0.32 to 0.55
|
0.43 percentage of cells
Interval 0.38 to 0.52
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
%S+ of Total B Cells-USA
|
0.21 percentage of cells
Interval 0.1 to 0.32
|
0.26 percentage of cells
Interval 0.2 to 0.37
|
0.34 percentage of cells
Interval 0.3 to 0.4
|
0.37 percentage of cells
Interval 0.27 to 0.54
|
0.3 percentage of cells
Interval 0.17 to 0.41
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
20 Participants
|
60 Participants
|
63 Participants
|
121 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
21 Participants
|
57 Participants
|
57 Participants
|
115 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-50 at Month 4-Total
|
21 Participants
|
45 Participants
|
42 Participants
|
75 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
28 Participants
|
72 Participants
|
78 Participants
|
148 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
22 Participants
|
56 Participants
|
55 Participants
|
114 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 4-Total
|
21 Participants
|
44 Participants
|
40 Participants
|
72 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
28 Participants
|
71 Participants
|
78 Participants
|
147 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
20 Participants
|
54 Participants
|
55 Participants
|
110 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total
|
20 Participants
|
38 Participants
|
37 Participants
|
69 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
13 Participants
|
58 Participants
|
61 Participants
|
112 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
22 Participants
|
56 Participants
|
59 Participants
|
112 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total
|
21 Participants
|
44 Participants
|
42 Participants
|
74 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
24 Participants
|
72 Participants
|
77 Participants
|
144 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
22 Participants
|
57 Participants
|
58 Participants
|
112 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 4-Total
|
21 Participants
|
44 Participants
|
41 Participants
|
72 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
28 Participants
|
72 Participants
|
82 Participants
|
149 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
19 Participants
|
55 Participants
|
57 Participants
|
115 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total
|
19 Participants
|
43 Participants
|
37 Participants
|
73 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
29 Participants
|
74 Participants
|
82 Participants
|
147 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
22 Participants
|
56 Participants
|
59 Participants
|
116 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total
|
21 Participants
|
45 Participants
|
42 Participants
|
75 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
14 Participants
|
60 Participants
|
59 Participants
|
114 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
21 Participants
|
54 Participants
|
56 Participants
|
110 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total
|
21 Participants
|
45 Participants
|
42 Participants
|
72 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by BAMA IgG1 at Visit 1, 2, 3, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-1000 at Month 0-Total
|
11484.4 MFI
Interval 5568.6 to 20553.6
|
22000 MFI
Interval 10672.4 to 22000.0
|
22000 MFI
Interval 5914.2 to 22000.0
|
14553.4 MFI
Interval 4370.4 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-1000 at Month 2-Total
|
5544.1 MFI
Interval 1989.5 to 12245.6
|
11097.6 MFI
Interval 3760.7 to 22000.0
|
9271.5 MFI
Interval 1901.1 to 21065.0
|
8335.5 MFI
Interval 2706.8 to 18749.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-1000 at Month 4-Total
|
2156 MFI
Interval 951.2 to 4403.2
|
6349 MFI
Interval 1452.9 to 19026.9
|
3660 MFI
Interval 1538.0 to 14339.0
|
3067.9 MFI
Interval 978.9 to 10026.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
229E-RBD-50 at Month 0-Total
|
5759.9 MFI
Interval 3973.1 to 8372.8
|
5035.8 MFI
Interval 3799.8 to 7984.2
|
5897.8 MFI
Interval 3326.8 to 8369.5
|
5698 MFI
Interval 3337.4 to 8032.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
229E-RBD-50 at Month 2-Total
|
6586 MFI
Interval 4399.0 to 8187.2
|
5076 MFI
Interval 2771.9 to 7887.1
|
5212.5 MFI
Interval 3398.5 to 7946.4
|
4738.2 MFI
Interval 2894.5 to 7440.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
229E-RBD-50 at Month 4-Total
|
5714 MFI
Interval 3953.8 to 8962.4
|
6275.5 MFI
Interval 3624.0 to 8627.8
|
6810.4 MFI
Interval 4639.9 to 9987.6
|
6235.8 MFI
Interval 3862.9 to 8359.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Total
|
18341.8 MFI
Interval 13014.6 to 22000.0
|
15357.9 MFI
Interval 9446.6 to 21100.9
|
13943.4 MFI
Interval 7657.2 to 22000.0
|
12162.5 MFI
Interval 6134.8 to 21400.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Total
|
13942 MFI
Interval 8989.5 to 17316.2
|
9134.4 MFI
Interval 5638.7 to 16769.2
|
8646.8 MFI
Interval 5308.2 to 15402.4
|
9715.4 MFI
Interval 5260.2 to 14721.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 4-Total
|
11015.5 MFI
Interval 8560.8 to 13422.3
|
9341 MFI
Interval 5824.8 to 14489.0
|
10458.6 MFI
Interval 6214.4 to 19640.3
|
10425.4 MFI
Interval 5139.8 to 14758.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total
|
18176.8 MFI
Interval 12582.2 to 22000.0
|
14720.5 MFI
Interval 8018.5 to 21628.1
|
16978.4 MFI
Interval 9741.4 to 22000.0
|
14320 MFI
Interval 6958.1 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total
|
17001.8 MFI
Interval 10625.8 to 22000.0
|
16950.5 MFI
Interval 9025.9 to 21921.2
|
13674.5 MFI
Interval 7867.2 to 20084.5
|
12047.8 MFI
Interval 7491.2 to 18459.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total
|
16352.5 MFI
Interval 7446.2 to 20204.3
|
14488 MFI
Interval 7171.8 to 20768.1
|
11621.1 MFI
Interval 8427.3 to 19273.6
|
12100.8 MFI
Interval 6926.9 to 21509.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Total
|
1310.2 MFI
Interval 759.1 to 2238.0
|
1197.9 MFI
Interval 37.8 to 2493.1
|
1319.2 MFI
Interval 94.0 to 3097.5
|
1318.1 MFI
Interval 8.6 to 3213.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Total
|
2241 MFI
Interval 1118.1 to 5181.4
|
1799.2 MFI
Interval 602.0 to 3704.5
|
1653.8 MFI
Interval 586.9 to 3214.2
|
1478.9 MFI
Interval 371.1 to 4411.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 4-Total
|
2414.3 MFI
Interval 1354.6 to 3212.0
|
1363.5 MFI
Interval 858.1 to 2593.1
|
1315.8 MFI
Interval 638.5 to 2685.6
|
1513.8 MFI
Interval 603.6 to 3079.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Total
|
22000 MFI
Interval 19473.1 to 22000.0
|
22000 MFI
Interval 17385.5 to 22000.0
|
22000 MFI
Interval 19581.8 to 22000.0
|
21808.2 MFI
Interval 16243.2 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Total
|
22000 MFI
Interval 22000.0 to 22000.0
|
22000 MFI
Interval 17780.2 to 22000.0
|
22000 MFI
Interval 17461.8 to 22000.0
|
21969 MFI
Interval 12920.0 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 4-Total
|
22000 MFI
Interval 14702.0 to 22000.0
|
22000 MFI
Interval 15984.6 to 22000.0
|
20646.2 MFI
Interval 15675.1 to 22000.0
|
20511.8 MFI
Interval 13061.6 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HKU1-RBD-50 at Month 0-Total
|
5172.5 MFI
Interval 3086.1 to 7727.9
|
4688 MFI
Interval 2801.8 to 6782.4
|
4923.8 MFI
Interval 3305.5 to 6598.2
|
4291.9 MFI
Interval 2400.6 to 6036.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HKU1-RBD-50 at Month 2-Total
|
4731.2 MFI
Interval 3587.2 to 5942.7
|
4175 MFI
Interval 1724.5 to 6107.0
|
4311.8 MFI
Interval 2721.6 to 6346.9
|
3500.8 MFI
Interval 1722.1 to 5579.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HKU1-RBD-50 at Month 4-Total
|
5317.8 MFI
Interval 3437.4 to 8881.1
|
5189.4 MFI
Interval 3668.8 to 6956.1
|
5507.8 MFI
Interval 3667.8 to 8611.8
|
5373 MFI
Interval 2680.8 to 7775.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
NL63-RBD-50 at Month 0-Total
|
14352.5 MFI
Interval 10012.1 to 17704.0
|
12258.5 MFI
Interval 9916.6 to 14972.5
|
10779.8 MFI
Interval 8010.2 to 16454.8
|
11885.5 MFI
Interval 8681.8 to 15936.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
NL63-RBD-50 at Month 2-Total
|
16886.5 MFI
Interval 15225.0 to 20130.5
|
15328.8 MFI
Interval 10445.8 to 18107.5
|
14236.9 MFI
Interval 9743.9 to 18173.8
|
13644.5 MFI
Interval 9569.6 to 18060.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
NL63-RBD-50 at Month 4-Total
|
16381 MFI
Interval 13413.5 to 20575.2
|
15586.1 MFI
Interval 12530.4 to 18276.2
|
16318.5 MFI
Interval 13572.4 to 19782.6
|
16580.9 MFI
Interval 12363.9 to 19943.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
OC43-RBD-50 at Month 0-Total
|
5351.5 MFI
Interval 2714.1 to 8942.0
|
4108.8 MFI
Interval 2664.0 to 6770.0
|
4605 MFI
Interval 1951.8 to 8643.8
|
3927.1 MFI
Interval 2424.0 to 6054.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
OC43-RBD-50 at Month 2-Total
|
6109.2 MFI
Interval 3276.5 to 10408.5
|
4069.5 MFI
Interval 2011.8 to 6808.0
|
4491.9 MFI
Interval 2332.1 to 7179.9
|
4055.2 MFI
Interval 2286.0 to 6998.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
OC43-RBD-50 at Month 4-Total
|
4053.5 MFI
Interval 2698.0 to 9458.4
|
5068.2 MFI
Interval 2519.1 to 7666.6
|
5437 MFI
Interval 3126.5 to 9777.9
|
5267.5 MFI
Interval 2268.0 to 7898.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 0-Total
|
3903.4 MFI
Interval 1181.2 to 8940.0
|
8110.5 MFI
Interval 1056.0 to 21923.8
|
6366.4 MFI
Interval 988.6 to 21668.6
|
4628.9 MFI
Interval 1459.1 to 13579.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 2-Total
|
1660.8 MFI
Interval 683.6 to 2666.8
|
2814.6 MFI
Interval 587.9 to 10179.6
|
1729.8 MFI
Interval 355.6 to 8003.2
|
1609 MFI
Interval 499.8 to 4622.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-1000 at Month 4-Total
|
463.5 MFI
Interval 279.2 to 1194.0
|
1509.5 MFI
Interval 310.9 to 5133.3
|
1116.8 MFI
Interval 324.4 to 4087.5
|
853.5 MFI
Interval 274.5 to 2743.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total
|
2736.9 MFI
Interval 1040.4 to 19813.4
|
13506.2 MFI
Interval 2016.5 to 22000.0
|
13011.4 MFI
Interval 1628.9 to 22000.0
|
12524.4 MFI
Interval 2197.4 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total
|
808.5 MFI
Interval 587.8 to 5196.0
|
2651.8 MFI
Interval 751.1 to 6471.6
|
2231.6 MFI
Interval 386.0 to 8176.2
|
2878 MFI
Interval 603.8 to 8151.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total
|
321.1 MFI
Interval 167.5 to 1147.1
|
760.8 MFI
Interval 240.2 to 2111.0
|
509.2 MFI
Interval 242.5 to 2733.0
|
556.9 MFI
Interval 236.8 to 1680.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total
|
2008.6 MFI
Interval 935.9 to 4564.1
|
9659.2 MFI
Interval 1642.7 to 21640.7
|
9512.8 MFI
Interval 1148.0 to 17840.2
|
3997.5 MFI
Interval 1077.9 to 11198.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total
|
1337.2 MFI
Interval 559.6 to 3004.9
|
2169.6 MFI
Interval 639.9 to 8637.3
|
1999.5 MFI
Interval 304.2 to 7686.8
|
1759.8 MFI
Interval 499.2 to 4893.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total
|
511.2 MFI
Interval 284.5 to 978.2
|
1627 MFI
Interval 312.2 to 5317.2
|
834.2 MFI
Interval 335.8 to 4397.5
|
636.5 MFI
Interval 201.9 to 2993.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 0-Total
|
3073.5 MFI
Interval 1047.4 to 8787.6
|
7604.5 MFI
Interval 596.2 to 22000.0
|
5603.8 MFI
Interval 718.8 to 21419.6
|
3894.1 MFI
Interval 1204.7 to 14907.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 2-Total
|
1460.2 MFI
Interval 355.9 to 2154.8
|
2109.2 MFI
Interval 368.8 to 10737.2
|
1499 MFI
Interval 226.2 to 6875.8
|
1481.8 MFI
Interval 265.2 to 5454.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-1000 at Month 4-Total
|
427 MFI
Interval 195.5 to 1025.5
|
1459.6 MFI
Interval 236.2 to 5309.6
|
741.9 MFI
Interval 232.6 to 4402.1
|
771.2 MFI
Interval 190.1 to 2820.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total
|
3146.6 MFI
Interval 972.2 to 5793.9
|
4770.2 MFI
Interval 1143.1 to 20761.3
|
7640.1 MFI
Interval 1228.6 to 15861.9
|
5985 MFI
Interval 1353.8 to 12621.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total
|
1136.9 MFI
Interval 675.5 to 2609.5
|
2766.2 MFI
Interval 620.3 to 9405.0
|
2739.5 MFI
Interval 316.5 to 8066.1
|
2470 MFI
Interval 555.2 to 7924.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total
|
701 MFI
Interval 381.5 to 968.1
|
2099.2 MFI
Interval 365.8 to 6293.5
|
1144.4 MFI
Interval 254.6 to 5062.8
|
923.2 MFI
Interval 179.9 to 4231.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total
|
9507.8 MFI
Interval 4309.0 to 16696.6
|
19343.6 MFI
Interval 5322.3 to 22000.0
|
14710.5 MFI
Interval 6038.0 to 22000.0
|
13203.8 MFI
Interval 5043.8 to 22000.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total
|
4872.2 MFI
Interval 2458.5 to 10428.5
|
9217.9 MFI
Interval 3680.4 to 22000.0
|
8247.1 MFI
Interval 1888.5 to 19664.8
|
7916.5 MFI
Interval 2783.6 to 17910.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total
|
2363.7 MFI
Interval 1155.0 to 3935.8
|
7105 MFI
Interval 1642.2 to 16111.9
|
3783 MFI
Interval 1509.8 to 13837.2
|
2925.1 MFI
Interval 1103.9 to 10373.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total
|
1747 MFI
Interval 293.9 to 3858.4
|
12005 MFI
Interval 1362.6 to 22000.0
|
8313.6 MFI
Interval 845.2 to 22000.0
|
3940.2 MFI
Interval 404.1 to 13471.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total
|
415.4 MFI
Interval 91.3 to 1434.9
|
1863.6 MFI
Interval 117.6 to 7913.3
|
685.2 MFI
Interval 60.8 to 8406.5
|
872.1 MFI
Interval 114.8 to 3358.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total
|
96.3 MFI
Interval 24.5 to 567.8
|
512 MFI
Interval 94.3 to 3209.9
|
332 MFI
Interval 26.5 to 2540.2
|
279.2 MFI
Interval 27.8 to 1415.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
1 Participants
|
19 Participants
|
23 Participants
|
33 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
26 Participants
|
65 Participants
|
72 Participants
|
140 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
1 Participants
|
10 Participants
|
14 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
27 Participants
|
65 Participants
|
74 Participants
|
141 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
1 Participants
|
11 Participants
|
16 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
28 Participants
|
73 Participants
|
78 Participants
|
154 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
1 Participants
|
21 Participants
|
24 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
29 Participants
|
74 Participants
|
78 Participants
|
150 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
1 Participants
|
17 Participants
|
21 Participants
|
41 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
28 Participants
|
66 Participants
|
73 Participants
|
143 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
1 Participants
|
17 Participants
|
19 Participants
|
39 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
29 Participants
|
73 Participants
|
77 Participants
|
151 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
1 Participants
|
19 Participants
|
22 Participants
|
41 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
26 Participants
|
63 Participants
|
70 Participants
|
136 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
1 Participants
|
10 Participants
|
14 Participants
|
20 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
31 Participants
|
75 Participants
|
79 Participants
|
150 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
2903.8 MFI
Interval 2903.8 to 2903.8
|
5407.5 MFI
Interval 2462.2 to 8652.2
|
3503.5 MFI
Interval 1660.2 to 9682.5
|
4610 MFI
Interval 2062.0 to 11666.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
4576.5 MFI
Interval 2270.9 to 7342.0
|
5373.1 MFI
Interval 1932.1 to 8753.1
|
4580.9 MFI
Interval 2000.5 to 8407.5
|
4309.1 MFI
Interval 2349.2 to 8847.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
2345.2 MFI
Interval 2345.2 to 2345.2
|
2048 MFI
Interval 539.0 to 2600.5
|
1415.2 MFI
Interval 377.0 to 2429.5
|
2385.5 MFI
Interval 946.0 to 3879.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
1529 MFI
Interval 438.1 to 7685.1
|
3675.8 MFI
Interval 431.4 to 11368.1
|
2504.8 MFI
Interval 394.8 to 6504.2
|
2839.1 MFI
Interval 641.9 to 7226.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
1487.2 MFI
Interval 1487.2 to 1487.2
|
603.2 MFI
Interval 144.8 to 974.0
|
207.5 MFI
Interval 1.0 to 999.0
|
844 MFI
Interval 145.0 to 1905.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
5275.2 MFI
Interval 3138.2 to 10723.5
|
7354.2 MFI
Interval 2928.0 to 13468.5
|
6335.5 MFI
Interval 3196.0 to 12738.0
|
6180.5 MFI
Interval 3182.8 to 11493.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
3674 MFI
Interval 3674.0 to 3674.0
|
2815.5 MFI
Interval 738.2 to 4352.5
|
1935.5 MFI
Interval 447.2 to 4011.0
|
3562 MFI
Interval 1412.5 to 6152.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
229E-RBD-50 at Month 0-Total
|
343 MFI
Interval 97.0 to 460.5
|
210.2 MFI
Interval 9.9 to 386.4
|
242.2 MFI
Interval 72.2 to 531.0
|
230.8 MFI
Interval 31.5 to 490.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
229E-RBD-50 at Month 2-Total
|
47 MFI
Interval 47.0 to 47.0
|
1 MFI
Interval 1.0 to 6.0
|
1 MFI
Interval 1.0 to 155.9
|
1 MFI
Interval 1.0 to 1.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Total
|
61.8 MFI
Interval 1.0 to 147.0
|
11.1 MFI
Interval 1.0 to 70.7
|
15.4 MFI
Interval 1.0 to 116.3
|
1 MFI
Interval 1.0 to 72.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Total
|
630.2 MFI
Interval 630.2 to 630.2
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total
|
321 MFI
Interval 124.9 to 754.5
|
296.2 MFI
Interval 109.2 to 1192.2
|
302.8 MFI
Interval 114.0 to 598.9
|
557.2 MFI
Interval 145.0 to 1748.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total
|
406.8 MFI
Interval 406.8 to 406.8
|
192.5 MFI
Interval 1.0 to 1158.2
|
63 MFI
Interval 1.0 to 326.8
|
306.5 MFI
Interval 35.8 to 1225.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Total
|
22.2 MFI
Interval 1.0 to 113.5
|
1 MFI
Interval 1.0 to 24.1
|
1 MFI
Interval 1.0 to 70.0
|
1 MFI
Interval 1.0 to 43.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Total
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Total
|
679 MFI
Interval 309.5 to 1903.1
|
519.5 MFI
Interval 106.9 to 2237.7
|
380.9 MFI
Interval 93.4 to 1072.4
|
555.5 MFI
Interval 130.5 to 2408.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Total
|
577.5 MFI
Interval 577.5 to 577.5
|
32.2 MFI
Interval 1.0 to 644.0
|
1 MFI
Interval 1.0 to 260.2
|
1 MFI
Interval 1.0 to 1058.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HKU1-RBD-50 at Month 0-Total
|
217 MFI
Interval 109.4 to 398.8
|
182.6 MFI
Interval 21.9 to 316.9
|
201.5 MFI
Interval 75.0 to 430.5
|
195.9 MFI
Interval 22.9 to 410.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HKU1-RBD-50 at Month 2-Total
|
204 MFI
Interval 204.0 to 204.0
|
1 MFI
Interval 1.0 to 92.8
|
1 MFI
Interval 1.0 to 103.0
|
1 MFI
Interval 1.0 to 18.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
NL63-RBD-50 at Month 0-Total
|
215.2 MFI
Interval 19.2 to 458.5
|
273.5 MFI
Interval 92.7 to 416.7
|
200.8 MFI
Interval 24.2 to 484.5
|
193.5 MFI
Interval 1.0 to 412.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
NL63-RBD-50 at Month 2-Total
|
152.5 MFI
Interval 152.5 to 152.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 81.8
|
1 MFI
Interval 1.0 to 11.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
OC43-RBD-50 at Month 0-Total
|
218.2 MFI
Interval 76.0 to 369.0
|
157.9 MFI
Interval 5.8 to 278.3
|
145.2 MFI
Interval 16.5 to 341.9
|
124 MFI
Interval 1.0 to 409.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
OC43-RBD-50 at Month 2-Total
|
50.5 MFI
Interval 50.5 to 50.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 48.5
|
1 MFI
Interval 1.0 to 28.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
1962.5 MFI
Interval 556.9 to 3298.5
|
2412.8 MFI
Interval 474.8 to 4158.2
|
1581.2 MFI
Interval 709.2 to 3565.5
|
1700 MFI
Interval 642.9 to 3822.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
1393.8 MFI
Interval 1393.8 to 1393.8
|
406.2 MFI
Interval 19.5 to 1083.0
|
171.2 MFI
Interval 1.0 to 918.2
|
205.8 MFI
Interval 1.0 to 974.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
6657.2 MFI
Interval 3747.1 to 14044.9
|
8643.2 MFI
Interval 4124.6 to 17004.2
|
7041 MFI
Interval 2795.5 to 11746.8
|
7569.5 MFI
Interval 3027.1 to 14175.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
1482.5 MFI
Interval 1482.5 to 1482.5
|
2162.8 MFI
Interval 789.0 to 7057.8
|
2270 MFI
Interval 442.2 to 3598.2
|
1330.8 MFI
Interval 246.0 to 3523.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
1908.4 MFI
Interval 582.6 to 3257.1
|
1739.8 MFI
Interval 484.5 to 4570.2
|
1538 MFI
Interval 531.6 to 4306.8
|
1670.5 MFI
Interval 540.8 to 4214.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
790 MFI
Interval 790.0 to 790.0
|
192.5 MFI
Interval 45.2 to 1028.8
|
210.8 MFI
Interval 1.0 to 926.0
|
565 MFI
Interval 36.0 to 1088.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
1233.2 MFI
Interval 494.2 to 2949.0
|
2218.9 MFI
Interval 358.8 to 5177.3
|
1769.9 MFI
Interval 524.5 to 4168.4
|
1702.4 MFI
Interval 666.5 to 3998.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
1479.5 MFI
Interval 1479.5 to 1479.5
|
414.2 MFI
Interval 16.0 to 1515.5
|
290.5 MFI
Interval 1.0 to 1200.5
|
662 MFI
Interval 127.8 to 1313.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
7638.2 MFI
Interval 4298.5 to 15088.2
|
9566.2 MFI
Interval 3286.8 to 21444.8
|
7286.5 MFI
Interval 3736.6 to 19084.7
|
8632.8 MFI
Interval 4030.4 to 18051.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
29 Participants
|
74 Participants
|
80 Participants
|
146 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
1 Participants
|
18 Participants
|
24 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
24 Participants
|
66 Participants
|
69 Participants
|
124 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
0 Participants
|
15 Participants
|
19 Participants
|
31 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
28 Participants
|
75 Participants
|
77 Participants
|
142 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
0 Participants
|
20 Participants
|
20 Participants
|
39 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
29 Participants
|
74 Participants
|
81 Participants
|
149 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
1 Participants
|
19 Participants
|
26 Participants
|
42 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
29 Participants
|
71 Participants
|
76 Participants
|
146 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
1 Participants
|
17 Participants
|
23 Participants
|
40 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
12 Participants
|
42 Participants
|
40 Participants
|
74 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
0 Participants
|
6 Participants
|
8 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
29 Participants
|
70 Participants
|
78 Participants
|
138 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
1 Participants
|
16 Participants
|
21 Participants
|
41 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
14 Participants
|
53 Participants
|
49 Participants
|
91 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
0 Participants
|
15 Participants
|
16 Participants
|
29 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-50 at Month 0-Total
|
8344.8 MFI
Interval 2822.9 to 16328.2
|
8379.1 MFI
Interval 3444.2 to 18318.1
|
8258.5 MFI
Interval 3107.2 to 15027.2
|
5754.8 MFI
Interval 2256.0 to 10838.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
2019-nCoV S/293F-50 at Month 2-Total
|
11670.8 MFI
Interval 11670.8 to 11670.8
|
4340.5 MFI
Interval 1324.5 to 7052.0
|
3227.5 MFI
Interval 1887.0 to 7967.5
|
2781.2 MFI
Interval 1566.5 to 6886.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
229E-RBD-50 at Month 0-Total
|
481.5 MFI
Interval 354.4 to 833.4
|
585.4 MFI
Interval 330.9 to 904.4
|
625.5 MFI
Interval 294.6 to 1097.2
|
459.5 MFI
Interval 283.8 to 886.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
229E-RBD-50 at Month 2-Total
|
299.2 MFI
Interval 299.2 to 299.2
|
250.2 MFI
Interval 204.2 to 382.2
|
306.2 MFI
Interval 202.8 to 480.5
|
508.8 MFI
Interval 282.8 to 909.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 0-Total
|
508.8 MFI
Interval 281.0 to 1276.0
|
422.6 MFI
Interval 233.3 to 882.8
|
465.8 MFI
Interval 278.6 to 1014.8
|
450 MFI
Interval 190.8 to 932.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-229E S1S2 ECD His-50 at Month 2-Total
|
278.2 MFI
Interval 278.2 to 278.2
|
387 MFI
Interval 258.8 to 698.0
|
575.2 MFI
Interval 171.0 to 918.5
|
614.2 MFI
Interval 176.0 to 1250.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total
|
791.2 MFI
Interval 544.1 to 2471.5
|
1293.8 MFI
Interval 579.1 to 2530.2
|
1414.2 MFI
Interval 660.6 to 3152.2
|
1510.5 MFI
Interval 671.0 to 3996.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total
|
2649.2 MFI
Interval 2649.2 to 2649.2
|
947 MFI
Interval 589.0 to 1494.0
|
1010 MFI
Interval 471.0 to 2905.5
|
1714.2 MFI
Interval 756.5 to 4510.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 0-Total
|
73.2 MFI
Interval 23.6 to 174.2
|
74.1 MFI
Interval 18.9 to 180.0
|
89.2 MFI
Interval 28.8 to 199.9
|
86.5 MFI
Interval 39.0 to 196.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50 at Month 2-Total
|
251.2 MFI
Interval 251.2 to 251.2
|
49.5 MFI
Interval 18.2 to 219.5
|
90.8 MFI
Interval 50.2 to 165.2
|
92 MFI
Interval 61.4 to 165.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 0-Total
|
2960.5 MFI
Interval 1315.6 to 4959.8
|
3252.2 MFI
Interval 1508.9 to 5773.4
|
2649 MFI
Interval 1489.4 to 6131.1
|
3493 MFI
Interval 1618.0 to 7392.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50 at Month 2-Total
|
4475.8 MFI
Interval 4475.8 to 4475.8
|
1773.8 MFI
Interval 866.8 to 3461.5
|
2548 MFI
Interval 1159.5 to 4868.8
|
3401.2 MFI
Interval 1486.2 to 7176.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HKU1-RBD-50 at Month 0-Total
|
515.5 MFI
Interval 268.2 to 712.2
|
448 MFI
Interval 288.6 to 847.8
|
490.2 MFI
Interval 287.0 to 832.5
|
436.8 MFI
Interval 281.5 to 842.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
HKU1-RBD-50 at Month 2-Total
|
293.5 MFI
Interval 293.5 to 293.5
|
358.2 MFI
Interval 181.5 to 774.5
|
376.2 MFI
Interval 210.8 to 559.5
|
447.8 MFI
Interval 236.0 to 847.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
NL63-RBD-50 at Month 0-Total
|
1086.5 MFI
Interval 805.5 to 1795.9
|
1097.6 MFI
Interval 697.4 to 2026.8
|
1582.5 MFI
Interval 849.0 to 2724.6
|
1166.5 MFI
Interval 596.2 to 2984.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
NL63-RBD-50 at Month 2-Total
|
604 MFI
Interval 604.0 to 604.0
|
774.8 MFI
Interval 637.8 to 1646.5
|
1395.8 MFI
Interval 689.0 to 2225.5
|
1269.5 MFI
Interval 676.0 to 3253.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
OC43-RBD-50 at Month 0-Total
|
463.8 MFI
Interval 229.0 to 919.1
|
486 MFI
Interval 305.1 to 965.7
|
431.5 MFI
Interval 294.4 to 1076.5
|
547 MFI
Interval 289.8 to 1032.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
OC43-RBD-50 at Month 2-Total
|
245 MFI
Interval 245.0 to 245.0
|
299 MFI
Interval 225.2 to 668.8
|
477.8 MFI
Interval 250.0 to 821.2
|
708.8 MFI
Interval 293.5 to 1571.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 0-Total
|
3886.2 MFI
Interval 1076.9 to 8525.4
|
4630.8 MFI
Interval 1414.1 to 9779.6
|
3334 MFI
Interval 893.9 to 7987.5
|
2041.2 MFI
Interval 730.8 to 5161.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 DB His-50 at Month 2-Total
|
630.8 MFI
Interval 630.8 to 630.8
|
1916.8 MFI
Interval 814.2 to 3611.5
|
1949.8 MFI
Interval 469.0 to 4851.2
|
1634.5 MFI
Interval 509.8 to 3837.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total
|
2037.2 MFI
Interval 765.6 to 4656.2
|
3927.8 MFI
Interval 759.2 to 7898.6
|
2168.5 MFI
Interval 531.6 to 6033.9
|
1297.8 MFI
Interval 489.8 to 3912.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total
|
209.2 MFI
Interval 209.2 to 209.2
|
849.2 MFI
Interval 431.2 to 1566.2
|
641.8 MFI
Interval 278.8 to 1748.2
|
908.2 MFI
Interval 434.0 to 2736.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total
|
3866.8 MFI
Interval 1276.2 to 8121.1
|
3721.9 MFI
Interval 1385.1 to 10293.8
|
3279.5 MFI
Interval 981.9 to 7809.2
|
2026.5 MFI
Interval 833.5 to 5152.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total
|
3622.8 MFI
Interval 3622.8 to 3622.8
|
1977.2 MFI
Interval 593.0 to 3498.2
|
1578.8 MFI
Interval 587.8 to 3617.2
|
1245.8 MFI
Interval 817.5 to 2715.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 0-Total
|
3496.8 MFI
Interval 705.1 to 7280.5
|
3516.6 MFI
Interval 965.5 to 10406.3
|
3014.5 MFI
Interval 670.2 to 7256.9
|
1579.5 MFI
Interval 485.0 to 4205.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1 C His-50 at Month 2-Total
|
342.8 MFI
Interval 342.8 to 342.8
|
1005.5 MFI
Interval 429.5 to 2490.0
|
760.5 MFI
Interval 244.5 to 2695.0
|
692 MFI
Interval 248.8 to 1840.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total
|
4231.8 MFI
Interval 1408.6 to 6416.8
|
5244.9 MFI
Interval 1482.2 to 10255.1
|
3988.2 MFI
Interval 1884.5 to 7836.8
|
3924.5 MFI
Interval 1327.5 to 6737.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total
|
4205.5 MFI
Interval 4205.5 to 4205.5
|
4024.8 MFI
Interval 2184.5 to 4734.8
|
3322.5 MFI
Interval 1349.2 to 4748.8
|
3798.2 MFI
Interval 1901.5 to 5377.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total
|
7566.2 MFI
Interval 2356.5 to 11938.8
|
7185.2 MFI
Interval 2694.5 to 14374.1
|
6511.5 MFI
Interval 2184.0 to 12132.6
|
4671.5 MFI
Interval 1874.0 to 10204.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total
|
12725.2 MFI
Interval 12725.2 to 12725.2
|
3087.5 MFI
Interval 1271.8 to 6934.5
|
3058.8 MFI
Interval 1070.5 to 8905.5
|
2807 MFI
Interval 1846.2 to 5988.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total
|
1366.9 MFI
Interval 216.4 to 6557.6
|
2209.1 MFI
Interval 514.8 to 7444.3
|
1690.8 MFI
Interval 124.0 to 5796.5
|
1249.5 MFI
Interval 246.5 to 3262.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total
|
214.8 MFI
Interval 214.8 to 214.8
|
579.8 MFI
Interval 176.2 to 2509.0
|
256.8 MFI
Interval 113.2 to 681.8
|
342 MFI
Interval 139.8 to 1390.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 0-Peru
|
21 Participants
|
48 Participants
|
48 Participants
|
50 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 0-Total
|
29 Participants
|
75 Participants
|
80 Participants
|
151 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 0-USA
|
8 Participants
|
27 Participants
|
32 Participants
|
101 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 12-Peru
|
—
|
1 Participants
|
1 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 12-Total
|
1 Participants
|
4 Participants
|
3 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 12-USA
|
1 Participants
|
3 Participants
|
2 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 2-Peru
|
15 Participants
|
31 Participants
|
25 Participants
|
23 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 2-Total
|
18 Participants
|
48 Participants
|
43 Participants
|
82 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 2-USA
|
3 Participants
|
17 Participants
|
18 Participants
|
59 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 4-Peru
|
1 Participants
|
1 Participants
|
1 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 4-Total
|
2 Participants
|
5 Participants
|
2 Participants
|
13 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614 at Month 4-USA
|
1 Participants
|
4 Participants
|
1 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 0-Peru
|
636.7 Titer
Interval 214.7 to 1804.3
|
2322 Titer
Interval 631.8 to 5904.3
|
1264 Titer
Interval 288.5 to 5638.2
|
574.8 Titer
Interval 180.0 to 1623.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 0-Total
|
370.7 Titer
Interval 155.8 to 931.7
|
1019 Titer
Interval 81.8 to 4617.1
|
682.8 Titer
Interval 87.1 to 1844.6
|
374.2 Titer
Interval 103.2 to 1205.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 0-USA
|
216.0 Titer
Interval 87.6 to 463.0
|
71.50 Titer
Interval 21.3 to 282.9
|
164.7 Titer
Interval 26.4 to 711.4
|
311.5 Titer
Interval 76.9 to 1095.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 12-Peru
|
—
|
964.4 Titer
Interval 964.4 to 964.4
|
866.7 Titer
Interval 866.7 to 866.7
|
120.2 Titer
Interval 65.1 to 289.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 12-Total
|
346.4 Titer
Interval 346.4 to 346.4
|
117.8 Titer
Interval 94.3 to 281.8
|
707.2 Titer
Interval 469.7 to 787.0
|
267.6 Titer
Interval 77.2 to 475.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 12-USA
|
346.4 Titer
Interval 346.4 to 346.4
|
106.1 Titer
Interval 72.0 to 158.8
|
469.7 Titer
Interval 351.0 to 588.5
|
411.9 Titer
Interval 113.2 to 608.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 2-Peru
|
47.20 Titer
Interval 20.6 to 82.0
|
228.8 Titer
Interval 104.0 to 893.6
|
152.2 Titer
Interval 22.6 to 500.1
|
220.7 Titer
Interval 47.5 to 347.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 2-Total
|
51.30 Titer
Interval 27.3 to 143.8
|
195.6 Titer
Interval 49.1 to 707.2
|
103.5 Titer
Interval 35.1 to 356.0
|
151.7 Titer
Interval 44.9 to 380.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 2-USA
|
151.8 Titer
Interval 138.6 to 291.1
|
50.60 Titer
Interval 27.2 to 180.2
|
75.00 Titer
Interval 36.3 to 156.7
|
120.4 Titer
Interval 40.9 to 391.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 4-Peru
|
113.2 Titer
Interval 113.2 to 113.2
|
151.7 Titer
Interval 151.7 to 151.7
|
29.40 Titer
Interval 29.4 to 29.4
|
239.0 Titer
Interval 121.6 to 370.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 4-Total
|
183.2 Titer
Interval 148.2 to 218.3
|
120.2 Titer
Interval 117.8 to 151.7
|
61.90 Titer
Interval 45.6 to 78.1
|
281.8 Titer
Interval 135.9 to 448.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID50 at Month 4-USA
|
253.3 Titer
Interval 253.3 to 253.3
|
119.0 Titer
Interval 103.1 to 271.7
|
94.30 Titer
Interval 94.3 to 94.3
|
346.4 Titer
Interval 187.1 to 450.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 0-Peru
|
129.4 Titer
Interval 52.3 to 237.6
|
579.7 Titer
Interval 136.6 to 1006.3
|
228.1 Titer
Interval 75.3 to 877.2
|
137.2 Titer
Interval 56.1 to 364.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 0-Total
|
120.2 Titer
Interval 40.2 to 178.1
|
213.3 Titer
Interval 25.5 to 810.2
|
144.0 Titer
Interval 29.2 to 554.4
|
105.7 Titer
Interval 31.3 to 242.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 0-USA
|
54.50 Titer
Interval 29.1 to 129.7
|
23.90 Titer
Interval 10.0 to 97.9
|
36.60 Titer
Interval 10.0 to 148.4
|
90.40 Titer
Interval 27.1 to 206.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 12-Peru
|
—
|
387.4 Titer
Interval 387.4 to 387.4
|
259.2 Titer
Interval 259.2 to 259.2
|
46.60 Titer
Interval 46.1 to 104.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 12-Total
|
120.4 Titer
Interval 120.4 to 120.4
|
44.10 Titer
Interval 30.6 to 111.5
|
189.4 Titer
Interval 138.4 to 224.3
|
88.90 Titer
Interval 39.5 to 152.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 12-USA
|
120.4 Titer
Interval 120.4 to 120.4
|
37.40 Titer
Interval 24.2 to 60.9
|
138.4 Titer
Interval 112.9 to 163.9
|
128.3 Titer
Interval 37.3 to 182.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 2-Peru
|
21.50 Titer
Interval 10.0 to 31.8
|
70.30 Titer
Interval 33.1 to 191.2
|
39.40 Titer
Interval 10.0 to 146.1
|
77.40 Titer
Interval 25.6 to 135.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 2-Total
|
24.00 Titer
Interval 10.0 to 45.9
|
51.60 Titer
Interval 20.5 to 176.9
|
35.00 Titer
Interval 10.0 to 119.4
|
41.70 Titer
Interval 10.0 to 138.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 2-USA
|
50.30 Titer
Interval 44.4 to 89.3
|
20.50 Titer
Interval 10.0 to 49.6
|
26.90 Titer
Interval 10.0 to 46.7
|
37.50 Titer
Interval 10.0 to 139.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 4-Peru
|
37.30 Titer
Interval 37.3 to 37.3
|
55.70 Titer
Interval 55.7 to 55.7
|
13.70 Titer
Interval 13.7 to 13.7
|
80.40 Titer
Interval 41.4 to 140.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 4-Total
|
59.00 Titer
Interval 48.1 to 69.8
|
46.60 Titer
Interval 44.1 to 55.7
|
22.20 Titer
Interval 17.9 to 26.4
|
111.5 Titer
Interval 46.6 to 148.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
VRC7480_G614-ID80 at Month 4-USA
|
80.70 Titer
Interval 80.7 to 80.7
|
45.40 Titer
Interval 39.2 to 81.4
|
30.60 Titer
Interval 30.6 to 30.6
|
120.4 Titer
Interval 62.6 to 138.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among Africa Cohort
Outcome measures
| Measure |
Group 1A
n=49 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=83 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=76 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=161 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 0-RSA
|
20 Participants
|
48 Participants
|
50 Participants
|
101 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 0-Total
|
22 Participants
|
61 Participants
|
60 Participants
|
146 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 0-non-RSA
|
2 Participants
|
13 Participants
|
10 Participants
|
45 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 12-RSA
|
7 Participants
|
22 Participants
|
24 Participants
|
56 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 12-Total
|
9 Participants
|
33 Participants
|
37 Participants
|
96 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 12-non-RSA
|
2 Participants
|
11 Participants
|
13 Participants
|
40 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 2-RSA
|
15 Participants
|
29 Participants
|
40 Participants
|
63 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 2-Total
|
16 Participants
|
37 Participants
|
52 Participants
|
106 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 2-non-RSA
|
1 Participants
|
8 Participants
|
12 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 4-RSA
|
15 Participants
|
27 Participants
|
36 Participants
|
65 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 4-Total
|
17 Participants
|
36 Participants
|
46 Participants
|
108 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G at Month 4-non-RSA
|
2 Participants
|
9 Participants
|
10 Participants
|
43 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among Africa Cohort
Outcome measures
| Measure |
Group 1A
n=49 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=83 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=76 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=161 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 0-RSA
|
341.2 Titer
Interval 110.2 to 1948.9
|
312.2 Titer
Interval 149.5 to 1607.4
|
269.1 Titer
Interval 127.5 to 884.9
|
320.3 Titer
Interval 115.3 to 1045.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 0-Total
|
341.2 Titer
Interval 80.9 to 1945.6
|
296.6 Titer
Interval 116.6 to 1463.5
|
240.7 Titer
Interval 74.5 to 903.0
|
360.1 Titer
Interval 93.9 to 1149.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 0-non-RSA
|
252.2 Titer
Interval 158.5 to 345.9
|
220.2 Titer
Interval 10.0 to 329.4
|
57.2 Titer
Interval 5.0 to 909.9
|
416.1 Titer
Interval 82.3 to 1386.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 12-RSA
|
7856.6 Titer
Interval 3305.9 to 16483.5
|
1884.6 Titer
Interval 512.0 to 11721.5
|
1657.3 Titer
Interval 346.8 to 6270.6
|
1591.4 Titer
Interval 256.7 to 9041.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 12-Total
|
6035.4 Titer
Interval 576.3 to 9886.8
|
1436.1 Titer
Interval 297.4 to 6307.1
|
600.3 Titer
Interval 233.6 to 3294.7
|
1194.2 Titer
Interval 285.7 to 7388.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 12-non-RSA
|
964.7 Titer
Interval 487.3 to 1442.0
|
347.6 Titer
Interval 275.1 to 1767.6
|
408.4 Titer
Interval 218.3 to 1370.6
|
872 Titer
Interval 358.0 to 6952.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 2-RSA
|
244.3 Titer
Interval 55.8 to 554.9
|
147.5 Titer
Interval 60.9 to 878.4
|
156.1 Titer
Interval 67.4 to 472.6
|
223.1 Titer
Interval 58.9 to 584.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 2-Total
|
201.6 Titer
Interval 52.4 to 494.3
|
98.8 Titer
Interval 34.7 to 310.9
|
133.4 Titer
Interval 39.3 to 429.7
|
157.5 Titer
Interval 54.3 to 477.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 2-non-RSA
|
100.9 Titer
Interval 53.0 to 148.9
|
36 Titer
Interval 5.0 to 52.4
|
26.4 Titer
Interval 7.4 to 263.5
|
124 Titer
Interval 48.1 to 360.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 4-RSA
|
279.6 Titer
Interval 25.1 to 801.6
|
570.1 Titer
Interval 54.3 to 1747.8
|
335.1 Titer
Interval 78.9 to 908.3
|
275.6 Titer
Interval 90.3 to 706.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 4-Total
|
222 Titer
Interval 15.0 to 687.1
|
203.6 Titer
Interval 54.3 to 1457.4
|
324.7 Titer
Interval 82.6 to 944.1
|
262.9 Titer
Interval 84.1 to 705.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID50 at Month 4-non-RSA
|
86.5 Titer
Interval 48.3 to 124.8
|
137.7 Titer
Interval 58.8 to 200.4
|
312.5 Titer
Interval 208.9 to 1661.1
|
205.5 Titer
Interval 69.5 to 563.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 0-RSA
|
100.3 Titer
Interval 37.6 to 619.6
|
117.8 Titer
Interval 34.6 to 475.7
|
68.2 Titer
Interval 34.7 to 201.9
|
77.2 Titer
Interval 32.9 to 233.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 0-Total
|
98.7 Titer
Interval 32.9 to 546.7
|
78.8 Titer
Interval 33.4 to 330.7
|
60.3 Titer
Interval 27.3 to 196.2
|
81.4 Titer
Interval 28.4 to 274.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 0-non-RSA
|
63.8 Titer
Interval 47.9 to 79.8
|
39.7 Titer
Interval 10.0 to 130.8
|
24.5 Titer
Interval 5.0 to 179.0
|
106.2 Titer
Interval 27.5 to 361.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 12-RSA
|
2749.2 Titer
Interval 590.8 to 4116.1
|
495.1 Titer
Interval 178.3 to 1335.7
|
410.6 Titer
Interval 115.5 to 1749.9
|
351.6 Titer
Interval 60.4 to 2756.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 12-Total
|
1076.7 Titer
Interval 104.9 to 2760.8
|
390.9 Titer
Interval 114.7 to 1196.3
|
182.2 Titer
Interval 62.2 to 794.2
|
250.7 Titer
Interval 83.5 to 2250.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 12-non-RSA
|
361.3 Titer
Interval 185.7 to 537.0
|
133.8 Titer
Interval 101.6 to 605.3
|
119.1 Titer
Interval 62.2 to 346.0
|
238.8 Titer
Interval 103.1 to 1837.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 2-RSA
|
55.8 Titer
Interval 10.0 to 131.9
|
39.3 Titer
Interval 14.4 to 197.3
|
36.6 Titer
Interval 12.5 to 116.9
|
60.4 Titer
Interval 23.4 to 158.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 2-Total
|
40.1 Titer
Interval 10.0 to 114.1
|
34.7 Titer
Interval 10.0 to 83.7
|
34.9 Titer
Interval 10.0 to 93.0
|
41.2 Titer
Interval 10.7 to 140.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 2-non-RSA
|
19.8 Titer
Interval 12.4 to 27.3
|
10 Titer
Interval 5.0 to 24.5
|
16.2 Titer
Interval 6.9 to 54.6
|
32.3 Titer
Interval 10.0 to 112.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 4-RSA
|
71.4 Titer
Interval 10.0 to 150.1
|
147.2 Titer
Interval 15.9 to 398.2
|
120.5 Titer
Interval 30.9 to 215.9
|
86.5 Titer
Interval 32.4 to 180.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 4-Total
|
54 Titer
Interval 10.0 to 134.1
|
54.1 Titer
Interval 15.9 to 339.6
|
119.9 Titer
Interval 31.1 to 232.0
|
73.7 Titer
Interval 26.7 to 180.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
SARS-Cov-2 D614G-ID80 at Month 4-non-RSA
|
23.3 Titer
Interval 16.6 to 29.9
|
40 Titer
Interval 21.2 to 47.0
|
119.2 Titer
Interval 43.3 to 363.7
|
50.5 Titer
Interval 24.2 to 180.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population (USA and Peru only), all available data at each visit
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort (USA and Peru)
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total
|
12 Participants
|
38 Participants
|
33 Participants
|
69 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total
|
16 Participants
|
39 Participants
|
38 Participants
|
60 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population (USA and Peru only), all available data at each visit
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total
|
4.1 Percent CD107a+ NK Cells
Interval 0.9 to 6.4
|
7.2 Percent CD107a+ NK Cells
Interval 1.5 to 14.6
|
5.6 Percent CD107a+ NK Cells
Interval 1.1 to 13.3
|
6.3 Percent CD107a+ NK Cells
Interval 2.2 to 14.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total
|
6.5 Percent CD107a+ NK Cells
Interval 4.7 to 13.7
|
9.7 Percent CD107a+ NK Cells
Interval 3.7 to 15.3
|
6.9 Percent CD107a+ NK Cells
Interval 2.9 to 14.1
|
5.8 Percent CD107a+ NK Cells
Interval 2.8 to 11.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population with positive responders (USA and Peru only), all available data at each visit
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Any COV2 at Month 0-Peru
|
17 Participants
|
40 Participants
|
41 Participants
|
45 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Any COV2 at Month 0-Total
|
22 Participants
|
58 Participants
|
66 Participants
|
126 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Any COV2 at Month 0-USA
|
5 Participants
|
18 Participants
|
25 Participants
|
81 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-E M at Month 0-Peru
|
10 Participants
|
37 Participants
|
32 Participants
|
36 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-E M at Month 0-Total
|
12 Participants
|
50 Participants
|
47 Participants
|
94 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-E M at Month 0-USA
|
2 Participants
|
13 Participants
|
15 Participants
|
58 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-N at Month 0-Peru
|
14 Participants
|
37 Participants
|
30 Participants
|
35 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-N at Month 0-Total
|
16 Participants
|
49 Participants
|
51 Participants
|
105 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-N at Month 0-USA
|
2 Participants
|
12 Participants
|
21 Participants
|
70 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF3a6 at Month 0-Peru
|
4 Participants
|
21 Participants
|
22 Participants
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF3a6 at Month 0-Total
|
5 Participants
|
26 Participants
|
32 Participants
|
63 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF3a6 at Month 0-USA
|
1 Participants
|
5 Participants
|
10 Participants
|
45 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-Peru
|
8 Participants
|
29 Participants
|
26 Participants
|
23 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-Total
|
9 Participants
|
34 Participants
|
35 Participants
|
64 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-USA
|
1 Participants
|
5 Participants
|
9 Participants
|
41 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S1 at Month 0-Peru
|
12 Participants
|
39 Participants
|
34 Participants
|
41 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S1 at Month 0-Total
|
16 Participants
|
53 Participants
|
53 Participants
|
109 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S1 at Month 0-USA
|
4 Participants
|
14 Participants
|
19 Participants
|
68 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S2 at Month 0-Peru
|
13 Participants
|
37 Participants
|
34 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S2 at Month 0-Total
|
17 Participants
|
48 Participants
|
54 Participants
|
100 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S2 at Month 0-USA
|
4 Participants
|
11 Participants
|
20 Participants
|
68 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Spike at Month 0-Peru
|
15 Participants
|
40 Participants
|
38 Participants
|
42 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Spike at Month 0-Total
|
20 Participants
|
54 Participants
|
61 Participants
|
117 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Spike at Month 0-USA
|
5 Participants
|
14 Participants
|
23 Participants
|
75 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Any COV2 at Month 0-Peru
|
12 Participants
|
34 Participants
|
42 Participants
|
34 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Any COV2 at Month 0-Total
|
17 Participants
|
53 Participants
|
64 Participants
|
98 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Any COV2 at Month 0-USA
|
5 Participants
|
19 Participants
|
22 Participants
|
64 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-E M at Month 0-Peru
|
0 Participants
|
3 Participants
|
7 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-E M at Month 0-Total
|
1 Participants
|
4 Participants
|
8 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-E M at Month 0-USA
|
1 Participants
|
1 Participants
|
1 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-N at Month 0-Peru
|
11 Participants
|
31 Participants
|
41 Participants
|
25 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-N at Month 0-Total
|
16 Participants
|
45 Participants
|
61 Participants
|
78 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-N at Month 0-USA
|
5 Participants
|
14 Participants
|
20 Participants
|
53 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF3a6 at Month 0-Peru
|
4 Participants
|
9 Participants
|
23 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF3a6 at Month 0-Total
|
5 Participants
|
13 Participants
|
30 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF3a6 at Month 0-USA
|
1 Participants
|
4 Participants
|
7 Participants
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-Peru
|
2 Participants
|
12 Participants
|
23 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-Total
|
2 Participants
|
16 Participants
|
25 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-USA
|
0 Participants
|
4 Participants
|
2 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S1 at Month 0-Peru
|
2 Participants
|
15 Participants
|
11 Participants
|
14 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S1 at Month 0-Total
|
2 Participants
|
20 Participants
|
17 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S1 at Month 0-USA
|
0 Participants
|
5 Participants
|
6 Participants
|
18 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S2 at Month 0-Peru
|
2 Participants
|
8 Participants
|
2 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S2 at Month 0-Total
|
2 Participants
|
11 Participants
|
2 Participants
|
15 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S2 at Month 0-USA
|
0 Participants
|
3 Participants
|
0 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Spike at Month 0-Peru
|
3 Participants
|
16 Participants
|
12 Participants
|
16 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Spike at Month 0-Total
|
3 Participants
|
23 Participants
|
18 Participants
|
38 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Spike at Month 0-USA
|
0 Participants
|
7 Participants
|
6 Participants
|
22 Participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population with positive responders (USA and Peru only), all available data at each visit
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Any COV2 at Month 0-Peru
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
1 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.6
|
0.8 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.3
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Any COV2 at Month 0-Total
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.8 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.5
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Any COV2 at Month 0-USA
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.7
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-E M at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-E M at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-E M at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-N at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF3a6 at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF3a6 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF3a6 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-ORF7a7b8 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S1 at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S1 at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S1 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S2 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S2 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-S2 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Spike at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.7
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Spike at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD4+-Spike at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Any COV2 at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-E M at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF3a6 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF3a6 at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Any COV2 at Month 0-Peru
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.4
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.6
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S1 at Month 0-USA
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S2 at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S2 at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Any COV2 at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-E M at Month 0-Peru
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-E M at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.0
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-N at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.0
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.9
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF3a6 at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S1 at Month 0-Total
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-ORF7a7b8 at Month 0-USA
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.5 to 0.6
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S1 at Month 0-Peru
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-S2 at Month 0-USA
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Spike at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Spike at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
CD8+-Spike at Month 0-USA
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). The sample will be included in the analysis only if the number of IgD- B cells is equal or greater than 1000 for that sample. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group among America Cohort
Outcome measures
| Measure |
Group 1A
n=37 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=88 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=92 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=171 Participants
1D: Symptomatic, \> 55
|
Group 2A
2A: Hospitalized, 18 - 55
|
Group 2B
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-Peru
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-Total
|
0 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-USA
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.05
|
0 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ of Total B Cells-Peru
|
0.05 percentage of cells
Interval 0.03 to 0.07
|
0.08 percentage of cells
Interval 0.05 to 0.16
|
0.07 percentage of cells
Interval 0.04 to 0.11
|
0.11 percentage of cells
Interval 0.07 to 0.16
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-Peru
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.06
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.02 percentage of cells
Interval 0.0 to 0.03
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-USA
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.0 to 0.07
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0 percentage of cells
Interval 0.0 to 0.02
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-Peru
|
0.1 percentage of cells
Interval 0.05 to 0.16
|
0.15 percentage of cells
Interval 0.08 to 0.31
|
0.13 percentage of cells
Interval 0.06 to 0.29
|
0.29 percentage of cells
Interval 0.14 to 0.37
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgA+ of Memory B Cells-Peru
|
0.09 percentage of cells
Interval 0.05 to 0.14
|
0.08 percentage of cells
Interval 0.03 to 0.12
|
0.07 percentage of cells
Interval 0.03 to 0.12
|
0.06 percentage of cells
Interval 0.03 to 0.12
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-Total
|
0.14 percentage of cells
Interval 0.06 to 0.21
|
0.13 percentage of cells
Interval 0.06 to 0.27
|
0.13 percentage of cells
Interval 0.05 to 0.28
|
0.2 percentage of cells
Interval 0.06 to 0.36
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-USA
|
0.22 percentage of cells
Interval 0.13 to 0.31
|
0.12 percentage of cells
Interval 0.05 to 0.2
|
0.14 percentage of cells
Interval 0.04 to 0.24
|
0.16 percentage of cells
Interval 0.04 to 0.33
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ of Total B Cells-Total
|
0.06 percentage of cells
Interval 0.04 to 0.08
|
0.07 percentage of cells
Interval 0.04 to 0.16
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.07 percentage of cells
Interval 0.03 to 0.12
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ of Total B Cells-USA
|
0.07 percentage of cells
Interval 0.06 to 0.12
|
0.05 percentage of cells
Interval 0.04 to 0.17
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.05 percentage of cells
Interval 0.03 to 0.09
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgA+ of Memory B Cells-Total
|
0.08 percentage of cells
Interval 0.04 to 0.13
|
0.08 percentage of cells
Interval 0.03 to 0.13
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgA+ of Memory B Cells-USA
|
0.05 percentage of cells
Interval 0.04 to 0.08
|
0.08 percentage of cells
Interval 0.03 to 0.14
|
0.05 percentage of cells
Interval 0.02 to 0.09
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgA+ of Total B Cells-Peru
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
0.01 percentage of cells
Interval 0.01 to 0.03
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-Total
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.07
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0 percentage of cells
Interval 0.0 to 0.03
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgG+ of Total B Cells-Peru
|
0.11 percentage of cells
Interval 0.06 to 0.25
|
0.18 percentage of cells
Interval 0.08 to 0.26
|
0.17 percentage of cells
Interval 0.11 to 0.29
|
0.21 percentage of cells
Interval 0.12 to 0.29
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgG+ of Total B Cells-Total
|
0.13 percentage of cells
Interval 0.06 to 0.23
|
0.11 percentage of cells
Interval 0.06 to 0.21
|
0.15 percentage of cells
Interval 0.06 to 0.25
|
0.16 percentage of cells
Interval 0.07 to 0.24
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgG+ of Total B Cells-USA
|
0.15 percentage of cells
Interval 0.1 to 0.17
|
0.07 percentage of cells
Interval 0.01 to 0.11
|
0.08 percentage of cells
Interval 0.04 to 0.11
|
0.13 percentage of cells
Interval 0.06 to 0.22
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-Peru
|
0.13 percentage of cells
Interval 0.1 to 0.15
|
0.13 percentage of cells
Interval 0.09 to 0.16
|
0.1 percentage of cells
Interval 0.07 to 0.14
|
0.11 percentage of cells
Interval 0.08 to 0.15
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-Total
|
0.11 percentage of cells
Interval 0.06 to 0.13
|
0.11 percentage of cells
Interval 0.08 to 0.16
|
0.09 percentage of cells
Interval 0.07 to 0.13
|
0.1 percentage of cells
Interval 0.07 to 0.15
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-USA
|
0.09 percentage of cells
Interval 0.06 to 0.1
|
0.1 percentage of cells
Interval 0.08 to 0.12
|
0.09 percentage of cells
Interval 0.06 to 0.11
|
0.09 percentage of cells
Interval 0.07 to 0.14
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgA+ of Total B Cells-Total
|
0.02 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgG+ of Memory B Cells-Peru
|
0.48 percentage of cells
Interval 0.33 to 0.95
|
0.77 percentage of cells
Interval 0.4 to 1.22
|
0.62 percentage of cells
Interval 0.33 to 1.15
|
1 percentage of cells
Interval 0.62 to 1.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgA+ of Total B Cells-USA
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgG+ of Memory B Cells-Total
|
0.52 percentage of cells
Interval 0.32 to 1.03
|
0.5 percentage of cells
Interval 0.31 to 1.0
|
0.62 percentage of cells
Interval 0.32 to 1.07
|
0.95 percentage of cells
Interval 0.38 to 1.44
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgG+ of Memory B Cells-USA
|
0.77 percentage of cells
Interval 0.29 to 1.13
|
0.34 percentage of cells
Interval 0.13 to 0.56
|
0.6 percentage of cells
Interval 0.29 to 0.97
|
0.86 percentage of cells
Interval 0.31 to 1.47
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgM+ of Memory B Cells-Peru
|
0.06 percentage of cells
Interval 0.03 to 0.14
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.04 percentage of cells
Interval 0.01 to 0.06
|
0.02 percentage of cells
Interval 0.0 to 0.04
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgM+ of Memory B Cells-Total
|
0.05 percentage of cells
Interval 0.02 to 0.12
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.04 percentage of cells
Interval 0.02 to 0.06
|
0.03 percentage of cells
Interval 0.0 to 0.06
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgM+ of Memory B Cells-USA
|
0.05 percentage of cells
Interval 0.02 to 0.08
|
0.06 percentage of cells
Interval 0.04 to 0.12
|
0.05 percentage of cells
Interval 0.02 to 0.08
|
0.03 percentage of cells
Interval 0.0 to 0.07
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgM+ of Total B Cells-Peru
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.01 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0 percentage of cells
Interval 0.0 to 0.01
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgM+ of Total B Cells-Total
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ IgM+ of Total B Cells-USA
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0 percentage of cells
Interval 0.0 to 0.01
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ of Total B Cells-Peru
|
0.33 percentage of cells
Interval 0.2 to 0.51
|
0.43 percentage of cells
Interval 0.28 to 0.56
|
0.4 percentage of cells
Interval 0.28 to 0.52
|
0.42 percentage of cells
Interval 0.3 to 0.52
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ of Total B Cells-Total
|
0.32 percentage of cells
Interval 0.22 to 0.42
|
0.32 percentage of cells
Interval 0.21 to 0.51
|
0.32 percentage of cells
Interval 0.21 to 0.48
|
0.33 percentage of cells
Interval 0.21 to 0.5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
%S+ of Total B Cells-USA
|
0.32 percentage of cells
Interval 0.28 to 0.34
|
0.24 percentage of cells
Interval 0.15 to 0.36
|
0.25 percentage of cells
Interval 0.17 to 0.28
|
0.3 percentage of cells
Interval 0.2 to 0.48
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3 , overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
n=388 Participants
3: Clinical spectrums
|
Group 8
n=388 Participants
Clinical spectrums , age 55+
|
Group 9
n=388 Participants
HIV
|
Group 10
n=388 Participants
Hypertension
|
Group 11
n=388 Participants
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 0-Peru
|
143 Participants
|
104 Participants
|
147 Participants
|
141 Participants
|
103 Participants
|
95 Participants
|
140 Participants
|
132 Participants
|
132 Participants
|
129 Participants
|
124 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 0-Total
|
248 Participants
|
181 Participants
|
252 Participants
|
206 Participants
|
157 Participants
|
136 Participants
|
241 Participants
|
228 Participants
|
224 Participants
|
210 Participants
|
204 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 0-USA
|
105 Participants
|
77 Participants
|
105 Participants
|
65 Participants
|
54 Participants
|
41 Participants
|
101 Participants
|
96 Participants
|
92 Participants
|
81 Participants
|
80 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 2-Peru
|
126 Participants
|
93 Participants
|
132 Participants
|
125 Participants
|
92 Participants
|
84 Participants
|
126 Participants
|
117 Participants
|
122 Participants
|
114 Participants
|
114 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 2-Total
|
235 Participants
|
168 Participants
|
241 Participants
|
187 Participants
|
141 Participants
|
124 Participants
|
224 Participants
|
216 Participants
|
224 Participants
|
190 Participants
|
201 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 2-USA
|
109 Participants
|
75 Participants
|
109 Participants
|
62 Participants
|
49 Participants
|
40 Participants
|
98 Participants
|
99 Participants
|
102 Participants
|
76 Participants
|
87 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 4-Peru
|
102 Participants
|
79 Participants
|
107 Participants
|
101 Participants
|
78 Participants
|
72 Participants
|
102 Participants
|
95 Participants
|
101 Participants
|
92 Participants
|
96 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 4-Total
|
172 Participants
|
130 Participants
|
173 Participants
|
145 Participants
|
116 Participants
|
98 Participants
|
164 Participants
|
160 Participants
|
164 Participants
|
139 Participants
|
151 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 4-USA
|
70 Participants
|
51 Participants
|
66 Participants
|
44 Participants
|
38 Participants
|
26 Participants
|
62 Participants
|
65 Participants
|
63 Participants
|
47 Participants
|
55 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 0-Peru
|
4 Participants
|
43 Participants
|
0 Participants
|
6 Participants
|
44 Participants
|
52 Participants
|
7 Participants
|
15 Participants
|
15 Participants
|
18 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 0-Total
|
16 Participants
|
83 Participants
|
12 Participants
|
58 Participants
|
107 Participants
|
128 Participants
|
23 Participants
|
36 Participants
|
40 Participants
|
54 Participants
|
60 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 0-USA
|
12 Participants
|
40 Participants
|
12 Participants
|
52 Participants
|
63 Participants
|
76 Participants
|
16 Participants
|
21 Participants
|
25 Participants
|
36 Participants
|
37 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 2-Peru
|
6 Participants
|
39 Participants
|
0 Participants
|
7 Participants
|
40 Participants
|
48 Participants
|
6 Participants
|
15 Participants
|
10 Participants
|
18 Participants
|
18 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 2-Total
|
15 Participants
|
82 Participants
|
9 Participants
|
63 Participants
|
109 Participants
|
126 Participants
|
26 Participants
|
34 Participants
|
26 Participants
|
60 Participants
|
49 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 2-USA
|
9 Participants
|
43 Participants
|
9 Participants
|
56 Participants
|
69 Participants
|
78 Participants
|
20 Participants
|
19 Participants
|
16 Participants
|
42 Participants
|
31 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 4-Peru
|
5 Participants
|
28 Participants
|
0 Participants
|
6 Participants
|
29 Participants
|
35 Participants
|
5 Participants
|
12 Participants
|
6 Participants
|
15 Participants
|
11 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 4-Total
|
11 Participants
|
53 Participants
|
10 Participants
|
38 Participants
|
67 Participants
|
85 Participants
|
19 Participants
|
23 Participants
|
19 Participants
|
44 Participants
|
32 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 4-USA
|
6 Participants
|
25 Participants
|
10 Participants
|
32 Participants
|
38 Participants
|
50 Participants
|
14 Participants
|
11 Participants
|
13 Participants
|
29 Participants
|
21 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 0-Peru
|
156 Participants
|
116 Participants
|
163 Participants
|
155 Participants
|
115 Participants
|
108 Participants
|
155 Participants
|
148 Participants
|
148 Participants
|
143 Participants
|
140 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 0-Total
|
306 Participants
|
220 Participants
|
309 Participants
|
241 Participants
|
184 Participants
|
173 Participants
|
291 Participants
|
288 Participants
|
285 Participants
|
259 Participants
|
258 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 0-USA
|
150 Participants
|
104 Participants
|
146 Participants
|
86 Participants
|
69 Participants
|
65 Participants
|
136 Participants
|
140 Participants
|
137 Participants
|
116 Participants
|
118 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 2-Peru
|
124 Participants
|
91 Participants
|
129 Participants
|
122 Participants
|
90 Participants
|
83 Participants
|
123 Participants
|
114 Participants
|
119 Participants
|
112 Participants
|
112 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 2-Total
|
233 Participants
|
166 Participants
|
236 Participants
|
181 Participants
|
136 Participants
|
125 Participants
|
221 Participants
|
214 Participants
|
223 Participants
|
189 Participants
|
201 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 2-USA
|
109 Participants
|
75 Participants
|
107 Participants
|
59 Participants
|
46 Participants
|
42 Participants
|
98 Participants
|
100 Participants
|
104 Participants
|
77 Participants
|
89 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 4-Peru
|
100 Participants
|
78 Participants
|
105 Participants
|
99 Participants
|
77 Participants
|
71 Participants
|
101 Participants
|
93 Participants
|
99 Participants
|
90 Participants
|
95 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 4-Total
|
167 Participants
|
126 Participants
|
168 Participants
|
140 Participants
|
112 Participants
|
97 Participants
|
159 Participants
|
156 Participants
|
160 Participants
|
136 Participants
|
148 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 4-USA
|
67 Participants
|
48 Participants
|
63 Participants
|
41 Participants
|
35 Participants
|
26 Participants
|
58 Participants
|
63 Participants
|
61 Participants
|
46 Participants
|
53 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 0-Peru
|
7 Participants
|
47 Participants
|
0 Participants
|
8 Participants
|
48 Participants
|
55 Participants
|
8 Participants
|
15 Participants
|
15 Participants
|
20 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru
|
5 Participants
|
26 Participants
|
0 Participants
|
6 Participants
|
27 Participants
|
30 Participants
|
3 Participants
|
12 Participants
|
6 Participants
|
12 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total
|
10 Participants
|
48 Participants
|
9 Participants
|
33 Participants
|
60 Participants
|
73 Participants
|
16 Participants
|
20 Participants
|
17 Participants
|
35 Participants
|
28 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA
|
5 Participants
|
22 Participants
|
9 Participants
|
27 Participants
|
33 Participants
|
43 Participants
|
13 Participants
|
8 Participants
|
11 Participants
|
23 Participants
|
18 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru
|
135 Participants
|
98 Participants
|
136 Participants
|
131 Participants
|
98 Participants
|
85 Participants
|
128 Participants
|
121 Participants
|
121 Participants
|
119 Participants
|
114 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total
|
232 Participants
|
170 Participants
|
232 Participants
|
188 Participants
|
147 Participants
|
121 Participants
|
221 Participants
|
209 Participants
|
204 Participants
|
193 Participants
|
185 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA
|
97 Participants
|
72 Participants
|
96 Participants
|
57 Participants
|
49 Participants
|
36 Participants
|
93 Participants
|
88 Participants
|
83 Participants
|
74 Participants
|
71 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru
|
124 Participants
|
90 Participants
|
129 Participants
|
121 Participants
|
89 Participants
|
82 Participants
|
123 Participants
|
114 Participants
|
119 Participants
|
111 Participants
|
112 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total
|
236 Participants
|
169 Participants
|
240 Participants
|
185 Participants
|
140 Participants
|
126 Participants
|
223 Participants
|
215 Participants
|
225 Participants
|
190 Participants
|
203 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA
|
112 Participants
|
79 Participants
|
111 Participants
|
64 Participants
|
51 Participants
|
44 Participants
|
100 Participants
|
101 Participants
|
106 Participants
|
79 Participants
|
91 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru
|
101 Participants
|
79 Participants
|
106 Participants
|
100 Participants
|
78 Participants
|
71 Participants
|
101 Participants
|
94 Participants
|
100 Participants
|
91 Participants
|
95 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total
|
170 Participants
|
129 Participants
|
171 Participants
|
143 Participants
|
115 Participants
|
97 Participants
|
162 Participants
|
159 Participants
|
162 Participants
|
138 Participants
|
149 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA
|
69 Participants
|
50 Participants
|
65 Participants
|
43 Participants
|
37 Participants
|
26 Participants
|
61 Participants
|
65 Participants
|
62 Participants
|
47 Participants
|
54 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru
|
1 Participants
|
38 Participants
|
0 Participants
|
5 Participants
|
38 Participants
|
51 Participants
|
8 Participants
|
15 Participants
|
15 Participants
|
17 Participants
|
22 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total
|
12 Participants
|
74 Participants
|
12 Participants
|
56 Participants
|
97 Participants
|
123 Participants
|
23 Participants
|
35 Participants
|
40 Participants
|
51 Participants
|
59 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA
|
11 Participants
|
36 Participants
|
12 Participants
|
51 Participants
|
59 Participants
|
72 Participants
|
15 Participants
|
20 Participants
|
25 Participants
|
34 Participants
|
37 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru
|
5 Participants
|
39 Participants
|
0 Participants
|
8 Participants
|
40 Participants
|
47 Participants
|
6 Participants
|
15 Participants
|
10 Participants
|
18 Participants
|
17 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total
|
13 Participants
|
80 Participants
|
9 Participants
|
64 Participants
|
109 Participants
|
123 Participants
|
26 Participants
|
34 Participants
|
24 Participants
|
59 Participants
|
46 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA
|
8 Participants
|
41 Participants
|
9 Participants
|
56 Participants
|
69 Participants
|
76 Participants
|
20 Participants
|
19 Participants
|
14 Participants
|
41 Participants
|
29 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru
|
5 Participants
|
27 Participants
|
0 Participants
|
6 Participants
|
28 Participants
|
35 Participants
|
5 Participants
|
12 Participants
|
6 Participants
|
15 Participants
|
11 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total
|
11 Participants
|
52 Participants
|
10 Participants
|
38 Participants
|
66 Participants
|
84 Participants
|
19 Participants
|
22 Participants
|
19 Participants
|
43 Participants
|
32 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA
|
6 Participants
|
25 Participants
|
10 Participants
|
32 Participants
|
38 Participants
|
49 Participants
|
14 Participants
|
10 Participants
|
13 Participants
|
28 Participants
|
21 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 0-Peru
|
154 Participants
|
114 Participants
|
160 Participants
|
153 Participants
|
114 Participants
|
105 Participants
|
152 Participants
|
145 Participants
|
145 Participants
|
140 Participants
|
137 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 0-Total
|
300 Participants
|
216 Participants
|
302 Participants
|
236 Participants
|
181 Participants
|
167 Participants
|
283 Participants
|
279 Participants
|
278 Participants
|
252 Participants
|
251 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 0-USA
|
146 Participants
|
102 Participants
|
142 Participants
|
83 Participants
|
67 Participants
|
62 Participants
|
131 Participants
|
134 Participants
|
133 Participants
|
112 Participants
|
114 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 2-Peru
|
125 Participants
|
91 Participants
|
131 Participants
|
123 Participants
|
90 Participants
|
83 Participants
|
125 Participants
|
116 Participants
|
121 Participants
|
113 Participants
|
113 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 2-Total
|
235 Participants
|
168 Participants
|
239 Participants
|
184 Participants
|
138 Participants
|
126 Participants
|
223 Participants
|
215 Participants
|
225 Participants
|
190 Participants
|
203 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 2-USA
|
110 Participants
|
77 Participants
|
108 Participants
|
61 Participants
|
48 Participants
|
43 Participants
|
98 Participants
|
99 Participants
|
104 Participants
|
77 Participants
|
90 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 4-Peru
|
100 Participants
|
78 Participants
|
105 Participants
|
99 Participants
|
77 Participants
|
71 Participants
|
101 Participants
|
93 Participants
|
99 Participants
|
90 Participants
|
95 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 4-Total
|
168 Participants
|
127 Participants
|
169 Participants
|
141 Participants
|
113 Participants
|
97 Participants
|
160 Participants
|
156 Participants
|
161 Participants
|
136 Participants
|
149 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 4-USA
|
68 Participants
|
49 Participants
|
64 Participants
|
42 Participants
|
36 Participants
|
26 Participants
|
59 Participants
|
63 Participants
|
62 Participants
|
46 Participants
|
54 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 0-Peru
|
6 Participants
|
46 Participants
|
0 Participants
|
7 Participants
|
46 Participants
|
55 Participants
|
8 Participants
|
15 Participants
|
15 Participants
|
20 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 0-Total
|
17 Participants
|
101 Participants
|
15 Participants
|
81 Participants
|
136 Participants
|
150 Participants
|
34 Participants
|
38 Participants
|
39 Participants
|
65 Participants
|
66 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 0-USA
|
11 Participants
|
55 Participants
|
15 Participants
|
74 Participants
|
90 Participants
|
95 Participants
|
26 Participants
|
23 Participants
|
24 Participants
|
45 Participants
|
43 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 2-Peru
|
6 Participants
|
40 Participants
|
0 Participants
|
8 Participants
|
41 Participants
|
48 Participants
|
6 Participants
|
15 Participants
|
10 Participants
|
18 Participants
|
18 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 0-Total
|
20 Participants
|
106 Participants
|
17 Participants
|
85 Participants
|
142 Participants
|
153 Participants
|
35 Participants
|
38 Participants
|
41 Participants
|
67 Participants
|
68 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 0-USA
|
13 Participants
|
59 Participants
|
17 Participants
|
77 Participants
|
94 Participants
|
98 Participants
|
27 Participants
|
23 Participants
|
26 Participants
|
47 Participants
|
45 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 2-Peru
|
5 Participants
|
38 Participants
|
0 Participants
|
7 Participants
|
39 Participants
|
46 Participants
|
6 Participants
|
15 Participants
|
10 Participants
|
17 Participants
|
17 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 2-Total
|
14 Participants
|
81 Participants
|
11 Participants
|
66 Participants
|
111 Participants
|
122 Participants
|
26 Participants
|
33 Participants
|
24 Participants
|
58 Participants
|
46 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 2-USA
|
9 Participants
|
43 Participants
|
11 Participants
|
59 Participants
|
72 Participants
|
76 Participants
|
20 Participants
|
18 Participants
|
14 Participants
|
41 Participants
|
29 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 4-Peru
|
5 Participants
|
27 Participants
|
0 Participants
|
6 Participants
|
28 Participants
|
34 Participants
|
4 Participants
|
12 Participants
|
6 Participants
|
15 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 4-Total
|
10 Participants
|
51 Participants
|
9 Participants
|
37 Participants
|
65 Participants
|
80 Participants
|
18 Participants
|
21 Participants
|
17 Participants
|
41 Participants
|
29 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 4-USA
|
5 Participants
|
24 Participants
|
9 Participants
|
31 Participants
|
37 Participants
|
46 Participants
|
14 Participants
|
9 Participants
|
11 Participants
|
26 Participants
|
19 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru
|
156 Participants
|
116 Participants
|
163 Participants
|
155 Participants
|
115 Participants
|
108 Participants
|
155 Participants
|
148 Participants
|
148 Participants
|
143 Participants
|
140 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total
|
306 Participants
|
219 Participants
|
312 Participants
|
244 Participants
|
185 Participants
|
171 Participants
|
290 Participants
|
284 Participants
|
285 Participants
|
257 Participants
|
258 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA
|
150 Participants
|
103 Participants
|
149 Participants
|
89 Participants
|
70 Participants
|
63 Participants
|
135 Participants
|
136 Participants
|
137 Participants
|
114 Participants
|
118 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru
|
121 Participants
|
88 Participants
|
126 Participants
|
119 Participants
|
87 Participants
|
82 Participants
|
120 Participants
|
111 Participants
|
117 Participants
|
109 Participants
|
111 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total
|
225 Participants
|
159 Participants
|
230 Participants
|
179 Participants
|
133 Participants
|
122 Participants
|
213 Participants
|
206 Participants
|
216 Participants
|
182 Participants
|
198 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA
|
104 Participants
|
71 Participants
|
104 Participants
|
60 Participants
|
46 Participants
|
40 Participants
|
93 Participants
|
95 Participants
|
99 Participants
|
73 Participants
|
87 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru
|
93 Participants
|
72 Participants
|
98 Participants
|
92 Participants
|
71 Participants
|
68 Participants
|
95 Participants
|
86 Participants
|
92 Participants
|
86 Participants
|
88 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total
|
154 Participants
|
116 Participants
|
155 Participants
|
131 Participants
|
104 Participants
|
91 Participants
|
148 Participants
|
144 Participants
|
147 Participants
|
129 Participants
|
136 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA
|
61 Participants
|
44 Participants
|
57 Participants
|
39 Participants
|
33 Participants
|
23 Participants
|
53 Participants
|
58 Participants
|
55 Participants
|
43 Participants
|
48 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru
|
7 Participants
|
47 Participants
|
0 Participants
|
8 Participants
|
48 Participants
|
55 Participants
|
8 Participants
|
15 Participants
|
15 Participants
|
20 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total
|
18 Participants
|
105 Participants
|
12 Participants
|
80 Participants
|
139 Participants
|
153 Participants
|
34 Participants
|
40 Participants
|
39 Participants
|
67 Participants
|
66 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA
|
11 Participants
|
58 Participants
|
12 Participants
|
72 Participants
|
91 Participants
|
98 Participants
|
26 Participants
|
25 Participants
|
24 Participants
|
47 Participants
|
43 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru
|
5 Participants
|
38 Participants
|
0 Participants
|
7 Participants
|
39 Participants
|
44 Participants
|
6 Participants
|
15 Participants
|
9 Participants
|
17 Participants
|
15 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total
|
14 Participants
|
80 Participants
|
9 Participants
|
60 Participants
|
106 Participants
|
117 Participants
|
26 Participants
|
33 Participants
|
23 Participants
|
57 Participants
|
41 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA
|
9 Participants
|
42 Participants
|
9 Participants
|
53 Participants
|
67 Participants
|
73 Participants
|
20 Participants
|
18 Participants
|
14 Participants
|
40 Participants
|
26 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 4-Peru
|
5 Participants
|
27 Participants
|
0 Participants
|
6 Participants
|
28 Participants
|
34 Participants
|
4 Participants
|
12 Participants
|
6 Participants
|
15 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 4-Total
|
10 Participants
|
51 Participants
|
9 Participants
|
37 Participants
|
65 Participants
|
81 Participants
|
18 Participants
|
22 Participants
|
17 Participants
|
42 Participants
|
29 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 4-USA
|
5 Participants
|
24 Participants
|
9 Participants
|
31 Participants
|
37 Participants
|
47 Participants
|
14 Participants
|
10 Participants
|
11 Participants
|
27 Participants
|
19 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru
|
156 Participants
|
116 Participants
|
163 Participants
|
155 Participants
|
115 Participants
|
108 Participants
|
156 Participants
|
148 Participants
|
148 Participants
|
142 Participants
|
140 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total
|
313 Participants
|
223 Participants
|
316 Participants
|
246 Participants
|
188 Participants
|
174 Participants
|
297 Participants
|
291 Participants
|
292 Participants
|
259 Participants
|
263 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA
|
157 Participants
|
107 Participants
|
153 Participants
|
91 Participants
|
73 Participants
|
66 Participants
|
141 Participants
|
143 Participants
|
144 Participants
|
117 Participants
|
123 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru
|
122 Participants
|
89 Participants
|
128 Participants
|
120 Participants
|
88 Participants
|
81 Participants
|
122 Participants
|
113 Participants
|
118 Participants
|
109 Participants
|
112 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total
|
233 Participants
|
166 Participants
|
237 Participants
|
184 Participants
|
139 Participants
|
123 Participants
|
221 Participants
|
212 Participants
|
223 Participants
|
184 Participants
|
202 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA
|
111 Participants
|
77 Participants
|
109 Participants
|
64 Participants
|
51 Participants
|
42 Participants
|
99 Participants
|
99 Participants
|
105 Participants
|
75 Participants
|
90 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru
|
96 Participants
|
74 Participants
|
100 Participants
|
93 Participants
|
73 Participants
|
67 Participants
|
97 Participants
|
88 Participants
|
94 Participants
|
85 Participants
|
91 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total
|
163 Participants
|
122 Participants
|
163 Participants
|
135 Participants
|
109 Participants
|
90 Participants
|
155 Participants
|
150 Participants
|
155 Participants
|
129 Participants
|
144 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA
|
67 Participants
|
48 Participants
|
63 Participants
|
42 Participants
|
36 Participants
|
23 Participants
|
58 Participants
|
62 Participants
|
61 Participants
|
44 Participants
|
53 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru
|
7 Participants
|
47 Participants
|
0 Participants
|
8 Participants
|
48 Participants
|
55 Participants
|
7 Participants
|
15 Participants
|
15 Participants
|
21 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total
|
18 Participants
|
108 Participants
|
15 Participants
|
85 Participants
|
143 Participants
|
157 Participants
|
34 Participants
|
40 Participants
|
39 Participants
|
72 Participants
|
68 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA
|
11 Participants
|
61 Participants
|
15 Participants
|
77 Participants
|
95 Participants
|
102 Participants
|
27 Participants
|
25 Participants
|
24 Participants
|
51 Participants
|
45 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru
|
6 Participants
|
39 Participants
|
0 Participants
|
8 Participants
|
40 Participants
|
47 Participants
|
6 Participants
|
15 Participants
|
10 Participants
|
19 Participants
|
16 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total
|
13 Participants
|
80 Participants
|
9 Participants
|
62 Participants
|
107 Participants
|
123 Participants
|
25 Participants
|
34 Participants
|
23 Participants
|
62 Participants
|
44 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA
|
7 Participants
|
41 Participants
|
9 Participants
|
54 Participants
|
67 Participants
|
76 Participants
|
19 Participants
|
19 Participants
|
13 Participants
|
43 Participants
|
28 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru
|
4 Participants
|
26 Participants
|
0 Participants
|
7 Participants
|
27 Participants
|
33 Participants
|
3 Participants
|
12 Participants
|
6 Participants
|
15 Participants
|
9 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total
|
9 Participants
|
50 Participants
|
9 Participants
|
37 Participants
|
63 Participants
|
82 Participants
|
17 Participants
|
22 Participants
|
17 Participants
|
43 Participants
|
28 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA
|
5 Participants
|
24 Participants
|
9 Participants
|
30 Participants
|
36 Participants
|
49 Participants
|
14 Participants
|
10 Participants
|
11 Participants
|
28 Participants
|
19 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru
|
159 Participants
|
119 Participants
|
166 Participants
|
158 Participants
|
118 Participants
|
109 Participants
|
158 Participants
|
149 Participants
|
151 Participants
|
146 Participants
|
143 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total
|
313 Participants
|
227 Participants
|
317 Participants
|
249 Participants
|
192 Participants
|
175 Participants
|
298 Participants
|
291 Participants
|
292 Participants
|
264 Participants
|
264 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 2-Total
|
14 Participants
|
81 Participants
|
10 Participants
|
65 Participants
|
111 Participants
|
123 Participants
|
26 Participants
|
34 Participants
|
24 Participants
|
59 Participants
|
46 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 2-USA
|
8 Participants
|
41 Participants
|
10 Participants
|
57 Participants
|
70 Participants
|
75 Participants
|
20 Participants
|
19 Participants
|
14 Participants
|
41 Participants
|
28 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA
|
6 Participants
|
25 Participants
|
10 Participants
|
32 Participants
|
38 Participants
|
50 Participants
|
14 Participants
|
11 Participants
|
13 Participants
|
29 Participants
|
21 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA
|
154 Participants
|
108 Participants
|
151 Participants
|
91 Participants
|
74 Participants
|
66 Participants
|
140 Participants
|
142 Participants
|
141 Participants
|
118 Participants
|
121 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru
|
125 Participants
|
92 Participants
|
130 Participants
|
123 Participants
|
91 Participants
|
84 Participants
|
124 Participants
|
115 Participants
|
120 Participants
|
113 Participants
|
113 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total
|
238 Participants
|
171 Participants
|
242 Participants
|
187 Participants
|
142 Participants
|
129 Participants
|
227 Participants
|
219 Participants
|
228 Participants
|
193 Participants
|
206 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total
|
172 Participants
|
130 Participants
|
173 Participants
|
145 Participants
|
116 Participants
|
98 Participants
|
164 Participants
|
160 Participants
|
164 Participants
|
139 Participants
|
151 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA
|
70 Participants
|
51 Participants
|
66 Participants
|
44 Participants
|
38 Participants
|
26 Participants
|
62 Participants
|
65 Participants
|
63 Participants
|
47 Participants
|
55 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA
|
113 Participants
|
79 Participants
|
112 Participants
|
64 Participants
|
51 Participants
|
45 Participants
|
103 Participants
|
104 Participants
|
108 Participants
|
80 Participants
|
93 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru
|
102 Participants
|
79 Participants
|
107 Participants
|
101 Participants
|
78 Participants
|
72 Participants
|
102 Participants
|
95 Participants
|
101 Participants
|
92 Participants
|
96 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru
|
7 Participants
|
47 Participants
|
0 Participants
|
8 Participants
|
48 Participants
|
57 Participants
|
8 Participants
|
17 Participants
|
15 Participants
|
20 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total
|
19 Participants
|
105 Participants
|
15 Participants
|
83 Participants
|
140 Participants
|
157 Participants
|
34 Participants
|
41 Participants
|
40 Participants
|
68 Participants
|
68 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA
|
12 Participants
|
58 Participants
|
15 Participants
|
75 Participants
|
92 Participants
|
100 Participants
|
26 Participants
|
24 Participants
|
25 Participants
|
48 Participants
|
45 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru
|
5 Participants
|
38 Participants
|
0 Participants
|
7 Participants
|
39 Participants
|
46 Participants
|
6 Participants
|
15 Participants
|
10 Participants
|
17 Participants
|
17 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total
|
15 Participants
|
82 Participants
|
11 Participants
|
66 Participants
|
111 Participants
|
124 Participants
|
26 Participants
|
34 Participants
|
25 Participants
|
60 Participants
|
47 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA
|
10 Participants
|
44 Participants
|
11 Participants
|
59 Participants
|
72 Participants
|
78 Participants
|
20 Participants
|
19 Participants
|
15 Participants
|
43 Participants
|
30 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru
|
5 Participants
|
28 Participants
|
0 Participants
|
6 Participants
|
29 Participants
|
35 Participants
|
5 Participants
|
12 Participants
|
6 Participants
|
15 Participants
|
11 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru
|
6 Participants
|
40 Participants
|
0 Participants
|
8 Participants
|
41 Participants
|
47 Participants
|
6 Participants
|
15 Participants
|
10 Participants
|
18 Participants
|
17 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru
|
136 Participants
|
99 Participants
|
138 Participants
|
133 Participants
|
99 Participants
|
86 Participants
|
130 Participants
|
124 Participants
|
123 Participants
|
120 Participants
|
115 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total
|
11 Participants
|
53 Participants
|
10 Participants
|
38 Participants
|
67 Participants
|
85 Participants
|
19 Participants
|
23 Participants
|
19 Participants
|
44 Participants
|
32 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total
|
13 Participants
|
80 Participants
|
9 Participants
|
61 Participants
|
107 Participants
|
119 Participants
|
24 Participants
|
34 Participants
|
23 Participants
|
55 Participants
|
43 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA
|
7 Participants
|
40 Participants
|
9 Participants
|
53 Participants
|
66 Participants
|
72 Participants
|
18 Participants
|
19 Participants
|
13 Participants
|
37 Participants
|
26 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru
|
5 Participants
|
29 Participants
|
0 Participants
|
7 Participants
|
30 Participants
|
36 Participants
|
5 Participants
|
12 Participants
|
6 Participants
|
16 Participants
|
11 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total
|
9 Participants
|
52 Participants
|
9 Participants
|
37 Participants
|
66 Participants
|
82 Participants
|
18 Participants
|
22 Participants
|
16 Participants
|
42 Participants
|
29 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA
|
4 Participants
|
23 Participants
|
9 Participants
|
30 Participants
|
36 Participants
|
46 Participants
|
13 Participants
|
10 Participants
|
10 Participants
|
26 Participants
|
18 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total
|
236 Participants
|
173 Participants
|
236 Participants
|
193 Participants
|
150 Participants
|
125 Participants
|
224 Participants
|
213 Participants
|
210 Participants
|
197 Participants
|
190 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA
|
100 Participants
|
74 Participants
|
98 Participants
|
60 Participants
|
51 Participants
|
39 Participants
|
94 Participants
|
89 Participants
|
87 Participants
|
77 Participants
|
75 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru
|
123 Participants
|
89 Participants
|
129 Participants
|
121 Participants
|
88 Participants
|
82 Participants
|
123 Participants
|
114 Participants
|
119 Participants
|
111 Participants
|
112 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total
|
228 Participants
|
161 Participants
|
232 Participants
|
180 Participants
|
134 Participants
|
122 Participants
|
217 Participants
|
207 Participants
|
218 Participants
|
186 Participants
|
198 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA
|
105 Participants
|
72 Participants
|
103 Participants
|
59 Participants
|
46 Participants
|
40 Participants
|
94 Participants
|
93 Participants
|
99 Participants
|
75 Participants
|
86 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru
|
103 Participants
|
79 Participants
|
108 Participants
|
101 Participants
|
78 Participants
|
72 Participants
|
103 Participants
|
96 Participants
|
102 Participants
|
92 Participants
|
97 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total
|
171 Participants
|
128 Participants
|
171 Participants
|
143 Participants
|
114 Participants
|
98 Participants
|
162 Participants
|
158 Participants
|
164 Participants
|
138 Participants
|
151 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA
|
68 Participants
|
49 Participants
|
63 Participants
|
42 Participants
|
36 Participants
|
26 Participants
|
59 Participants
|
62 Participants
|
62 Participants
|
46 Participants
|
54 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru
|
2 Participants
|
39 Participants
|
0 Participants
|
5 Participants
|
39 Participants
|
52 Participants
|
8 Participants
|
14 Participants
|
15 Participants
|
18 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total
|
11 Participants
|
74 Participants
|
11 Participants
|
54 Participants
|
97 Participants
|
122 Participants
|
23 Participants
|
34 Participants
|
37 Participants
|
50 Participants
|
57 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA
|
9 Participants
|
35 Participants
|
11 Participants
|
49 Participants
|
58 Participants
|
70 Participants
|
15 Participants
|
20 Participants
|
22 Participants
|
32 Participants
|
34 Participants
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
n=388 Participants
3: Clinical spectrums
|
Group 8
n=388 Participants
Clinical spectrums , age 55+
|
Group 9
n=388 Participants
HIV
|
Group 10
n=388 Participants
Hypertension
|
Group 11
n=388 Participants
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total
|
6277.8 MFI
Interval 1428.5 to 15321.2
|
5957.2 MFI
Interval 1353.8 to 14702.0
|
5957.2 MFI
Interval 1476.2 to 14716.8
|
6797.8 MFI
Interval 1605.9 to 16543.5
|
6667.5 MFI
Interval 1605.9 to 15640.6
|
5303.8 MFI
Interval 1316.0 to 15341.2
|
5731 MFI
Interval 1194.5 to 15326.0
|
5030.1 MFI
Interval 984.8 to 14531.9
|
5896.4 MFI
Interval 1303.1 to 15346.5
|
4911.9 MFI
Interval 1297.1 to 14660.5
|
5892.2 MFI
Interval 1282.2 to 15384.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total
|
2590 MFI
Interval 656.5 to 8193.8
|
2470 MFI
Interval 656.5 to 8218.5
|
2552.8 MFI
Interval 595.2 to 8034.6
|
2753.5 MFI
Interval 555.2 to 9210.0
|
2573.2 MFI
Interval 697.2 to 9068.9
|
1726.5 MFI
Interval 505.6 to 8188.0
|
2510.6 MFI
Interval 544.8 to 8164.3
|
2272.1 MFI
Interval 414.4 to 7757.5
|
2573.2 MFI
Interval 573.6 to 8164.3
|
1912.4 MFI
Interval 544.8 to 7761.7
|
2470 MFI
Interval 548.2 to 8157.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total
|
1046.5 MFI
Interval 277.2 to 4434.6
|
1147 MFI
Interval 359.3 to 4412.0
|
945.4 MFI
Interval 246.9 to 4309.5
|
1046.5 MFI
Interval 329.3 to 4479.9
|
1148.8 MFI
Interval 360.0 to 4479.9
|
884.8 MFI
Interval 312.2 to 4401.8
|
945.4 MFI
Interval 214.2 to 4406.9
|
884.8 MFI
Interval 185.2 to 4132.5
|
1004.9 MFI
Interval 261.8 to 4816.6
|
876 MFI
Interval 277.2 to 4271.5
|
945.4 MFI
Interval 261.8 to 4406.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total
|
1058.1 MFI
Interval 230.9 to 3826.0
|
4785.8 MFI
Interval 790.2 to 14319.4
|
340.1 MFI
Interval 27.9 to 4403.9
|
3834.1 MFI
Interval 392.4 to 10674.8
|
4569.5 MFI
Interval 642.3 to 12663.8
|
5896.4 MFI
Interval 914.8 to 13916.0
|
5444.2 MFI
Interval 1243.5 to 10841.9
|
9464 MFI
Interval 3187.6 to 16543.5
|
3761 MFI
Interval 535.5 to 10641.1
|
7128.5 MFI
Interval 834.1 to 13892.2
|
5030.1 MFI
Interval 677.1 to 12021.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total
|
517.6 MFI
Interval 148.9 to 2100.6
|
2524.2 MFI
Interval 321.5 to 7310.0
|
411.1 MFI
Interval 258.9 to 5514.1
|
1542 MFI
Interval 565.0 to 3908.2
|
1917.5 MFI
Interval 439.4 to 6580.4
|
2753.5 MFI
Interval 626.8 to 7757.4
|
2286 MFI
Interval 646.5 to 7051.5
|
2875 MFI
Interval 1687.5 to 13120.5
|
1364.5 MFI
Interval 305.6 to 3685.8
|
3353.2 MFI
Interval 585.1 to 8034.6
|
2411.6 MFI
Interval 611.9 to 6926.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total
|
292.5 MFI
Interval 64.6 to 506.6
|
573.5 MFI
Interval 151.6 to 4182.0
|
479.5 MFI
Interval 132.8 to 4063.2
|
577.6 MFI
Interval 137.1 to 2494.4
|
619.4 MFI
Interval 161.2 to 4130.2
|
985.8 MFI
Interval 170.2 to 4123.5
|
707.4 MFI
Interval 336.4 to 2884.1
|
1651 MFI
Interval 683.1 to 6957.1
|
685.2 MFI
Interval 162.0 to 1241.5
|
1212.5 MFI
Interval 165.2 to 4377.2
|
893.4 MFI
Interval 173.6 to 3046.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total
|
14710.5 MFI
Interval 5851.0 to 22000.0
|
14693.8 MFI
Interval 5594.5 to 22000.0
|
14647.8 MFI
Interval 6049.2 to 22000.0
|
17197.8 MFI
Interval 6452.1 to 22000.0
|
17197.8 MFI
Interval 6562.0 to 22000.0
|
12621.5 MFI
Interval 5571.5 to 22000.0
|
14620.6 MFI
Interval 5322.3 to 22000.0
|
12577.9 MFI
Interval 4422.8 to 22000.0
|
14418.5 MFI
Interval 5569.6 to 22000.0
|
12974.4 MFI
Interval 5580.1 to 22000.0
|
13901.5 MFI
Interval 5169.9 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total
|
8793 MFI
Interval 2807.7 to 19804.5
|
8316.5 MFI
Interval 3213.8 to 19446.9
|
8364.6 MFI
Interval 2783.6 to 18903.7
|
8985.2 MFI
Interval 2959.4 to 21977.7
|
9365.2 MFI
Interval 3355.8 to 21955.4
|
7229 MFI
Interval 2497.5 to 18788.5
|
8293.9 MFI
Interval 2528.4 to 18809.6
|
7503.6 MFI
Interval 2407.3 to 18640.9
|
8299.5 MFI
Interval 2596.5 to 19108.4
|
7492.8 MFI
Interval 2497.5 to 18579.2
|
7791 MFI
Interval 2559.6 to 18934.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total
|
4139.5 MFI
Interval 1453.5 to 12774.0
|
4330.5 MFI
Interval 1577.2 to 12902.2
|
3959.6 MFI
Interval 1368.2 to 12176.1
|
4351 MFI
Interval 1561.1 to 13770.2
|
5145 MFI
Interval 1720.5 to 13932.6
|
3484 MFI
Interval 1391.1 to 12454.6
|
3991.9 MFI
Interval 1217.0 to 12655.1
|
3081.1 MFI
Interval 1132.3 to 11488.0
|
3935.8 MFI
Interval 1391.1 to 13703.2
|
3145.1 MFI
Interval 1389.2 to 11574.7
|
3495.2 MFI
Interval 1311.0 to 13569.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total
|
4467.4 MFI
Interval 1171.0 to 9711.5
|
11566.1 MFI
Interval 3761.4 to 22000.0
|
1821.1 MFI
Interval 250.3 to 6792.7
|
9321.1 MFI
Interval 1993.9 to 19944.7
|
10636 MFI
Interval 3449.1 to 22000.0
|
14039.4 MFI
Interval 4790.8 to 22000.0
|
11599 MFI
Interval 4053.8 to 19094.5
|
19488.8 MFI
Interval 9478.8 to 22000.0
|
12534.2 MFI
Interval 4142.6 to 22000.0
|
15897.5 MFI
Interval 3136.4 to 22000.0
|
14175.8 MFI
Interval 5279.6 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total
|
2182.5 MFI
Interval 189.0 to 5763.9
|
7004 MFI
Interval 1692.2 to 17791.0
|
1718.8 MFI
Interval 240.5 to 5993.8
|
5330.8 MFI
Interval 2061.0 to 12400.8
|
5994.6 MFI
Interval 2407.3 to 14209.0
|
8793 MFI
Interval 3058.1 to 18745.2
|
7004 MFI
Interval 2798.8 to 16619.2
|
11160.5 MFI
Interval 6801.9 to 20498.2
|
5687 MFI
Interval 1814.8 to 14112.8
|
9950.8 MFI
Interval 3375.2 to 19247.2
|
8293.9 MFI
Interval 2418.6 to 17063.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total
|
1020 MFI
Interval 300.2 to 2101.5
|
2475.5 MFI
Interval 654.2 to 11270.1
|
1830 MFI
Interval 852.5 to 6023.1
|
2116.6 MFI
Interval 698.0 to 7486.7
|
2238.8 MFI
Interval 737.1 to 10305.0
|
3983.5 MFI
Interval 1111.0 to 11925.0
|
2599.9 MFI
Interval 1850.8 to 6494.4
|
7803.8 MFI
Interval 2931.2 to 18528.0
|
2206.5 MFI
Interval 1100.2 to 5812.5
|
5903.2 MFI
Interval 920.6 to 13074.4
|
3783 MFI
Interval 1289.0 to 9704.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total
|
5490.5 MFI
Interval 841.0 to 22000.0
|
5184.6 MFI
Interval 757.2 to 22000.0
|
5305.8 MFI
Interval 868.9 to 22000.0
|
6094.2 MFI
Interval 996.5 to 22000.0
|
7176 MFI
Interval 1151.7 to 22000.0
|
7429.1 MFI
Interval 1142.4 to 22000.0
|
5216.2 MFI
Interval 863.4 to 22000.0
|
4557 MFI
Interval 502.2 to 21406.0
|
5490.5 MFI
Interval 868.0 to 22000.0
|
5190.6 MFI
Interval 823.8 to 22000.0
|
5783 MFI
Interval 858.8 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total
|
1003.4 MFI
Interval 103.7 to 5128.0
|
986.2 MFI
Interval 100.8 to 4982.8
|
986.2 MFI
Interval 101.0 to 4982.8
|
1344 MFI
Interval 108.4 to 7489.8
|
1396.9 MFI
Interval 103.7 to 7881.1
|
793.2 MFI
Interval 90.9 to 6866.3
|
986.2 MFI
Interval 101.0 to 4494.8
|
665.9 MFI
Interval 68.8 to 4359.7
|
1003.4 MFI
Interval 93.4 to 5128.0
|
805.5 MFI
Interval 92.2 to 5145.0
|
979 MFI
Interval 90.9 to 5178.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total
|
338.8 MFI
Interval 38.4 to 2167.5
|
368.2 MFI
Interval 52.4 to 2176.9
|
324 MFI
Interval 32.4 to 2174.8
|
371.5 MFI
Interval 46.0 to 2540.2
|
383.6 MFI
Interval 59.6 to 2585.6
|
379.2 MFI
Interval 50.9 to 2174.8
|
371.5 MFI
Interval 38.2 to 2189.2
|
258.8 MFI
Interval 22.1 to 1965.8
|
358.5 MFI
Interval 29.4 to 2155.2
|
299.4 MFI
Interval 38.9 to 2087.9
|
328 MFI
Interval 26.0 to 2167.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total
|
245.8 MFI
Interval 3.0 to 1931.0
|
4697.5 MFI
Interval 394.7 to 20450.7
|
173 MFI
Interval 8.7 to 1331.1
|
1493.2 MFI
Interval 175.9 to 8039.2
|
3231.6 MFI
Interval 244.4 to 15086.0
|
3469.6 MFI
Interval 329.1 to 17448.8
|
1559.1 MFI
Interval 46.1 to 8833.2
|
8441 MFI
Interval 1834.0 to 22000.0
|
2025.2 MFI
Interval 187.2 to 10074.1
|
4045.6 MFI
Interval 274.6 to 18452.3
|
2676.8 MFI
Interval 375.0 to 11769.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total
|
92.2 MFI
Interval 3.4 to 715.9
|
692.4 MFI
Interval 43.6 to 3752.1
|
39 MFI
Interval 9.6 to 334.1
|
355 MFI
Interval 24.1 to 1465.6
|
454.2 MFI
Interval 55.1 to 2194.9
|
883.8 MFI
Interval 101.0 to 4256.0
|
313.1 MFI
Interval 18.1 to 3626.2
|
1859.5 MFI
Interval 827.4 to 9648.6
|
361.2 MFI
Interval 67.8 to 3031.5
|
1046 MFI
Interval 88.1 to 3826.2
|
437.2 MFI
Interval 163.5 to 3292.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total
|
21.2 MFI
Interval 2.5 to 377.2
|
252.5 MFI
Interval 19.5 to 1865.0
|
172.6 MFI
Interval 12.6 to 523.1
|
171 MFI
Interval 6.0 to 601.3
|
189.2 MFI
Interval 19.5 to 1354.6
|
275.8 MFI
Interval 18.8 to 1964.2
|
99.8 MFI
Interval 16.8 to 456.2
|
1242 MFI
Interval 256.1 to 4546.8
|
152.8 MFI
Interval 31.8 to 387.8
|
324 MFI
Interval 4.0 to 2069.9
|
259.8 MFI
Interval 40.0 to 1770.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-N at Month 4-Total
|
5278.5 MFI
Interval 2654.6 to 8500.8
|
5197.2 MFI
Interval 2654.6 to 8500.8
|
5084.2 MFI
Interval 2647.1 to 8505.2
|
5180.8 MFI
Interval 2734.0 to 8573.0
|
5197.2 MFI
Interval 2716.0 to 8685.4
|
5014.6 MFI
Interval 2362.6 to 7717.4
|
5172.2 MFI
Interval 2760.1 to 8515.4
|
5074.1 MFI
Interval 2289.9 to 7816.8
|
5068.2 MFI
Interval 2428.5 to 7898.2
|
5076.2 MFI
Interval 2234.1 to 7843.8
|
4994.2 MFI
Interval 2261.9 to 7573.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-Y at Month 0-Total
|
2889 MFI
Interval 1346.3 to 5184.4
|
4563.8 MFI
Interval 2505.5 to 6532.6
|
2867.8 MFI
Interval 2124.6 to 5668.1
|
3976.2 MFI
Interval 2257.1 to 6190.0
|
4318.9 MFI
Interval 2317.3 to 6505.1
|
3843 MFI
Interval 2227.7 to 6062.1
|
3117.5 MFI
Interval 1859.2 to 5219.5
|
4143.8 MFI
Interval 2184.0 to 5491.8
|
4958 MFI
Interval 2906.1 to 7416.4
|
3533.5 MFI
Interval 1821.8 to 5099.1
|
4471.8 MFI
Interval 2781.4 to 6984.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-Y at Month 2-Total
|
2733.8 MFI
Interval 1846.8 to 6103.2
|
4774.8 MFI
Interval 2637.4 to 7509.4
|
4265.9 MFI
Interval 1875.8 to 7046.3
|
4748.1 MFI
Interval 1748.1 to 7575.7
|
4790.9 MFI
Interval 2488.2 to 7749.9
|
4374.5 MFI
Interval 2389.3 to 7490.4
|
3227.8 MFI
Interval 1492.9 to 6747.8
|
4783 MFI
Interval 2449.0 to 8253.8
|
5511.6 MFI
Interval 2727.1 to 8294.2
|
4810.8 MFI
Interval 2777.8 to 6952.4
|
5194 MFI
Interval 2882.6 to 8128.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-Y at Month 4-Total
|
3639.8 MFI
Interval 2210.8 to 4224.8
|
4980 MFI
Interval 2560.2 to 7899.2
|
5997.9 MFI
Interval 2683.6 to 7579.4
|
4952.2 MFI
Interval 2275.2 to 7267.4
|
4980 MFI
Interval 2296.8 to 7434.0
|
5359.5 MFI
Interval 2804.6 to 8505.2
|
4119.2 MFI
Interval 2193.2 to 7379.2
|
6604 MFI
Interval 3837.5 to 10017.8
|
6917.4 MFI
Interval 4145.6 to 9177.4
|
5267.5 MFI
Interval 3179.2 to 10017.8
|
7069.8 MFI
Interval 4119.2 to 10017.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-1000-N at Month 0-Total
|
6112.2 MFI
Interval 1395.9 to 18561.8
|
6626 MFI
Interval 1401.4 to 18561.8
|
5654.9 MFI
Interval 1394.4 to 18179.1
|
7577.5 MFI
Interval 1538.4 to 20529.9
|
8402.5 MFI
Interval 1684.8 to 20938.4
|
6269.5 MFI
Interval 1204.9 to 19740.6
|
5736.8 MFI
Interval 1261.7 to 18723.8
|
4846.8 MFI
Interval 1054.8 to 17239.6
|
5605.8 MFI
Interval 1207.1 to 18613.7
|
5408.8 MFI
Interval 1307.9 to 17605.1
|
5630.5 MFI
Interval 1183.2 to 19230.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-1000-N at Month 2-Total
|
2192 MFI
Interval 585.6 to 6499.6
|
2048.1 MFI
Interval 584.8 to 6592.7
|
2039.8 MFI
Interval 587.8 to 6414.5
|
2409.2 MFI
Interval 609.0 to 8690.5
|
2440.4 MFI
Interval 622.9 to 8932.0
|
1574.5 MFI
Interval 365.7 to 6567.6
|
2033 MFI
Interval 558.2 to 6439.5
|
1626.9 MFI
Interval 410.2 to 5818.3
|
1742.2 MFI
Interval 536.1 to 6508.9
|
1655.6 MFI
Interval 536.1 to 6102.7
|
1712 MFI
Interval 513.1 to 6729.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-1000-N at Month 4-Total
|
969 MFI
Interval 309.1 to 3808.6
|
1020.2 MFI
Interval 323.0 to 3617.6
|
836.9 MFI
Interval 283.9 to 3774.9
|
958.2 MFI
Interval 313.6 to 4088.1
|
1157.8 MFI
Interval 356.2 to 3716.5
|
796.8 MFI
Interval 301.9 to 4101.5
|
969 MFI
Interval 293.5 to 4083.2
|
691 MFI
Interval 276.5 to 3621.0
|
870.5 MFI
Interval 293.5 to 4100.2
|
764.8 MFI
Interval 296.2 to 3814.2
|
845.4 MFI
Interval 280.4 to 4100.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-1000-Y at Month 0-Total
|
1174.4 MFI
Interval 258.6 to 2923.2
|
4122.1 MFI
Interval 1011.9 to 15666.8
|
390.8 MFI
Interval 1.0 to 4847.5
|
2841.8 MFI
Interval 506.4 to 10564.5
|
4012 MFI
Interval 905.6 to 13077.2
|
4669.8 MFI
Interval 1230.6 to 14181.0
|
3328.2 MFI
Interval 690.5 to 9756.9
|
10169.5 MFI
Interval 2653.2 to 21961.9
|
4199 MFI
Interval 1002.8 to 12758.0
|
4847.5 MFI
Interval 466.8 to 16765.2
|
4638.5 MFI
Interval 1342.9 to 13059.7
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-1000-Y at Month 2-Total
|
588 MFI
Interval 88.5 to 1688.6
|
1592.5 MFI
Interval 436.8 to 5293.5
|
418.8 MFI
Interval 100.9 to 907.6
|
1164.2 MFI
Interval 360.0 to 3250.1
|
1388.8 MFI
Interval 410.8 to 4213.2
|
2390.5 MFI
Interval 608.2 to 5812.9
|
1520.5 MFI
Interval 513.1 to 4649.2
|
2760.2 MFI
Interval 1676.5 to 9347.0
|
1211.8 MFI
Interval 475.2 to 4381.5
|
2616.8 MFI
Interval 550.5 to 5819.9
|
2056.5 MFI
Interval 613.8 to 4632.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-1000-Y at Month 4-Total
|
226.5 MFI
Interval 133.0 to 663.2
|
648.9 MFI
Interval 173.2 to 3811.4
|
595.2 MFI
Interval 447.4 to 1263.6
|
517.9 MFI
Interval 174.8 to 1819.3
|
648.9 MFI
Interval 182.4 to 3541.8
|
870.5 MFI
Interval 257.2 to 2800.0
|
638.5 MFI
Interval 288.5 to 956.6
|
1931.5 MFI
Interval 1077.5 to 6169.6
|
509.2 MFI
Interval 264.1 to 1517.8
|
1160.8 MFI
Interval 225.9 to 3445.0
|
789.4 MFI
Interval 403.5 to 1675.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total
|
12799.8 MFI
Interval 2044.1 to 22000.0
|
13604.2 MFI
Interval 2192.4 to 22000.0
|
12849 MFI
Interval 2153.2 to 22000.0
|
13088.5 MFI
Interval 2391.6 to 22000.0
|
14063.8 MFI
Interval 2494.0 to 22000.0
|
13531.5 MFI
Interval 1927.0 to 22000.0
|
11886.9 MFI
Interval 1883.5 to 22000.0
|
11614.5 MFI
Interval 1806.4 to 22000.0
|
13518.9 MFI
Interval 1948.5 to 22000.0
|
12524.4 MFI
Interval 2102.8 to 22000.0
|
12249.8 MFI
Interval 1882.0 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total
|
2712.6 MFI
Interval 618.1 to 8031.9
|
3177.2 MFI
Interval 690.5 to 8193.8
|
2496 MFI
Interval 603.8 to 8006.8
|
2949.5 MFI
Interval 664.2 to 7406.5
|
3634 MFI
Interval 706.7 to 8431.0
|
2042.2 MFI
Interval 534.8 to 6959.5
|
2276.8 MFI
Interval 580.1 to 7335.4
|
2042.2 MFI
Interval 527.4 to 6960.5
|
2578.4 MFI
Interval 586.4 to 8015.1
|
2235.8 MFI
Interval 570.0 to 6850.6
|
2188.6 MFI
Interval 583.6 to 7803.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total
|
554 MFI
Interval 238.0 to 2161.0
|
645.5 MFI
Interval 290.6 to 2248.2
|
519.9 MFI
Interval 236.1 to 2123.5
|
515.1 MFI
Interval 262.0 to 2003.0
|
684.2 MFI
Interval 291.4 to 2238.4
|
520.1 MFI
Interval 238.6 to 2063.4
|
530.8 MFI
Interval 237.7 to 1932.3
|
471.8 MFI
Interval 209.9 to 1834.7
|
562.2 MFI
Interval 237.1 to 2222.4
|
497.9 MFI
Interval 235.9 to 2003.0
|
554 MFI
Interval 236.1 to 2189.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total
|
2446.9 MFI
Interval 257.4 to 14302.8
|
8591 MFI
Interval 1481.6 to 22000.0
|
474.2 MFI
Interval 176.1 to 4311.5
|
7330.2 MFI
Interval 823.0 to 20153.2
|
8591 MFI
Interval 1457.2 to 22000.0
|
11080.2 MFI
Interval 1907.4 to 22000.0
|
11964.5 MFI
Interval 2066.5 to 22000.0
|
18448.9 MFI
Interval 3083.5 to 22000.0
|
5702.8 MFI
Interval 1539.4 to 15439.5
|
10451.2 MFI
Interval 448.0 to 22000.0
|
10848.6 MFI
Interval 2425.0 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total
|
743 MFI
Interval 117.5 to 2214.2
|
1519 MFI
Interval 420.2 to 5682.8
|
705.9 MFI
Interval 181.1 to 2720.7
|
1769.8 MFI
Interval 402.2 to 8091.2
|
1746.2 MFI
Interval 431.5 to 5970.2
|
3119.4 MFI
Interval 656.8 to 8048.0
|
3486.5 MFI
Interval 671.8 to 8151.2
|
4889.4 MFI
Interval 1580.3 to 9442.2
|
1078.5 MFI
Interval 589.2 to 5049.2
|
2712.6 MFI
Interval 678.6 to 9358.6
|
3296.5 MFI
Interval 625.1 to 6635.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total
|
427.5 MFI
Interval 190.8 to 617.2
|
409.4 MFI
Interval 175.7 to 1094.6
|
506.2 MFI
Interval 177.1 to 733.1
|
531.6 MFI
Interval 106.3 to 1372.3
|
427.5 MFI
Interval 169.4 to 1139.9
|
515.1 MFI
Interval 229.3 to 1846.2
|
398.9 MFI
Interval 200.6 to 2714.5
|
962.6 MFI
Interval 497.5 to 4748.5
|
416.5 MFI
Interval 190.1 to 881.5
|
573.9 MFI
Interval 236.3 to 1794.0
|
442 MFI
Interval 207.9 to 1308.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total
|
6729.6 MFI
Interval 1411.3 to 17060.8
|
6397.5 MFI
Interval 1429.2 to 17470.2
|
6116 MFI
Interval 1474.4 to 16115.8
|
8441.2 MFI
Interval 1513.8 to 18425.0
|
8630.4 MFI
Interval 2155.9 to 18162.2
|
8091.1 MFI
Interval 1719.6 to 18162.2
|
5885.8 MFI
Interval 1262.0 to 17378.2
|
4892.4 MFI
Interval 1014.9 to 15449.3
|
7081 MFI
Interval 1383.0 to 17507.8
|
5452.5 MFI
Interval 1233.0 to 16424.0
|
7897.2 MFI
Interval 1411.3 to 17908.7
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total
|
2060.5 MFI
Interval 555.5 to 6803.0
|
2018.8 MFI
Interval 564.8 to 6822.1
|
2016 MFI
Interval 553.9 to 6577.5
|
2361 MFI
Interval 643.5 to 7825.2
|
2397.1 MFI
Interval 681.0 to 8594.2
|
1742.1 MFI
Interval 434.7 to 5788.2
|
2000 MFI
Interval 474.8 to 6768.3
|
1595.6 MFI
Interval 402.9 to 5788.2
|
1984 MFI
Interval 489.8 to 6512.5
|
1653.2 MFI
Interval 493.4 to 5788.2
|
1928.5 MFI
Interval 489.5 to 7137.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total
|
948.5 MFI
Interval 299.9 to 3899.0
|
1037.6 MFI
Interval 319.8 to 3900.8
|
843.1 MFI
Interval 273.7 to 3873.3
|
987.8 MFI
Interval 317.9 to 4360.8
|
1192 MFI
Interval 348.4 to 4310.1
|
828.2 MFI
Interval 288.4 to 3829.6
|
889.8 MFI
Interval 262.3 to 3975.6
|
636.2 MFI
Interval 233.2 to 3523.0
|
852 MFI
Interval 284.5 to 4194.8
|
651 MFI
Interval 275.0 to 3667.2
|
834.2 MFI
Interval 263.8 to 4296.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total
|
1027.9 MFI
Interval 84.6 to 2607.2
|
3242.9 MFI
Interval 817.8 to 13852.2
|
278 MFI
Interval 44.5 to 1890.9
|
2650.2 MFI
Interval 577.4 to 7324.0
|
3143.1 MFI
Interval 668.6 to 12575.8
|
3930.6 MFI
Interval 829.8 to 12134.4
|
2550.5 MFI
Interval 154.6 to 9876.0
|
6608.9 MFI
Interval 2433.0 to 17724.8
|
2706 MFI
Interval 632.1 to 8552.0
|
7081 MFI
Interval 737.5 to 14116.5
|
2931.9 MFI
Interval 739.4 to 9459.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total
|
464.8 MFI
Interval 37.8 to 1475.5
|
1530.9 MFI
Interval 387.0 to 4825.1
|
218.5 MFI
Interval 76.9 to 846.8
|
857 MFI
Interval 303.2 to 2440.4
|
1177.2 MFI
Interval 385.2 to 4011.0
|
1984 MFI
Interval 492.2 to 6733.6
|
1470.2 MFI
Interval 509.0 to 3766.5
|
2944.5 MFI
Interval 1505.6 to 10990.1
|
1153 MFI
Interval 384.9 to 3760.7
|
2174 MFI
Interval 479.8 to 7575.2
|
1835.5 MFI
Interval 509.6 to 4802.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total
|
249 MFI
Interval 128.5 to 426.0
|
435.4 MFI
Interval 173.2 to 3385.9
|
351.6 MFI
Interval 227.8 to 1244.0
|
329.8 MFI
Interval 149.6 to 1633.1
|
369.9 MFI
Interval 184.1 to 2818.1
|
688.2 MFI
Interval 257.9 to 3793.9
|
459.1 MFI
Interval 334.2 to 1232.5
|
2427 MFI
Interval 483.6 to 8349.2
|
444.8 MFI
Interval 240.0 to 1865.0
|
1209 MFI
Interval 239.8 to 4150.0
|
636.2 MFI
Interval 273.2 to 2592.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-1000-N at Month 0-Total
|
5749.2 MFI
Interval 1013.5 to 19426.4
|
5840.9 MFI
Interval 1065.2 to 19804.8
|
5270.8 MFI
Interval 1097.2 to 18916.2
|
6567 MFI
Interval 1357.8 to 20734.9
|
7419.8 MFI
Interval 1374.8 to 21077.8
|
4992 MFI
Interval 934.4 to 19775.6
|
5146.4 MFI
Interval 839.2 to 19649.8
|
4258.2 MFI
Interval 704.8 to 17988.0
|
5061.5 MFI
Interval 905.1 to 18752.1
|
4639.8 MFI
Interval 992.0 to 18554.5
|
5023.5 MFI
Interval 839.2 to 19084.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-1000-N at Month 2-Total
|
1735.9 MFI
Interval 351.6 to 6368.3
|
1719.5 MFI
Interval 373.8 to 6311.1
|
1718.1 MFI
Interval 347.8 to 6091.2
|
1913.9 MFI
Interval 355.1 to 8352.1
|
2054.5 MFI
Interval 414.0 to 8352.1
|
1464.6 MFI
Interval 276.8 to 6040.8
|
1646.9 MFI
Interval 318.8 to 6280.4
|
1455.4 MFI
Interval 258.6 to 5586.8
|
1571.5 MFI
Interval 302.7 to 6096.8
|
1464.6 MFI
Interval 283.0 to 6096.8
|
1557.2 MFI
Interval 286.0 to 6412.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-1000-N at Month 4-Total
|
781 MFI
Interval 232.8 to 4491.0
|
776.1 MFI
Interval 259.2 to 4004.2
|
741.9 MFI
Interval 210.4 to 4269.4
|
795.2 MFI
Interval 240.6 to 4670.4
|
1001.6 MFI
Interval 268.1 to 4269.4
|
718 MFI
Interval 237.8 to 4642.0
|
775.5 MFI
Interval 223.2 to 4568.0
|
597.2 MFI
Interval 199.2 to 4099.2
|
752.2 MFI
Interval 219.2 to 4647.5
|
683.2 MFI
Interval 223.2 to 4116.8
|
741.9 MFI
Interval 206.9 to 4670.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-1000-Y at Month 0-Total
|
1047.2 MFI
Interval 253.9 to 2268.5
|
3491.4 MFI
Interval 665.9 to 15547.7
|
434.8 MFI
Interval 22.2 to 2114.2
|
2149.2 MFI
Interval 353.6 to 8389.4
|
3311.8 MFI
Interval 563.0 to 11397.0
|
4395.6 MFI
Interval 791.4 to 15229.9
|
3026.1 MFI
Interval 618.1 to 7905.6
|
9263.5 MFI
Interval 2702.5 to 22000.0
|
3529.5 MFI
Interval 539.4 to 12927.5
|
7261 MFI
Interval 525.8 to 17691.2
|
3837.6 MFI
Interval 669.4 to 12453.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-1000-Y at Month 2-Total
|
324 MFI
Interval 66.5 to 1153.2
|
1460.2 MFI
Interval 236.8 to 5483.8
|
175.8 MFI
Interval 87.0 to 776.5
|
776.5 MFI
Interval 205.4 to 2233.6
|
995.8 MFI
Interval 220.2 to 4688.8
|
1748.8 MFI
Interval 324.0 to 5654.2
|
979.5 MFI
Interval 268.5 to 4179.8
|
4179.8 MFI
Interval 1485.5 to 11767.1
|
1180.2 MFI
Interval 274.2 to 5120.1
|
2153.2 MFI
Interval 439.2 to 5506.8
|
1527 MFI
Interval 318.6 to 5453.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-1000-Y at Month 4-Total
|
223.2 MFI
Interval 126.8 to 573.0
|
502.9 MFI
Interval 135.1 to 4529.5
|
404.5 MFI
Interval 287.8 to 1558.1
|
400.1 MFI
Interval 113.0 to 1795.1
|
429 MFI
Interval 135.1 to 3779.6
|
771.2 MFI
Interval 191.0 to 3485.8
|
392 MFI
Interval 195.5 to 950.2
|
1766.5 MFI
Interval 703.8 to 8320.6
|
425.2 MFI
Interval 202.1 to 1531.5
|
1073 MFI
Interval 161.1 to 4140.2
|
607.5 MFI
Interval 232.6 to 1822.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-1000-N at Month 0-Total
|
21989.8 MFI
Interval 7432.8 to 22000.0
|
21924.8 MFI
Interval 5983.1 to 22000.0
|
21849.4 MFI
Interval 7671.6 to 22000.0
|
22000 MFI
Interval 8074.5 to 22000.0
|
22000 MFI
Interval 8187.4 to 22000.0
|
22000 MFI
Interval 8304.9 to 22000.0
|
21664.4 MFI
Interval 7036.2 to 22000.0
|
20217 MFI
Interval 5081.0 to 22000.0
|
21972.8 MFI
Interval 6757.0 to 22000.0
|
20312 MFI
Interval 6287.0 to 22000.0
|
22000 MFI
Interval 7581.1 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-1000-N at Month 2-Total
|
9624.5 MFI
Interval 2984.2 to 20483.8
|
9478 MFI
Interval 3120.6 to 20452.5
|
9065.8 MFI
Interval 2876.8 to 20056.2
|
10137.4 MFI
Interval 2844.3 to 22000.0
|
10664.6 MFI
Interval 2844.3 to 22000.0
|
7601 MFI
Interval 2509.1 to 20175.0
|
8898.8 MFI
Interval 2675.8 to 20282.1
|
7601 MFI
Interval 2010.0 to 19418.0
|
9065.8 MFI
Interval 2711.8 to 20421.2
|
7577 MFI
Interval 2621.2 to 18828.5
|
8894.8 MFI
Interval 2522.9 to 20959.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-1000-N at Month 4-Total
|
4279 MFI
Interval 1288.0 to 14394.3
|
4413 MFI
Interval 1514.2 to 14348.0
|
3677.9 MFI
Interval 1125.2 to 14200.1
|
4408.1 MFI
Interval 1408.0 to 14901.8
|
4763.8 MFI
Interval 1662.5 to 15050.4
|
3660 MFI
Interval 1159.1 to 14274.0
|
4158 MFI
Interval 1054.6 to 14581.6
|
3196.9 MFI
Interval 989.9 to 12670.5
|
3695.8 MFI
Interval 1159.1 to 14837.0
|
3414.9 MFI
Interval 1146.9 to 13275.6
|
3660 MFI
Interval 1096.8 to 14966.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-1000-Y at Month 0-Total
|
4569.9 MFI
Interval 558.9 to 13484.9
|
16577.6 MFI
Interval 5504.6 to 22000.0
|
1313.2 MFI
Interval 195.2 to 7612.6
|
10749.1 MFI
Interval 2478.1 to 22000.0
|
14683.4 MFI
Interval 4002.6 to 22000.0
|
16814.5 MFI
Interval 4307.8 to 22000.0
|
9277.6 MFI
Interval 1466.2 to 22000.0
|
22000 MFI
Interval 10521.1 to 22000.0
|
13720.2 MFI
Interval 3015.0 to 22000.0
|
22000 MFI
Interval 4025.2 to 22000.0
|
13720.2 MFI
Interval 4110.8 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-1000-Y at Month 2-Total
|
2711.8 MFI
Interval 129.6 to 6004.5
|
6956.8 MFI
Interval 1850.0 to 16844.2
|
759 MFI
Interval 182.9 to 5334.6
|
5077.1 MFI
Interval 1741.8 to 13177.6
|
6829.5 MFI
Interval 1988.8 to 15928.2
|
9271.5 MFI
Interval 2747.0 to 19418.0
|
8553.8 MFI
Interval 1792.2 to 15764.8
|
12426.2 MFI
Interval 6736.9 to 21241.9
|
4956.2 MFI
Interval 1901.1 to 16606.4
|
11437.8 MFI
Interval 2336.2 to 20313.4
|
7388.8 MFI
Interval 2720.2 to 17521.3
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-1000-Y at Month 4-Total
|
958.5 MFI
Interval 261.5 to 1857.2
|
2272.5 MFI
Interval 554.8 to 13357.6
|
2031.9 MFI
Interval 764.0 to 5144.6
|
1777 MFI
Interval 524.5 to 8249.4
|
2265 MFI
Interval 608.2 to 11582.6
|
3382.2 MFI
Interval 999.5 to 13315.5
|
2125.2 MFI
Interval 1665.2 to 5108.5
|
8224.2 MFI
Interval 2391.2 to 21245.9
|
2586.8 MFI
Interval 956.9 to 5435.5
|
4913.5 MFI
Interval 930.2 to 15008.4
|
3382.2 MFI
Interval 1415.0 to 9555.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-N at Month 0-Total
|
5540 MFI
Interval 3473.0 to 8258.8
|
5035.8 MFI
Interval 3318.1 to 8428.1
|
5623.4 MFI
Interval 3593.2 to 8113.5
|
5836.9 MFI
Interval 3609.8 to 8493.4
|
5609 MFI
Interval 3440.2 to 8486.8
|
5818.2 MFI
Interval 3744.0 to 8513.5
|
5574.5 MFI
Interval 3448.4 to 8262.9
|
5444.8 MFI
Interval 3314.8 to 8098.2
|
5766.9 MFI
Interval 3392.8 to 8260.1
|
5536.8 MFI
Interval 3678.8 to 8098.2
|
5775.5 MFI
Interval 3456.6 to 8520.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-N at Month 2-Total
|
5174.8 MFI
Interval 2927.1 to 8040.9
|
4738.2 MFI
Interval 2894.5 to 7856.0
|
5268.5 MFI
Interval 3002.0 to 8012.8
|
5494 MFI
Interval 3159.8 to 8219.2
|
4801.8 MFI
Interval 2921.6 to 8006.0
|
5268.5 MFI
Interval 3370.4 to 7887.1
|
5279 MFI
Interval 2945.0 to 8037.5
|
4890.2 MFI
Interval 2902.9 to 7926.7
|
5057.6 MFI
Interval 2969.5 to 7946.4
|
4936.8 MFI
Interval 2991.9 to 7896.9
|
5174.8 MFI
Interval 3272.6 to 7974.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-N at Month 4-Total
|
6282.2 MFI
Interval 3977.9 to 8734.1
|
6242.8 MFI
Interval 3980.8 to 8614.3
|
6289 MFI
Interval 3985.2 to 9007.6
|
6379.5 MFI
Interval 4149.4 to 9789.0
|
6274 MFI
Interval 4094.1 to 9642.9
|
6289 MFI
Interval 4307.6 to 8392.5
|
6334.2 MFI
Interval 4053.5 to 8639.6
|
6275 MFI
Interval 3951.9 to 8639.6
|
6289 MFI
Interval 4030.2 to 8793.2
|
6439.2 MFI
Interval 4094.1 to 8614.3
|
6282.2 MFI
Interval 4053.1 to 8734.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-Y at Month 0-Total
|
5227.2 MFI
Interval 2054.2 to 5914.5
|
5877 MFI
Interval 3827.8 to 7704.2
|
3361.8 MFI
Interval 1933.2 to 6372.1
|
4230.4 MFI
Interval 2810.8 to 6882.3
|
5522.2 MFI
Interval 3367.8 to 7766.8
|
5418.8 MFI
Interval 3251.2 to 7770.5
|
5256 MFI
Interval 3314.4 to 6943.9
|
5786.5 MFI
Interval 3598.8 to 7804.5
|
5288 MFI
Interval 3688.6 to 7387.4
|
5449.5 MFI
Interval 2743.6 to 8031.1
|
5284.8 MFI
Interval 3283.0 to 7182.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-Y at Month 2-Total
|
4083.2 MFI
Interval 3500.0 to 5991.9
|
5584.2 MFI
Interval 3557.1 to 7987.2
|
3677.4 MFI
Interval 2271.0 to 4456.0
|
4425.9 MFI
Interval 2664.4 to 6593.4
|
5078.5 MFI
Interval 3219.3 to 7872.6
|
4986.8 MFI
Interval 2838.2 to 7947.7
|
4654.2 MFI
Interval 2924.1 to 6766.0
|
5982 MFI
Interval 4185.8 to 7856.0
|
4939.2 MFI
Interval 2564.2 to 7112.2
|
5106.8 MFI
Interval 2686.2 to 8144.1
|
4693.2 MFI
Interval 2564.2 to 7217.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-Y at Month 4-Total
|
6172.5 MFI
Interval 4225.2 to 7904.2
|
6873 MFI
Interval 4187.8 to 9007.6
|
5991.4 MFI
Interval 3176.1 to 6940.4
|
5991.4 MFI
Interval 3157.6 to 7880.9
|
6451.2 MFI
Interval 3748.5 to 8392.5
|
6235.8 MFI
Interval 3804.7 to 9948.3
|
4989 MFI
Interval 3787.8 to 9733.8
|
6878 MFI
Interval 5495.2 to 10318.8
|
5978.9 MFI
Interval 3714.5 to 8065.7
|
6014.2 MFI
Interval 3782.4 to 9913.6
|
6198 MFI
Interval 3624.0 to 8119.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-N at Month 0-Total
|
14162.9 MFI
Interval 7994.5 to 21650.9
|
14355 MFI
Interval 8411.5 to 21795.0
|
13899 MFI
Interval 7734.8 to 21510.5
|
14104.4 MFI
Interval 8279.0 to 21412.0
|
14305.4 MFI
Interval 8220.8 to 21459.3
|
16171.8 MFI
Interval 9845.8 to 22000.0
|
14013.5 MFI
Interval 8116.6 to 21986.4
|
14355 MFI
Interval 8407.5 to 21893.4
|
14162.9 MFI
Interval 8040.0 to 21979.6
|
14355 MFI
Interval 8204.0 to 22000.0
|
14321.1 MFI
Interval 8362.0 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-N at Month 2-Total
|
9586.8 MFI
Interval 5500.8 to 15912.5
|
9248.6 MFI
Interval 5464.1 to 14802.1
|
9590.6 MFI
Interval 5548.9 to 15837.0
|
9633 MFI
Interval 5769.9 to 15966.0
|
9108.8 MFI
Interval 5308.2 to 14737.4
|
11154.8 MFI
Interval 6583.8 to 16753.0
|
9652.1 MFI
Interval 5709.2 to 16035.9
|
9613.6 MFI
Interval 5558.7 to 15992.8
|
9574.4 MFI
Interval 5548.9 to 15992.8
|
9677.5 MFI
Interval 5735.5 to 16035.9
|
9798 MFI
Interval 6045.0 to 16144.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-N at Month 4-Total
|
10361.8 MFI
Interval 6110.5 to 15266.8
|
9486 MFI
Interval 6122.4 to 14005.1
|
10086.5 MFI
Interval 6078.1 to 15237.9
|
10455.5 MFI
Interval 6122.4 to 15026.1
|
9645.5 MFI
Interval 6122.4 to 14005.1
|
10725.5 MFI
Interval 7237.2 to 17708.5
|
10408.6 MFI
Interval 6251.1 to 16007.9
|
10458.6 MFI
Interval 6351.4 to 15892.9
|
9838 MFI
Interval 6078.1 to 15237.9
|
10148.5 MFI
Interval 6257.5 to 15266.8
|
10458.6 MFI
Interval 6251.1 to 16007.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-Y at Month 0-Total
|
10434.5 MFI
Interval 6422.4 to 15676.5
|
12464.8 MFI
Interval 6964.0 to 21070.2
|
13250.5 MFI
Interval 9134.8 to 22000.0
|
13181 MFI
Interval 6074.3 to 22000.0
|
13155.8 MFI
Interval 7391.9 to 21785.3
|
11441.5 MFI
Interval 6040.8 to 19863.4
|
12464.8 MFI
Interval 6699.1 to 19873.2
|
10571.5 MFI
Interval 3394.6 to 17391.2
|
11550.1 MFI
Interval 6209.4 to 17355.2
|
11759.5 MFI
Interval 6604.9 to 19733.8
|
11550.1 MFI
Interval 5329.9 to 18223.3
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-Y at Month 2-Total
|
9540.6 MFI
Interval 7691.7 to 12558.4
|
9870.5 MFI
Interval 6493.5 to 16509.5
|
8755.8 MFI
Interval 7061.2 to 16964.2
|
9129.8 MFI
Interval 5404.0 to 14616.2
|
9817.5 MFI
Interval 6491.8 to 16085.0
|
8861.8 MFI
Interval 5176.6 to 14424.0
|
8364.2 MFI
Interval 4660.8 to 13029.8
|
9246 MFI
Interval 5611.0 to 14104.8
|
9662.2 MFI
Interval 5779.2 to 13466.2
|
9195.8 MFI
Interval 5418.9 to 14914.5
|
8986 MFI
Interval 4097.8 to 12570.7
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-Y at Month 4-Total
|
9386.8 MFI
Interval 7725.8 to 13002.2
|
12195 MFI
Interval 6172.5 to 17234.1
|
12681.8 MFI
Interval 7818.5 to 14691.6
|
9651.5 MFI
Interval 6075.0 to 16727.0
|
10725.5 MFI
Interval 6172.5 to 17234.1
|
8857.8 MFI
Interval 5071.8 to 13845.6
|
9061.5 MFI
Interval 3213.4 to 12950.6
|
7908 MFI
Interval 5275.7 to 12630.5
|
12775.5 MFI
Interval 7253.1 to 15017.1
|
10489 MFI
Interval 5023.8 to 14830.8
|
8486.1 MFI
Interval 5120.7 to 13096.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total
|
15344 MFI
Interval 8541.5 to 22000.0
|
15952.5 MFI
Interval 8730.8 to 22000.0
|
15079 MFI
Interval 8305.9 to 22000.0
|
15229.8 MFI
Interval 8748.2 to 22000.0
|
15612.2 MFI
Interval 9132.9 to 22000.0
|
15373.5 MFI
Interval 8777.1 to 22000.0
|
14854.8 MFI
Interval 8136.1 to 22000.0
|
15364.2 MFI
Interval 8301.6 to 22000.0
|
15128.1 MFI
Interval 8269.6 to 22000.0
|
15053.5 MFI
Interval 8476.2 to 22000.0
|
15128.1 MFI
Interval 8648.3 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total
|
13900.9 MFI
Interval 8117.6 to 20949.1
|
14306 MFI
Interval 7868.5 to 20955.6
|
13531.1 MFI
Interval 7893.0 to 21146.7
|
13900.9 MFI
Interval 7869.1 to 21318.1
|
13900.9 MFI
Interval 7174.1 to 20962.2
|
13272.5 MFI
Interval 8844.9 to 19898.2
|
13385.6 MFI
Interval 7946.0 to 20937.8
|
13674.5 MFI
Interval 8254.5 to 21485.2
|
13636.8 MFI
Interval 7912.5 to 21278.0
|
13289.4 MFI
Interval 8231.2 to 18974.3
|
13599 MFI
Interval 7962.8 to 20936.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total
|
13428.8 MFI
Interval 7426.6 to 21301.6
|
13633.4 MFI
Interval 7487.9 to 21319.9
|
12463.2 MFI
Interval 7149.4 to 20989.4
|
12836.9 MFI
Interval 7083.6 to 21079.9
|
12836.9 MFI
Interval 7487.9 to 21203.3
|
13838 MFI
Interval 7546.5 to 22000.0
|
12836.9 MFI
Interval 7391.4 to 20993.3
|
13915 MFI
Interval 8153.1 to 21358.9
|
12878 MFI
Interval 7098.2 to 21338.2
|
12795.8 MFI
Interval 7302.8 to 21018.2
|
12878 MFI
Interval 7200.5 to 20934.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total
|
10845.4 MFI
Interval 3583.1 to 19334.5
|
13251.2 MFI
Interval 6947.3 to 21628.1
|
10994 MFI
Interval 4651.0 to 22000.0
|
14726.2 MFI
Interval 7111.8 to 22000.0
|
14590.5 MFI
Interval 7245.2 to 22000.0
|
14590.8 MFI
Interval 7128.4 to 21713.1
|
16454 MFI
Interval 8119.5 to 22000.0
|
12192.5 MFI
Interval 6866.1 to 19986.5
|
13531.5 MFI
Interval 7623.0 to 19807.2
|
14860.1 MFI
Interval 6737.5 to 21933.6
|
13531.5 MFI
Interval 6395.5 to 21852.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total
|
9758 MFI
Interval 5391.1 to 19430.1
|
12312 MFI
Interval 8227.7 to 20364.9
|
11412.8 MFI
Interval 7895.8 to 18992.5
|
13072.5 MFI
Interval 7929.2 to 19438.0
|
13072.5 MFI
Interval 8254.5 to 20084.5
|
14208.1 MFI
Interval 6780.3 to 21527.6
|
14306 MFI
Interval 5419.5 to 21651.0
|
11415.8 MFI
Interval 4406.6 to 17363.2
|
10813 MFI
Interval 6863.0 to 17054.0
|
16129.8 MFI
Interval 6936.6 to 22000.0
|
12770.5 MFI
Interval 6104.6 to 21566.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total
|
10934.5 MFI
Interval 6837.0 to 14251.5
|
12053.1 MFI
Interval 6855.2 to 19187.6
|
17832.9 MFI
Interval 12435.7 to 20171.8
|
12901.2 MFI
Interval 8906.9 to 19788.9
|
12901.2 MFI
Interval 6855.2 to 20640.8
|
12048.5 MFI
Interval 6837.0 to 20820.8
|
13150 MFI
Interval 5131.4 to 19789.8
|
8077.2 MFI
Interval 6668.9 to 15701.9
|
12795.8 MFI
Interval 9247.1 to 18014.5
|
13440.5 MFI
Interval 8778.4 to 20358.9
|
12795.8 MFI
Interval 8737.2 to 20902.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total
|
1217.2 MFI
Interval 36.1 to 2830.1
|
1260.8 MFI
Interval 88.8 to 2830.2
|
1197.8 MFI
Interval 50.0 to 2784.2
|
1104.8 MFI
Interval 1.0 to 2667.9
|
1088.1 MFI
Interval 1.0 to 2720.4
|
1323 MFI
Interval 375.4 to 2953.1
|
1273.5 MFI
Interval 87.5 to 2885.5
|
1356.9 MFI
Interval 245.1 to 3060.4
|
1242.5 MFI
Interval 56.4 to 2830.0
|
1319.2 MFI
Interval 240.0 to 2885.5
|
1261.2 MFI
Interval 94.0 to 2751.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total
|
1679.1 MFI
Interval 473.9 to 3929.6
|
1679.1 MFI
Interval 473.9 to 3960.1
|
1675.2 MFI
Interval 475.2 to 3784.4
|
1527.8 MFI
Interval 464.5 to 3498.5
|
1478.8 MFI
Interval 408.4 to 3505.9
|
1820 MFI
Interval 668.6 to 4187.6
|
1741.6 MFI
Interval 474.3 to 4184.8
|
1897 MFI
Interval 602.0 to 4211.8
|
1664.5 MFI
Interval 475.4 to 3834.2
|
1830.2 MFI
Interval 602.0 to 4081.8
|
1727.2 MFI
Interval 578.4 to 3784.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total
|
1363.5 MFI
Interval 621.2 to 2960.8
|
1333 MFI
Interval 685.6 to 2722.2
|
1394.2 MFI
Interval 634.1 to 2856.8
|
1363.5 MFI
Interval 654.6 to 2714.9
|
1411 MFI
Interval 743.1 to 2659.5
|
1552.5 MFI
Interval 812.4 to 2903.1
|
1545.6 MFI
Interval 654.3 to 3009.9
|
1562.5 MFI
Interval 733.6 to 3075.3
|
1335.9 MFI
Interval 621.1 to 2748.6
|
1552.5 MFI
Interval 730.8 to 2845.5
|
1335.9 MFI
Interval 642.9 to 2813.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total
|
2299.1 MFI
Interval 1198.5 to 3590.0
|
1510 MFI
Interval 158.8 to 2889.2
|
2677.2 MFI
Interval 2077.2 to 6059.5
|
1957.6 MFI
Interval 249.6 to 4215.7
|
1645.6 MFI
Interval 247.2 to 3436.8
|
1120.5 MFI
Interval 1.0 to 2830.0
|
1393.8 MFI
Interval 280.5 to 2859.8
|
127.5 MFI
Interval 1.0 to 2085.1
|
1949 MFI
Interval 304.4 to 3190.2
|
1010.2 MFI
Interval 1.0 to 2833.9
|
1741.8 MFI
Interval 43.6 to 3475.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total
|
3012.5 MFI
Interval 1207.8 to 4247.8
|
2125.8 MFI
Interval 756.5 to 3926.8
|
4362.1 MFI
Interval 2866.1 to 5211.4
|
3182.1 MFI
Interval 869.6 to 4806.2
|
2238.2 MFI
Interval 761.4 to 4315.1
|
1452.4 MFI
Interval 263.6 to 3797.0
|
1430 MFI
Interval 837.9 to 3048.8
|
762.5 MFI
Interval 1.0 to 2576.0
|
3515 MFI
Interval 1013.8 to 4724.4
|
1267.1 MFI
Interval 210.3 to 3486.1
|
1864.6 MFI
Interval 15.4 to 4528.7
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total
|
2059.2 MFI
Interval 1473.2 to 3659.5
|
1934.2 MFI
Interval 630.0 to 3356.1
|
3604.2 MFI
Interval 1965.5 to 4232.3
|
2059.2 MFI
Interval 621.6 to 3999.8
|
1572.5 MFI
Interval 619.4 to 3487.2
|
1301 MFI
Interval 593.9 to 3029.5
|
1171.2 MFI
Interval 621.4 to 2791.1
|
717.8 MFI
Interval 462.6 to 1925.3
|
2880.2 MFI
Interval 2152.4 to 4232.3
|
1123 MFI
Interval 583.8 to 3066.2
|
2445.6 MFI
Interval 692.4 to 3525.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total
|
22000 MFI
Interval 16980.8 to 22000.0
|
22000 MFI
Interval 17027.2 to 22000.0
|
22000 MFI
Interval 16922.8 to 22000.0
|
22000 MFI
Interval 16906.6 to 22000.0
|
22000 MFI
Interval 17092.6 to 22000.0
|
22000 MFI
Interval 18309.2 to 22000.0
|
22000 MFI
Interval 16892.4 to 22000.0
|
22000 MFI
Interval 17177.6 to 22000.0
|
22000 MFI
Interval 16620.8 to 22000.0
|
22000 MFI
Interval 18468.4 to 22000.0
|
22000 MFI
Interval 16947.5 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total
|
22000 MFI
Interval 16149.0 to 22000.0
|
22000 MFI
Interval 16274.5 to 22000.0
|
22000 MFI
Interval 15539.4 to 22000.0
|
22000 MFI
Interval 15276.0 to 22000.0
|
22000 MFI
Interval 15363.2 to 22000.0
|
22000 MFI
Interval 17560.4 to 22000.0
|
22000 MFI
Interval 15539.4 to 22000.0
|
22000 MFI
Interval 15891.9 to 22000.0
|
22000 MFI
Interval 15539.4 to 22000.0
|
22000 MFI
Interval 16459.8 to 22000.0
|
22000 MFI
Interval 16261.9 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total
|
22000 MFI
Interval 13984.4 to 22000.0
|
21328.8 MFI
Interval 14838.8 to 22000.0
|
21915.8 MFI
Interval 13366.9 to 22000.0
|
21542 MFI
Interval 13396.5 to 22000.0
|
21215.8 MFI
Interval 14371.8 to 22000.0
|
22000 MFI
Interval 13789.6 to 22000.0
|
22000 MFI
Interval 13752.4 to 22000.0
|
22000 MFI
Interval 13775.9 to 22000.0
|
21464.1 MFI
Interval 13352.1 to 22000.0
|
22000 MFI
Interval 13715.4 to 22000.0
|
21464.1 MFI
Interval 13381.7 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total
|
21827.4 MFI
Interval 11741.1 to 22000.0
|
21722.8 MFI
Interval 16631.5 to 22000.0
|
22000 MFI
Interval 16126.2 to 22000.0
|
22000 MFI
Interval 16863.9 to 22000.0
|
22000 MFI
Interval 16671.0 to 22000.0
|
22000 MFI
Interval 14793.8 to 22000.0
|
22000 MFI
Interval 19158.1 to 22000.0
|
21957 MFI
Interval 14654.5 to 22000.0
|
22000 MFI
Interval 19182.1 to 22000.0
|
21481.5 MFI
Interval 12894.1 to 22000.0
|
22000 MFI
Interval 16189.2 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total
|
21122.2 MFI
Interval 6817.9 to 22000.0
|
22000 MFI
Interval 13111.4 to 22000.0
|
22000 MFI
Interval 14191.8 to 22000.0
|
22000 MFI
Interval 16294.8 to 22000.0
|
22000 MFI
Interval 15806.2 to 22000.0
|
22000 MFI
Interval 12757.6 to 22000.0
|
22000 MFI
Interval 12896.1 to 22000.0
|
22000 MFI
Interval 9418.6 to 22000.0
|
22000 MFI
Interval 14486.9 to 22000.0
|
22000 MFI
Interval 12234.4 to 22000.0
|
22000 MFI
Interval 12669.7 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total
|
21542 MFI
Interval 9215.2 to 22000.0
|
22000 MFI
Interval 11375.4 to 22000.0
|
22000 MFI
Interval 19783.4 to 22000.0
|
22000 MFI
Interval 14339.1 to 22000.0
|
22000 MFI
Interval 12813.2 to 22000.0
|
21072.5 MFI
Interval 13772.6 to 22000.0
|
20669.2 MFI
Interval 14014.9 to 22000.0
|
19283 MFI
Interval 13732.2 to 22000.0
|
22000 MFI
Interval 14838.8 to 22000.0
|
21188.5 MFI
Interval 14041.5 to 22000.0
|
22000 MFI
Interval 14045.2 to 22000.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-N at Month 0-Total
|
4417.8 MFI
Interval 2746.1 to 6576.1
|
4383.6 MFI
Interval 2775.2 to 6561.8
|
4546.1 MFI
Interval 2765.1 to 6857.2
|
4850.5 MFI
Interval 2905.2 to 7278.0
|
4692.8 MFI
Interval 2974.2 to 7264.4
|
5022.9 MFI
Interval 3345.5 to 8375.9
|
4383.2 MFI
Interval 2761.2 to 6568.8
|
4653.8 MFI
Interval 2743.5 to 6942.6
|
4315 MFI
Interval 2738.2 to 6761.0
|
4788.8 MFI
Interval 2897.6 to 7145.5
|
4315 MFI
Interval 2776.8 to 7037.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-N at Month 2-Total
|
4034.5 MFI
Interval 1986.9 to 5865.8
|
4248.2 MFI
Interval 2262.9 to 5911.7
|
4042.5 MFI
Interval 2044.9 to 6017.1
|
4372 MFI
Interval 2817.6 to 6127.2
|
4358.2 MFI
Interval 2854.8 to 6138.5
|
4139.1 MFI
Interval 2557.3 to 6591.2
|
4112.5 MFI
Interval 2055.8 to 6024.2
|
4050.5 MFI
Interval 2009.0 to 6019.5
|
4042.5 MFI
Interval 1953.6 to 5883.4
|
4042.5 MFI
Interval 2023.3 to 6037.8
|
4042.5 MFI
Interval 2023.3 to 5823.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-N at Month 4-Total
|
5357.8 MFI
Interval 2918.0 to 7899.5
|
5541.8 MFI
Interval 3507.6 to 8396.4
|
5383.2 MFI
Interval 3186.5 to 8259.6
|
5495.5 MFI
Interval 3426.4 to 8225.7
|
5584.8 MFI
Interval 3833.5 to 8528.8
|
5370.6 MFI
Interval 3426.4 to 8367.6
|
5373 MFI
Interval 3051.5 to 8064.2
|
5055.8 MFI
Interval 2913.6 to 8272.2
|
5228.9 MFI
Interval 2941.2 to 8127.0
|
5383.4 MFI
Interval 3280.9 to 8084.4
|
5277.8 MFI
Interval 3107.8 to 8194.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-Y at Month 0-Total
|
4014.5 MFI
Interval 1340.1 to 5740.2
|
4322.4 MFI
Interval 2267.9 to 6536.6
|
3121.6 MFI
Interval 1741.8 to 4286.8
|
3371 MFI
Interval 1201.2 to 4831.2
|
3816.2 MFI
Interval 1881.8 to 5827.6
|
3808.2 MFI
Interval 2207.6 to 5560.6
|
3781.8 MFI
Interval 1995.2 to 5438.0
|
3517.2 MFI
Interval 2284.6 to 5247.6
|
4487.5 MFI
Interval 2625.0 to 5996.5
|
3514.5 MFI
Interval 1768.2 to 5308.8
|
4487.5 MFI
Interval 2497.2 to 6027.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-Y at Month 2-Total
|
3942.5 MFI
Interval 1654.8 to 6107.0
|
3638.5 MFI
Interval 1545.8 to 5786.7
|
2232.6 MFI
Interval 1599.6 to 4732.1
|
2740.8 MFI
Interval 1434.0 to 4985.0
|
3377.5 MFI
Interval 1529.0 to 5631.6
|
3904.6 MFI
Interval 1762.5 to 5503.4
|
3206.8 MFI
Interval 1463.9 to 4969.1
|
3692.8 MFI
Interval 1885.5 to 5108.5
|
3929.6 MFI
Interval 2085.7 to 5930.9
|
3819.8 MFI
Interval 1925.7 to 5725.0
|
3929.6 MFI
Interval 1840.6 to 6738.3
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-Y at Month 4-Total
|
5655.8 MFI
Interval 3042.5 to 8611.8
|
4234.1 MFI
Interval 2646.6 to 6917.3
|
3042.5 MFI
Interval 2783.0 to 5575.8
|
3923.8 MFI
Interval 2481.8 to 7135.1
|
4078 MFI
Interval 2576.5 to 7010.5
|
5343.1 MFI
Interval 2780.5 to 7547.3
|
4047 MFI
Interval 2234.0 to 8611.8
|
5655.8 MFI
Interval 4656.2 to 6671.0
|
6419.4 MFI
Interval 3050.0 to 7731.9
|
4933.5 MFI
Interval 2775.5 to 8353.4
|
5759.2 MFI
Interval 2756.6 to 7543.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-N at Month 0-Total
|
11600.8 MFI
Interval 8579.2 to 16044.8
|
11438.5 MFI
Interval 8578.4 to 16118.8
|
11798.5 MFI
Interval 8604.9 to 16323.5
|
11690 MFI
Interval 8630.5 to 15990.8
|
11552.5 MFI
Interval 8604.9 to 15991.8
|
12737 MFI
Interval 9631.6 to 16947.6
|
11934.4 MFI
Interval 8766.1 to 16323.5
|
12039.9 MFI
Interval 8746.9 to 16474.7
|
11325 MFI
Interval 8483.4 to 15863.2
|
12258.5 MFI
Interval 9282.1 to 16751.5
|
11577 MFI
Interval 8577.6 to 16306.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-N at Month 2-Total
|
14274.4 MFI
Interval 9800.2 to 17933.1
|
14453.2 MFI
Interval 10202.0 to 17954.2
|
14451 MFI
Interval 9913.2 to 18514.5
|
14451 MFI
Interval 10485.8 to 18706.0
|
14572.8 MFI
Interval 10482.1 to 18011.6
|
14715 MFI
Interval 10478.5 to 18309.5
|
14500.8 MFI
Interval 10190.8 to 18212.8
|
14500.8 MFI
Interval 10359.3 to 18272.9
|
14233.2 MFI
Interval 9725.5 to 18003.1
|
14537.2 MFI
Interval 10434.0 to 18795.6
|
14315.5 MFI
Interval 9904.7 to 17844.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-N at Month 4-Total
|
16414.2 MFI
Interval 12580.9 to 19445.1
|
16306.5 MFI
Interval 13066.1 to 19400.0
|
16447.5 MFI
Interval 12503.2 to 19669.0
|
16602.5 MFI
Interval 13493.2 to 19859.0
|
16491.6 MFI
Interval 13475.5 to 19451.8
|
16491.6 MFI
Interval 13385.2 to 19765.3
|
16381 MFI
Interval 12521.4 to 19641.5
|
16491.6 MFI
Interval 12923.2 to 19848.9
|
16171.4 MFI
Interval 12404.4 to 19110.0
|
16547.5 MFI
Interval 13296.8 to 20137.7
|
16171.4 MFI
Interval 12436.3 to 19400.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-Y at Month 0-Total
|
13903.1 MFI
Interval 12099.9 to 16639.2
|
12877.8 MFI
Interval 9393.5 to 16104.2
|
13636.2 MFI
Interval 9850.0 to 14738.5
|
12419.9 MFI
Interval 8924.6 to 16561.6
|
12258.5 MFI
Interval 8996.0 to 16271.8
|
11313 MFI
Interval 8231.9 to 15137.6
|
10177 MFI
Interval 7687.0 to 14040.5
|
11280.8 MFI
Interval 8628.9 to 13364.6
|
13838.4 MFI
Interval 11187.8 to 16813.8
|
9958.9 MFI
Interval 7794.7 to 14416.5
|
12831.8 MFI
Interval 9190.8 to 15914.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-Y at Month 2-Total
|
15792.8 MFI
Interval 13948.6 to 20541.5
|
14215.4 MFI
Interval 9762.2 to 19158.4
|
14352.6 MFI
Interval 11602.3 to 15600.5
|
14352.6 MFI
Interval 9472.9 to 17838.1
|
14201.5 MFI
Interval 9538.2 to 18307.4
|
13960.9 MFI
Interval 9762.2 to 18030.9
|
13571.2 MFI
Interval 9980.9 to 17495.4
|
13393.8 MFI
Interval 8592.8 to 17077.0
|
15355.8 MFI
Interval 13623.7 to 19755.8
|
13876.8 MFI
Interval 9103.0 to 16381.2
|
14499.8 MFI
Interval 11288.4 to 19325.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-Y at Month 4-Total
|
16049.2 MFI
Interval 13916.5 to 20575.2
|
16792.5 MFI
Interval 11795.5 to 20184.8
|
16101.2 MFI
Interval 15348.4 to 17799.4
|
15638.1 MFI
Interval 10814.6 to 18445.9
|
16153.2 MFI
Interval 11497.0 to 19545.0
|
16189.5 MFI
Interval 12415.0 to 19226.0
|
16206 MFI
Interval 12923.2 to 18796.0
|
15900.2 MFI
Interval 12352.1 to 18463.5
|
17928.2 MFI
Interval 15974.5 to 20689.9
|
16009.5 MFI
Interval 12006.6 to 18225.5
|
16867 MFI
Interval 15559.8 to 20416.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-N at Month 0-Total
|
4186.9 MFI
Interval 2478.1 to 6786.4
|
4099.1 MFI
Interval 2372.1 to 6822.8
|
4223.5 MFI
Interval 2477.2 to 6737.6
|
4186.9 MFI
Interval 2459.5 to 6814.8
|
4116.1 MFI
Interval 2459.5 to 6946.5
|
4630 MFI
Interval 2549.4 to 7625.1
|
4232 MFI
Interval 2482.1 to 6762.0
|
4132 MFI
Interval 2480.5 to 6810.8
|
3974.1 MFI
Interval 2340.8 to 6538.6
|
4412.8 MFI
Interval 2502.5 to 6884.8
|
4099.1 MFI
Interval 2339.8 to 6666.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-N at Month 2-Total
|
4366.9 MFI
Interval 2376.6 to 7504.3
|
4089.5 MFI
Interval 2295.0 to 7386.2
|
4240 MFI
Interval 2375.2 to 7488.8
|
4196.2 MFI
Interval 2393.0 to 7230.9
|
4069.5 MFI
Interval 2286.0 to 7110.5
|
4187.5 MFI
Interval 2291.9 to 7386.2
|
4389.8 MFI
Interval 2388.2 to 7524.1
|
4231.5 MFI
Interval 2290.5 to 7281.8
|
4187.5 MFI
Interval 2295.0 to 7054.2
|
4086.2 MFI
Interval 2279.8 to 7551.0
|
4086.2 MFI
Interval 2282.9 to 7054.2
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
n=388 Participants
3: Clinical spectrums
|
Group 8
n=388 Participants
Clinical spectrums , age 55+
|
Group 9
n=388 Participants
HIV
|
Group 10
n=388 Participants
Hypertension
|
Group 11
n=388 Participants
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA
|
2 Participants
|
14 Participants
|
3 Participants
|
24 Participants
|
29 Participants
|
28 Participants
|
10 Participants
|
5 Participants
|
3 Participants
|
16 Participants
|
8 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 0-Peru
|
153 Participants
|
114 Participants
|
159 Participants
|
152 Participants
|
113 Participants
|
101 Participants
|
151 Participants
|
141 Participants
|
144 Participants
|
139 Participants
|
136 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 0-Total
|
292 Participants
|
211 Participants
|
294 Participants
|
233 Participants
|
178 Participants
|
157 Participants
|
277 Participants
|
266 Participants
|
271 Participants
|
242 Participants
|
244 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 0-USA
|
139 Participants
|
97 Participants
|
135 Participants
|
81 Participants
|
65 Participants
|
56 Participants
|
126 Participants
|
125 Participants
|
127 Participants
|
103 Participants
|
108 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 2-Peru
|
18 Participants
|
14 Participants
|
19 Participants
|
17 Participants
|
13 Participants
|
12 Participants
|
19 Participants
|
15 Participants
|
17 Participants
|
16 Participants
|
17 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 2-Total
|
56 Participants
|
44 Participants
|
56 Participants
|
38 Participants
|
29 Participants
|
28 Participants
|
52 Participants
|
51 Participants
|
54 Participants
|
43 Participants
|
49 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 2-USA
|
38 Participants
|
30 Participants
|
37 Participants
|
21 Participants
|
16 Participants
|
16 Participants
|
33 Participants
|
36 Participants
|
37 Participants
|
27 Participants
|
32 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 0-Peru
|
6 Participants
|
45 Participants
|
0 Participants
|
7 Participants
|
46 Participants
|
58 Participants
|
8 Participants
|
18 Participants
|
15 Participants
|
20 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 0-Total
|
15 Participants
|
96 Participants
|
13 Participants
|
74 Participants
|
129 Participants
|
150 Participants
|
30 Participants
|
41 Participants
|
36 Participants
|
65 Participants
|
63 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 0-USA
|
9 Participants
|
51 Participants
|
13 Participants
|
67 Participants
|
83 Participants
|
92 Participants
|
22 Participants
|
23 Participants
|
21 Participants
|
45 Participants
|
40 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 2-Peru
|
1 Participants
|
5 Participants
|
0 Participants
|
2 Participants
|
6 Participants
|
7 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 2-Total
|
4 Participants
|
16 Participants
|
4 Participants
|
22 Participants
|
31 Participants
|
32 Participants
|
8 Participants
|
9 Participants
|
6 Participants
|
17 Participants
|
11 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 2-USA
|
3 Participants
|
11 Participants
|
4 Participants
|
20 Participants
|
25 Participants
|
25 Participants
|
8 Participants
|
5 Participants
|
4 Participants
|
14 Participants
|
9 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru
|
159 Participants
|
117 Participants
|
165 Participants
|
157 Participants
|
116 Participants
|
107 Participants
|
157 Participants
|
147 Participants
|
150 Participants
|
145 Participants
|
142 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total
|
314 Participants
|
226 Participants
|
317 Participants
|
249 Participants
|
190 Participants
|
171 Participants
|
296 Participants
|
291 Participants
|
293 Participants
|
263 Participants
|
263 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA
|
155 Participants
|
109 Participants
|
152 Participants
|
92 Participants
|
74 Participants
|
64 Participants
|
139 Participants
|
144 Participants
|
143 Participants
|
118 Participants
|
121 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru
|
26 Participants
|
21 Participants
|
29 Participants
|
27 Participants
|
20 Participants
|
20 Participants
|
29 Participants
|
25 Participants
|
27 Participants
|
25 Participants
|
26 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total
|
83 Participants
|
66 Participants
|
83 Participants
|
58 Participants
|
46 Participants
|
49 Participants
|
79 Participants
|
80 Participants
|
82 Participants
|
66 Participants
|
76 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA
|
57 Participants
|
45 Participants
|
54 Participants
|
31 Participants
|
26 Participants
|
29 Participants
|
50 Participants
|
55 Participants
|
55 Participants
|
41 Participants
|
50 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru
|
6 Participants
|
48 Participants
|
0 Participants
|
8 Participants
|
49 Participants
|
58 Participants
|
8 Participants
|
18 Participants
|
15 Participants
|
20 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total
|
19 Participants
|
107 Participants
|
16 Participants
|
84 Participants
|
143 Participants
|
162 Participants
|
37 Participants
|
42 Participants
|
40 Participants
|
70 Participants
|
70 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA
|
13 Participants
|
59 Participants
|
16 Participants
|
76 Participants
|
94 Participants
|
104 Participants
|
29 Participants
|
24 Participants
|
25 Participants
|
50 Participants
|
47 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru
|
3 Participants
|
8 Participants
|
0 Participants
|
2 Participants
|
9 Participants
|
9 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
4 Participants
|
3 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total
|
6 Participants
|
23 Participants
|
6 Participants
|
31 Participants
|
43 Participants
|
40 Participants
|
10 Participants
|
9 Participants
|
7 Participants
|
23 Participants
|
13 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA
|
3 Participants
|
15 Participants
|
6 Participants
|
29 Participants
|
34 Participants
|
31 Participants
|
10 Participants
|
5 Participants
|
5 Participants
|
19 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru
|
161 Participants
|
120 Participants
|
167 Participants
|
159 Participants
|
119 Participants
|
108 Participants
|
159 Participants
|
149 Participants
|
152 Participants
|
146 Participants
|
144 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total
|
312 Participants
|
226 Participants
|
317 Participants
|
250 Participants
|
192 Participants
|
172 Participants
|
296 Participants
|
289 Participants
|
291 Participants
|
263 Participants
|
263 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA
|
151 Participants
|
106 Participants
|
150 Participants
|
91 Participants
|
73 Participants
|
64 Participants
|
137 Participants
|
140 Participants
|
139 Participants
|
117 Participants
|
119 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru
|
23 Participants
|
19 Participants
|
25 Participants
|
23 Participants
|
18 Participants
|
16 Participants
|
25 Participants
|
21 Participants
|
23 Participants
|
21 Participants
|
22 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total
|
75 Participants
|
58 Participants
|
74 Participants
|
49 Participants
|
39 Participants
|
42 Participants
|
71 Participants
|
71 Participants
|
73 Participants
|
58 Participants
|
67 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA
|
52 Participants
|
39 Participants
|
49 Participants
|
26 Participants
|
21 Participants
|
26 Participants
|
46 Participants
|
50 Participants
|
50 Participants
|
37 Participants
|
45 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru
|
6 Participants
|
47 Participants
|
0 Participants
|
8 Participants
|
48 Participants
|
59 Participants
|
8 Participants
|
18 Participants
|
15 Participants
|
21 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total
|
19 Participants
|
105 Participants
|
14 Participants
|
81 Participants
|
139 Participants
|
159 Participants
|
35 Participants
|
42 Participants
|
40 Participants
|
68 Participants
|
68 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA
|
13 Participants
|
58 Participants
|
14 Participants
|
73 Participants
|
91 Participants
|
100 Participants
|
27 Participants
|
24 Participants
|
25 Participants
|
47 Participants
|
45 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru
|
2 Participants
|
6 Participants
|
0 Participants
|
2 Participants
|
7 Participants
|
9 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
4 Participants
|
3 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total
|
5 Participants
|
22 Participants
|
6 Participants
|
31 Participants
|
41 Participants
|
38 Participants
|
9 Participants
|
9 Participants
|
7 Participants
|
22 Participants
|
13 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA
|
3 Participants
|
16 Participants
|
6 Participants
|
29 Participants
|
34 Participants
|
29 Participants
|
9 Participants
|
5 Participants
|
5 Participants
|
18 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru
|
156 Participants
|
117 Participants
|
161 Participants
|
154 Participants
|
116 Participants
|
105 Participants
|
153 Participants
|
144 Participants
|
146 Participants
|
142 Participants
|
139 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total
|
297 Participants
|
215 Participants
|
297 Participants
|
237 Participants
|
182 Participants
|
164 Participants
|
279 Participants
|
272 Participants
|
275 Participants
|
248 Participants
|
249 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA
|
141 Participants
|
98 Participants
|
136 Participants
|
83 Participants
|
66 Participants
|
59 Participants
|
126 Participants
|
128 Participants
|
129 Participants
|
106 Participants
|
110 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru
|
24 Participants
|
19 Participants
|
25 Participants
|
23 Participants
|
18 Participants
|
18 Participants
|
25 Participants
|
21 Participants
|
23 Participants
|
22 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total
|
73 Participants
|
56 Participants
|
73 Participants
|
50 Participants
|
40 Participants
|
41 Participants
|
66 Participants
|
67 Participants
|
71 Participants
|
57 Participants
|
66 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA
|
49 Participants
|
37 Participants
|
48 Participants
|
27 Participants
|
22 Participants
|
23 Participants
|
41 Participants
|
46 Participants
|
48 Participants
|
35 Participants
|
43 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru
|
5 Participants
|
44 Participants
|
0 Participants
|
7 Participants
|
45 Participants
|
56 Participants
|
8 Participants
|
17 Participants
|
15 Participants
|
19 Participants
|
22 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total
|
13 Participants
|
95 Participants
|
13 Participants
|
73 Participants
|
128 Participants
|
146 Participants
|
31 Participants
|
38 Participants
|
35 Participants
|
62 Participants
|
61 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA
|
8 Participants
|
51 Participants
|
13 Participants
|
66 Participants
|
83 Participants
|
90 Participants
|
23 Participants
|
21 Participants
|
20 Participants
|
43 Participants
|
39 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru
|
1 Participants
|
6 Participants
|
0 Participants
|
2 Participants
|
7 Participants
|
7 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 0-Peru
|
160 Participants
|
119 Participants
|
165 Participants
|
157 Participants
|
118 Participants
|
107 Participants
|
157 Participants
|
147 Participants
|
150 Participants
|
144 Participants
|
143 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 0-Total
|
312 Participants
|
225 Participants
|
316 Participants
|
248 Participants
|
191 Participants
|
172 Participants
|
295 Participants
|
288 Participants
|
290 Participants
|
262 Participants
|
263 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 0-USA
|
152 Participants
|
106 Participants
|
151 Participants
|
91 Participants
|
73 Participants
|
65 Participants
|
138 Participants
|
141 Participants
|
140 Participants
|
118 Participants
|
120 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 2-Peru
|
24 Participants
|
20 Participants
|
26 Participants
|
24 Participants
|
19 Participants
|
18 Participants
|
26 Participants
|
22 Participants
|
24 Participants
|
23 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 2-Total
|
78 Participants
|
61 Participants
|
77 Participants
|
51 Participants
|
41 Participants
|
46 Participants
|
74 Participants
|
74 Participants
|
76 Participants
|
62 Participants
|
70 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 2-USA
|
54 Participants
|
41 Participants
|
51 Participants
|
27 Participants
|
22 Participants
|
28 Participants
|
48 Participants
|
52 Participants
|
52 Participants
|
39 Participants
|
47 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 0-Peru
|
5 Participants
|
46 Participants
|
0 Participants
|
8 Participants
|
47 Participants
|
58 Participants
|
8 Participants
|
18 Participants
|
15 Participants
|
21 Participants
|
22 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 0-Total
|
18 Participants
|
105 Participants
|
14 Participants
|
82 Participants
|
139 Participants
|
158 Participants
|
35 Participants
|
42 Participants
|
40 Participants
|
68 Participants
|
67 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 0-USA
|
13 Participants
|
59 Participants
|
14 Participants
|
74 Participants
|
92 Participants
|
100 Participants
|
27 Participants
|
24 Participants
|
25 Participants
|
47 Participants
|
45 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 2-Peru
|
2 Participants
|
6 Participants
|
0 Participants
|
2 Participants
|
7 Participants
|
8 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 2-Total
|
5 Participants
|
22 Participants
|
6 Participants
|
32 Participants
|
42 Participants
|
37 Participants
|
9 Participants
|
9 Participants
|
7 Participants
|
21 Participants
|
13 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 2-USA
|
3 Participants
|
16 Participants
|
6 Participants
|
30 Participants
|
35 Participants
|
29 Participants
|
9 Participants
|
5 Participants
|
5 Participants
|
18 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 0-Peru
|
148 Participants
|
109 Participants
|
154 Participants
|
147 Participants
|
108 Participants
|
98 Participants
|
146 Participants
|
137 Participants
|
139 Participants
|
135 Participants
|
131 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 0-Total
|
279 Participants
|
199 Participants
|
283 Participants
|
226 Participants
|
170 Participants
|
150 Participants
|
266 Participants
|
255 Participants
|
258 Participants
|
232 Participants
|
231 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 0-USA
|
131 Participants
|
90 Participants
|
129 Participants
|
79 Participants
|
62 Participants
|
52 Participants
|
120 Participants
|
118 Participants
|
119 Participants
|
97 Participants
|
100 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 2-Peru
|
14 Participants
|
11 Participants
|
14 Participants
|
12 Participants
|
10 Participants
|
9 Participants
|
14 Participants
|
12 Participants
|
12 Participants
|
11 Participants
|
12 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 2-Total
|
43 Participants
|
33 Participants
|
42 Participants
|
28 Participants
|
23 Participants
|
20 Participants
|
39 Participants
|
39 Participants
|
40 Participants
|
32 Participants
|
35 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 2-USA
|
29 Participants
|
22 Participants
|
28 Participants
|
16 Participants
|
13 Participants
|
11 Participants
|
25 Participants
|
27 Participants
|
28 Participants
|
21 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 0-Peru
|
6 Participants
|
45 Participants
|
0 Participants
|
7 Participants
|
46 Participants
|
56 Participants
|
8 Participants
|
17 Participants
|
15 Participants
|
19 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 0-Total
|
16 Participants
|
96 Participants
|
12 Participants
|
69 Participants
|
125 Participants
|
145 Participants
|
29 Participants
|
40 Participants
|
37 Participants
|
63 Participants
|
64 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 0-USA
|
10 Participants
|
51 Participants
|
12 Participants
|
62 Participants
|
79 Participants
|
89 Participants
|
21 Participants
|
23 Participants
|
22 Participants
|
44 Participants
|
41 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 2-Peru
|
0 Participants
|
3 Participants
|
0 Participants
|
2 Participants
|
4 Participants
|
5 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 2-Total
|
2 Participants
|
12 Participants
|
3 Participants
|
17 Participants
|
22 Participants
|
25 Participants
|
6 Participants
|
6 Participants
|
5 Participants
|
13 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 2-USA
|
2 Participants
|
9 Participants
|
3 Participants
|
15 Participants
|
18 Participants
|
20 Participants
|
6 Participants
|
4 Participants
|
3 Participants
|
10 Participants
|
8 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru
|
160 Participants
|
120 Participants
|
166 Participants
|
158 Participants
|
119 Participants
|
109 Participants
|
158 Participants
|
149 Participants
|
151 Participants
|
147 Participants
|
143 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total
|
316 Participants
|
231 Participants
|
319 Participants
|
251 Participants
|
194 Participants
|
176 Participants
|
301 Participants
|
293 Participants
|
295 Participants
|
267 Participants
|
267 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA
|
156 Participants
|
111 Participants
|
153 Participants
|
93 Participants
|
75 Participants
|
67 Participants
|
143 Participants
|
144 Participants
|
144 Participants
|
120 Participants
|
124 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru
|
20 Participants
|
16 Participants
|
22 Participants
|
20 Participants
|
15 Participants
|
14 Participants
|
22 Participants
|
18 Participants
|
20 Participants
|
19 Participants
|
19 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total
|
72 Participants
|
57 Participants
|
71 Participants
|
46 Participants
|
37 Participants
|
41 Participants
|
68 Participants
|
67 Participants
|
70 Participants
|
55 Participants
|
65 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA
|
52 Participants
|
41 Participants
|
49 Participants
|
26 Participants
|
22 Participants
|
27 Participants
|
46 Participants
|
49 Participants
|
50 Participants
|
36 Participants
|
46 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru
|
6 Participants
|
46 Participants
|
0 Participants
|
8 Participants
|
47 Participants
|
57 Participants
|
8 Participants
|
17 Participants
|
15 Participants
|
19 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total
|
19 Participants
|
104 Participants
|
16 Participants
|
84 Participants
|
141 Participants
|
159 Participants
|
34 Participants
|
42 Participants
|
40 Participants
|
68 Participants
|
68 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA
|
13 Participants
|
58 Participants
|
16 Participants
|
76 Participants
|
94 Participants
|
102 Participants
|
26 Participants
|
25 Participants
|
25 Participants
|
49 Participants
|
45 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru
|
2 Participants
|
6 Participants
|
0 Participants
|
2 Participants
|
7 Participants
|
8 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total
|
4 Participants
|
19 Participants
|
5 Participants
|
30 Participants
|
39 Participants
|
35 Participants
|
8 Participants
|
9 Participants
|
6 Participants
|
21 Participants
|
11 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA
|
2 Participants
|
13 Participants
|
5 Participants
|
28 Participants
|
32 Participants
|
27 Participants
|
8 Participants
|
5 Participants
|
4 Participants
|
18 Participants
|
8 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru
|
152 Participants
|
114 Participants
|
158 Participants
|
151 Participants
|
113 Participants
|
103 Participants
|
151 Participants
|
142 Participants
|
143 Participants
|
139 Participants
|
135 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total
|
287 Participants
|
207 Participants
|
290 Participants
|
232 Participants
|
177 Participants
|
158 Participants
|
274 Participants
|
265 Participants
|
265 Participants
|
240 Participants
|
237 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA
|
135 Participants
|
93 Participants
|
132 Participants
|
81 Participants
|
64 Participants
|
55 Participants
|
123 Participants
|
123 Participants
|
122 Participants
|
101 Participants
|
102 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru
|
18 Participants
|
14 Participants
|
18 Participants
|
16 Participants
|
13 Participants
|
13 Participants
|
18 Participants
|
16 Participants
|
16 Participants
|
15 Participants
|
16 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total
|
54 Participants
|
41 Participants
|
54 Participants
|
37 Participants
|
29 Participants
|
29 Participants
|
49 Participants
|
50 Participants
|
52 Participants
|
42 Participants
|
47 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA
|
36 Participants
|
27 Participants
|
36 Participants
|
21 Participants
|
16 Participants
|
16 Participants
|
31 Participants
|
34 Participants
|
36 Participants
|
27 Participants
|
31 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru
|
6 Participants
|
44 Participants
|
0 Participants
|
7 Participants
|
45 Participants
|
55 Participants
|
7 Participants
|
16 Participants
|
15 Participants
|
19 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total
|
16 Participants
|
96 Participants
|
13 Participants
|
71 Participants
|
126 Participants
|
145 Participants
|
29 Participants
|
38 Participants
|
38 Participants
|
63 Participants
|
66 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA
|
10 Participants
|
52 Participants
|
13 Participants
|
64 Participants
|
81 Participants
|
90 Participants
|
22 Participants
|
22 Participants
|
23 Participants
|
44 Participants
|
43 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru
|
0 Participants
|
4 Participants
|
0 Participants
|
2 Participants
|
5 Participants
|
5 Participants
|
0 Participants
|
2 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total
|
3 Participants
|
16 Participants
|
3 Participants
|
20 Participants
|
28 Participants
|
28 Participants
|
8 Participants
|
7 Participants
|
5 Participants
|
15 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA
|
3 Participants
|
12 Participants
|
3 Participants
|
18 Participants
|
23 Participants
|
23 Participants
|
8 Participants
|
5 Participants
|
3 Participants
|
12 Participants
|
8 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total
|
3 Participants
|
20 Participants
|
3 Participants
|
26 Participants
|
36 Participants
|
35 Participants
|
10 Participants
|
9 Participants
|
5 Participants
|
19 Participants
|
10 Participants
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
n=388 Participants
3: Clinical spectrums
|
Group 8
n=388 Participants
Clinical spectrums , age 55+
|
Group 9
n=388 Participants
HIV
|
Group 10
n=388 Participants
Hypertension
|
Group 11
n=388 Participants
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 0-Total
|
6714.8 MFI
Interval 3175.5 to 12619.5
|
6505.5 MFI
Interval 2988.5 to 11434.0
|
6657.1 MFI
Interval 3173.7 to 12470.5
|
6717.8 MFI
Interval 3218.6 to 12565.2
|
6796.4 MFI
Interval 3091.3 to 11935.9
|
6335.5 MFI
Interval 2958.2 to 12565.2
|
6576.2 MFI
Interval 3091.3 to 12270.0
|
5847.5 MFI
Interval 2812.1 to 11832.5
|
6703 MFI
Interval 3085.7 to 12651.0
|
6254.2 MFI
Interval 3177.9 to 11998.9
|
6703 MFI
Interval 2948.6 to 12812.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 2-Total
|
3302.6 MFI
Interval 1426.4 to 4901.2
|
3307 MFI
Interval 1213.5 to 4617.2
|
3146.2 MFI
Interval 1213.5 to 4824.0
|
3002.2 MFI
Interval 595.0 to 4824.0
|
3240 MFI
Interval 620.9 to 4776.5
|
2815.5 MFI
Interval 1070.4 to 4376.5
|
3146.2 MFI
Interval 1373.0 to 4673.1
|
3002.2 MFI
Interval 726.6 to 4776.5
|
3193.1 MFI
Interval 1311.0 to 4901.2
|
2880 MFI
Interval 1040.9 to 4776.5
|
3074.2 MFI
Interval 1246.0 to 4800.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 0-Total
|
5043.9 MFI
Interval 1256.1 to 6848.0
|
6335.1 MFI
Interval 3284.1 to 13264.6
|
3630 MFI
Interval 320.5 to 7354.2
|
5487.2 MFI
Interval 2629.2 to 11416.2
|
6175.8 MFI
Interval 3056.6 to 12609.4
|
6524.4 MFI
Interval 3232.5 to 11935.9
|
5381.5 MFI
Interval 2736.1 to 12524.9
|
9506.1 MFI
Interval 5069.1 to 16105.3
|
5317.5 MFI
Interval 3193.5 to 8108.1
|
6800 MFI
Interval 2082.1 to 12771.0
|
5585.5 MFI
Interval 3350.2 to 9871.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 2-Total
|
983.1 MFI
Interval 1.0 to 2103.1
|
2880 MFI
Interval 1377.8 to 5805.1
|
3467.5 MFI
Interval 1951.0 to 3837.9
|
3467.5 MFI
Interval 1718.5 to 4519.4
|
3079.8 MFI
Interval 1447.8 to 4617.2
|
3467.5 MFI
Interval 1343.5 to 6583.5
|
3472.5 MFI
Interval 429.8 to 5169.8
|
3838.8 MFI
Interval 3079.8 to 4617.2
|
3273.6 MFI
Interval 1220.7 to 3636.6
|
3562 MFI
Interval 1447.8 to 4617.2
|
3327.5 MFI
Interval 1628.5 to 3954.7
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-N at Month 0-Total
|
250.5 MFI
Interval 39.1 to 489.1
|
252.1 MFI
Interval 44.6 to 473.3
|
251.5 MFI
Interval 36.0 to 510.5
|
246.4 MFI
Interval 35.2 to 473.1
|
251.2 MFI
Interval 43.2 to 453.0
|
252.9 MFI
Interval 60.1 to 440.6
|
252.1 MFI
Interval 40.0 to 482.2
|
224.2 MFI
Interval 34.6 to 460.2
|
225 MFI
Interval 31.5 to 471.2
|
241.4 MFI
Interval 60.1 to 459.6
|
233.8 MFI
Interval 37.0 to 471.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-N at Month 2-Total
|
1 MFI
Interval 1.0 to 24.1
|
1 MFI
Interval 1.0 to 19.8
|
1 MFI
Interval 1.0 to 19.8
|
1 MFI
Interval 1.0 to 6.0
|
1 MFI
Interval 1.0 to 11.4
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 19.0
|
1 MFI
Interval 1.0 to 26.3
|
1 MFI
Interval 1.0 to 18.2
|
1 MFI
Interval 1.0 to 26.3
|
1 MFI
Interval 1.0 to 1.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-Y at Month 0-Total
|
116.5 MFI
Interval 1.0 to 501.5
|
200.2 MFI
Interval 4.8 to 521.3
|
160.9 MFI
Interval 35.9 to 306.8
|
220.6 MFI
Interval 45.9 to 536.4
|
221 MFI
Interval 19.2 to 548.0
|
220.6 MFI
Interval 4.6 to 576.2
|
192.1 MFI
Interval 24.3 to 724.8
|
333 MFI
Interval 70.5 to 637.6
|
345.2 MFI
Interval 109.5 to 633.5
|
202.4 MFI
Interval 1.0 to 599.9
|
293 MFI
Interval 33.6 to 574.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-Y at Month 2-Total
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 15.1
|
1 MFI
Interval 1.0 to 33.0
|
1 MFI
Interval 1.0 to 60.5
|
1 MFI
Interval 1.0 to 51.5
|
1 MFI
Interval 1.0 to 160.5
|
1 MFI
Interval 1.0 to 19.8
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 31.1
|
1 MFI
Interval 1.0 to 16.8
|
10.4 MFI
Interval 1.0 to 358.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-N at Month 0-Total
|
13.8 MFI
Interval 1.0 to 100.4
|
17.2 MFI
Interval 1.0 to 80.3
|
12.1 MFI
Interval 1.0 to 100.4
|
2.5 MFI
Interval 1.0 to 75.9
|
4.2 MFI
Interval 1.0 to 72.2
|
23.4 MFI
Interval 1.0 to 108.6
|
13.8 MFI
Interval 1.0 to 99.6
|
13.8 MFI
Interval 1.0 to 102.1
|
9.9 MFI
Interval 1.0 to 96.2
|
21.2 MFI
Interval 1.0 to 102.1
|
12.1 MFI
Interval 1.0 to 104.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-N at Month 2-Total
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-Y at Month 0-Total
|
1 MFI
Interval 1.0 to 59.0
|
1 MFI
Interval 1.0 to 116.8
|
1 MFI
Interval 1.0 to 59.0
|
24 MFI
Interval 1.0 to 150.2
|
18.1 MFI
Interval 1.0 to 133.3
|
1 MFI
Interval 1.0 to 73.2
|
1 MFI
Interval 1.0 to 101.1
|
1 MFI
Interval 1.0 to 70.3
|
26 MFI
Interval 1.0 to 113.4
|
1 MFI
Interval 1.0 to 67.9
|
5.2 MFI
Interval 1.0 to 77.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-Y at Month 2-Total
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1042.5
|
1 MFI
Interval 1.0 to 33.5
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 31.2
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
15.2 MFI
Interval 1.0 to 148.9
|
1 MFI
Interval 1.0 to 209.5
|
1 MFI
Interval 1.0 to 35.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total
|
389.4 MFI
Interval 132.7 to 1182.0
|
396.8 MFI
Interval 145.5 to 973.8
|
370.1 MFI
Interval 129.1 to 1109.1
|
341.9 MFI
Interval 114.4 to 947.2
|
359 MFI
Interval 141.6 to 939.8
|
419.2 MFI
Interval 157.8 to 1087.6
|
369 MFI
Interval 141.8 to 1088.2
|
369 MFI
Interval 127.8 to 1028.8
|
376.9 MFI
Interval 126.9 to 1125.8
|
395.8 MFI
Interval 148.2 to 1206.4
|
377.5 MFI
Interval 137.5 to 1121.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total
|
167.4 MFI
Interval 1.0 to 826.1
|
186.8 MFI
Interval 1.0 to 584.0
|
156.2 MFI
Interval 1.0 to 652.8
|
115.2 MFI
Interval 1.0 to 479.8
|
161.5 MFI
Interval 1.0 to 532.5
|
192.5 MFI
Interval 1.0 to 793.2
|
164.5 MFI
Interval 1.0 to 835.1
|
186.8 MFI
Interval 1.0 to 848.9
|
160.9 MFI
Interval 1.0 to 673.4
|
161.5 MFI
Interval 1.0 to 694.1
|
158.2 MFI
Interval 1.0 to 714.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total
|
312 MFI
Interval 125.5 to 707.8
|
349.4 MFI
Interval 102.9 to 1831.8
|
514.2 MFI
Interval 147.2 to 1809.0
|
450.2 MFI
Interval 177.5 to 2485.8
|
432.2 MFI
Interval 121.8 to 1854.6
|
337.4 MFI
Interval 89.4 to 1169.6
|
478.1 MFI
Interval 44.3 to 1963.3
|
490.9 MFI
Interval 167.3 to 1806.4
|
371.2 MFI
Interval 204.8 to 1259.9
|
354.2 MFI
Interval 92.0 to 982.8
|
354.4 MFI
Interval 125.2 to 1194.7
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total
|
1 MFI
Interval 1.0 to 541.8
|
112.2 MFI
Interval 1.0 to 1257.8
|
1346.5 MFI
Interval 326.8 to 1859.5
|
371 MFI
Interval 60.6 to 1827.6
|
164.5 MFI
Interval 1.0 to 1255.8
|
150 MFI
Interval 1.0 to 819.2
|
150 MFI
Interval 1.0 to 502.8
|
63 MFI
Interval 1.0 to 150.0
|
651.2 MFI
Interval 140.6 to 1392.9
|
170.2 MFI
Interval 35.8 to 1532.2
|
293.4 MFI
Interval 121.7 to 1214.7
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total
|
1 MFI
Interval 1.0 to 53.9
|
1 MFI
Interval 1.0 to 54.2
|
1 MFI
Interval 1.0 to 51.7
|
1 MFI
Interval 1.0 to 42.1
|
1 MFI
Interval 1.0 to 41.5
|
1 MFI
Interval 1.0 to 64.6
|
1 MFI
Interval 1.0 to 52.1
|
1 MFI
Interval 1.0 to 54.2
|
1 MFI
Interval 1.0 to 50.4
|
1 MFI
Interval 1.0 to 58.5
|
1 MFI
Interval 1.0 to 52.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total
|
1 MFI
Interval 1.0 to 15.8
|
1 MFI
Interval 1.0 to 44.5
|
4.5 MFI
Interval 1.0 to 75.5
|
7.1 MFI
Interval 1.0 to 76.8
|
1 MFI
Interval 1.0 to 58.4
|
1 MFI
Interval 1.0 to 35.5
|
1 MFI
Interval 1.0 to 51.4
|
1 MFI
Interval 1.0 to 11.5
|
14 MFI
Interval 1.0 to 57.0
|
1 MFI
Interval 1.0 to 22.8
|
1 MFI
Interval 1.0 to 51.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 360.4
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 76.1
|
1 MFI
Interval 1.0 to 14.8
|
1 MFI
Interval 1.0 to 193.7
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total
|
519.8 MFI
Interval 124.5 to 1842.5
|
480.6 MFI
Interval 131.5 to 1640.4
|
476 MFI
Interval 124.5 to 1752.2
|
410.8 MFI
Interval 93.9 to 1394.8
|
419.5 MFI
Interval 118.5 to 1479.0
|
475.8 MFI
Interval 164.2 to 1686.9
|
492.1 MFI
Interval 128.3 to 1757.1
|
480.6 MFI
Interval 131.9 to 1715.2
|
448.5 MFI
Interval 113.2 to 1882.8
|
500.8 MFI
Interval 133.6 to 1791.0
|
464.2 MFI
Interval 117.6 to 1772.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total
|
12.2 MFI
Interval 1.0 to 573.8
|
11.2 MFI
Interval 1.0 to 571.9
|
2.9 MFI
Interval 1.0 to 521.9
|
1 MFI
Interval 1.0 to 352.9
|
5.6 MFI
Interval 1.0 to 498.4
|
22.2 MFI
Interval 1.0 to 575.6
|
10.2 MFI
Interval 1.0 to 570.0
|
10.2 MFI
Interval 1.0 to 577.5
|
1 MFI
Interval 1.0 to 559.6
|
11.2 MFI
Interval 1.0 to 564.8
|
1 MFI
Interval 1.0 to 570.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total
|
397.8 MFI
Interval 105.0 to 1386.8
|
523.2 MFI
Interval 94.3 to 2453.6
|
967 MFI
Interval 105.0 to 2514.5
|
825.8 MFI
Interval 272.2 to 4158.5
|
610.2 MFI
Interval 127.4 to 3077.8
|
519.8 MFI
Interval 93.0 to 1923.5
|
513.8 MFI
Interval 12.1 to 2798.4
|
629.5 MFI
Interval 65.6 to 3871.4
|
861.8 MFI
Interval 224.0 to 1671.5
|
476 MFI
Interval 98.2 to 1650.5
|
618.8 MFI
Interval 131.0 to 1779.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total
|
1 MFI
Interval 1.0 to 172.9
|
2.9 MFI
Interval 1.0 to 329.2
|
1326.5 MFI
Interval 245.5 to 2615.1
|
233.1 MFI
Interval 1.0 to 2884.8
|
8.5 MFI
Interval 1.0 to 805.8
|
1 MFI
Interval 1.0 to 457.8
|
1 MFI
Interval 1.0 to 377.2
|
1 MFI
Interval 1.0 to 222.5
|
222.5 MFI
Interval 103.0 to 706.6
|
1 MFI
Interval 1.0 to 683.3
|
222.5 MFI
Interval 1.0 to 434.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-N at Month 0-Total
|
207 MFI
Interval 59.1 to 384.9
|
207.4 MFI
Interval 59.9 to 395.2
|
203.8 MFI
Interval 46.2 to 380.5
|
203.8 MFI
Interval 48.5 to 380.2
|
208.1 MFI
Interval 59.4 to 380.1
|
207.1 MFI
Interval 78.1 to 378.1
|
204 MFI
Interval 45.0 to 372.1
|
191.6 MFI
Interval 43.4 to 361.4
|
193 MFI
Interval 39.9 to 374.4
|
205.1 MFI
Interval 71.8 to 370.6
|
183.9 MFI
Interval 40.4 to 387.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-N at Month 2-Total
|
1 MFI
Interval 1.0 to 84.1
|
1 MFI
Interval 1.0 to 55.8
|
1 MFI
Interval 1.0 to 81.2
|
1 MFI
Interval 1.0 to 68.8
|
1 MFI
Interval 1.0 to 16.6
|
1 MFI
Interval 1.0 to 1.6
|
1 MFI
Interval 1.0 to 62.2
|
1 MFI
Interval 1.0 to 75.0
|
1 MFI
Interval 1.0 to 71.9
|
1 MFI
Interval 1.0 to 75.0
|
1 MFI
Interval 1.0 to 17.3
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-Y at Month 0-Total
|
123.5 MFI
Interval 1.0 to 196.5
|
175.8 MFI
Interval 18.7 to 356.3
|
150.5 MFI
Interval 29.5 to 312.8
|
179.2 MFI
Interval 31.6 to 385.1
|
177.5 MFI
Interval 29.6 to 385.8
|
174 MFI
Interval 13.2 to 411.1
|
167.2 MFI
Interval 10.0 to 566.9
|
246.8 MFI
Interval 1.0 to 569.0
|
213.4 MFI
Interval 81.4 to 517.4
|
157.9 MFI
Interval 1.0 to 445.2
|
212.2 MFI
Interval 65.3 to 367.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-Y at Month 2-Total
|
1 MFI
Interval 1.0 to 204.2
|
1 MFI
Interval 1.0 to 107.9
|
1 MFI
Interval 1.0 to 130.6
|
1 MFI
Interval 1.0 to 129.8
|
1 MFI
Interval 1.0 to 123.0
|
1 MFI
Interval 1.0 to 233.0
|
1 MFI
Interval 1.0 to 352.0
|
1 MFI
Interval 1.0 to 123.0
|
1 MFI
Interval 1.0 to 529.1
|
1 MFI
Interval 1.0 to 123.0
|
62 MFI
Interval 1.0 to 737.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-N at Month 0-Total
|
219.8 MFI
Interval 21.8 to 447.5
|
224.5 MFI
Interval 28.8 to 453.0
|
218.2 MFI
Interval 17.8 to 448.2
|
200.8 MFI
Interval 19.6 to 436.2
|
219.5 MFI
Interval 20.7 to 447.1
|
208.9 MFI
Interval 17.6 to 441.8
|
219.2 MFI
Interval 17.5 to 444.8
|
214.8 MFI
Interval 12.8 to 433.0
|
201.1 MFI
Interval 11.8 to 433.0
|
202.6 MFI
Interval 23.6 to 433.0
|
195.2 MFI
Interval 11.6 to 433.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-N at Month 2-Total
|
1 MFI
Interval 1.0 to 62.0
|
1 MFI
Interval 1.0 to 57.2
|
1 MFI
Interval 1.0 to 57.2
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 6.1
|
1 MFI
Interval 1.0 to 8.0
|
1 MFI
Interval 1.0 to 30.1
|
1 MFI
Interval 1.0 to 51.2
|
1 MFI
Interval 1.0 to 48.2
|
1 MFI
Interval 1.0 to 51.2
|
1 MFI
Interval 1.0 to 8.7
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-Y at Month 0-Total
|
131.5 MFI
Interval 1.0 to 245.5
|
193.2 MFI
Interval 1.0 to 401.2
|
131.5 MFI
Interval 1.0 to 381.2
|
258.2 MFI
Interval 1.0 to 498.1
|
202.6 MFI
Interval 1.0 to 427.6
|
217.2 MFI
Interval 8.7 to 446.4
|
170 MFI
Interval 1.0 to 514.2
|
245.5 MFI
Interval 23.2 to 495.4
|
284.5 MFI
Interval 32.3 to 548.6
|
246 MFI
Interval 1.0 to 512.8
|
296.2 MFI
Interval 20.4 to 534.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-Y at Month 2-Total
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 8.0
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 131.6
|
1 MFI
Interval 1.0 to 110.8
|
1 MFI
Interval 1.0 to 110.8
|
1 MFI
Interval 1.0 to 110.8
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 28.4
|
1 MFI
Interval 1.0 to 11.2
|
1 MFI
Interval 1.0 to 189.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-N at Month 0-Total
|
154.1 MFI
Interval 1.2 to 358.6
|
152.2 MFI
Interval 1.2 to 339.2
|
151.5 MFI
Interval 1.0 to 361.1
|
150.6 MFI
Interval 1.0 to 350.1
|
158.8 MFI
Interval 3.0 to 337.5
|
158.8 MFI
Interval 1.0 to 310.2
|
146.5 MFI
Interval 1.0 to 339.2
|
142.8 MFI
Interval 1.0 to 339.2
|
138.2 MFI
Interval 1.0 to 323.6
|
156 MFI
Interval 1.1 to 337.5
|
145.2 MFI
Interval 1.0 to 323.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-N at Month 2-Total
|
1 MFI
Interval 1.0 to 21.4
|
1 MFI
Interval 1.0 to 28.8
|
1 MFI
Interval 1.0 to 16.8
|
1 MFI
Interval 1.0 to 16.8
|
1 MFI
Interval 1.0 to 22.8
|
1 MFI
Interval 1.0 to 1.0
|
1 MFI
Interval 1.0 to 7.2
|
1 MFI
Interval 1.0 to 17.9
|
1 MFI
Interval 1.0 to 17.3
|
1 MFI
Interval 1.0 to 13.4
|
1 MFI
Interval 1.0 to 1.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-Y at Month 0-Total
|
41.4 MFI
Interval 1.0 to 237.8
|
123 MFI
Interval 1.0 to 390.2
|
73.8 MFI
Interval 1.0 to 233.0
|
136.6 MFI
Interval 6.1 to 359.4
|
127 MFI
Interval 1.0 to 380.8
|
130 MFI
Interval 1.0 to 425.6
|
138.2 MFI
Interval 1.0 to 476.8
|
159.8 MFI
Interval 74.0 to 450.5
|
218.2 MFI
Interval 22.8 to 520.8
|
121.5 MFI
Interval 1.0 to 405.8
|
158.4 MFI
Interval 1.0 to 464.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-Y at Month 2-Total
|
1 MFI
Interval 1.0 to 125.2
|
1 MFI
Interval 1.0 to 1.0
|
10 MFI
Interval 1.0 to 122.8
|
1 MFI
Interval 1.0 to 33.8
|
1 MFI
Interval 1.0 to 19.0
|
1 MFI
Interval 1.0 to 121.0
|
1 MFI
Interval 1.0 to 388.0
|
1 MFI
Interval 1.0 to 48.5
|
5.5 MFI
Interval 1.0 to 258.3
|
1 MFI
Interval 1.0 to 48.5
|
29.5 MFI
Interval 1.0 to 417.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 0-Total
|
1930 MFI
Interval 666.7 to 4088.1
|
1917.8 MFI
Interval 610.6 to 3822.1
|
1917.8 MFI
Interval 666.7 to 4009.2
|
1963.8 MFI
Interval 803.5 to 4047.9
|
2080 MFI
Interval 803.0 to 4008.5
|
1815.5 MFI
Interval 595.1 to 3818.5
|
1888.6 MFI
Interval 654.5 to 3853.4
|
1757.4 MFI
Interval 544.4 to 3732.0
|
1866.4 MFI
Interval 550.7 to 3981.6
|
1859.2 MFI
Interval 679.1 to 3786.4
|
1848.5 MFI
Interval 534.1 to 4034.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 2-Total
|
295.6 MFI
Interval 1.0 to 1049.1
|
228.5 MFI
Interval 1.0 to 1017.8
|
277.8 MFI
Interval 1.0 to 1037.8
|
133.2 MFI
Interval 1.0 to 1037.8
|
171.2 MFI
Interval 1.0 to 1027.8
|
35.2 MFI
Interval 1.0 to 720.2
|
205.8 MFI
Interval 1.0 to 996.0
|
205.8 MFI
Interval 1.0 to 946.2
|
211.2 MFI
Interval 1.0 to 1022.8
|
133.2 MFI
Interval 1.0 to 946.2
|
130.5 MFI
Interval 1.0 to 913.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 0-Total
|
846 MFI
Interval 111.2 to 1581.2
|
1623.5 MFI
Interval 587.8 to 3900.8
|
846 MFI
Interval 185.2 to 1512.8
|
1392.2 MFI
Interval 259.9 to 3686.8
|
1563.8 MFI
Interval 468.1 to 3827.6
|
1936.8 MFI
Interval 619.1 to 3975.9
|
1617 MFI
Interval 398.4 to 4047.9
|
2579.5 MFI
Interval 1091.0 to 4715.5
|
1696.2 MFI
Interval 926.6 to 3524.1
|
1738.5 MFI
Interval 356.0 to 4191.0
|
1982.8 MFI
Interval 925.1 to 3346.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 2-Total
|
43.9 MFI
Interval 1.0 to 482.1
|
346.5 MFI
Interval 1.0 to 1136.4
|
205.8 MFI
Interval 5.1 to 557.2
|
346.5 MFI
Interval 1.0 to 857.4
|
277.8 MFI
Interval 1.0 to 985.2
|
514.2 MFI
Interval 33.5 to 1537.8
|
419.8 MFI
Interval 1.0 to 2137.2
|
985.2 MFI
Interval 194.0 to 1362.2
|
576.1 MFI
Interval 154.6 to 1051.4
|
427.8 MFI
Interval 21.5 to 1362.2
|
898.1 MFI
Interval 421.6 to 1208.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total
|
7626.2 MFI
Interval 3266.3 to 14672.5
|
7312.8 MFI
Interval 3108.5 to 14197.5
|
7626.2 MFI
Interval 3330.2 to 14595.2
|
7569.5 MFI
Interval 3347.0 to 14658.2
|
7366.4 MFI
Interval 3346.1 to 14458.9
|
7442 MFI
Interval 3104.1 to 14613.2
|
7378.5 MFI
Interval 3137.7 to 14801.3
|
7378.5 MFI
Interval 3035.7 to 14164.5
|
7790.1 MFI
Interval 3101.9 to 14631.2
|
7442 MFI
Interval 3315.1 to 14132.0
|
7941.5 MFI
Interval 3072.0 to 14668.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total
|
1840 MFI
Interval 474.7 to 4095.7
|
1827 MFI
Interval 521.0 to 4059.2
|
1827 MFI
Interval 415.8 to 4059.2
|
1404.5 MFI
Interval 274.8 to 3572.8
|
1506 MFI
Interval 273.8 to 3828.8
|
1482.5 MFI
Interval 327.9 to 4294.0
|
1827 MFI
Interval 463.9 to 4212.8
|
1506 MFI
Interval 287.6 to 4049.4
|
2007.9 MFI
Interval 403.6 to 4208.9
|
1404.5 MFI
Interval 287.6 to 3397.5
|
1840 MFI
Interval 379.4 to 4330.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total
|
5257.5 MFI
Interval 519.5 to 9089.2
|
7812.2 MFI
Interval 3193.9 to 14319.1
|
3931.8 MFI
Interval 376.5 to 9487.2
|
7043.4 MFI
Interval 2226.6 to 13076.2
|
7683 MFI
Interval 3027.1 to 14193.2
|
7369.9 MFI
Interval 3238.2 to 13901.4
|
7799 MFI
Interval 3179.4 to 11897.2
|
8540.8 MFI
Interval 4301.8 to 18738.2
|
4657.2 MFI
Interval 3342.2 to 10291.0
|
7179.2 MFI
Interval 1347.8 to 14683.0
|
5919 MFI
Interval 3413.9 to 11878.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total
|
778.1 MFI
Interval 1.0 to 1594.1
|
1404.5 MFI
Interval 280.8 to 3625.0
|
1047.2 MFI
Interval 408.9 to 2175.9
|
2177 MFI
Interval 1060.2 to 4345.5
|
1787.8 MFI
Interval 726.5 to 3893.8
|
1827 MFI
Interval 485.5 to 3598.2
|
924.5 MFI
Interval 1.0 to 3572.8
|
2177 MFI
Interval 1385.5 to 3132.5
|
1184.4 MFI
Interval 331.9 to 1486.1
|
2183 MFI
Interval 1321.5 to 4205.0
|
1358.1 MFI
Interval 593.5 to 2177.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total
|
1770.9 MFI
Interval 548.4 to 4375.2
|
1617.5 MFI
Interval 524.4 to 4186.6
|
1739.8 MFI
Interval 553.6 to 4362.8
|
1781 MFI
Interval 701.0 to 4524.8
|
1670.5 MFI
Interval 709.2 to 4355.0
|
1617.5 MFI
Interval 534.6 to 4380.4
|
1670.5 MFI
Interval 544.4 to 4286.1
|
1542.6 MFI
Interval 513.1 to 4212.4
|
1703.5 MFI
Interval 519.9 to 4369.1
|
1590.4 MFI
Interval 538.3 to 4327.4
|
1660.2 MFI
Interval 501.5 to 4376.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total
|
441.5 MFI
Interval 5.5 to 1058.4
|
441.2 MFI
Interval 1.0 to 1002.0
|
422 MFI
Interval 1.0 to 1081.2
|
441.2 MFI
Interval 1.0 to 1217.2
|
441.2 MFI
Interval 1.0 to 1066.0
|
241.2 MFI
Interval 1.0 to 1032.9
|
340.5 MFI
Interval 1.0 to 1043.9
|
303 MFI
Interval 1.0 to 1066.0
|
382.5 MFI
Interval 1.0 to 1083.1
|
303 MFI
Interval 1.0 to 1066.0
|
321.8 MFI
Interval 1.0 to 1079.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total
|
923 MFI
Interval 20.5 to 1634.5
|
1957.2 MFI
Interval 579.0 to 4535.8
|
650.2 MFI
Interval 114.5 to 2615.0
|
1366.1 MFI
Interval 166.3 to 3626.4
|
1634.5 MFI
Interval 410.4 to 4225.4
|
1801.8 MFI
Interval 513.1 to 4168.9
|
1184 MFI
Interval 286.9 to 4187.2
|
2906.5 MFI
Interval 1431.9 to 5722.5
|
1478.5 MFI
Interval 706.6 to 2867.2
|
1917.8 MFI
Interval 180.0 to 4153.8
|
1610.8 MFI
Interval 730.2 to 2924.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total
|
75 MFI
Interval 1.0 to 2548.4
|
267.2 MFI
Interval 1.0 to 1624.6
|
143.2 MFI
Interval 102.6 to 765.6
|
246.5 MFI
Interval 48.9 to 942.5
|
267.2 MFI
Interval 1.0 to 1037.0
|
595 MFI
Interval 108.5 to 1088.8
|
610.2 MFI
Interval 1.0 to 2049.8
|
771.8 MFI
Interval 595.0 to 1002.0
|
405.8 MFI
Interval 81.6 to 807.1
|
595 MFI
Interval 7.0 to 1002.0
|
666.2 MFI
Interval 173.4 to 1015.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 0-Total
|
1957.5 MFI
Interval 629.2 to 4714.1
|
1828.2 MFI
Interval 513.6 to 4705.1
|
1870.2 MFI
Interval 620.9 to 4651.9
|
1960.5 MFI
Interval 784.8 to 4710.5
|
1954.5 MFI
Interval 759.1 to 4726.4
|
1859.2 MFI
Interval 582.8 to 4329.2
|
1859.2 MFI
Interval 592.7 to 4706.1
|
1737.2 MFI
Interval 511.5 to 4163.8
|
1859.2 MFI
Interval 544.4 to 4694.1
|
1788 MFI
Interval 613.9 to 4329.2
|
1833.5 MFI
Interval 467.0 to 4715.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 2-Total
|
657.5 MFI
Interval 52.4 to 1488.5
|
662 MFI
Interval 68.2 to 1331.2
|
616 MFI
Interval 28.8 to 1479.5
|
414.2 MFI
Interval 41.8 to 1535.5
|
489.8 MFI
Interval 48.9 to 1525.5
|
235.8 MFI
Interval 1.0 to 1174.1
|
489.8 MFI
Interval 28.4 to 1322.2
|
352.5 MFI
Interval 27.8 to 1264.5
|
552.9 MFI
Interval 38.5 to 1368.3
|
352.5 MFI
Interval 27.8 to 1322.2
|
442.6 MFI
Interval 28.2 to 1288.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 0-Total
|
769.8 MFI
Interval 43.0 to 1224.2
|
1804 MFI
Interval 620.0 to 3977.2
|
764 MFI
Interval 100.8 to 2152.5
|
1163.9 MFI
Interval 249.6 to 3520.0
|
1649.9 MFI
Interval 283.6 to 3782.9
|
1754.2 MFI
Interval 456.4 to 4710.2
|
1365.8 MFI
Interval 231.0 to 3437.1
|
2437.8 MFI
Interval 1085.1 to 5691.8
|
1446 MFI
Interval 621.9 to 3643.2
|
1960.5 MFI
Interval 209.2 to 4737.8
|
1797.5 MFI
Interval 741.1 to 3816.3
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 2-Total
|
164.5 MFI
Interval 1.0 to 425.1
|
274.2 MFI
Interval 8.5 to 1540.2
|
227.2 MFI
Interval 183.0 to 862.5
|
781.2 MFI
Interval 94.8 to 1157.5
|
616 MFI
Interval 28.8 to 1196.2
|
957 MFI
Interval 93.2 to 1835.2
|
1034.2 MFI
Interval 68.2 to 2020.2
|
1200.5 MFI
Interval 616.0 to 1658.2
|
681.2 MFI
Interval 170.7 to 1287.1
|
690.5 MFI
Interval 78.0 to 1547.0
|
1117.5 MFI
Interval 243.1 to 1544.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total
|
8735.5 MFI
Interval 3844.9 to 19163.8
|
8549.5 MFI
Interval 3712.5 to 18041.2
|
8681.9 MFI
Interval 3850.4 to 19160.0
|
8765.8 MFI
Interval 4036.2 to 19141.5
|
8713.8 MFI
Interval 4025.8 to 18259.8
|
8805.4 MFI
Interval 3857.8 to 18034.1
|
8650 MFI
Interval 3810.0 to 18958.5
|
7990.9 MFI
Interval 3471.6 to 17828.5
|
9101.8 MFI
Interval 3862.4 to 19167.5
|
8273.5 MFI
Interval 3881.8 to 17676.2
|
9262.8 MFI
Interval 3662.2 to 20130.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total
|
4900 MFI
Interval 1970.3 to 10938.6
|
5013.2 MFI
Interval 2166.2 to 10498.8
|
4119.8 MFI
Interval 1952.5 to 10498.8
|
4254.2 MFI
Interval 1952.5 to 8678.0
|
4964.2 MFI
Interval 2019.1 to 11795.6
|
3503.5 MFI
Interval 1849.2 to 10045.4
|
4368.2 MFI
Interval 2004.8 to 10045.4
|
4254.2 MFI
Interval 1918.2 to 10045.4
|
4311.2 MFI
Interval 1948.8 to 10938.6
|
4119.8 MFI
Interval 1925.6 to 10045.4
|
4187 MFI
Interval 1941.4 to 10646.7
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total
|
6368 MFI
Interval 2888.2 to 12087.5
|
8827 MFI
Interval 3931.2 to 21444.8
|
7395.6 MFI
Interval 2701.9 to 10007.4
|
6568.5 MFI
Interval 2955.0 to 18021.0
|
8258.2 MFI
Interval 3384.4 to 19087.8
|
8430.2 MFI
Interval 3821.5 to 19205.6
|
8172 MFI
Interval 3921.9 to 17855.4
|
15769.5 MFI
Interval 5942.3 to 22000.0
|
5506.5 MFI
Interval 3730.7 to 10496.1
|
8827 MFI
Interval 2814.0 to 22000.0
|
6517.8 MFI
Interval 3862.2 to 11943.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total
|
2803.2 MFI
Interval 1525.2 to 4454.8
|
3715.2 MFI
Interval 1454.1 to 8568.9
|
8445.8 MFI
Interval 5613.2 to 9084.0
|
5013.2 MFI
Interval 2391.2 to 10453.5
|
4119.8 MFI
Interval 1898.8 to 9642.2
|
5260.2 MFI
Interval 2074.0 to 10696.0
|
6527 MFI
Interval 743.8 to 10696.0
|
4964.2 MFI
Interval 3969.2 to 11944.0
|
5613.2 MFI
Interval 3304.9 to 7430.6
|
5013.2 MFI
Interval 2736.5 to 11944.0
|
6101.5 MFI
Interval 3241.4 to 8133.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total
|
4718.9 MFI
Interval 2289.4 to 8954.2
|
4662.5 MFI
Interval 2207.5 to 8345.1
|
4645 MFI
Interval 2278.4 to 8763.1
|
4753 MFI
Interval 2345.2 to 8839.8
|
4781.2 MFI
Interval 2296.4 to 8438.8
|
4504.2 MFI
Interval 2184.6 to 8824.9
|
4609 MFI
Interval 2281.1 to 8537.1
|
4350 MFI
Interval 2116.0 to 8313.2
|
4645 MFI
Interval 2203.8 to 8824.9
|
4549.4 MFI
Interval 2273.0 to 8537.1
|
4650.5 MFI
Interval 2116.0 to 8918.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total
|
2095.1 MFI
Interval 685.5 to 3415.7
|
2071.8 MFI
Interval 547.8 to 2944.8
|
2048 MFI
Interval 548.0 to 3405.5
|
1910 MFI
Interval 456.5 to 2971.2
|
2048 MFI
Interval 468.9 to 2958.0
|
1731 MFI
Interval 510.1 to 2826.8
|
2048 MFI
Interval 641.1 to 3138.1
|
1891 MFI
Interval 543.4 to 2958.0
|
1979 MFI
Interval 601.6 to 3415.7
|
1781.5 MFI
Interval 543.4 to 2958.0
|
1836.2 MFI
Interval 541.2 to 3380.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total
|
3164 MFI
Interval 1113.8 to 4364.8
|
4366.2 MFI
Interval 2277.0 to 9720.5
|
2512.2 MFI
Interval 321.8 to 5041.0
|
3896 MFI
Interval 1654.4 to 6961.9
|
4330.5 MFI
Interval 2186.0 to 8894.9
|
4522.2 MFI
Interval 2245.0 to 8542.2
|
3506 MFI
Interval 1710.4 to 10522.6
|
6569.9 MFI
Interval 3530.6 to 11213.2
|
3914.5 MFI
Interval 2287.9 to 7157.9
|
4473 MFI
Interval 1636.4 to 8731.8
|
3945 MFI
Interval 2460.2 to 6991.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total
|
719.1 MFI
Interval 1.0 to 1535.8
|
1748.2 MFI
Interval 719.1 to 4054.0
|
2177 MFI
Interval 1542.5 to 2305.0
|
2177 MFI
Interval 1329.5 to 3375.6
|
2071.8 MFI
Interval 946.0 to 3446.2
|
2211 MFI
Interval 775.5 to 4123.8
|
2385.5 MFI
Interval 202.8 to 3879.0
|
2739 MFI
Interval 2254.8 to 4154.8
|
2192.4 MFI
Interval 855.5 to 2288.8
|
2254.8 MFI
Interval 947.5 to 4154.8
|
2209.4 MFI
Interval 1238.6 to 2457.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total
|
2900.2 MFI
Interval 554.0 to 8391.0
|
2824.9 MFI
Interval 454.8 to 8155.4
|
2865.8 MFI
Interval 540.8 to 8208.0
|
3243.5 MFI
Interval 732.4 to 8411.1
|
3017.8 MFI
Interval 628.2 to 8396.5
|
2733.1 MFI
Interval 516.0 to 8411.1
|
2890 MFI
Interval 531.5 to 8396.5
|
2222.8 MFI
Interval 411.0 to 7521.5
|
2839.2 MFI
Interval 471.8 to 8266.8
|
2733.1 MFI
Interval 521.2 to 8050.3
|
2698.6 MFI
Interval 429.2 to 8393.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total
|
668.4 MFI
Interval 128.8 to 1719.1
|
650.2 MFI
Interval 119.8 to 1568.2
|
603.2 MFI
Interval 126.8 to 1599.8
|
603 MFI
Interval 119.8 to 1672.2
|
634 MFI
Interval 128.1 to 1741.6
|
581 MFI
Interval 83.8 to 1216.6
|
603.2 MFI
Interval 113.2 to 1584.0
|
521.2 MFI
Interval 36.0 to 1495.0
|
603.1 MFI
Interval 119.4 to 1576.1
|
581 MFI
Interval 113.2 to 1431.8
|
592.4 MFI
Interval 118.8 to 1498.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total
|
394.8 MFI
Interval 1.8 to 2021.8
|
2698.6 MFI
Interval 516.0 to 7375.9
|
259.8 MFI
Interval 6.0 to 4336.8
|
1502.9 MFI
Interval 100.9 to 6241.9
|
2556 MFI
Interval 263.5 to 6594.0
|
2839.1 MFI
Interval 431.4 to 7203.9
|
1047 MFI
Interval 140.9 to 4342.2
|
4505 MFI
Interval 2362.8 to 10177.8
|
2308.5 MFI
Interval 469.9 to 6322.8
|
2852.4 MFI
Interval 9.8 to 6997.0
|
2941.8 MFI
Interval 596.4 to 6333.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total
|
1 MFI
Interval 1.0 to 467.8
|
349 MFI
Interval 56.2 to 1743.8
|
59.5 MFI
Interval 1.0 to 1413.2
|
809.2 MFI
Interval 89.0 to 1527.8
|
581 MFI
Interval 59.5 to 1502.8
|
686.5 MFI
Interval 149.0 to 1811.0
|
581.8 MFI
Interval 119.8 to 1672.2
|
1672.2 MFI
Interval 903.0 to 1811.0
|
644.4 MFI
Interval 3.2 to 1765.4
|
844 MFI
Interval 199.0 to 1811.0
|
873.8 MFI
Interval 46.8 to 2033.0
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
n=388 Participants
3: Clinical spectrums
|
Group 8
n=388 Participants
Clinical spectrums , age 55+
|
Group 9
n=388 Participants
HIV
|
Group 10
n=388 Participants
Hypertension
|
Group 11
n=388 Participants
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 0-USA
|
11 Participants
|
48 Participants
|
9 Participants
|
55 Participants
|
70 Participants
|
82 Participants
|
21 Participants
|
23 Participants
|
20 Participants
|
41 Participants
|
36 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru
|
22 Participants
|
19 Participants
|
24 Participants
|
23 Participants
|
18 Participants
|
18 Participants
|
24 Participants
|
20 Participants
|
23 Participants
|
21 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 0-Peru
|
160 Participants
|
119 Participants
|
167 Participants
|
158 Participants
|
118 Participants
|
109 Participants
|
159 Participants
|
149 Participants
|
153 Participants
|
146 Participants
|
145 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 0-Total
|
310 Participants
|
224 Participants
|
316 Participants
|
248 Participants
|
190 Participants
|
174 Participants
|
295 Participants
|
286 Participants
|
292 Participants
|
260 Participants
|
266 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 0-USA
|
150 Participants
|
105 Participants
|
149 Participants
|
90 Participants
|
72 Participants
|
65 Participants
|
136 Participants
|
137 Participants
|
139 Participants
|
114 Participants
|
121 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 2-Peru
|
25 Participants
|
20 Participants
|
28 Participants
|
26 Participants
|
19 Participants
|
20 Participants
|
28 Participants
|
24 Participants
|
26 Participants
|
25 Participants
|
25 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 2-Total
|
80 Participants
|
63 Participants
|
81 Participants
|
56 Participants
|
44 Participants
|
46 Participants
|
74 Participants
|
77 Participants
|
79 Participants
|
65 Participants
|
73 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 2-USA
|
55 Participants
|
43 Participants
|
53 Participants
|
30 Participants
|
25 Participants
|
26 Participants
|
46 Participants
|
53 Participants
|
53 Participants
|
40 Participants
|
48 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 0-Peru
|
7 Participants
|
48 Participants
|
0 Participants
|
9 Participants
|
49 Participants
|
58 Participants
|
8 Participants
|
18 Participants
|
14 Participants
|
21 Participants
|
22 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 0-Total
|
19 Participants
|
105 Participants
|
13 Participants
|
81 Participants
|
139 Participants
|
155 Participants
|
34 Participants
|
43 Participants
|
37 Participants
|
69 Participants
|
63 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 0-USA
|
12 Participants
|
57 Participants
|
13 Participants
|
72 Participants
|
90 Participants
|
97 Participants
|
26 Participants
|
25 Participants
|
23 Participants
|
48 Participants
|
41 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 2-Peru
|
3 Participants
|
8 Participants
|
0 Participants
|
2 Participants
|
9 Participants
|
8 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 2-Total
|
6 Participants
|
23 Participants
|
5 Participants
|
30 Participants
|
42 Participants
|
40 Participants
|
12 Participants
|
9 Participants
|
7 Participants
|
21 Participants
|
13 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 2-USA
|
3 Participants
|
15 Participants
|
5 Participants
|
28 Participants
|
33 Participants
|
32 Participants
|
12 Participants
|
5 Participants
|
5 Participants
|
18 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 0-Peru
|
152 Participants
|
113 Participants
|
157 Participants
|
149 Participants
|
112 Participants
|
102 Participants
|
150 Participants
|
139 Participants
|
144 Participants
|
137 Participants
|
136 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 0-Total
|
267 Participants
|
191 Participants
|
274 Participants
|
220 Participants
|
168 Participants
|
146 Participants
|
255 Participants
|
242 Participants
|
250 Participants
|
222 Participants
|
226 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 0-USA
|
115 Participants
|
78 Participants
|
117 Participants
|
71 Participants
|
56 Participants
|
44 Participants
|
105 Participants
|
103 Participants
|
106 Participants
|
85 Participants
|
90 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 2-Peru
|
21 Participants
|
17 Participants
|
23 Participants
|
22 Participants
|
16 Participants
|
17 Participants
|
23 Participants
|
19 Participants
|
22 Participants
|
20 Participants
|
22 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 2-Total
|
61 Participants
|
47 Participants
|
62 Participants
|
46 Participants
|
35 Participants
|
34 Participants
|
56 Participants
|
58 Participants
|
61 Participants
|
48 Participants
|
57 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 2-USA
|
40 Participants
|
30 Participants
|
39 Participants
|
24 Participants
|
19 Participants
|
17 Participants
|
33 Participants
|
39 Participants
|
39 Participants
|
28 Participants
|
35 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 0-Peru
|
5 Participants
|
44 Participants
|
0 Participants
|
8 Participants
|
45 Participants
|
55 Participants
|
7 Participants
|
18 Participants
|
13 Participants
|
20 Participants
|
21 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 0-Total
|
16 Participants
|
92 Participants
|
9 Participants
|
63 Participants
|
115 Participants
|
137 Participants
|
28 Participants
|
41 Participants
|
33 Participants
|
61 Participants
|
57 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 2-Peru
|
2 Participants
|
6 Participants
|
0 Participants
|
1 Participants
|
7 Participants
|
6 Participants
|
0 Participants
|
4 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 2-Total
|
4 Participants
|
18 Participants
|
3 Participants
|
19 Participants
|
30 Participants
|
31 Participants
|
9 Participants
|
7 Participants
|
4 Participants
|
17 Participants
|
8 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 2-USA
|
2 Participants
|
12 Participants
|
3 Participants
|
18 Participants
|
23 Participants
|
25 Participants
|
9 Participants
|
3 Participants
|
3 Participants
|
14 Participants
|
7 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru
|
159 Participants
|
118 Participants
|
164 Participants
|
155 Participants
|
117 Participants
|
107 Participants
|
155 Participants
|
147 Participants
|
153 Participants
|
142 Participants
|
145 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total
|
301 Participants
|
215 Participants
|
305 Participants
|
238 Participants
|
181 Participants
|
165 Participants
|
285 Participants
|
282 Participants
|
285 Participants
|
249 Participants
|
258 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA
|
142 Participants
|
97 Participants
|
141 Participants
|
83 Participants
|
64 Participants
|
58 Participants
|
130 Participants
|
135 Participants
|
132 Participants
|
107 Participants
|
113 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru
|
27 Participants
|
22 Participants
|
30 Participants
|
29 Participants
|
21 Participants
|
21 Participants
|
29 Participants
|
26 Participants
|
29 Participants
|
26 Participants
|
28 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total
|
73 Participants
|
57 Participants
|
74 Participants
|
54 Participants
|
42 Participants
|
40 Participants
|
67 Participants
|
71 Participants
|
73 Participants
|
59 Participants
|
67 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA
|
46 Participants
|
35 Participants
|
44 Participants
|
25 Participants
|
21 Participants
|
19 Participants
|
38 Participants
|
45 Participants
|
44 Participants
|
33 Participants
|
39 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru
|
5 Participants
|
46 Participants
|
0 Participants
|
9 Participants
|
47 Participants
|
57 Participants
|
9 Participants
|
17 Participants
|
11 Participants
|
22 Participants
|
19 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total
|
21 Participants
|
107 Participants
|
17 Participants
|
84 Participants
|
141 Participants
|
157 Participants
|
37 Participants
|
40 Participants
|
37 Participants
|
73 Participants
|
64 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA
|
16 Participants
|
61 Participants
|
17 Participants
|
75 Participants
|
94 Participants
|
100 Participants
|
28 Participants
|
23 Participants
|
26 Participants
|
51 Participants
|
45 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru
|
3 Participants
|
8 Participants
|
0 Participants
|
1 Participants
|
9 Participants
|
9 Participants
|
1 Participants
|
4 Participants
|
1 Participants
|
4 Participants
|
2 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total
|
6 Participants
|
22 Participants
|
5 Participants
|
25 Participants
|
37 Participants
|
39 Participants
|
12 Participants
|
8 Participants
|
6 Participants
|
20 Participants
|
12 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA
|
3 Participants
|
14 Participants
|
5 Participants
|
24 Participants
|
28 Participants
|
30 Participants
|
11 Participants
|
4 Participants
|
5 Participants
|
16 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru
|
162 Participants
|
119 Participants
|
169 Participants
|
160 Participants
|
118 Participants
|
110 Participants
|
161 Participants
|
151 Participants
|
154 Participants
|
148 Participants
|
146 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total
|
314 Participants
|
226 Participants
|
319 Participants
|
251 Participants
|
191 Participants
|
176 Participants
|
299 Participants
|
290 Participants
|
294 Participants
|
264 Participants
|
268 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA
|
152 Participants
|
107 Participants
|
150 Participants
|
91 Participants
|
73 Participants
|
66 Participants
|
138 Participants
|
139 Participants
|
140 Participants
|
116 Participants
|
122 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru
|
26 Participants
|
21 Participants
|
30 Participants
|
28 Participants
|
20 Participants
|
22 Participants
|
30 Participants
|
26 Participants
|
28 Participants
|
27 Participants
|
27 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total
|
82 Participants
|
65 Participants
|
83 Participants
|
58 Participants
|
45 Participants
|
49 Participants
|
77 Participants
|
79 Participants
|
82 Participants
|
67 Participants
|
76 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA
|
56 Participants
|
44 Participants
|
53 Participants
|
30 Participants
|
25 Participants
|
27 Participants
|
47 Participants
|
53 Participants
|
54 Participants
|
40 Participants
|
49 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru
|
7 Participants
|
50 Participants
|
0 Participants
|
9 Participants
|
51 Participants
|
59 Participants
|
8 Participants
|
18 Participants
|
15 Participants
|
21 Participants
|
23 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total
|
19 Participants
|
107 Participants
|
14 Participants
|
82 Participants
|
142 Participants
|
157 Participants
|
34 Participants
|
43 Participants
|
39 Participants
|
69 Participants
|
65 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA
|
12 Participants
|
57 Participants
|
14 Participants
|
73 Participants
|
91 Participants
|
98 Participants
|
26 Participants
|
25 Participants
|
24 Participants
|
48 Participants
|
42 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru
|
4 Participants
|
9 Participants
|
0 Participants
|
2 Participants
|
10 Participants
|
8 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total
|
6 Participants
|
23 Participants
|
5 Participants
|
30 Participants
|
43 Participants
|
39 Participants
|
11 Participants
|
9 Participants
|
6 Participants
|
21 Participants
|
12 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA
|
2 Participants
|
14 Participants
|
5 Participants
|
28 Participants
|
33 Participants
|
31 Participants
|
11 Participants
|
5 Participants
|
4 Participants
|
18 Participants
|
9 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 0-Peru
|
160 Participants
|
119 Participants
|
166 Participants
|
158 Participants
|
118 Participants
|
109 Participants
|
158 Participants
|
148 Participants
|
152 Participants
|
146 Participants
|
144 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 0-Total
|
304 Participants
|
219 Participants
|
309 Participants
|
244 Participants
|
186 Participants
|
169 Participants
|
288 Participants
|
280 Participants
|
284 Participants
|
256 Participants
|
258 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 0-USA
|
144 Participants
|
100 Participants
|
143 Participants
|
86 Participants
|
68 Participants
|
60 Participants
|
130 Participants
|
132 Participants
|
132 Participants
|
110 Participants
|
114 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 2-Peru
|
25 Participants
|
20 Participants
|
27 Participants
|
25 Participants
|
19 Participants
|
20 Participants
|
27 Participants
|
23 Participants
|
25 Participants
|
24 Participants
|
25 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 2-Total
|
77 Participants
|
61 Participants
|
77 Participants
|
54 Participants
|
43 Participants
|
43 Participants
|
70 Participants
|
72 Participants
|
75 Participants
|
60 Participants
|
70 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 2-USA
|
52 Participants
|
41 Participants
|
50 Participants
|
29 Participants
|
24 Participants
|
23 Participants
|
43 Participants
|
49 Participants
|
50 Participants
|
36 Participants
|
45 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 0-Peru
|
6 Participants
|
47 Participants
|
0 Participants
|
8 Participants
|
48 Participants
|
57 Participants
|
8 Participants
|
18 Participants
|
14 Participants
|
20 Participants
|
22 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 0-Total
|
18 Participants
|
103 Participants
|
13 Participants
|
78 Participants
|
136 Participants
|
153 Participants
|
34 Participants
|
42 Participants
|
38 Participants
|
66 Participants
|
64 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 0-USA
|
12 Participants
|
56 Participants
|
13 Participants
|
70 Participants
|
88 Participants
|
96 Participants
|
26 Participants
|
24 Participants
|
24 Participants
|
46 Participants
|
42 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 2-Peru
|
2 Participants
|
7 Participants
|
0 Participants
|
2 Participants
|
8 Participants
|
7 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 2-Total
|
4 Participants
|
20 Participants
|
4 Participants
|
27 Participants
|
38 Participants
|
38 Participants
|
11 Participants
|
9 Participants
|
6 Participants
|
21 Participants
|
11 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 2-USA
|
2 Participants
|
13 Participants
|
4 Participants
|
25 Participants
|
30 Participants
|
31 Participants
|
11 Participants
|
5 Participants
|
4 Participants
|
18 Participants
|
9 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru
|
104 Participants
|
78 Participants
|
107 Participants
|
104 Participants
|
77 Participants
|
67 Participants
|
101 Participants
|
90 Participants
|
102 Participants
|
90 Participants
|
97 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total
|
163 Participants
|
114 Participants
|
165 Participants
|
140 Participants
|
105 Participants
|
85 Participants
|
151 Participants
|
135 Participants
|
156 Participants
|
124 Participants
|
140 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA
|
59 Participants
|
36 Participants
|
58 Participants
|
36 Participants
|
28 Participants
|
18 Participants
|
50 Participants
|
45 Participants
|
54 Participants
|
34 Participants
|
43 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru
|
9 Participants
|
7 Participants
|
11 Participants
|
11 Participants
|
7 Participants
|
6 Participants
|
11 Participants
|
7 Participants
|
10 Participants
|
9 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total
|
29 Participants
|
21 Participants
|
29 Participants
|
22 Participants
|
16 Participants
|
12 Participants
|
25 Participants
|
25 Participants
|
28 Participants
|
20 Participants
|
26 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA
|
20 Participants
|
14 Participants
|
18 Participants
|
11 Participants
|
9 Participants
|
6 Participants
|
14 Participants
|
18 Participants
|
18 Participants
|
11 Participants
|
16 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru
|
3 Participants
|
29 Participants
|
0 Participants
|
3 Participants
|
30 Participants
|
40 Participants
|
6 Participants
|
17 Participants
|
5 Participants
|
17 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total
|
5 Participants
|
54 Participants
|
3 Participants
|
28 Participants
|
63 Participants
|
83 Participants
|
17 Participants
|
33 Participants
|
12 Participants
|
44 Participants
|
28 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA
|
2 Participants
|
25 Participants
|
3 Participants
|
25 Participants
|
33 Participants
|
43 Participants
|
11 Participants
|
16 Participants
|
7 Participants
|
27 Participants
|
18 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru
|
2 Participants
|
4 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
5 Participants
|
0 Participants
|
4 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total
|
2 Participants
|
10 Participants
|
2 Participants
|
9 Participants
|
15 Participants
|
19 Participants
|
6 Participants
|
6 Participants
|
3 Participants
|
11 Participants
|
5 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA
|
0 Participants
|
6 Participants
|
2 Participants
|
9 Participants
|
11 Participants
|
14 Participants
|
6 Participants
|
2 Participants
|
2 Participants
|
9 Participants
|
4 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru
|
157 Participants
|
116 Participants
|
163 Participants
|
154 Participants
|
115 Participants
|
106 Participants
|
155 Participants
|
145 Participants
|
150 Participants
|
142 Participants
|
142 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total
|
297 Participants
|
214 Participants
|
303 Participants
|
239 Participants
|
182 Participants
|
165 Participants
|
282 Participants
|
272 Participants
|
280 Participants
|
247 Participants
|
254 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA
|
140 Participants
|
98 Participants
|
140 Participants
|
85 Participants
|
67 Participants
|
59 Participants
|
127 Participants
|
127 Participants
|
130 Participants
|
105 Participants
|
112 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total
|
75 Participants
|
60 Participants
|
75 Participants
|
52 Participants
|
42 Participants
|
43 Participants
|
68 Participants
|
70 Participants
|
74 Participants
|
59 Participants
|
69 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru
|
6 Participants
|
47 Participants
|
0 Participants
|
9 Participants
|
48 Participants
|
57 Participants
|
8 Participants
|
18 Participants
|
13 Participants
|
21 Participants
|
21 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA
|
8 Participants
|
40 Participants
|
9 Participants
|
43 Participants
|
55 Participants
|
61 Participants
|
10 Participants
|
18 Participants
|
20 Participants
|
33 Participants
|
29 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru
|
2 Participants
|
5 Participants
|
0 Participants
|
1 Participants
|
6 Participants
|
6 Participants
|
0 Participants
|
4 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA
|
53 Participants
|
41 Participants
|
51 Participants
|
29 Participants
|
24 Participants
|
25 Participants
|
44 Participants
|
50 Participants
|
51 Participants
|
38 Participants
|
46 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total
|
3 Participants
|
15 Participants
|
2 Participants
|
17 Participants
|
26 Participants
|
29 Participants
|
8 Participants
|
8 Participants
|
5 Participants
|
16 Participants
|
9 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA
|
1 Participants
|
10 Participants
|
2 Participants
|
16 Participants
|
20 Participants
|
23 Participants
|
8 Participants
|
4 Participants
|
4 Participants
|
13 Participants
|
8 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total
|
18 Participants
|
101 Participants
|
12 Participants
|
76 Participants
|
133 Participants
|
150 Participants
|
33 Participants
|
43 Participants
|
35 Participants
|
68 Participants
|
61 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA
|
12 Participants
|
54 Participants
|
12 Participants
|
67 Participants
|
85 Participants
|
93 Participants
|
25 Participants
|
25 Participants
|
22 Participants
|
47 Participants
|
40 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru
|
2 Participants
|
5 Participants
|
0 Participants
|
1 Participants
|
6 Participants
|
6 Participants
|
0 Participants
|
4 Participants
|
1 Participants
|
3 Participants
|
1 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total
|
4 Participants
|
19 Participants
|
4 Participants
|
27 Participants
|
37 Participants
|
36 Participants
|
11 Participants
|
9 Participants
|
5 Participants
|
20 Participants
|
10 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA
|
2 Participants
|
14 Participants
|
4 Participants
|
26 Participants
|
31 Participants
|
30 Participants
|
11 Participants
|
5 Participants
|
4 Participants
|
17 Participants
|
9 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru
|
120 Participants
|
85 Participants
|
124 Participants
|
118 Participants
|
84 Participants
|
74 Participants
|
118 Participants
|
109 Participants
|
110 Participants
|
107 Participants
|
104 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total
|
195 Participants
|
128 Participants
|
198 Participants
|
158 Participants
|
112 Participants
|
96 Participants
|
191 Participants
|
174 Participants
|
173 Participants
|
157 Participants
|
158 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA
|
75 Participants
|
43 Participants
|
74 Participants
|
40 Participants
|
28 Participants
|
22 Participants
|
73 Participants
|
65 Participants
|
63 Participants
|
50 Participants
|
54 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru
|
21 Participants
|
18 Participants
|
23 Participants
|
22 Participants
|
17 Participants
|
17 Participants
|
23 Participants
|
19 Participants
|
22 Participants
|
20 Participants
|
22 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total
|
57 Participants
|
45 Participants
|
58 Participants
|
43 Participants
|
34 Participants
|
31 Participants
|
52 Participants
|
52 Participants
|
55 Participants
|
44 Participants
|
51 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA
|
36 Participants
|
27 Participants
|
35 Participants
|
21 Participants
|
17 Participants
|
14 Participants
|
29 Participants
|
33 Participants
|
33 Participants
|
24 Participants
|
29 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru
|
4 Participants
|
39 Participants
|
0 Participants
|
6 Participants
|
40 Participants
|
50 Participants
|
6 Participants
|
15 Participants
|
14 Participants
|
17 Participants
|
20 Participants
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total
|
12 Participants
|
79 Participants
|
9 Participants
|
49 Participants
|
95 Participants
|
111 Participants
|
16 Participants
|
33 Participants
|
34 Participants
|
50 Participants
|
49 Participants
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
n=388 Participants
3: Clinical spectrums
|
Group 8
n=388 Participants
Clinical spectrums , age 55+
|
Group 9
n=388 Participants
HIV
|
Group 10
n=388 Participants
Hypertension
|
Group 11
n=388 Participants
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total
|
1485.6 MFI
Interval 625.0 to 3958.3
|
4067 MFI
Interval 1010.0 to 8654.9
|
2278.8 MFI
Interval 549.8 to 3108.0
|
2519.5 MFI
Interval 1520.6 to 5080.2
|
2807 MFI
Interval 1369.8 to 6934.5
|
3087.5 MFI
Interval 1817.5 to 6611.5
|
2816.5 MFI
Interval 2093.5 to 5510.2
|
5988.8 MFI
Interval 2231.5 to 9204.0
|
2629.8 MFI
Interval 674.5 to 4857.8
|
5119.8 MFI
Interval 2167.2 to 7942.2
|
2399.1 MFI
Interval 1180.8 to 5810.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total
|
1744.4 MFI
Interval 300.6 to 5873.2
|
1398.4 MFI
Interval 216.4 to 5873.2
|
1690.8 MFI
Interval 295.6 to 5638.1
|
2149.9 MFI
Interval 317.8 to 7224.1
|
1948.2 MFI
Interval 245.0 to 7281.8
|
1547.2 MFI
Interval 225.1 to 5986.4
|
1646.5 MFI
Interval 323.4 to 5370.8
|
1360.8 MFI
Interval 224.6 to 4783.1
|
1593.5 MFI
Interval 226.0 to 6049.8
|
1667.2 MFI
Interval 323.2 to 5936.5
|
1592 MFI
Interval 225.1 to 5443.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 0-Total
|
7557.6 MFI
Interval 2929.8 to 14389.8
|
6875.2 MFI
Interval 2794.2 to 14286.1
|
7658 MFI
Interval 3024.7 to 14622.6
|
8354.6 MFI
Interval 3296.6 to 16184.8
|
8285 MFI
Interval 3423.6 to 16183.2
|
7325.5 MFI
Interval 2802.2 to 15131.5
|
7542.5 MFI
Interval 2767.1 to 14875.8
|
6569.8 MFI
Interval 2615.1 to 13142.6
|
7557.6 MFI
Interval 2768.4 to 14875.8
|
6934.2 MFI
Interval 2802.2 to 13813.0
|
7548.5 MFI
Interval 2750.8 to 15093.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-N at Month 2-Total
|
3795.1 MFI
Interval 1839.1 to 7132.3
|
3154.8 MFI
Interval 1724.5 to 6588.0
|
3758 MFI
Interval 1724.5 to 7246.2
|
3951.5 MFI
Interval 1877.2 to 7265.5
|
3758 MFI
Interval 1882.1 to 7158.8
|
3301.5 MFI
Interval 1805.8 to 6779.5
|
3758 MFI
Interval 1645.5 to 7147.6
|
3227.5 MFI
Interval 1546.9 to 7048.4
|
3618 MFI
Interval 1685.0 to 7132.3
|
3136.2 MFI
Interval 1625.9 to 6746.5
|
3839.1 MFI
Interval 1765.1 to 7162.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 0-Total
|
2914.2 MFI
Interval 796.8 to 8142.0
|
7904.1 MFI
Interval 2678.6 to 13718.0
|
1643.2 MFI
Interval 190.2 to 4629.8
|
5132.5 MFI
Interval 1634.2 to 8695.9
|
5966 MFI
Interval 1700.5 to 11838.5
|
7152 MFI
Interval 2636.4 to 12849.1
|
5832.2 MFI
Interval 2604.6 to 8963.0
|
9327.8 MFI
Interval 5674.1 to 19226.1
|
4969 MFI
Interval 2559.5 to 8537.9
|
7639.2 MFI
Interval 1589.6 to 14543.4
|
6037.8 MFI
Interval 2787.1 to 10148.3
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
2019-nCoV S/293F-50-Y at Month 2-Total
|
1780.2 MFI
Interval 718.4 to 4146.1
|
5632.8 MFI
Interval 1242.1 to 9509.2
|
1923.2 MFI
Interval 643.4 to 3306.8
|
3154.8 MFI
Interval 1499.8 to 5749.1
|
3227.5 MFI
Interval 1472.2 to 7117.0
|
3832.2 MFI
Interval 1527.2 to 7392.8
|
2658.2 MFI
Interval 1527.2 to 7044.8
|
6300 MFI
Interval 3112.8 to 10458.8
|
2329.2 MFI
Interval 800.1 to 5488.9
|
6300 MFI
Interval 1566.5 to 9431.2
|
2749.2 MFI
Interval 1218.1 to 6122.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-N at Month 0-Total
|
524.4 MFI
Interval 301.6 to 980.0
|
521.2 MFI
Interval 291.9 to 903.4
|
533.2 MFI
Interval 317.9 to 970.4
|
546.2 MFI
Interval 334.3 to 966.9
|
556.2 MFI
Interval 331.8 to 914.2
|
487.5 MFI
Interval 325.2 to 898.0
|
517.5 MFI
Interval 304.8 to 943.1
|
506.6 MFI
Interval 291.7 to 916.1
|
513 MFI
Interval 299.2 to 933.8
|
520.5 MFI
Interval 298.0 to 925.0
|
504 MFI
Interval 317.1 to 930.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-N at Month 2-Total
|
339.6 MFI
Interval 217.4 to 715.7
|
321 MFI
Interval 202.8 to 649.5
|
341 MFI
Interval 219.0 to 708.8
|
321 MFI
Interval 205.2 to 708.8
|
321 MFI
Interval 203.5 to 784.2
|
299.2 MFI
Interval 204.8 to 494.5
|
338.2 MFI
Interval 219.1 to 670.2
|
341 MFI
Interval 214.1 to 722.6
|
339.6 MFI
Interval 211.7 to 715.7
|
313.5 MFI
Interval 207.2 to 663.2
|
329.9 MFI
Interval 210.1 to 697.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-Y at Month 0-Total
|
419.5 MFI
Interval 259.8 to 808.5
|
510.4 MFI
Interval 318.6 to 1026.1
|
320.8 MFI
Interval 222.2 to 673.8
|
466.8 MFI
Interval 241.9 to 879.0
|
487 MFI
Interval 276.5 to 979.0
|
582.4 MFI
Interval 288.4 to 1055.2
|
525.5 MFI
Interval 293.6 to 1076.1
|
725.2 MFI
Interval 345.5 to 1233.2
|
624.8 MFI
Interval 300.1 to 1056.8
|
520 MFI
Interval 300.8 to 1059.4
|
582.4 MFI
Interval 288.5 to 1040.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
229E-RBD-50-Y at Month 2-Total
|
402.4 MFI
Interval 260.5 to 561.1
|
382.8 MFI
Interval 303.9 to 807.5
|
445 MFI
Interval 209.8 to 699.8
|
445 MFI
Interval 240.2 to 713.8
|
382.2 MFI
Interval 242.0 to 691.0
|
480.5 MFI
Interval 295.8 to 938.0
|
445 MFI
Interval 195.8 to 909.8
|
480.5 MFI
Interval 295.8 to 700.0
|
394.6 MFI
Interval 283.2 to 692.4
|
459.2 MFI
Interval 295.8 to 1034.8
|
490.1 MFI
Interval 307.9 to 1342.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-N at Month 0-Total
|
463.1 MFI
Interval 229.6 to 989.9
|
429.5 MFI
Interval 218.2 to 876.0
|
469.1 MFI
Interval 239.5 to 999.6
|
467.2 MFI
Interval 249.6 to 1023.6
|
439.5 MFI
Interval 232.7 to 916.6
|
451.8 MFI
Interval 220.0 to 888.2
|
463.1 MFI
Interval 221.3 to 954.7
|
467.2 MFI
Interval 231.6 to 972.4
|
465.6 MFI
Interval 226.7 to 954.7
|
453.8 MFI
Interval 220.0 to 986.5
|
465.8 MFI
Interval 235.1 to 935.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-N at Month 2-Total
|
465.8 MFI
Interval 174.8 to 984.4
|
447 MFI
Interval 176.0 to 885.5
|
533.2 MFI
Interval 190.2 to 1058.2
|
486.5 MFI
Interval 187.5 to 1095.0
|
483 MFI
Interval 203.4 to 1133.1
|
402 MFI
Interval 166.9 to 873.8
|
483 MFI
Interval 188.9 to 915.8
|
482.8 MFI
Interval 173.5 to 1037.4
|
484.8 MFI
Interval 184.6 to 973.9
|
483 MFI
Interval 166.9 to 967.5
|
482.9 MFI
Interval 178.9 to 912.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-Y at Month 0-Total
|
603.8 MFI
Interval 286.8 to 954.5
|
588.1 MFI
Interval 246.6 to 1187.1
|
286.8 MFI
Interval 128.5 to 491.2
|
436.8 MFI
Interval 159.1 to 889.0
|
492.8 MFI
Interval 199.5 to 1059.0
|
472.5 MFI
Interval 238.1 to 1052.9
|
567.5 MFI
Interval 267.9 to 1090.8
|
465.5 MFI
Interval 230.1 to 1041.9
|
508.8 MFI
Interval 260.0 to 1061.6
|
480.1 MFI
Interval 275.0 to 959.3
|
456.9 MFI
Interval 183.8 to 1091.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-229E S1S2 ECD His-50-Y at Month 2-Total
|
822.8 MFI
Interval 573.6 to 1036.1
|
698 MFI
Interval 198.0 to 1529.5
|
303.2 MFI
Interval 137.8 to 633.1
|
482.8 MFI
Interval 227.1 to 915.8
|
603.8 MFI
Interval 176.0 to 918.5
|
670.5 MFI
Interval 282.2 to 1320.2
|
786 MFI
Interval 149.8 to 1699.8
|
614.2 MFI
Interval 293.5 to 843.5
|
608.1 MFI
Interval 253.9 to 1556.9
|
561 MFI
Interval 284.2 to 1250.2
|
791.8 MFI
Interval 289.0 to 1697.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total
|
1381 MFI
Interval 613.0 to 3349.1
|
1351.8 MFI
Interval 601.5 to 3152.2
|
1451.1 MFI
Interval 628.4 to 3349.1
|
1417.8 MFI
Interval 621.6 to 3305.0
|
1433.1 MFI
Interval 613.0 to 3206.4
|
1240 MFI
Interval 607.0 to 2576.8
|
1309.2 MFI
Interval 608.9 to 2958.9
|
1309.2 MFI
Interval 607.4 to 3080.4
|
1398.9 MFI
Interval 608.9 to 3305.0
|
1351.8 MFI
Interval 614.0 to 2959.8
|
1418.5 MFI
Interval 617.4 to 3281.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total
|
1281.4 MFI
Interval 609.1 to 3178.1
|
1266.5 MFI
Interval 528.5 to 3260.0
|
1462.2 MFI
Interval 615.8 to 3150.8
|
1582 MFI
Interval 459.5 to 3499.2
|
1582 MFI
Interval 434.1 to 4022.1
|
1296.2 MFI
Interval 561.1 to 2817.0
|
1226.5 MFI
Interval 604.0 to 2817.0
|
1296.2 MFI
Interval 561.1 to 3205.4
|
1478.1 MFI
Interval 575.1 to 3178.1
|
1462.2 MFI
Interval 602.4 to 3123.6
|
1379.2 MFI
Interval 595.7 to 3132.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total
|
1310 MFI
Interval 646.8 to 2772.2
|
1416.4 MFI
Interval 690.2 to 3500.2
|
809.2 MFI
Interval 499.0 to 1310.0
|
1310 MFI
Interval 605.2 to 3067.9
|
1350.2 MFI
Interval 626.0 to 3168.5
|
1563.2 MFI
Interval 651.9 to 3921.3
|
3089 MFI
Interval 976.8 to 5111.9
|
1754 MFI
Interval 695.6 to 4131.2
|
1348 MFI
Interval 697.5 to 2720.9
|
1440.9 MFI
Interval 621.6 to 4846.4
|
1297.5 MFI
Interval 593.8 to 3024.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total
|
1340.1 MFI
Interval 874.9 to 1979.1
|
1296.2 MFI
Interval 779.9 to 2465.0
|
847.5 MFI
Interval 551.6 to 1376.6
|
1009.5 MFI
Interval 821.5 to 2090.6
|
1266.5 MFI
Interval 798.2 to 2437.5
|
1266.5 MFI
Interval 619.0 to 3471.5
|
2905.5 MFI
Interval 615.8 to 4816.8
|
1266.5 MFI
Interval 1010.0 to 1888.2
|
811.8 MFI
Interval 653.6 to 1193.1
|
1255.2 MFI
Interval 619.0 to 3150.8
|
963.6 MFI
Interval 650.9 to 3450.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total
|
83.9 MFI
Interval 30.4 to 186.0
|
84.5 MFI
Interval 30.9 to 186.0
|
86.1 MFI
Interval 30.9 to 195.9
|
80.5 MFI
Interval 30.0 to 185.6
|
83.8 MFI
Interval 29.9 to 186.1
|
76.5 MFI
Interval 30.5 to 177.2
|
80.5 MFI
Interval 30.0 to 189.8
|
86.1 MFI
Interval 30.5 to 188.0
|
79.4 MFI
Interval 30.1 to 184.4
|
83.2 MFI
Interval 31.2 to 184.2
|
78.8 MFI
Interval 30.5 to 181.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total
|
589.8 MFI
Interval 456.8 to 1429.9
|
876.2 MFI
Interval 421.4 to 1747.1
|
1491.8 MFI
Interval 410.8 to 2433.4
|
773.5 MFI
Interval 297.5 to 1529.0
|
782.5 MFI
Interval 371.5 to 1566.2
|
1427.5 MFI
Interval 447.8 to 3236.0
|
567.8 MFI
Interval 520.0 to 2017.2
|
2332.5 MFI
Interval 876.2 to 3236.0
|
978.6 MFI
Interval 303.0 to 1598.6
|
1427.5 MFI
Interval 431.2 to 2332.5
|
1406 MFI
Interval 432.6 to 3156.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total
|
3082.4 MFI
Interval 1055.1 to 7041.6
|
2691.8 MFI
Interval 1040.0 to 6749.0
|
3168.6 MFI
Interval 1084.2 to 7416.5
|
3524.9 MFI
Interval 1171.8 to 8455.2
|
3351.5 MFI
Interval 1164.6 to 8437.3
|
3151.2 MFI
Interval 1049.8 to 8212.8
|
3168.6 MFI
Interval 1002.5 to 7701.1
|
2649.5 MFI
Interval 877.6 to 6580.1
|
3061.9 MFI
Interval 998.4 to 7450.0
|
3001 MFI
Interval 1056.0 to 7034.8
|
3151.2 MFI
Interval 1003.5 to 7433.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total
|
1470.5 MFI
Interval 708.7 to 3436.8
|
1275.8 MFI
Interval 704.8 to 2869.2
|
1574.2 MFI
Interval 704.8 to 3598.8
|
1739.8 MFI
Interval 679.0 to 3617.2
|
1724 MFI
Interval 691.9 to 3457.2
|
1177 MFI
Interval 642.5 to 3266.8
|
1341.2 MFI
Interval 663.1 to 3457.2
|
1315 MFI
Interval 615.4 to 3061.9
|
1527.5 MFI
Interval 698.3 to 3436.8
|
1275.8 MFI
Interval 615.4 to 3061.9
|
1576.5 MFI
Interval 706.1 to 3477.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total
|
1629.8 MFI
Interval 297.8 to 4646.2
|
3462.6 MFI
Interval 877.6 to 7865.3
|
739.8 MFI
Interval 64.8 to 1493.8
|
1596 MFI
Interval 524.1 to 3955.9
|
2043 MFI
Interval 739.8 to 5212.0
|
2536.5 MFI
Interval 906.7 to 6080.9
|
2051.2 MFI
Interval 920.6 to 3452.1
|
5076.8 MFI
Interval 1966.5 to 9966.8
|
2043 MFI
Interval 975.5 to 4485.8
|
2627.8 MFI
Interval 701.2 to 6589.3
|
2188.4 MFI
Interval 929.8 to 5065.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total
|
726.2 MFI
Interval 195.2 to 2527.2
|
1844 MFI
Interval 462.6 to 5081.6
|
1038.5 MFI
Interval 129.2 to 1260.8
|
1076.5 MFI
Interval 726.5 to 2339.8
|
1245.8 MFI
Interval 637.8 to 2869.2
|
1578.8 MFI
Interval 815.2 to 3598.8
|
1480.8 MFI
Interval 710.0 to 2719.8
|
2486.2 MFI
Interval 897.5 to 4301.5
|
1088.1 MFI
Interval 270.4 to 1856.5
|
2486.2 MFI
Interval 817.5 to 3868.0
|
1118 MFI
Interval 387.4 to 2372.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 0-Total
|
2394.5 MFI
Interval 651.1 to 6589.9
|
1982.5 MFI
Interval 613.6 to 6713.0
|
2510.4 MFI
Interval 747.1 to 6663.3
|
3158.4 MFI
Interval 852.5 to 8476.1
|
2897.8 MFI
Interval 863.5 to 7763.1
|
2319.2 MFI
Interval 654.0 to 7507.2
|
2408 MFI
Interval 637.4 to 6835.2
|
1943.6 MFI
Interval 521.9 to 6082.2
|
2338.9 MFI
Interval 613.3 to 6666.4
|
2299.5 MFI
Interval 686.5 to 6668.0
|
2385.5 MFI
Interval 607.8 to 6904.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-N at Month 2-Total
|
728.9 MFI
Interval 281.6 to 2464.1
|
685.8 MFI
Interval 280.2 to 1988.8
|
806.8 MFI
Interval 282.0 to 2490.0
|
1005.5 MFI
Interval 334.5 to 2631.8
|
806.8 MFI
Interval 308.2 to 2512.5
|
683.2 MFI
Interval 241.2 to 1775.4
|
806.8 MFI
Interval 255.8 to 2389.0
|
685.8 MFI
Interval 246.6 to 2256.9
|
783.6 MFI
Interval 281.6 to 2355.8
|
683.2 MFI
Interval 264.5 to 1775.4
|
799.8 MFI
Interval 280.7 to 2317.3
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 0-Total
|
1173.5 MFI
Interval 155.0 to 2577.8
|
2609.4 MFI
Interval 634.1 to 5814.9
|
398 MFI
Interval 124.0 to 1588.5
|
1189 MFI
Interval 319.9 to 3025.5
|
1594 MFI
Interval 398.0 to 4820.5
|
1974.8 MFI
Interval 592.3 to 5858.1
|
1538.5 MFI
Interval 380.4 to 4476.8
|
4003.8 MFI
Interval 1591.2 to 9347.0
|
1236.2 MFI
Interval 721.6 to 4351.2
|
1995.5 MFI
Interval 235.4 to 5414.5
|
1542.1 MFI
Interval 682.1 to 4819.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1 C His-50-Y at Month 2-Total
|
507.4 MFI
Interval 125.2 to 1239.4
|
1246.8 MFI
Interval 213.0 to 3447.4
|
233.8 MFI
Interval 150.1 to 742.0
|
639.2 MFI
Interval 227.8 to 1860.9
|
692 MFI
Interval 233.8 to 1988.8
|
1005.5 MFI
Interval 308.0 to 2569.5
|
587 MFI
Interval 332.0 to 2212.0
|
1988.8 MFI
Interval 1246.8 to 4975.8
|
381.6 MFI
Interval 187.4 to 2226.2
|
1988.8 MFI
Interval 262.8 to 2615.5
|
605.4 MFI
Interval 204.6 to 2168.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total
|
4301.8 MFI
Interval 1626.6 to 8135.1
|
4204.2 MFI
Interval 1601.6 to 7936.2
|
4301.8 MFI
Interval 1664.3 to 8056.5
|
5034.8 MFI
Interval 1863.1 to 8639.4
|
4939.6 MFI
Interval 1843.6 to 8625.1
|
4170.8 MFI
Interval 1598.2 to 7188.2
|
4166.2 MFI
Interval 1552.1 to 7669.7
|
3801.1 MFI
Interval 1380.8 to 6992.2
|
4313.2 MFI
Interval 1631.4 to 8081.0
|
3988.2 MFI
Interval 1550.5 to 7227.2
|
4304 MFI
Interval 1622.6 to 8008.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total
|
3782 MFI
Interval 1942.9 to 5202.2
|
3754.5 MFI
Interval 1739.2 to 5279.2
|
3765.8 MFI
Interval 1901.5 to 5176.5
|
3765.8 MFI
Interval 1956.8 to 5881.0
|
3751.8 MFI
Interval 1820.4 to 5848.0
|
3751.8 MFI
Interval 1352.8 to 4472.0
|
3754.5 MFI
Interval 1588.9 to 5094.6
|
3751.8 MFI
Interval 1588.9 to 4887.4
|
3782 MFI
Interval 1860.9 to 5202.2
|
3751.8 MFI
Interval 1588.9 to 5094.6
|
3882.9 MFI
Interval 1735.3 to 5135.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total
|
1898 MFI
Interval 909.8 to 3229.2
|
3958.9 MFI
Interval 1487.8 to 7725.8
|
1028.2 MFI
Interval 186.8 to 2677.8
|
2637 MFI
Interval 1038.6 to 5050.4
|
3327.8 MFI
Interval 1218.0 to 6484.2
|
3883.9 MFI
Interval 1519.8 to 8689.6
|
3819 MFI
Interval 1530.1 to 8144.5
|
6570.5 MFI
Interval 3450.2 to 12725.8
|
2637 MFI
Interval 1110.9 to 5671.4
|
4747.5 MFI
Interval 1559.6 to 9377.4
|
3316.1 MFI
Interval 1332.6 to 6684.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total
|
2216.5 MFI
Interval 439.8 to 4718.0
|
4113.8 MFI
Interval 1691.4 to 5094.6
|
3754.5 MFI
Interval 439.4 to 4698.2
|
3754.5 MFI
Interval 1231.1 to 4699.2
|
4024.8 MFI
Interval 1349.2 to 4994.5
|
3765.8 MFI
Interval 2247.2 to 6445.2
|
4663.8 MFI
Interval 2247.2 to 5881.0
|
5377.8 MFI
Interval 4072.8 to 6530.8
|
3758.8 MFI
Interval 952.9 to 5015.3
|
4072.8 MFI
Interval 2388.8 to 5377.8
|
3625 MFI
Interval 2041.4 to 5548.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total
|
5887.6 MFI
Interval 2353.9 to 11713.9
|
5561.2 MFI
Interval 2254.1 to 11675.2
|
6100.2 MFI
Interval 2466.4 to 11901.9
|
7121.5 MFI
Interval 2726.7 to 12942.1
|
6966.2 MFI
Interval 2841.6 to 13160.5
|
5866 MFI
Interval 2259.5 to 11578.8
|
5874.6 MFI
Interval 2188.8 to 11854.2
|
5140.5 MFI
Interval 1839.7 to 11182.2
|
6004.9 MFI
Interval 2171.1 to 11649.2
|
5596.8 MFI
Interval 2259.5 to 11463.5
|
6126.5 MFI
Interval 2173.5 to 11625.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total
|
3073.1 MFI
Interval 1801.4 to 6992.8
|
2872.8 MFI
Interval 1753.0 to 5526.5
|
3058.8 MFI
Interval 1753.0 to 7225.5
|
3528.5 MFI
Interval 1817.5 to 7225.5
|
3087.5 MFI
Interval 1819.5 to 6889.6
|
2834.8 MFI
Interval 1532.9 to 7080.0
|
3003.2 MFI
Interval 1637.8 to 7051.1
|
2872.8 MFI
Interval 1382.0 to 6418.9
|
3031 MFI
Interval 1732.6 to 6992.8
|
2604.8 MFI
Interval 1499.1 to 6773.0
|
3073.1 MFI
Interval 1770.1 to 7109.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total
|
2540 MFI
Interval 847.5 to 6597.5
|
5649.4 MFI
Interval 1964.1 to 11326.7
|
1798 MFI
Interval 257.0 to 3157.0
|
3157 MFI
Interval 1381.9 to 6686.5
|
4603.8 MFI
Interval 1663.5 to 9602.5
|
5388.6 MFI
Interval 2087.1 to 11423.8
|
3981.8 MFI
Interval 2100.6 to 7298.0
|
10308.2 MFI
Interval 4789.4 to 15768.0
|
4522 MFI
Interval 2228.6 to 11140.0
|
5840.5 MFI
Interval 1625.8 to 12851.0
|
4577 MFI
Interval 2032.5 to 11164.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total
|
90.8 MFI
Interval 40.2 to 172.0
|
90.8 MFI
Interval 41.0 to 194.6
|
91.4 MFI
Interval 47.1 to 187.1
|
88.4 MFI
Interval 49.1 to 190.3
|
93.2 MFI
Interval 48.2 to 221.4
|
84.2 MFI
Interval 38.2 to 164.8
|
86.8 MFI
Interval 38.8 to 186.5
|
86.8 MFI
Interval 41.8 to 167.8
|
90.8 MFI
Interval 43.4 to 187.8
|
89.9 MFI
Interval 45.5 to 183.9
|
89 MFI
Interval 38.8 to 167.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total
|
94 MFI
Interval 56.0 to 214.8
|
85.9 MFI
Interval 31.3 to 203.8
|
69.8 MFI
Interval 44.5 to 147.2
|
94.5 MFI
Interval 46.1 to 213.6
|
86 MFI
Interval 32.5 to 196.2
|
92.1 MFI
Interval 32.2 to 209.6
|
128.2 MFI
Interval 46.8 to 188.5
|
73 MFI
Interval 38.4 to 209.9
|
105 MFI
Interval 51.5 to 299.9
|
86.9 MFI
Interval 30.8 to 205.7
|
95 MFI
Interval 33.0 to 290.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total
|
65.2 MFI
Interval 54.2 to 210.6
|
80.5 MFI
Interval 52.9 to 152.1
|
33.6 MFI
Interval 9.9 to 70.2
|
91.4 MFI
Interval 37.1 to 164.8
|
80.4 MFI
Interval 38.2 to 158.4
|
93.2 MFI
Interval 51.9 to 190.3
|
98 MFI
Interval 82.0 to 167.8
|
121.2 MFI
Interval 89.0 to 195.5
|
79 MFI
Interval 49.1 to 96.2
|
88.6 MFI
Interval 36.2 to 159.5
|
94.5 MFI
Interval 57.0 to 194.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total
|
3141.6 MFI
Interval 1489.9 to 6449.9
|
2869.5 MFI
Interval 1365.4 to 6218.6
|
3285.8 MFI
Interval 1553.4 to 6457.3
|
3177.8 MFI
Interval 1476.4 to 6430.0
|
2926.1 MFI
Interval 1371.4 to 6366.1
|
2708.8 MFI
Interval 1470.5 to 5545.2
|
3002.4 MFI
Interval 1454.0 to 6082.0
|
3069.2 MFI
Interval 1471.3 to 6185.0
|
3141.6 MFI
Interval 1518.5 to 6368.2
|
3213.8 MFI
Interval 1491.8 to 6056.5
|
3270.5 MFI
Interval 1620.4 to 6307.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total
|
2630.5 MFI
Interval 1201.6 to 6157.4
|
2467 MFI
Interval 1071.2 to 6169.2
|
2895.8 MFI
Interval 1205.8 to 6153.5
|
2701 MFI
Interval 1066.5 to 6424.0
|
2625.5 MFI
Interval 870.6 to 6587.6
|
3008.5 MFI
Interval 1197.5 to 5088.8
|
2625.5 MFI
Interval 1197.5 to 5397.8
|
2701 MFI
Interval 1197.5 to 6092.6
|
2952.1 MFI
Interval 1201.6 to 6157.4
|
2895.8 MFI
Interval 1207.1 to 5601.0
|
2952.1 MFI
Interval 1206.4 to 5986.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total
|
3285.8 MFI
Interval 1675.5 to 5733.0
|
3430.2 MFI
Interval 1817.9 to 6647.2
|
2578.2 MFI
Interval 972.2 to 3085.8
|
3085.8 MFI
Interval 1603.4 to 6145.2
|
3274.5 MFI
Interval 1675.5 to 6222.8
|
3515.8 MFI
Interval 1548.5 to 6838.9
|
4889.5 MFI
Interval 2332.2 to 9436.5
|
3706.2 MFI
Interval 1825.6 to 7798.9
|
3356.8 MFI
Interval 1364.1 to 6156.6
|
3097.1 MFI
Interval 1587.2 to 7991.9
|
2747.6 MFI
Interval 1138.3 to 6393.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total
|
3165.8 MFI
Interval 2112.6 to 5410.4
|
3008.5 MFI
Interval 2083.9 to 4999.2
|
2402.5 MFI
Interval 1052.1 to 4075.6
|
2436 MFI
Interval 1403.8 to 5873.5
|
2701 MFI
Interval 1407.0 to 5308.8
|
2467 MFI
Interval 1323.0 to 6968.0
|
5715.2 MFI
Interval 2030.0 to 8553.8
|
1773.8 MFI
Interval 1486.2 to 4229.5
|
2419.2 MFI
Interval 1884.1 to 3397.9
|
2436 MFI
Interval 1123.0 to 7176.2
|
2419.2 MFI
Interval 1207.0 to 6396.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-N at Month 0-Total
|
458.5 MFI
Interval 287.0 to 820.2
|
460.9 MFI
Interval 286.6 to 817.4
|
473.5 MFI
Interval 288.4 to 832.6
|
484.1 MFI
Interval 292.9 to 848.5
|
491.5 MFI
Interval 301.6 to 833.6
|
476.8 MFI
Interval 281.5 to 805.2
|
448.8 MFI
Interval 271.0 to 832.8
|
453 MFI
Interval 271.2 to 809.0
|
449.6 MFI
Interval 273.6 to 808.1
|
481.6 MFI
Interval 299.0 to 816.7
|
453 MFI
Interval 273.6 to 797.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-N at Month 2-Total
|
403.9 MFI
Interval 236.0 to 738.8
|
403.2 MFI
Interval 210.8 to 774.5
|
403.2 MFI
Interval 236.0 to 767.5
|
409.2 MFI
Interval 239.0 to 847.0
|
442.8 MFI
Interval 239.9 to 943.2
|
358.2 MFI
Interval 173.0 to 758.1
|
376.2 MFI
Interval 202.9 to 739.1
|
393 MFI
Interval 217.1 to 758.1
|
395.2 MFI
Interval 220.3 to 753.4
|
404.5 MFI
Interval 229.8 to 777.9
|
388.4 MFI
Interval 213.9 to 726.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-Y at Month 0-Total
|
475.5 MFI
Interval 269.0 to 1433.0
|
457.8 MFI
Interval 273.6 to 856.4
|
362.5 MFI
Interval 223.2 to 833.0
|
405.2 MFI
Interval 236.2 to 767.8
|
414.8 MFI
Interval 260.8 to 832.8
|
447.2 MFI
Interval 281.1 to 877.2
|
567.8 MFI
Interval 328.9 to 826.6
|
514.2 MFI
Interval 327.2 to 1603.5
|
547.9 MFI
Interval 325.2 to 1146.7
|
387.2 MFI
Interval 243.1 to 874.1
|
520 MFI
Interval 306.2 to 1071.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
HKU1-RBD-50-Y at Month 2-Total
|
484.2 MFI
Interval 168.4 to 758.4
|
404.5 MFI
Interval 282.5 to 712.5
|
481 MFI
Interval 209.2 to 673.9
|
403.2 MFI
Interval 202.9 to 620.4
|
383.8 MFI
Interval 210.8 to 622.5
|
442.8 MFI
Interval 291.5 to 729.5
|
536.2 MFI
Interval 421.8 to 787.5
|
536.2 MFI
Interval 397.5 to 729.2
|
577.2 MFI
Interval 439.8 to 744.0
|
403.2 MFI
Interval 236.0 to 587.5
|
577.2 MFI
Interval 389.1 to 1098.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-N at Month 0-Total
|
1211.6 MFI
Interval 675.3 to 2475.4
|
1191.2 MFI
Interval 651.0 to 2317.8
|
1224.5 MFI
Interval 699.7 to 2506.1
|
1211.6 MFI
Interval 703.9 to 2231.5
|
1213.1 MFI
Interval 689.3 to 2508.4
|
1191.2 MFI
Interval 681.2 to 2022.5
|
1192.4 MFI
Interval 640.8 to 2311.5
|
1197.6 MFI
Interval 663.4 to 2556.6
|
1235 MFI
Interval 723.1 to 2493.1
|
1217 MFI
Interval 657.5 to 2302.5
|
1241 MFI
Interval 747.5 to 2322.1
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-N at Month 2-Total
|
1096.9 MFI
Interval 607.0 to 2441.9
|
1048.8 MFI
Interval 604.0 to 2371.0
|
1186.8 MFI
Interval 637.8 to 2654.5
|
1269.5 MFI
Interval 676.0 to 2654.5
|
1289.2 MFI
Interval 663.4 to 3099.6
|
1128.2 MFI
Interval 526.5 to 2825.1
|
1185.8 MFI
Interval 632.1 to 2679.5
|
1225.2 MFI
Interval 643.0 to 2825.1
|
1206 MFI
Interval 669.1 to 2441.9
|
1186.8 MFI
Interval 594.0 to 2310.1
|
1186.2 MFI
Interval 679.2 to 2243.3
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-Y at Month 0-Total
|
1619 MFI
Interval 967.8 to 3627.0
|
1351.5 MFI
Interval 784.4 to 2656.1
|
1170.5 MFI
Interval 584.2 to 2664.0
|
1288.5 MFI
Interval 628.6 to 3303.4
|
1241 MFI
Interval 699.5 to 2510.8
|
1282.5 MFI
Interval 712.1 to 2879.1
|
1708.2 MFI
Interval 1000.1 to 4031.9
|
1582.5 MFI
Interval 752.9 to 2322.1
|
917.5 MFI
Interval 589.2 to 2738.8
|
1258 MFI
Interval 745.6 to 3099.6
|
1075.1 MFI
Interval 596.2 to 3270.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
NL63-RBD-50-Y at Month 2-Total
|
1627.4 MFI
Interval 1262.0 to 3635.0
|
1467.5 MFI
Interval 737.9 to 3210.5
|
1126.5 MFI
Interval 726.9 to 2826.1
|
942.5 MFI
Interval 594.0 to 2578.9
|
1067.2 MFI
Interval 626.5 to 1800.0
|
1186.8 MFI
Interval 712.2 to 2371.0
|
1566.2 MFI
Interval 1033.8 to 2249.2
|
1048.8 MFI
Interval 626.5 to 1454.8
|
867.2 MFI
Interval 547.8 to 4077.3
|
1185.8 MFI
Interval 712.2 to 3291.2
|
1402.5 MFI
Interval 590.0 to 4310.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-N at Month 0-Total
|
485.8 MFI
Interval 289.6 to 993.6
|
459.5 MFI
Interval 270.9 to 884.5
|
497.8 MFI
Interval 296.1 to 1034.0
|
489.9 MFI
Interval 297.8 to 884.9
|
469.9 MFI
Interval 288.9 to 884.1
|
477.2 MFI
Interval 267.0 to 990.2
|
482.6 MFI
Interval 276.2 to 1009.1
|
484.5 MFI
Interval 280.1 to 987.1
|
479.1 MFI
Interval 289.8 to 1020.9
|
500 MFI
Interval 268.0 to 1037.8
|
484.2 MFI
Interval 283.4 to 1005.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-N at Month 2-Total
|
494.6 MFI
Interval 272.7 to 1033.3
|
471 MFI
Interval 252.0 to 987.2
|
492 MFI
Interval 276.8 to 1042.5
|
492 MFI
Interval 283.8 to 1030.2
|
492 MFI
Interval 281.6 to 1036.9
|
423.5 MFI
Interval 246.4 to 1132.4
|
471 MFI
Interval 251.0 to 979.0
|
497.2 MFI
Interval 257.4 to 1067.1
|
484.4 MFI
Interval 260.1 to 1042.8
|
477.8 MFI
Interval 269.8 to 1252.9
|
484.4 MFI
Interval 248.8 to 1019.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-Y at Month 0-Total
|
571.2 MFI
Interval 303.0 to 1478.8
|
556.9 MFI
Interval 329.9 to 1173.3
|
457.5 MFI
Interval 215.0 to 977.8
|
524.2 MFI
Interval 268.6 to 1151.4
|
527 MFI
Interval 290.0 to 1114.0
|
510.1 MFI
Interval 300.4 to 1067.4
|
598 MFI
Interval 372.8 to 1044.0
|
673 MFI
Interval 330.2 to 1216.8
|
576 MFI
Interval 295.5 to 1034.8
|
469.6 MFI
Interval 314.2 to 906.7
|
510.1 MFI
Interval 313.1 to 1103.6
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
OC43-RBD-50-Y at Month 2-Total
|
570.5 MFI
Interval 308.1 to 1176.1
|
708.8 MFI
Interval 313.6 to 1521.4
|
699.8 MFI
Interval 168.9 to 811.6
|
552.2 MFI
Interval 222.1 to 978.5
|
497.2 MFI
Interval 247.8 to 914.5
|
699.8 MFI
Interval 293.5 to 1016.8
|
920.8 MFI
Interval 598.8 to 1271.2
|
491 MFI
Interval 451.2 to 805.0
|
756.9 MFI
Interval 593.8 to 940.1
|
708.8 MFI
Interval 276.0 to 941.2
|
756.9 MFI
Interval 350.2 to 1626.3
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 0-Total
|
2970.9 MFI
Interval 985.9 to 7455.9
|
2799.5 MFI
Interval 935.0 to 7520.0
|
3017.9 MFI
Interval 1062.2 to 7505.8
|
3695.4 MFI
Interval 1232.6 to 8754.6
|
3567.9 MFI
Interval 1267.2 to 8539.2
|
2997.5 MFI
Interval 956.5 to 8169.8
|
3041.8 MFI
Interval 934.6 to 7614.7
|
2583 MFI
Interval 773.8 to 7069.1
|
2923.6 MFI
Interval 908.6 to 7470.1
|
2882.5 MFI
Interval 1011.2 to 7591.2
|
3038.2 MFI
Interval 880.9 to 7700.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-N at Month 2-Total
|
1792.5 MFI
Interval 547.2 to 3940.6
|
1634.5 MFI
Interval 498.0 to 3583.2
|
1828.5 MFI
Interval 596.8 to 3889.0
|
1916.8 MFI
Interval 613.2 to 4095.5
|
1909.5 MFI
Interval 547.4 to 3863.2
|
1360.8 MFI
Interval 441.9 to 3133.9
|
1828.5 MFI
Interval 483.5 to 3724.5
|
1561.5 MFI
Interval 534.8 to 3597.4
|
1824.8 MFI
Interval 587.5 to 3850.4
|
1433.2 MFI
Interval 597.0 to 3133.9
|
1865.2 MFI
Interval 522.2 to 3781.0
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 0-Total
|
1625.8 MFI
Interval 569.5 to 2977.0
|
2914.4 MFI
Interval 900.7 to 6144.4
|
583.2 MFI
Interval 326.5 to 2002.5
|
1765.2 MFI
Interval 500.9 to 3842.6
|
2041.2 MFI
Interval 610.8 to 5292.5
|
2737.1 MFI
Interval 790.4 to 6520.1
|
1532.8 MFI
Interval 637.6 to 5278.5
|
4335.2 MFI
Interval 2076.8 to 9723.9
|
1765.2 MFI
Interval 977.6 to 5405.9
|
2495.6 MFI
Interval 371.2 to 5380.9
|
2082.6 MFI
Interval 1009.9 to 5510.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 DB His-50-Y at Month 2-Total
|
1048.4 MFI
Interval 527.4 to 2301.8
|
2167.2 MFI
Interval 632.4 to 5276.4
|
651.5 MFI
Interval 438.9 to 1636.0
|
1159.2 MFI
Interval 454.8 to 2832.1
|
1634.5 MFI
Interval 559.8 to 3183.0
|
1828.5 MFI
Interval 651.5 to 4926.5
|
1433.2 MFI
Interval 709.8 to 4926.5
|
3183.2 MFI
Interval 1949.8 to 7526.0
|
1143 MFI
Interval 443.3 to 3432.1
|
2579.5 MFI
Interval 448.5 to 5104.5
|
1361.2 MFI
Interval 610.8 to 4612.3
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total
|
2068.6 MFI
Interval 606.9 to 5988.2
|
2155.8 MFI
Interval 594.4 to 6034.0
|
1993.4 MFI
Interval 596.1 to 5864.7
|
2203.2 MFI
Interval 781.9 to 6285.1
|
2453.6 MFI
Interval 798.8 to 6563.8
|
1929 MFI
Interval 553.8 to 5346.0
|
1964.6 MFI
Interval 521.1 to 5898.6
|
1771 MFI
Interval 521.1 to 5312.6
|
2015.6 MFI
Interval 600.8 to 5794.8
|
1929 MFI
Interval 563.0 to 5746.2
|
1994 MFI
Interval 558.4 to 5594.8
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total
|
859.8 MFI
Interval 421.5 to 1999.6
|
835.8 MFI
Interval 425.8 to 2017.2
|
835.8 MFI
Interval 425.8 to 1993.8
|
870.2 MFI
Interval 431.2 to 2536.5
|
870.2 MFI
Interval 429.1 to 2490.9
|
654.2 MFI
Interval 285.5 to 1388.9
|
849.2 MFI
Interval 386.6 to 1956.5
|
773.5 MFI
Interval 405.2 to 1774.2
|
842.5 MFI
Interval 426.7 to 2058.1
|
778.5 MFI
Interval 417.2 to 1774.2
|
780.5 MFI
Interval 426.1 to 1945.4
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total
|
520.8 MFI
Interval 354.2 to 1115.2
|
1467.9 MFI
Interval 490.6 to 4494.6
|
416.2 MFI
Interval 323.2 to 2175.8
|
1115.2 MFI
Interval 358.1 to 3474.4
|
1358 MFI
Interval 416.2 to 3924.2
|
1905.1 MFI
Interval 514.5 to 6368.9
|
1308.5 MFI
Interval 849.0 to 4181.8
|
3375.5 MFI
Interval 1170.4 to 9410.9
|
1126.8 MFI
Interval 428.9 to 4308.6
|
1899.5 MFI
Interval 356.7 to 6107.2
|
1553.8 MFI
Interval 462.0 to 6273.2
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total
|
407.9 MFI
Interval 145.1 to 1527.6
|
342 MFI
Interval 143.2 to 1132.0
|
409 MFI
Interval 144.0 to 1578.0
|
454.2 MFI
Interval 154.0 to 2098.0
|
443.8 MFI
Interval 148.6 to 1727.5
|
286.8 MFI
Interval 113.4 to 1250.8
|
406.8 MFI
Interval 137.4 to 1450.4
|
286.8 MFI
Interval 126.6 to 1340.5
|
385 MFI
Interval 140.1 to 1420.2
|
311.8 MFI
Interval 141.9 to 1373.6
|
352.6 MFI
Interval 133.9 to 1348.9
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total
|
359.8 MFI
Interval 124.0 to 906.8
|
1740 MFI
Interval 295.8 to 4387.5
|
390.1 MFI
Interval 88.1 to 679.0
|
825 MFI
Interval 182.2 to 1938.8
|
1306.2 MFI
Interval 275.6 to 3696.6
|
1593.5 MFI
Interval 284.8 to 4236.5
|
533.5 MFI
Interval 83.1 to 3520.4
|
2728.8 MFI
Interval 1067.5 to 8798.9
|
1297 MFI
Interval 422.6 to 3501.1
|
1256.2 MFI
Interval 101.8 to 3551.5
|
1329.8 MFI
Interval 419.8 to 3966.5
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total
|
143.4 MFI
Interval 71.1 to 525.2
|
532.8 MFI
Interval 143.4 to 2287.5
|
145.5 MFI
Interval 123.4 to 331.5
|
214.8 MFI
Interval 135.2 to 617.4
|
283 MFI
Interval 139.8 to 1118.8
|
552.5 MFI
Interval 160.2 to 1510.8
|
254.5 MFI
Interval 143.2 to 1357.2
|
1132 MFI
Interval 443.8 to 5594.5
|
387.8 MFI
Interval 176.7 to 1948.9
|
553 MFI
Interval 143.2 to 1510.8
|
560.5 MFI
Interval 197.1 to 1606.0
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-N at Month 0-Total
|
301 Participants
|
292 Participants
|
296 Participants
|
265 Participants
|
191 Participants
|
303 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-N at Month 12-Total
|
18 Participants
|
20 Participants
|
—
|
15 Participants
|
6 Participants
|
15 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-N at Month 2-Total
|
171 Participants
|
171 Participants
|
165 Participants
|
149 Participants
|
106 Participants
|
168 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-N at Month 4-Total
|
20 Participants
|
19 Participants
|
—
|
15 Participants
|
10 Participants
|
17 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-Y at Month 0-Total
|
34 Participants
|
43 Participants
|
39 Participants
|
70 Participants
|
144 Participants
|
32 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-Y at Month 12-Total
|
4 Participants
|
2 Participants
|
22 Participants
|
7 Participants
|
16 Participants
|
7 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-Y at Month 2-Total
|
20 Participants
|
20 Participants
|
26 Participants
|
42 Participants
|
85 Participants
|
23 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-Y at Month 4-Total
|
2 Participants
|
3 Participants
|
22 Participants
|
7 Participants
|
12 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3,4, overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 0-USA
|
197.2 Titer
Interval 80.5 to 642.4
|
608.3 Titer
Interval 216.0 to 1333.7
|
169.2 Titer
Interval 64.6 to 1072.5
|
462.9 Titer
Interval 21.3 to 1214.1
|
238.9 Titer
Interval 51.3 to 985.2
|
121.1 Titer
Interval 10.0 to 740.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 12-Peru
|
—
|
—
|
289.6 Titer
Interval 92.7 to 678.9
|
—
|
866.7 Titer
Interval 578.1 to 915.5
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 12-Total
|
322.1 Titer
Interval 197.8 to 485.8
|
232.2 Titer
Interval 118.6 to 239.0
|
281.8 Titer
Interval 103.8 to 549.9
|
281.8 Titer
Interval 239.0 to 716.7
|
346.4 Titer
Interval 232.2 to 707.2
|
346.9 Titer
Interval 85.5 to 633.4
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 12-USA
|
322.1 Titer
Interval 197.8 to 485.8
|
232.2 Titer
Interval 118.6 to 239.0
|
263.8 Titer
Interval 108.5 to 475.0
|
281.8 Titer
Interval 239.0 to 716.7
|
314.1 Titer
Interval 142.9 to 564.2
|
346.9 Titer
Interval 85.5 to 633.4
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 2-Peru
|
95.30 Titer
Interval 19.9 to 131.8
|
1087 Titer
Interval 378.9 to 1402.8
|
447.6 Titer
Interval 186.6 to 713.1
|
198.0 Titer
Interval 19.6 to 545.6
|
86.20 Titer
Interval 20.3 to 334.8
|
39.90 Titer
Interval 15.1 to 77.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 2-Total
|
133.7 Titer
Interval 58.9 to 310.5
|
443.2 Titer
Interval 212.7 to 1229.1
|
201.4 Titer
Interval 112.9 to 599.9
|
176.0 Titer
Interval 59.5 to 578.9
|
96.20 Titer
Interval 30.3 to 341.9
|
122.3 Titer
Interval 30.6 to 253.3
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 2-USA
|
157.2 Titer
Interval 84.8 to 355.4
|
318.9 Titer
Interval 211.7 to 341.6
|
157.2 Titer
Interval 84.8 to 430.5
|
167.0 Titer
Interval 85.6 to 562.1
|
125.4 Titer
Interval 37.0 to 337.1
|
157.2 Titer
Interval 41.9 to 295.2
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 4-Peru
|
—
|
—
|
151.7 Titer
Interval 84.8 to 245.7
|
—
|
60.30 Titer
Interval 44.8 to 106.0
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 4-Total
|
94.30 Titer
Interval 49.7 to 410.3
|
281.8 Titer
Interval 170.4 to 500.4
|
209.7 Titer
Interval 91.9 to 420.9
|
314.1 Titer
Interval 111.9 to 517.4
|
134.7 Titer
Interval 59.3 to 330.2
|
94.30 Titer
Interval 32.0 to 282.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 4-USA
|
94.30 Titer
Interval 49.7 to 410.3
|
281.8 Titer
Interval 170.4 to 500.4
|
253.3 Titer
Interval 106.1 to 448.9
|
314.1 Titer
Interval 111.9 to 517.4
|
253.3 Titer
Interval 76.6 to 397.0
|
94.30 Titer
Interval 32.0 to 282.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 0-Peru
|
214.7 Titer
Interval 57.9 to 685.8
|
183.0 Titer
Interval 55.4 to 603.6
|
222.7 Titer
Interval 60.8 to 679.1
|
211.1 Titer
Interval 57.9 to 631.9
|
225.3 Titer
Interval 80.4 to 644.9
|
222.7 Titer
Interval 74.9 to 679.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 0-Total
|
126.4 Titer
Interval 30.3 to 420.2
|
104.4 Titer
Interval 27.9 to 365.4
|
126.1 Titer
Interval 30.1 to 507.3
|
107.9 Titer
Interval 31.0 to 403.7
|
147.1 Titer
Interval 37.8 to 527.8
|
133.2 Titer
Interval 32.2 to 527.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 0-USA
|
56.00 Titer
Interval 19.8 to 171.1
|
48.00 Titer
Interval 18.7 to 146.0
|
55.20 Titer
Interval 21.1 to 163.3
|
48.00 Titer
Interval 21.5 to 145.0
|
52.00 Titer
Interval 22.3 to 151.8
|
67.00 Titer
Interval 22.8 to 171.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 12-Peru
|
104.3 Titer
Interval 46.4 to 197.3
|
104.3 Titer
Interval 46.4 to 197.3
|
—
|
104.3 Titer
Interval 46.4 to 197.3
|
46.40 Titer
Interval 36.4 to 68.8
|
104.3 Titer
Interval 46.4 to 197.3
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 12-Total
|
104.3 Titer
Interval 40.7 to 158.8
|
116.0 Titer
Interval 42.4 to 183.1
|
—
|
75.50 Titer
Interval 29.1 to 141.2
|
45.10 Titer
Interval 16.6 to 46.5
|
87.30 Titer
Interval 45.1 to 131.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 12-USA
|
92.50 Titer
Interval 34.0 to 141.8
|
120.4 Titer
Interval 37.3 to 182.2
|
—
|
44.10 Titer
Interval 24.4 to 128.3
|
25.80 Titer
Interval 16.6 to 34.9
|
80.40 Titer
Interval 42.4 to 122.4
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 2-Peru
|
57.40 Titer
Interval 20.8 to 157.1
|
39.80 Titer
Interval 10.0 to 131.7
|
39.80 Titer
Interval 15.2 to 145.6
|
54.60 Titer
Interval 20.8 to 145.9
|
65.00 Titer
Interval 25.9 to 161.2
|
57.40 Titer
Interval 22.5 to 148.2
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 2-Total
|
38.60 Titer
Interval 10.0 to 137.3
|
35.40 Titer
Interval 10.0 to 120.5
|
35.50 Titer
Interval 10.0 to 122.4
|
33.50 Titer
Interval 10.0 to 118.5
|
41.60 Titer
Interval 10.0 to 145.9
|
38.40 Titer
Interval 10.0 to 139.5
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 2-USA
|
30.00 Titer
Interval 10.0 to 67.1
|
30.00 Titer
Interval 10.0 to 80.6
|
30.00 Titer
Interval 10.0 to 67.1
|
22.80 Titer
Interval 10.0 to 53.1
|
30.00 Titer
Interval 10.0 to 51.6
|
31.40 Titer
Interval 10.0 to 79.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 4-Peru
|
55.70 Titer
Interval 30.6 to 87.3
|
55.70 Titer
Interval 30.6 to 87.3
|
—
|
55.70 Titer
Interval 30.6 to 87.3
|
80.40 Titer
Interval 46.3 to 140.7
|
55.70 Titer
Interval 30.6 to 87.3
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 4-Total
|
73.50 Titer
Interval 37.3 to 127.8
|
62.60 Titer
Interval 30.6 to 127.8
|
—
|
59.20 Titer
Interval 29.1 to 97.4
|
80.40 Titer
Interval 50.6 to 153.4
|
80.70 Titer
Interval 46.6 to 138.2
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-N at Month 4-USA
|
96.10 Titer
Interval 46.0 to 130.4
|
71.70 Titer
Interval 40.7 to 130.4
|
—
|
62.60 Titer
Interval 35.5 to 104.2
|
100.4 Titer
Interval 58.6 to 147.9
|
116.0 Titer
Interval 76.2 to 147.9
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 0-Peru
|
209.0 Titer
Interval 100.9 to 354.6
|
739.4 Titer
Interval 278.5 to 1080.6
|
147.1 Titer
Interval 67.7 to 259.1
|
354.1 Titer
Interval 102.9 to 695.5
|
143.2 Titer
Interval 47.1 to 748.7
|
54.70 Titer
Interval 25.6 to 106.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 0-Total
|
83.90 Titer
Interval 26.1 to 259.8
|
222.3 Titer
Interval 128.8 to 658.5
|
81.50 Titer
Interval 25.2 to 259.1
|
143.9 Titer
Interval 11.3 to 400.1
|
104.4 Titer
Interval 22.7 to 287.5
|
34.60 Titer
Interval 10.0 to 142.6
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 0-USA
|
54.00 Titer
Interval 25.2 to 165.3
|
164.6 Titer
Interval 54.5 to 260.5
|
52.40 Titer
Interval 18.6 to 246.4
|
126.6 Titer
Interval 10.0 to 243.2
|
75.30 Titer
Interval 16.9 to 211.6
|
32.50 Titer
Interval 10.0 to 144.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 12-Peru
|
—
|
—
|
104.3 Titer
Interval 46.4 to 197.3
|
—
|
259.2 Titer
Interval 181.7 to 323.3
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 12-Total
|
122.9 Titer
Interval 73.2 to 166.2
|
73.50 Titer
Interval 39.2 to 80.4
|
104.3 Titer
Interval 40.7 to 170.4
|
111.5 Titer
Interval 80.4 to 187.6
|
120.4 Titer
Interval 73.5 to 185.8
|
135.0 Titer
Interval 29.1 to 184.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 12-USA
|
122.9 Titer
Interval 73.2 to 166.2
|
73.50 Titer
Interval 39.2 to 80.4
|
99.40 Titer
Interval 35.6 to 164.4
|
111.5 Titer
Interval 80.4 to 187.6
|
116.0 Titer
Interval 46.3 to 176.3
|
135.0 Titer
Interval 29.1 to 184.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 2-Peru
|
31.50 Titer
Interval 9.9 to 39.1
|
311.5 Titer
Interval 117.0 to 462.0
|
127.8 Titer
Interval 63.8 to 183.2
|
58.60 Titer
Interval 10.9 to 162.3
|
26.60 Titer
Interval 10.0 to 115.6
|
15.50 Titer
Interval 10.0 to 31.5
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 2-Total
|
38.40 Titer
Interval 23.4 to 95.1
|
112.0 Titer
Interval 56.4 to 314.9
|
70.80 Titer
Interval 41.8 to 154.0
|
52.60 Titer
Interval 26.5 to 170.5
|
34.80 Titer
Interval 10.0 to 105.5
|
47.60 Titer
Interval 10.0 to 76.5
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 2-USA
|
49.30 Titer
Interval 30.6 to 156.1
|
58.80 Titer
Interval 54.1 to 77.7
|
55.70 Titer
Interval 30.6 to 128.3
|
52.60 Titer
Interval 31.0 to 172.2
|
38.60 Titer
Interval 10.0 to 80.7
|
49.90 Titer
Interval 11.9 to 78.6
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 4-Peru
|
—
|
—
|
55.70 Titer
Interval 30.6 to 87.3
|
—
|
13.70 Titer
Interval 10.6 to 34.7
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 4-Total
|
30.60 Titer
Interval 17.8 to 108.2
|
111.5 Titer
Interval 67.9 to 144.2
|
68.10 Titer
Interval 30.6 to 130.4
|
116.0 Titer
Interval 40.7 to 147.9
|
49.90 Titer
Interval 16.4 to 118.2
|
30.60 Titer
Interval 14.7 to 85.9
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID80-Y at Month 4-USA
|
30.60 Titer
Interval 17.8 to 108.2
|
111.5 Titer
Interval 67.9 to 144.2
|
80.70 Titer
Interval 37.4 to 133.0
|
116.0 Titer
Interval 40.7 to 147.9
|
80.70 Titer
Interval 27.5 to 124.1
|
30.60 Titer
Interval 14.7 to 85.9
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 0-Peru
|
968.4 Titer
Interval 227.3 to 3639.6
|
848.1 Titer
Interval 209.2 to 2962.4
|
994.9 Titer
Interval 237.4 to 3617.3
|
961.9 Titer
Interval 226.2 to 3611.1
|
983.4 Titer
Interval 328.7 to 3161.2
|
978.7 Titer
Interval 289.6 to 3617.3
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 0-Total
|
493.3 Titer
Interval 93.3 to 1874.2
|
367.1 Titer
Interval 84.5 to 1654.7
|
475.2 Titer
Interval 93.3 to 1874.2
|
410.6 Titer
Interval 101.7 to 1836.3
|
618.6 Titer
Interval 144.1 to 1912.1
|
522.1 Titer
Interval 109.5 to 1939.2
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 0-USA
|
241.8 Titer
Interval 52.1 to 769.5
|
190.8 Titer
Interval 52.8 to 603.2
|
238.8 Titer
Interval 53.1 to 714.8
|
190.8 Titer
Interval 58.7 to 553.1
|
226.3 Titer
Interval 62.0 to 627.5
|
256.5 Titer
Interval 67.7 to 749.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 12-Peru
|
289.6 Titer
Interval 92.7 to 678.9
|
289.6 Titer
Interval 92.7 to 678.9
|
—
|
289.6 Titer
Interval 92.7 to 678.9
|
92.70 Titer
Interval 55.9 to 212.9
|
289.6 Titer
Interval 92.7 to 678.9
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 12-Total
|
281.8 Titer
Interval 89.2 to 549.9
|
318.0 Titer
Interval 108.5 to 633.4
|
—
|
204.9 Titer
Interval 63.9 to 445.6
|
91.50 Titer
Interval 61.5 to 119.6
|
245.7 Titer
Interval 115.5 to 460.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 12-USA
|
263.8 Titer
Interval 99.9 to 475.0
|
346.4 Titer
Interval 113.2 to 608.8
|
—
|
117.8 Titer
Interval 60.3 to 411.9
|
89.00 Titer
Interval 74.6 to 103.4
|
239.0 Titer
Interval 116.6 to 367.4
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 2-Peru
|
196.3 Titer
Interval 46.8 to 558.9
|
152.2 Titer
Interval 40.6 to 351.6
|
152.2 Titer
Interval 43.4 to 420.5
|
186.6 Titer
Interval 46.8 to 464.3
|
213.0 Titer
Interval 53.3 to 572.9
|
196.3 Titer
Interval 47.4 to 504.5
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 2-Total
|
134.2 Titer
Interval 39.1 to 430.5
|
105.1 Titer
Interval 37.4 to 343.5
|
105.1 Titer
Interval 38.7 to 349.1
|
96.20 Titer
Interval 39.7 to 343.5
|
160.2 Titer
Interval 47.4 to 461.4
|
134.2 Titer
Interval 42.3 to 416.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 2-USA
|
88.30 Titer
Interval 35.4 to 318.9
|
88.30 Titer
Interval 35.4 to 282.8
|
88.30 Titer
Interval 35.4 to 325.7
|
59.40 Titer
Interval 36.6 to 206.0
|
88.30 Titer
Interval 39.1 to 237.0
|
91.20 Titer
Interval 38.3 to 333.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 4-Peru
|
151.7 Titer
Interval 84.8 to 245.7
|
151.7 Titer
Interval 84.8 to 245.7
|
—
|
151.7 Titer
Interval 84.8 to 245.7
|
239.0 Titer
Interval 142.9 to 370.4
|
151.7 Titer
Interval 84.8 to 245.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 4-Total
|
232.2 Titer
Interval 113.2 to 411.9
|
187.1 Titer
Interval 94.3 to 411.9
|
—
|
169.4 Titer
Interval 78.6 to 293.0
|
239.0 Titer
Interval 137.0 to 440.6
|
245.7 Titer
Interval 120.2 to 411.9
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-N at Month 4-USA
|
267.6 Titer
Interval 119.6 to 448.2
|
220.2 Titer
Interval 111.9 to 448.2
|
—
|
187.1 Titer
Interval 89.6 to 350.5
|
318.6 Titer
Interval 170.4 to 517.4
|
314.1 Titer
Interval 236.8 to 517.4
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 0-Peru
|
822.9 Titer
Interval 332.0 to 1611.0
|
3196 Titer
Interval 1616.4 to 7903.4
|
522.1 Titer
Interval 276.9 to 1267.3
|
1141 Titer
Interval 441.7 to 3161.2
|
609.9 Titer
Interval 184.7 to 3745.2
|
197.1 Titer
Interval 76.2 to 438.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
VRC7480_G614-ID50-Y at Month 0-Total
|
216.0 Titer
Interval 81.6 to 1289.4
|
1196 Titer
Interval 495.3 to 3195.5
|
347.6 Titer
Interval 86.5 to 1125.9
|
594.9 Titer
Interval 48.0 to 1590.3
|
336.8 Titer
Interval 67.2 to 1617.1
|
125.6 Titer
Interval 10.0 to 723.6
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and comorbidity group among Africa Cohort
Outcome measures
| Measure |
Group 1A
n=372 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=372 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=372 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=372 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=372 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=372 Participants
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-N at Month 0-Total
|
277 Participants
|
248 Participants
|
255 Participants
|
218 Participants
|
239 Participants
|
264 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-N at Month 12-Total
|
169 Participants
|
155 Participants
|
153 Participants
|
141 Participants
|
142 Participants
|
160 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-N at Month 2-Total
|
202 Participants
|
183 Participants
|
184 Participants
|
158 Participants
|
168 Participants
|
190 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-N at Month 4-Total
|
200 Participants
|
178 Participants
|
182 Participants
|
158 Participants
|
168 Participants
|
186 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-Y at Month 0-Total
|
15 Participants
|
44 Participants
|
37 Participants
|
74 Participants
|
53 Participants
|
28 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-Y at Month 12-Total
|
7 Participants
|
21 Participants
|
23 Participants
|
35 Participants
|
34 Participants
|
16 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-Y at Month 2-Total
|
10 Participants
|
29 Participants
|
28 Participants
|
54 Participants
|
44 Participants
|
22 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-Y at Month 4-Total
|
8 Participants
|
30 Participants
|
26 Participants
|
50 Participants
|
40 Participants
|
22 Participants
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0, 2, 4, 12Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and comorbidity group among Africa Cohort
Outcome measures
| Measure |
Group 1A
n=372 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=372 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=372 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=372 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=372 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=372 Participants
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 0-RSA
|
320.3 Titer
Interval 122.8 to 1294.1
|
271.3 Titer
Interval 86.3 to 994.0
|
366.3 Titer
Interval 144.7 to 1459.7
|
278.1 Titer
Interval 79.0 to 1150.1
|
416.9 Titer
Interval 157.5 to 1624.2
|
362.2 Titer
Interval 142.2 to 1463.4
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 0-Total
|
309.6 Titer
Interval 82.4 to 1298.5
|
253.5 Titer
Interval 72.1 to 939.4
|
361.7 Titer
Interval 113.6 to 1442.8
|
250.5 Titer
Interval 68.6 to 1023.9
|
366.3 Titer
Interval 126.2 to 1540.7
|
351.6 Titer
Interval 110.3 to 1442.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 0-non-RSA
|
232.5 Titer
Interval 19.3 to 1265.1
|
221.6 Titer
Interval 10.0 to 677.6
|
329.4 Titer
Interval 48.6 to 1149.0
|
202.8 Titer
Interval 10.0 to 645.7
|
329.4 Titer
Interval 58.3 to 1316.1
|
276 Titer
Interval 47.5 to 1265.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 12-RSA
|
1742.4 Titer
Interval 292.3 to 8145.0
|
1425.4 Titer
Interval 256.7 to 7759.7
|
1582.1 Titer
Interval 284.9 to 8241.1
|
1496.8 Titer
Interval 275.5 to 7565.8
|
2820.3 Titer
Interval 477.3 to 10782.0
|
2369.6 Titer
Interval 334.5 to 9595.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 12-Total
|
1254.7 Titer
Interval 286.6 to 7080.4
|
848.1 Titer
Interval 261.0 to 6522.5
|
830.5 Titer
Interval 284.9 to 7123.1
|
830.5 Titer
Interval 247.3 to 6188.3
|
1755.3 Titer
Interval 358.2 to 7816.6
|
1577.6 Titer
Interval 295.9 to 7302.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 12-non-RSA
|
636.2 Titer
Interval 260.7 to 3480.7
|
636.2 Titer
Interval 270.9 to 3186.7
|
636.2 Titer
Interval 281.6 to 3957.2
|
602.8 Titer
Interval 246.1 to 2443.4
|
702.3 Titer
Interval 293.3 to 4599.5
|
681.2 Titer
Interval 281.6 to 3957.2
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 2-RSA
|
191.6 Titer
Interval 58.8 to 664.2
|
148.1 Titer
Interval 57.1 to 521.1
|
198.4 Titer
Interval 64.9 to 664.2
|
123.7 Titer
Interval 55.4 to 508.1
|
246.2 Titer
Interval 68.4 to 826.6
|
208 Titer
Interval 67.1 to 780.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 2-Total
|
147.6 Titer
Interval 46.0 to 467.2
|
116.2 Titer
Interval 40.9 to 414.5
|
155.3 Titer
Interval 48.9 to 464.8
|
99.6 Titer
Interval 37.0 to 351.8
|
155.3 Titer
Interval 52.7 to 538.4
|
150.5 Titer
Interval 51.7 to 514.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 2-non-RSA
|
63 Titer
Interval 10.0 to 257.0
|
56.2 Titer
Interval 9.1 to 237.2
|
71.4 Titer
Interval 10.0 to 254.9
|
53.3 Titer
Interval 10.0 to 227.5
|
80 Titer
Interval 10.0 to 251.2
|
63 Titer
Interval 10.0 to 252.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 4-RSA
|
310.6 Titer
Interval 81.0 to 912.4
|
275.1 Titer
Interval 75.6 to 904.8
|
337.3 Titer
Interval 90.3 to 1237.2
|
292.5 Titer
Interval 77.1 to 880.5
|
446.4 Titer
Interval 108.6 to 1341.2
|
356.5 Titer
Interval 103.6 to 1293.5
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 4-Total
|
259.4 Titer
Interval 75.8 to 881.9
|
235 Titer
Interval 71.4 to 749.8
|
280.8 Titer
Interval 87.7 to 938.0
|
236.8 Titer
Interval 72.1 to 722.4
|
299.8 Titer
Interval 94.0 to 1121.2
|
276.1 Titer
Interval 87.7 to 994.3
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-N at Month 4-non-RSA
|
185.4 Titer
Interval 63.8 to 580.8
|
163 Titer
Interval 60.4 to 528.8
|
214.4 Titer
Interval 85.1 to 563.2
|
163 Titer
Interval 60.4 to 465.9
|
188.7 Titer
Interval 75.4 to 569.1
|
188.7 Titer
Interval 71.4 to 580.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 0-RSA
|
361.8 Titer
Interval 202.4 to 1767.7
|
1106.8 Titer
Interval 488.7 to 2381.0
|
174.8 Titer
Interval 59.9 to 504.2
|
689.3 Titer
Interval 203.1 to 1606.2
|
227.1 Titer
Interval 35.9 to 569.9
|
186.1 Titer
Interval 26.2 to 474.5
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 0-Total
|
394.8 Titer
Interval 207.0 to 1402.2
|
1145.5 Titer
Interval 488.7 to 2381.0
|
154.5 Titer
Interval 52.9 to 506.9
|
689.3 Titer
Interval 200.0 to 1644.9
|
199.3 Titer
Interval 27.4 to 539.5
|
186.1 Titer
Interval 25.7 to 435.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 0-non-RSA
|
507.9 Titer
Interval 443.0 to 572.9
|
1632.8 Titer
Interval 718.6 to 2125.5
|
103.7 Titer
Interval 8.2 to 731.7
|
705.7 Titer
Interval 133.1 to 1806.3
|
10 Titer
Interval 5.0 to 338.1
|
174.1 Titer
Interval 92.0 to 256.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 12-RSA
|
1246.4 Titer
Interval 224.8 to 12091.3
|
6407.6 Titer
Interval 1692.3 to 10890.6
|
2629.1 Titer
Interval 1161.5 to 8464.3
|
5164.1 Titer
Interval 361.6 to 17312.4
|
284.9 Titer
Interval 102.7 to 1573.2
|
396.8 Titer
Interval 93.8 to 2533.5
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 12-Total
|
2196 Titer
Interval 248.8 to 12252.1
|
3743.2 Titer
Interval 872.0 to 11384.1
|
2598.1 Titer
Interval 1007.8 to 7966.6
|
4233.8 Titer
Interval 361.6 to 16089.4
|
247.3 Titer
Interval 89.0 to 1689.3
|
246.3 Titer
Interval 67.0 to 1315.3
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 12-non-RSA
|
9114.5 Titer
Interval 9114.5 to 9114.5
|
872 Titer
Interval 317.7 to 10965.7
|
2567.1 Titer
Interval 111.6 to 3393.2
|
3155.1 Titer
Interval 516.8 to 10496.6
|
237.5 Titer
Interval 55.5 to 2202.8
|
10 Titer
Interval 10.0 to 10.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 2-RSA
|
161.7 Titer
Interval 93.6 to 422.0
|
424.4 Titer
Interval 168.0 to 962.5
|
93.6 Titer
Interval 51.0 to 502.2
|
308 Titer
Interval 115.1 to 916.6
|
134.2 Titer
Interval 10.0 to 271.6
|
72.9 Titer
Interval 10.0 to 271.6
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 4-RSA
|
90.6 Titer
Interval 27.3 to 209.3
|
83.7 Titer
Interval 23.0 to 207.0
|
102.4 Titer
Interval 30.5 to 265.7
|
81.9 Titer
Interval 22.9 to 202.1
|
118.1 Titer
Interval 34.6 to 293.6
|
113.5 Titer
Interval 33.7 to 271.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 4-Total
|
66.6 Titer
Interval 25.3 to 206.7
|
57.1 Titer
Interval 23.9 to 188.9
|
84.6 Titer
Interval 28.6 to 217.9
|
55.6 Titer
Interval 24.0 to 176.3
|
96.3 Titer
Interval 31.7 to 238.1
|
86.5 Titer
Interval 29.1 to 226.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 4-non-RSA
|
43.8 Titer
Interval 24.2 to 177.1
|
43.3 Titer
Interval 23.9 to 150.6
|
50.2 Titer
Interval 27.5 to 174.7
|
43.3 Titer
Interval 24.1 to 147.2
|
48.4 Titer
Interval 24.2 to 175.5
|
45.4 Titer
Interval 24.2 to 177.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 0-RSA
|
106.7 Titer
Interval 59.1 to 383.7
|
267.9 Titer
Interval 120.6 to 573.9
|
46.5 Titer
Interval 15.4 to 102.7
|
181.5 Titer
Interval 60.1 to 420.7
|
52.2 Titer
Interval 10.0 to 138.1
|
49.7 Titer
Interval 10.0 to 131.6
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 0-Total
|
120.8 Titer
Interval 61.3 to 267.6
|
309.3 Titer
Interval 120.6 to 597.9
|
42.1 Titer
Interval 11.0 to 104.6
|
181.5 Titer
Interval 58.0 to 465.6
|
47.8 Titer
Interval 10.0 to 131.4
|
49.7 Titer
Interval 10.0 to 131.2
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 0-non-RSA
|
144.6 Titer
Interval 133.1 to 156.0
|
396.2 Titer
Interval 143.4 to 623.4
|
28.4 Titer
Interval 7.5 to 202.6
|
174.4 Titer
Interval 49.3 to 574.2
|
10 Titer
Interval 5.0 to 31.2
|
59.7 Titer
Interval 34.9 to 84.6
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 12-RSA
|
378.4 Titer
Interval 57.1 to 2969.3
|
2077.3 Titer
Interval 472.3 to 3267.6
|
576.2 Titer
Interval 270.0 to 1781.6
|
1076.4 Titer
Interval 129.1 to 4163.6
|
62.8 Titer
Interval 35.9 to 392.2
|
88.3 Titer
Interval 32.1 to 458.3
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 12-Total
|
694.1 Titer
Interval 59.0 to 3157.7
|
971.6 Titer
Interval 238.8 to 3310.6
|
530.3 Titer
Interval 218.2 to 1524.3
|
1022.7 Titer
Interval 129.1 to 3560.9
|
62.8 Titer
Interval 34.0 to 601.6
|
63.9 Titer
Interval 26.2 to 301.9
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 12-non-RSA
|
2587.7 Titer
Interval 2587.7 to 2587.7
|
238.8 Titer
Interval 89.2 to 2238.4
|
484.4 Titer
Interval 41.8 to 600.6
|
728 Titer
Interval 145.9 to 2451.8
|
65.9 Titer
Interval 19.8 to 694.1
|
10 Titer
Interval 10.0 to 10.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 2-RSA
|
57.3 Titer
Interval 37.4 to 105.0
|
142.1 Titer
Interval 42.8 to 202.9
|
35.2 Titer
Interval 7.5 to 137.0
|
109.5 Titer
Interval 34.6 to 197.1
|
34.3 Titer
Interval 10.0 to 62.9
|
26.6 Titer
Interval 10.0 to 46.2
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 2-Total
|
39.3 Titer
Interval 31.3 to 87.3
|
142.1 Titer
Interval 41.2 to 217.1
|
29.9 Titer
Interval 7.5 to 137.0
|
87.1 Titer
Interval 32.4 to 197.5
|
33.5 Titer
Interval 10.0 to 60.6
|
26.6 Titer
Interval 10.0 to 54.5
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 2-non-RSA
|
31.7 Titer
Interval 28.5 to 35.0
|
146.1 Titer
Interval 39.3 to 419.2
|
10.2 Titer
Interval 7.5 to 72.3
|
53 Titer
Interval 22.5 to 197.1
|
10 Titer
Interval 5.0 to 51.0
|
43.7 Titer
Interval 24.3 to 63.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 4-RSA
|
147.2 Titer
Interval 88.5 to 423.7
|
169.7 Titer
Interval 61.2 to 295.9
|
41.1 Titer
Interval 19.2 to 169.7
|
136.3 Titer
Interval 39.1 to 401.5
|
38.7 Titer
Interval 10.0 to 139.5
|
31.3 Titer
Interval 10.0 to 153.2
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 4-Total
|
139.5 Titer
Interval 52.6 to 215.9
|
177.1 Titer
Interval 61.2 to 306.8
|
34.7 Titer
Interval 10.5 to 169.8
|
137.9 Titer
Interval 36.6 to 357.4
|
38.7 Titer
Interval 10.0 to 139.5
|
31.3 Titer
Interval 10.0 to 144.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-Y at Month 4-non-RSA
|
66.7 Titer
Interval 59.6 to 73.7
|
205.9 Titer
Interval 97.5 to 391.5
|
7.5 Titer
Interval 6.7 to 156.2
|
153.5 Titer
Interval 37.0 to 288.8
|
36.1 Titer
Interval 22.3 to 179.4
|
64 Titer
Interval 37.0 to 91.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 2-Total
|
129.6 Titer
Interval 78.3 to 317.6
|
424.4 Titer
Interval 168.0 to 1097.9
|
66 Titer
Interval 44.7 to 502.2
|
307 Titer
Interval 97.0 to 878.3
|
120.8 Titer
Interval 10.0 to 275.6
|
72.9 Titer
Interval 10.0 to 274.3
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 2-non-RSA
|
92 Titer
Interval 73.2 to 110.8
|
552.1 Titer
Interval 183.0 to 1563.3
|
52.9 Titer
Interval 8.2 to 217.6
|
211.4 Titer
Interval 56.2 to 822.6
|
48.9 Titer
Interval 5.0 to 337.9
|
243.5 Titer
Interval 124.3 to 362.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 4-RSA
|
546.3 Titer
Interval 286.9 to 1239.8
|
657.1 Titer
Interval 253.4 to 1347.8
|
146.1 Titer
Interval 66.6 to 705.2
|
528.4 Titer
Interval 178.2 to 1415.1
|
165.5 Titer
Interval 13.5 to 467.2
|
104.4 Titer
Interval 10.0 to 467.2
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 4-Total
|
474.5 Titer
Interval 267.3 to 891.8
|
657.1 Titer
Interval 253.4 to 1347.8
|
104.4 Titer
Interval 54.2 to 705.4
|
528.4 Titer
Interval 144.2 to 1382.3
|
165.5 Titer
Interval 13.5 to 467.2
|
104.4 Titer
Interval 10.0 to 452.4
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID50-Y at Month 4-non-RSA
|
310.4 Titer
Interval 288.9 to 332.0
|
767.5 Titer
Interval 258.2 to 1314.0
|
25.8 Titer
Interval 8.2 to 598.7
|
445.3 Titer
Interval 117.7 to 1170.2
|
145.6 Titer
Interval 45.3 to 665.1
|
171.6 Titer
Interval 90.8 to 252.4
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 0-RSA
|
82.2 Titer
Interval 34.2 to 294.2
|
62.8 Titer
Interval 30.9 to 210.9
|
100.1 Titer
Interval 35.2 to 357.0
|
61.3 Titer
Interval 26.6 to 238.2
|
100.5 Titer
Interval 37.1 to 398.2
|
98.2 Titer
Interval 35.1 to 357.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 0-Total
|
79.4 Titer
Interval 29.0 to 276.7
|
58.2 Titer
Interval 24.6 to 207.6
|
98.5 Titer
Interval 32.0 to 322.8
|
55.1 Titer
Interval 24.4 to 222.7
|
100.1 Titer
Interval 34.3 to 355.6
|
93 Titer
Interval 31.7 to 332.0
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 0-non-RSA
|
47.8 Titer
Interval 10.0 to 255.3
|
45.7 Titer
Interval 10.0 to 184.4
|
50.4 Titer
Interval 23.8 to 233.6
|
43.4 Titer
Interval 10.0 to 181.4
|
95.8 Titer
Interval 24.6 to 268.6
|
49.6 Titer
Interval 13.5 to 255.3
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 12-RSA
|
492.2 Titer
Interval 106.2 to 2650.7
|
345.7 Titer
Interval 62.8 to 1910.0
|
392.2 Titer
Interval 62.8 to 2760.8
|
390.9 Titer
Interval 62.8 to 1749.9
|
794.6 Titer
Interval 135.6 to 3207.8
|
694.3 Titer
Interval 113.8 to 2878.6
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 12-Total
|
295.6 Titer
Interval 97.4 to 1735.7
|
227.3 Titer
Interval 68.3 to 1550.2
|
224 Titer
Interval 70.6 to 1837.0
|
224 Titer
Interval 63.9 to 1357.0
|
508.1 Titer
Interval 122.3 to 2347.2
|
407 Titer
Interval 104.8 to 2126.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 12-non-RSA
|
179.1 Titer
Interval 87.0 to 952.1
|
179.1 Titer
Interval 94.3 to 907.5
|
179.1 Titer
Interval 98.1 to 978.7
|
173.2 Titer
Interval 70.6 to 757.7
|
190.8 Titer
Interval 104.7 to 1000.0
|
187.5 Titer
Interval 98.1 to 978.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 2-RSA
|
42 Titer
Interval 13.4 to 173.5
|
39.3 Titer
Interval 10.0 to 143.2
|
43.7 Titer
Interval 20.9 to 174.8
|
37.7 Titer
Interval 10.0 to 141.3
|
75.4 Titer
Interval 22.3 to 187.2
|
61.4 Titer
Interval 21.8 to 185.1
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 2-Total
|
36.4 Titer
Interval 10.0 to 137.2
|
34.4 Titer
Interval 10.0 to 117.0
|
37.7 Titer
Interval 10.0 to 134.0
|
33.5 Titer
Interval 10.0 to 104.8
|
38.8 Titer
Interval 10.0 to 153.6
|
37.7 Titer
Interval 10.0 to 147.8
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
SARS-Cov-2 D614G-ID80-N at Month 2-non-RSA
|
23.6 Titer
Interval 10.0 to 65.5
|
22.8 Titer
Interval 7.5 to 52.0
|
25.2 Titer
Interval 10.0 to 59.2
|
22.6 Titer
Interval 10.0 to 43.2
|
25.7 Titer
Interval 10.0 to 62.4
|
24.5 Titer
Interval 10.0 to 53.0
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population (USA and Peru only), all available data at each visit
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total
|
131 Participants
|
138 Participants
|
124 Participants
|
104 Participants
|
140 Participants
|
93 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total
|
21 Participants
|
14 Participants
|
28 Participants
|
48 Participants
|
12 Participants
|
59 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total
|
126 Participants
|
140 Participants
|
127 Participants
|
114 Participants
|
140 Participants
|
95 Participants
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total
|
27 Participants
|
13 Participants
|
26 Participants
|
39 Participants
|
13 Participants
|
58 Participants
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population (USA and Peru only), all available data at each visit
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total
|
6 Percent CD107a+ NK Cells
Interval 1.3 to 13.8
|
6 Percent CD107a+ NK Cells
Interval 1.4 to 13.6
|
4.9 Percent CD107a+ NK Cells
Interval 1.3 to 12.5
|
5.1 Percent CD107a+ NK Cells
Interval 1.4 to 13.3
|
6.6 Percent CD107a+ NK Cells
Interval 1.8 to 14.1
|
6.6 Percent CD107a+ NK Cells
Interval 1.8 to 14.9
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total
|
4.2 Percent CD107a+ NK Cells
Interval 1.6 to 12.2
|
5 Percent CD107a+ NK Cells
Interval 2.2 to 14.1
|
13 Percent CD107a+ NK Cells
Interval 3.8 to 20.8
|
7.5 Percent CD107a+ NK Cells
Interval 1.4 to 15.5
|
1.8 Percent CD107a+ NK Cells
Interval 0.1 to 6.0
|
4.5 Percent CD107a+ NK Cells
Interval 1.1 to 11.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total
|
6.7 Percent CD107a+ NK Cells
Interval 2.9 to 13.1
|
6.9 Percent CD107a+ NK Cells
Interval 2.9 to 13.3
|
6.4 Percent CD107a+ NK Cells
Interval 2.9 to 13.0
|
8 Percent CD107a+ NK Cells
Interval 3.3 to 13.5
|
8 Percent CD107a+ NK Cells
Interval 3.2 to 13.4
|
8.6 Percent CD107a+ NK Cells
Interval 3.4 to 13.7
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort
Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total
|
8.2 Percent CD107a+ NK Cells
Interval 4.1 to 12.9
|
6.1 Percent CD107a+ NK Cells
Interval 3.1 to 9.6
|
10 Percent CD107a+ NK Cells
Interval 3.4 to 15.1
|
5.9 Percent CD107a+ NK Cells
Interval 2.4 to 10.2
|
4.3 Percent CD107a+ NK Cells
Interval 0.6 to 8.2
|
5.7 Percent CD107a+ NK Cells
Interval 2.6 to 11.4
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population with positive responders (USA and Peru only), all available data at each visit
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1, overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
n=388 Participants
3: Clinical spectrums
|
Group 8
n=388 Participants
Clinical spectrums , age 55+
|
Group 9
n=388 Participants
HIV
|
Group 10
n=388 Participants
Hypertension
|
Group 11
n=388 Participants
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-N at Month 0-Total
|
30 Participants
|
24 Participants
|
30 Participants
|
27 Participants
|
23 Participants
|
23 Participants
|
28 Participants
|
29 Participants
|
30 Participants
|
26 Participants
|
28 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-N at Month 0-Peru
|
18 Participants
|
14 Participants
|
18 Participants
|
18 Participants
|
14 Participants
|
15 Participants
|
18 Participants
|
18 Participants
|
18 Participants
|
15 Participants
|
18 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-N at Month 0-USA
|
12 Participants
|
10 Participants
|
12 Participants
|
9 Participants
|
9 Participants
|
8 Participants
|
10 Participants
|
11 Participants
|
12 Participants
|
11 Participants
|
10 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-Y at Month 0-Peru
|
0 Participants
|
4 Participants
|
0 Participants
|
0 Participants
|
4 Participants
|
3 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
3 Participants
|
0 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-Y at Month 0-USA
|
0 Participants
|
2 Participants
|
0 Participants
|
3 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-Y at Month 0-Peru
|
0 Participants
|
10 Participants
|
0 Participants
|
0 Participants
|
10 Participants
|
12 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
5 Participants
|
4 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-Y at Month 0-Total
|
0 Participants
|
21 Participants
|
2 Participants
|
20 Participants
|
31 Participants
|
32 Participants
|
9 Participants
|
9 Participants
|
6 Participants
|
10 Participants
|
12 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-Y at Month 0-Total
|
0 Participants
|
6 Participants
|
0 Participants
|
3 Participants
|
7 Participants
|
7 Participants
|
2 Participants
|
1 Participants
|
0 Participants
|
4 Participants
|
2 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-Y at Month 0-USA
|
0 Participants
|
11 Participants
|
2 Participants
|
20 Participants
|
21 Participants
|
20 Participants
|
7 Participants
|
6 Participants
|
3 Participants
|
5 Participants
|
8 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-N at Month 0-USA
|
29 Participants
|
19 Participants
|
27 Participants
|
10 Participants
|
9 Participants
|
11 Participants
|
23 Participants
|
24 Participants
|
26 Participants
|
25 Participants
|
21 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-N at Month 0-Peru
|
47 Participants
|
37 Participants
|
47 Participants
|
47 Participants
|
37 Participants
|
35 Participants
|
45 Participants
|
44 Participants
|
44 Participants
|
42 Participants
|
43 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-N at Month 0-Total
|
82 Participants
|
61 Participants
|
80 Participants
|
62 Participants
|
51 Participants
|
50 Participants
|
73 Participants
|
73 Participants
|
76 Participants
|
72 Participants
|
70 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-N at Month 0-USA
|
35 Participants
|
24 Participants
|
33 Participants
|
15 Participants
|
14 Participants
|
15 Participants
|
28 Participants
|
29 Participants
|
32 Participants
|
30 Participants
|
27 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-N at Month 0-Peru
|
139 Participants
|
105 Participants
|
143 Participants
|
138 Participants
|
104 Participants
|
91 Participants
|
135 Participants
|
128 Participants
|
132 Participants
|
124 Participants
|
125 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-N at Month 0-Total
|
263 Participants
|
189 Participants
|
261 Participants
|
209 Participants
|
160 Participants
|
138 Participants
|
245 Participants
|
236 Participants
|
242 Participants
|
212 Participants
|
217 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-N at Month 0-USA
|
124 Participants
|
84 Participants
|
118 Participants
|
71 Participants
|
56 Participants
|
47 Participants
|
110 Participants
|
108 Participants
|
110 Participants
|
88 Participants
|
92 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-Y at Month 0-Peru
|
4 Participants
|
38 Participants
|
0 Participants
|
5 Participants
|
39 Participants
|
52 Participants
|
8 Participants
|
15 Participants
|
11 Participants
|
19 Participants
|
18 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-Y at Month 0-Total
|
9 Participants
|
83 Participants
|
11 Participants
|
63 Participants
|
112 Participants
|
134 Participants
|
27 Participants
|
36 Participants
|
30 Participants
|
60 Participants
|
55 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-Y at Month 0-USA
|
5 Participants
|
45 Participants
|
11 Participants
|
58 Participants
|
73 Participants
|
82 Participants
|
19 Participants
|
21 Participants
|
19 Participants
|
41 Participants
|
37 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-N at Month 0-Peru
|
114 Participants
|
87 Participants
|
115 Participants
|
113 Participants
|
86 Participants
|
71 Participants
|
108 Participants
|
100 Participants
|
108 Participants
|
98 Participants
|
102 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-N at Month 0-Total
|
200 Participants
|
144 Participants
|
197 Participants
|
161 Participants
|
123 Participants
|
103 Participants
|
182 Participants
|
170 Participants
|
187 Participants
|
154 Participants
|
170 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-N at Month 0-USA
|
86 Participants
|
57 Participants
|
82 Participants
|
48 Participants
|
37 Participants
|
32 Participants
|
74 Participants
|
70 Participants
|
79 Participants
|
56 Participants
|
68 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-Y at Month 0-Peru
|
1 Participants
|
28 Participants
|
0 Participants
|
2 Participants
|
29 Participants
|
44 Participants
|
7 Participants
|
15 Participants
|
7 Participants
|
17 Participants
|
13 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-Y at Month 0-Total
|
3 Participants
|
59 Participants
|
6 Participants
|
42 Participants
|
80 Participants
|
100 Participants
|
21 Participants
|
33 Participants
|
16 Participants
|
49 Participants
|
33 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-Y at Month 0-USA
|
2 Participants
|
31 Participants
|
6 Participants
|
40 Participants
|
51 Participants
|
56 Participants
|
14 Participants
|
18 Participants
|
9 Participants
|
32 Participants
|
20 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-N at Month 0-Peru
|
113 Participants
|
85 Participants
|
116 Participants
|
113 Participants
|
84 Participants
|
74 Participants
|
110 Participants
|
103 Participants
|
108 Participants
|
99 Participants
|
103 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-N at Month 0-Total
|
214 Participants
|
152 Participants
|
214 Participants
|
169 Participants
|
127 Participants
|
111 Participants
|
196 Participants
|
192 Participants
|
201 Participants
|
168 Participants
|
181 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-N at Month 0-USA
|
101 Participants
|
67 Participants
|
98 Participants
|
56 Participants
|
43 Participants
|
37 Participants
|
86 Participants
|
89 Participants
|
93 Participants
|
69 Participants
|
78 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-Y at Month 0-Peru
|
3 Participants
|
31 Participants
|
0 Participants
|
3 Participants
|
32 Participants
|
42 Participants
|
6 Participants
|
13 Participants
|
8 Participants
|
17 Participants
|
13 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-Y at Month 0-Total
|
7 Participants
|
69 Participants
|
7 Participants
|
52 Participants
|
94 Participants
|
110 Participants
|
25 Participants
|
29 Participants
|
20 Participants
|
53 Participants
|
40 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-Y at Month 0-USA
|
4 Participants
|
38 Participants
|
7 Participants
|
49 Participants
|
62 Participants
|
68 Participants
|
19 Participants
|
16 Participants
|
12 Participants
|
36 Participants
|
27 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-N at Month 0-Peru
|
65 Participants
|
49 Participants
|
65 Participants
|
63 Participants
|
48 Participants
|
40 Participants
|
61 Participants
|
58 Participants
|
63 Participants
|
52 Participants
|
59 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-N at Month 0-Total
|
124 Participants
|
87 Participants
|
120 Participants
|
93 Participants
|
71 Participants
|
62 Participants
|
113 Participants
|
107 Participants
|
115 Participants
|
90 Participants
|
103 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-N at Month 0-USA
|
59 Participants
|
38 Participants
|
55 Participants
|
30 Participants
|
23 Participants
|
22 Participants
|
52 Participants
|
49 Participants
|
52 Participants
|
38 Participants
|
44 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-Y at Month 0-Peru
|
0 Participants
|
16 Participants
|
0 Participants
|
2 Participants
|
17 Participants
|
25 Participants
|
4 Participants
|
7 Participants
|
2 Participants
|
13 Participants
|
6 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-Y at Month 0-Total
|
2 Participants
|
39 Participants
|
6 Participants
|
33 Participants
|
55 Participants
|
64 Participants
|
13 Participants
|
19 Participants
|
11 Participants
|
36 Participants
|
23 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-Y at Month 0-USA
|
2 Participants
|
23 Participants
|
6 Participants
|
31 Participants
|
38 Participants
|
39 Participants
|
9 Participants
|
12 Participants
|
9 Participants
|
23 Participants
|
17 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-N at Month 0-Peru
|
84 Participants
|
62 Participants
|
86 Participants
|
85 Participants
|
61 Participants
|
51 Participants
|
81 Participants
|
74 Participants
|
83 Participants
|
71 Participants
|
77 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-N at Month 0-Total
|
138 Participants
|
92 Participants
|
138 Participants
|
111 Participants
|
79 Participants
|
70 Participants
|
127 Participants
|
118 Participants
|
133 Participants
|
107 Participants
|
120 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-N at Month 0-USA
|
54 Participants
|
30 Participants
|
52 Participants
|
26 Participants
|
18 Participants
|
19 Participants
|
46 Participants
|
44 Participants
|
50 Participants
|
36 Participants
|
43 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-Y at Month 0-Peru
|
2 Participants
|
24 Participants
|
0 Participants
|
1 Participants
|
25 Participants
|
35 Participants
|
5 Participants
|
12 Participants
|
3 Participants
|
15 Participants
|
9 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-Y at Month 0-Total
|
4 Participants
|
50 Participants
|
4 Participants
|
31 Participants
|
63 Participants
|
72 Participants
|
15 Participants
|
24 Participants
|
9 Participants
|
35 Participants
|
22 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-Y at Month 0-USA
|
2 Participants
|
26 Participants
|
4 Participants
|
30 Participants
|
38 Participants
|
37 Participants
|
10 Participants
|
12 Participants
|
6 Participants
|
20 Participants
|
13 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-N at Month 0-Peru
|
123 Participants
|
93 Participants
|
126 Participants
|
124 Participants
|
92 Participants
|
81 Participants
|
119 Participants
|
114 Participants
|
117 Participants
|
108 Participants
|
110 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-N at Month 0-Total
|
225 Participants
|
162 Participants
|
222 Participants
|
181 Participants
|
136 Participants
|
119 Participants
|
208 Participants
|
203 Participants
|
207 Participants
|
178 Participants
|
185 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-N at Month 0-USA
|
102 Participants
|
69 Participants
|
96 Participants
|
57 Participants
|
44 Participants
|
38 Participants
|
89 Participants
|
89 Participants
|
90 Participants
|
70 Participants
|
75 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-Y at Month 0-Peru
|
3 Participants
|
33 Participants
|
0 Participants
|
2 Participants
|
34 Participants
|
45 Participants
|
7 Participants
|
12 Participants
|
9 Participants
|
18 Participants
|
16 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-Y at Month 0-Total
|
6 Participants
|
69 Participants
|
9 Participants
|
50 Participants
|
95 Participants
|
112 Participants
|
23 Participants
|
28 Participants
|
24 Participants
|
53 Participants
|
46 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-Y at Month 0-USA
|
3 Participants
|
36 Participants
|
9 Participants
|
48 Participants
|
61 Participants
|
67 Participants
|
16 Participants
|
16 Participants
|
15 Participants
|
35 Participants
|
30 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-N at Month 0-Peru
|
113 Participants
|
82 Participants
|
116 Participants
|
111 Participants
|
81 Participants
|
75 Participants
|
110 Participants
|
102 Participants
|
111 Participants
|
99 Participants
|
105 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-N at Month 0-Total
|
213 Participants
|
150 Participants
|
211 Participants
|
165 Participants
|
124 Participants
|
112 Participants
|
199 Participants
|
186 Participants
|
200 Participants
|
167 Participants
|
179 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-N at Month 0-USA
|
100 Participants
|
68 Participants
|
95 Participants
|
54 Participants
|
43 Participants
|
37 Participants
|
89 Participants
|
84 Participants
|
89 Participants
|
68 Participants
|
74 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-Y at Month 0-Peru
|
3 Participants
|
34 Participants
|
0 Participants
|
5 Participants
|
35 Participants
|
41 Participants
|
6 Participants
|
14 Participants
|
5 Participants
|
17 Participants
|
11 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-Y at Month 0-Total
|
6 Participants
|
69 Participants
|
8 Participants
|
54 Participants
|
95 Participants
|
107 Participants
|
20 Participants
|
33 Participants
|
19 Participants
|
52 Participants
|
40 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-Y at Month 0-USA
|
3 Participants
|
35 Participants
|
8 Participants
|
49 Participants
|
60 Participants
|
66 Participants
|
14 Participants
|
19 Participants
|
14 Participants
|
35 Participants
|
29 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-N at Month 0-Peru
|
131 Participants
|
98 Participants
|
135 Participants
|
130 Participants
|
97 Participants
|
88 Participants
|
128 Participants
|
121 Participants
|
126 Participants
|
117 Participants
|
119 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-Y at Month 0-Peru
|
0 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
2 Participants
|
4 Participants
|
1 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
1 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-N at Month 0-Total
|
244 Participants
|
174 Participants
|
242 Participants
|
193 Participants
|
146 Participants
|
131 Participants
|
227 Participants
|
219 Participants
|
226 Participants
|
196 Participants
|
203 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-N at Month 0-USA
|
113 Participants
|
76 Participants
|
107 Participants
|
63 Participants
|
49 Participants
|
43 Participants
|
99 Participants
|
98 Participants
|
100 Participants
|
79 Participants
|
84 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-Y at Month 0-Peru
|
4 Participants
|
37 Participants
|
0 Participants
|
5 Participants
|
38 Participants
|
47 Participants
|
7 Participants
|
14 Participants
|
9 Participants
|
18 Participants
|
16 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-Y at Month 0-Total
|
8 Participants
|
78 Participants
|
10 Participants
|
59 Participants
|
106 Participants
|
121 Participants
|
25 Participants
|
33 Participants
|
26 Participants
|
56 Participants
|
49 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-Y at Month 0-USA
|
4 Participants
|
41 Participants
|
10 Participants
|
54 Participants
|
68 Participants
|
74 Participants
|
18 Participants
|
19 Participants
|
17 Participants
|
38 Participants
|
33 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-N at Month 0-Peru
|
117 Participants
|
88 Participants
|
122 Participants
|
117 Participants
|
87 Participants
|
89 Participants
|
118 Participants
|
111 Participants
|
115 Participants
|
109 Participants
|
111 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-N at Month 0-Total
|
218 Participants
|
165 Participants
|
221 Participants
|
176 Participants
|
138 Participants
|
131 Participants
|
211 Participants
|
203 Participants
|
210 Participants
|
191 Participants
|
193 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-N at Month 0-USA
|
101 Participants
|
77 Participants
|
99 Participants
|
59 Participants
|
51 Participants
|
42 Participants
|
93 Participants
|
92 Participants
|
95 Participants
|
82 Participants
|
82 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-Y at Month 0-Peru
|
5 Participants
|
34 Participants
|
0 Participants
|
5 Participants
|
35 Participants
|
33 Participants
|
4 Participants
|
11 Participants
|
7 Participants
|
13 Participants
|
11 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-Y at Month 0-Total
|
14 Participants
|
67 Participants
|
11 Participants
|
56 Participants
|
94 Participants
|
101 Participants
|
21 Participants
|
29 Participants
|
22 Participants
|
41 Participants
|
39 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-Y at Month 0-USA
|
9 Participants
|
33 Participants
|
11 Participants
|
51 Participants
|
59 Participants
|
68 Participants
|
17 Participants
|
18 Participants
|
15 Participants
|
28 Participants
|
28 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-N at Month 0-Peru
|
13 Participants
|
11 Participants
|
13 Participants
|
13 Participants
|
11 Participants
|
9 Participants
|
12 Participants
|
12 Participants
|
12 Participants
|
11 Participants
|
12 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-N at Month 0-Total
|
29 Participants
|
24 Participants
|
28 Participants
|
24 Participants
|
20 Participants
|
17 Participants
|
26 Participants
|
28 Participants
|
26 Participants
|
21 Participants
|
24 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-Y at Month 0-Total
|
1 Participants
|
6 Participants
|
2 Participants
|
6 Participants
|
10 Participants
|
13 Participants
|
4 Participants
|
2 Participants
|
4 Participants
|
9 Participants
|
6 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-N at Month 0-USA
|
16 Participants
|
13 Participants
|
15 Participants
|
11 Participants
|
9 Participants
|
8 Participants
|
14 Participants
|
16 Participants
|
14 Participants
|
10 Participants
|
12 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-N at Month 0-Peru
|
103 Participants
|
76 Participants
|
108 Participants
|
103 Participants
|
75 Participants
|
75 Participants
|
104 Participants
|
97 Participants
|
101 Participants
|
95 Participants
|
97 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-N at Month 0-Total
|
188 Participants
|
143 Participants
|
191 Participants
|
152 Participants
|
117 Participants
|
111 Participants
|
182 Participants
|
174 Participants
|
183 Participants
|
164 Participants
|
168 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-Y at Month 0-Peru
|
5 Participants
|
32 Participants
|
0 Participants
|
5 Participants
|
33 Participants
|
33 Participants
|
4 Participants
|
11 Participants
|
7 Participants
|
13 Participants
|
11 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-Y at Month 0-Total
|
12 Participants
|
57 Participants
|
9 Participants
|
48 Participants
|
83 Participants
|
89 Participants
|
18 Participants
|
26 Participants
|
17 Participants
|
36 Participants
|
32 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-Y at Month 0-USA
|
7 Participants
|
25 Participants
|
9 Participants
|
43 Participants
|
50 Participants
|
56 Participants
|
14 Participants
|
15 Participants
|
10 Participants
|
23 Participants
|
21 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-Y at Month 0-USA
|
1 Participants
|
4 Participants
|
2 Participants
|
6 Participants
|
8 Participants
|
9 Participants
|
3 Participants
|
1 Participants
|
3 Participants
|
7 Participants
|
5 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-N at Month 0-Peru
|
46 Participants
|
34 Participants
|
50 Participants
|
47 Participants
|
33 Participants
|
33 Participants
|
48 Participants
|
44 Participants
|
45 Participants
|
46 Participants
|
44 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-N at Month 0-Total
|
73 Participants
|
52 Participants
|
77 Participants
|
61 Participants
|
44 Participants
|
43 Participants
|
75 Participants
|
68 Participants
|
69 Participants
|
66 Participants
|
66 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-N at Month 0-USA
|
27 Participants
|
18 Participants
|
27 Participants
|
14 Participants
|
11 Participants
|
10 Participants
|
27 Participants
|
24 Participants
|
24 Participants
|
20 Participants
|
22 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-Y at Month 0-Peru
|
4 Participants
|
16 Participants
|
0 Participants
|
3 Participants
|
17 Participants
|
17 Participants
|
2 Participants
|
6 Participants
|
5 Participants
|
4 Participants
|
6 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-Y at Month 0-Total
|
7 Participants
|
28 Participants
|
3 Participants
|
19 Participants
|
36 Participants
|
37 Participants
|
5 Participants
|
12 Participants
|
11 Participants
|
14 Participants
|
14 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-Y at Month 0-USA
|
3 Participants
|
12 Participants
|
3 Participants
|
16 Participants
|
19 Participants
|
20 Participants
|
3 Participants
|
6 Participants
|
6 Participants
|
10 Participants
|
8 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-N at Month 0-USA
|
85 Participants
|
67 Participants
|
83 Participants
|
49 Participants
|
42 Participants
|
36 Participants
|
78 Participants
|
77 Participants
|
82 Participants
|
69 Participants
|
71 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-Y at Month 0-Peru
|
2 Participants
|
16 Participants
|
0 Participants
|
3 Participants
|
17 Participants
|
17 Participants
|
2 Participants
|
7 Participants
|
5 Participants
|
4 Participants
|
5 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-N at Month 0-Peru
|
42 Participants
|
33 Participants
|
42 Participants
|
42 Participants
|
33 Participants
|
31 Participants
|
40 Participants
|
39 Participants
|
39 Participants
|
38 Participants
|
38 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-N at Month 0-Total
|
71 Participants
|
52 Participants
|
69 Participants
|
52 Participants
|
42 Participants
|
42 Participants
|
63 Participants
|
63 Participants
|
65 Participants
|
63 Participants
|
59 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-N at Month 0-Peru
|
49 Participants
|
35 Participants
|
51 Participants
|
48 Participants
|
34 Participants
|
34 Participants
|
49 Participants
|
44 Participants
|
46 Participants
|
47 Participants
|
46 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-N at Month 0-Total
|
67 Participants
|
49 Participants
|
71 Participants
|
59 Participants
|
44 Participants
|
38 Participants
|
66 Participants
|
60 Participants
|
59 Participants
|
60 Participants
|
57 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-Y at Month 0-Peru
|
0 Participants
|
9 Participants
|
0 Participants
|
0 Participants
|
9 Participants
|
11 Participants
|
2 Participants
|
3 Participants
|
3 Participants
|
4 Participants
|
4 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-Y at Month 0-Total
|
0 Participants
|
19 Participants
|
2 Participants
|
19 Participants
|
29 Participants
|
29 Participants
|
8 Participants
|
8 Participants
|
6 Participants
|
8 Participants
|
12 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-Y at Month 0-Total
|
4 Participants
|
22 Participants
|
0 Participants
|
12 Participants
|
27 Participants
|
33 Participants
|
5 Participants
|
11 Participants
|
12 Participants
|
11 Participants
|
14 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-Y at Month 0-USA
|
2 Participants
|
6 Participants
|
0 Participants
|
9 Participants
|
10 Participants
|
16 Participants
|
3 Participants
|
4 Participants
|
7 Participants
|
7 Participants
|
9 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-N at Month 0-USA
|
18 Participants
|
14 Participants
|
20 Participants
|
11 Participants
|
10 Participants
|
4 Participants
|
17 Participants
|
16 Participants
|
13 Participants
|
13 Participants
|
11 Participants
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-Y at Month 0-USA
|
0 Participants
|
10 Participants
|
2 Participants
|
19 Participants
|
20 Participants
|
18 Participants
|
6 Participants
|
5 Participants
|
3 Participants
|
4 Participants
|
8 Participants
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population with positive responders (USA and Peru only), all available data at each visit
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and Comorbidity Group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
n=388 Participants
3: Clinical spectrums
|
Group 8
n=388 Participants
Clinical spectrums , age 55+
|
Group 9
n=388 Participants
HIV
|
Group 10
n=388 Participants
Hypertension
|
Group 11
n=388 Participants
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-Y at Month 0-USA
|
0 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.0
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-N at Month 0-Peru
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.3
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.2
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.3
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.3
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.2
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.3
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.3
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.3
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.3
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.3
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-Y at Month 0-USA
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.0
|
1 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.8 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.8 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.0
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-N at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-N at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-Y at Month 0-Peru
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-Y at Month 0-Total
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-E M-Y at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-N at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-Y at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-Y at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-N-Y at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-N at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-Y at Month 0-Peru
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-Y at Month 0-Total
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 0.8
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF3a6-Y at Month 0-USA
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 0.8
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-N at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-Y at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
0 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.0
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-Y at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-ORF7a7b8-Y at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-N at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-N at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-N at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-Y at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-Y at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S1-Y at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-N at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-Y at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-Y at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-S2-Y at Month 0-USA
|
0 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-N at Month 0-Peru
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-N at Month 0-Total
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-N at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-Y at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.5
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.4 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-Y at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Spike-Y at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-N at Month 0-Peru
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.3
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.3
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.2
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.3
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.3
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.1
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.1
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.1
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-N at Month 0-Total
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.1
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.0
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-N at Month 0-USA
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-Y at Month 0-Peru
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.6
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.1
|
—
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.4 to 0.6
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.1
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.5 to 2.5
|
1 % T cells expressing IFN-g/IL-2
Interval 0.9 to 1.0
|
1.1 % T cells expressing IFN-g/IL-2
Interval 0.7 to 7.9
|
0.8 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.6
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 2.3
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.1
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-Y at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.0
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.1
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.1 to 1.2
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.1
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Any COV2-Y at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-N at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-N at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-Y at Month 0-Peru
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
—
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-E M-Y at Month 0-Total
|
0 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.0
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-N at Month 0-Peru
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-N at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-N at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-Y at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
—
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.0
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.5 to 0.6
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 5.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-Y at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 1.2
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-N-Y at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-N at Month 0-Peru
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-N at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-N at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-Y at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.8
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
1 % T cells expressing IFN-g/IL-2
Interval 0.7 to 1.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-Y at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.9
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF3a6-Y at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-N at Month 0-Peru
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.9
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-N at Month 0-Total
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-Y at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
1.1 % T cells expressing IFN-g/IL-2
Interval 0.6 to 1.9
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.8
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-Y at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-ORF7a7b8-Y at Month 0-USA
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.3
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-N at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-Y at Month 0-Peru
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
—
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-Y at Month 0-Total
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S1-Y at Month 0-USA
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-N at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-N at Month 0-USA
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-Y at Month 0-Peru
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.9
|
—
|
—
|
—
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.9
|
—
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-Y at Month 0-Total
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.8
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.6 to 0.6
|
—
|
0.8 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-S2-Y at Month 0-USA
|
—
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.6 to 0.6
|
—
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.6 to 0.6
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-N at Month 0-Peru
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-N at Month 0-Total
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-N at Month 0-USA
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.6
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-Y at Month 0-Peru
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
—
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.4
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.4
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 2.7
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-Y at Month 0-Total
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.2 to 1.0
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD8+-Spike-Y at Month 0-USA
|
—
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.1
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.3
|
0.1 % T cells expressing IFN-g/IL-2
Interval 0.0 to 0.1
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.7
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.1 to 0.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-N at Month 0-Total
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.0
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-N at Month 0-USA
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.0
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.9
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.0
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.9
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.8
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.9
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.9
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.0
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.0
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.9
|
0.5 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.0
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-Y at Month 0-Peru
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.4
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.4
|
—
|
0.2 % T cells expressing IFN-g/IL-2
Interval 0.2 to 0.5
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.4
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.3
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.2
|
1.1 % T cells expressing IFN-g/IL-2
Interval 0.7 to 1.6
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.0
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.7 to 1.3
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
|
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
CD4+-Any COV2-Y at Month 0-Total
|
0.3 % T cells expressing IFN-g/IL-2
Interval 0.3 to 0.9
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.3
|
0.4 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.2
|
0.7 % T cells expressing IFN-g/IL-2
Interval 0.4 to 1.1
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.8 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.2
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.1
|
0.9 % T cells expressing IFN-g/IL-2
Interval 0.5 to 1.2
|
0.6 % T cells expressing IFN-g/IL-2
Interval 0.3 to 1.0
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). The sample will be included in the analysis only if the number of IgD- B cells is equal or greater than 1000 for that sample. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and comorbidity group among America Cohort
Outcome measures
| Measure |
Group 1A
n=388 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=388 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=388 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=388 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=388 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=388 Participants
2B: Hospitalized, \> 55
|
Group 3
n=388 Participants
3: Clinical spectrums
|
Group 8
n=388 Participants
Clinical spectrums , age 55+
|
Group 9
n=388 Participants
HIV
|
Group 10
n=388 Participants
Hypertension
|
Group 11
n=388 Participants
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-N-Peru
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-N-Total
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-N-USA
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.00 percentage of cells
Interval 0.0 to 0.03
|
0.00 percentage of cells
Interval 0.0 to 0.03
|
0.00 percentage of cells
Interval 0.0 to 0.03
|
0.00 percentage of cells
Interval 0.0 to 0.03
|
0.00 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.00 percentage of cells
Interval 0.0 to 0.04
|
0.00 percentage of cells
Interval 0.0 to 0.04
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-Y-Peru
|
0.02 percentage of cells
Interval 0.0 to 0.05
|
0.05 percentage of cells
Interval 0.03 to 0.08
|
0.02 percentage of cells
Interval 0.0 to 0.04
|
0.02 percentage of cells
Interval 0.0 to 0.06
|
0.03 percentage of cells
Interval 0.01 to 0.08
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.02 percentage of cells
Interval 0.0 to 0.05
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
—
|
0.03 percentage of cells
Interval 0.0 to 0.03
|
0.02 percentage of cells
Interval 0.0 to 0.06
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-Y-Total
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.02 percentage of cells
Interval 0.0 to 0.06
|
0.03 percentage of cells
Interval 0.0 to 0.07
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.02 percentage of cells
Interval 0.0 to 0.06
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgA+ of Memory B Cells-Y-USA
|
0.00 percentage of cells
Interval 0.0 to 0.03
|
0.02 percentage of cells
Interval 0.0 to 0.05
|
0.05 percentage of cells
Interval 0.01 to 0.08
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.04
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-N-Peru
|
0.16 percentage of cells
Interval 0.08 to 0.31
|
0.15 percentage of cells
Interval 0.07 to 0.31
|
0.16 percentage of cells
Interval 0.08 to 0.33
|
0.15 percentage of cells
Interval 0.07 to 0.3
|
0.15 percentage of cells
Interval 0.07 to 0.32
|
0.16 percentage of cells
Interval 0.09 to 0.33
|
0.15 percentage of cells
Interval 0.08 to 0.31
|
0.16 percentage of cells
Interval 0.08 to 0.32
|
0.15 percentage of cells
Interval 0.07 to 0.32
|
0.16 percentage of cells
Interval 0.08 to 0.32
|
0.15 percentage of cells
Interval 0.07 to 0.3
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-N-Total
|
0.15 percentage of cells
Interval 0.06 to 0.3
|
0.15 percentage of cells
Interval 0.06 to 0.3
|
0.15 percentage of cells
Interval 0.06 to 0.31
|
0.15 percentage of cells
Interval 0.06 to 0.3
|
0.15 percentage of cells
Interval 0.05 to 0.3
|
0.16 percentage of cells
Interval 0.06 to 0.31
|
0.15 percentage of cells
Interval 0.06 to 0.3
|
0.15 percentage of cells
Interval 0.06 to 0.31
|
0.16 percentage of cells
Interval 0.06 to 0.31
|
0.16 percentage of cells
Interval 0.07 to 0.32
|
0.15 percentage of cells
Interval 0.06 to 0.31
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-N-USA
|
0.12 percentage of cells
Interval 0.04 to 0.24
|
0.15 percentage of cells
Interval 0.05 to 0.29
|
0.15 percentage of cells
Interval 0.05 to 0.3
|
0.14 percentage of cells
Interval 0.05 to 0.28
|
0.14 percentage of cells
Interval 0.04 to 0.28
|
0.15 percentage of cells
Interval 0.05 to 0.3
|
0.15 percentage of cells
Interval 0.05 to 0.28
|
0.14 percentage of cells
Interval 0.05 to 0.28
|
0.16 percentage of cells
Interval 0.06 to 0.3
|
0.19 percentage of cells
Interval 0.06 to 0.32
|
0.16 percentage of cells
Interval 0.03 to 0.31
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-Y-Peru
|
0.13 percentage of cells
Interval 0.06 to 0.35
|
0.38 percentage of cells
Interval 0.19 to 0.46
|
0.12 percentage of cells
Interval 0.08 to 0.18
|
0.18 percentage of cells
Interval 0.09 to 0.34
|
0.27 percentage of cells
Interval 0.12 to 0.4
|
0.08 percentage of cells
Interval 0.05 to 0.16
|
0.14 percentage of cells
Interval 0.05 to 0.36
|
0.11 percentage of cells
Interval 0.06 to 0.18
|
—
|
0.10 percentage of cells
Interval 0.06 to 0.14
|
0.17 percentage of cells
Interval 0.09 to 0.33
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-Y-Total
|
0.15 percentage of cells
Interval 0.06 to 0.31
|
0.20 percentage of cells
Interval 0.1 to 0.37
|
0.12 percentage of cells
Interval 0.04 to 0.22
|
0.20 percentage of cells
Interval 0.07 to 0.32
|
0.22 percentage of cells
Interval 0.11 to 0.32
|
0.12 percentage of cells
Interval 0.04 to 0.25
|
0.15 percentage of cells
Interval 0.05 to 0.32
|
0.15 percentage of cells
Interval 0.05 to 0.28
|
0.06 percentage of cells
Interval 0.0 to 0.14
|
0.13 percentage of cells
Interval 0.05 to 0.25
|
0.15 percentage of cells
Interval 0.06 to 0.28
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgG+ of Memory B Cells-Y-USA
|
0.16 percentage of cells
Interval 0.05 to 0.3
|
0.17 percentage of cells
Interval 0.07 to 0.26
|
0.12 percentage of cells
Interval 0.0 to 0.24
|
0.22 percentage of cells
Interval 0.06 to 0.29
|
0.21 percentage of cells
Interval 0.1 to 0.3
|
0.15 percentage of cells
Interval 0.04 to 0.27
|
0.15 percentage of cells
Interval 0.05 to 0.29
|
0.19 percentage of cells
Interval 0.04 to 0.28
|
0.06 percentage of cells
Interval 0.0 to 0.14
|
0.13 percentage of cells
Interval 0.05 to 0.26
|
0.15 percentage of cells
Interval 0.05 to 0.26
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-N-Peru
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-N-Total
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-N-USA
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.03
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-Y-Peru
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.14
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.00 percentage of cells
Interval 0.0 to 0.0
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
—
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-Y-Total
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.0
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ IgM+ of Memory B Cells-Y-USA
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.02 percentage of cells
Interval 0.0 to 0.05
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.0
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ of Total B Cells-N-Peru
|
0.07 percentage of cells
Interval 0.05 to 0.12
|
0.08 percentage of cells
Interval 0.05 to 0.13
|
0.08 percentage of cells
Interval 0.05 to 0.13
|
0.08 percentage of cells
Interval 0.05 to 0.13
|
0.07 percentage of cells
Interval 0.04 to 0.13
|
0.08 percentage of cells
Interval 0.05 to 0.13
|
0.07 percentage of cells
Interval 0.05 to 0.12
|
0.08 percentage of cells
Interval 0.05 to 0.13
|
0.08 percentage of cells
Interval 0.05 to 0.13
|
0.08 percentage of cells
Interval 0.05 to 0.13
|
0.08 percentage of cells
Interval 0.05 to 0.13
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ of Total B Cells-N-Total
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.07 percentage of cells
Interval 0.04 to 0.12
|
0.07 percentage of cells
Interval 0.04 to 0.12
|
0.06 percentage of cells
Interval 0.03 to 0.12
|
0.06 percentage of cells
Interval 0.03 to 0.12
|
0.07 percentage of cells
Interval 0.04 to 0.12
|
0.07 percentage of cells
Interval 0.04 to 0.11
|
0.07 percentage of cells
Interval 0.04 to 0.12
|
0.07 percentage of cells
Interval 0.04 to 0.12
|
0.07 percentage of cells
Interval 0.04 to 0.13
|
0.07 percentage of cells
Interval 0.04 to 0.12
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ of Total B Cells-N-USA
|
0.04 percentage of cells
Interval 0.02 to 0.07
|
0.05 percentage of cells
Interval 0.03 to 0.1
|
0.05 percentage of cells
Interval 0.03 to 0.09
|
0.05 percentage of cells
Interval 0.03 to 0.09
|
0.05 percentage of cells
Interval 0.03 to 0.09
|
0.05 percentage of cells
Interval 0.03 to 0.1
|
0.04 percentage of cells
Interval 0.03 to 0.09
|
0.05 percentage of cells
Interval 0.03 to 0.1
|
0.06 percentage of cells
Interval 0.03 to 0.1
|
0.06 percentage of cells
Interval 0.03 to 0.12
|
0.04 percentage of cells
Interval 0.03 to 0.12
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ of Total B Cells-Y-Peru
|
0.10 percentage of cells
Interval 0.05 to 0.16
|
0.19 percentage of cells
Interval 0.11 to 0.28
|
0.05 percentage of cells
Interval 0.04 to 0.07
|
0.08 percentage of cells
Interval 0.05 to 0.13
|
0.10 percentage of cells
Interval 0.07 to 0.13
|
0.05 percentage of cells
Interval 0.04 to 0.12
|
0.12 percentage of cells
Interval 0.04 to 0.15
|
0.07 percentage of cells
Interval 0.04 to 0.16
|
—
|
0.07 percentage of cells
Interval 0.05 to 0.09
|
0.08 percentage of cells
Interval 0.05 to 0.13
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ of Total B Cells-Y-Total
|
0.07 percentage of cells
Interval 0.04 to 0.13
|
0.06 percentage of cells
Interval 0.04 to 0.13
|
0.07 percentage of cells
Interval 0.04 to 0.17
|
0.07 percentage of cells
Interval 0.04 to 0.12
|
0.08 percentage of cells
Interval 0.06 to 0.11
|
0.06 percentage of cells
Interval 0.04 to 0.13
|
0.07 percentage of cells
Interval 0.04 to 0.13
|
0.06 percentage of cells
Interval 0.04 to 0.12
|
0.03 percentage of cells
Interval 0.02 to 0.05
|
0.05 percentage of cells
Interval 0.03 to 0.09
|
0.06 percentage of cells
Interval 0.04 to 0.11
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%RBD+ of Total B Cells-Y-USA
|
0.06 percentage of cells
Interval 0.04 to 0.1
|
0.05 percentage of cells
Interval 0.03 to 0.11
|
0.14 percentage of cells
Interval 0.03 to 0.27
|
0.06 percentage of cells
Interval 0.04 to 0.1
|
0.06 percentage of cells
Interval 0.05 to 0.1
|
0.06 percentage of cells
Interval 0.04 to 0.13
|
0.06 percentage of cells
Interval 0.04 to 0.11
|
0.06 percentage of cells
Interval 0.03 to 0.09
|
0.03 percentage of cells
Interval 0.02 to 0.05
|
0.05 percentage of cells
Interval 0.03 to 0.09
|
0.06 percentage of cells
Interval 0.03 to 0.09
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Memory B Cells-N-Peru
|
0.08 percentage of cells
Interval 0.03 to 0.12
|
0.07 percentage of cells
Interval 0.03 to 0.12
|
0.07 percentage of cells
Interval 0.03 to 0.13
|
0.07 percentage of cells
Interval 0.03 to 0.12
|
0.07 percentage of cells
Interval 0.03 to 0.12
|
0.08 percentage of cells
Interval 0.03 to 0.13
|
0.08 percentage of cells
Interval 0.03 to 0.13
|
0.08 percentage of cells
Interval 0.03 to 0.13
|
0.07 percentage of cells
Interval 0.03 to 0.13
|
0.07 percentage of cells
Interval 0.03 to 0.13
|
0.07 percentage of cells
Interval 0.03 to 0.12
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Memory B Cells-N-Total
|
0.07 percentage of cells
Interval 0.03 to 0.11
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.07 percentage of cells
Interval 0.03 to 0.11
|
0.07 percentage of cells
Interval 0.03 to 0.11
|
0.07 percentage of cells
Interval 0.03 to 0.11
|
0.07 percentage of cells
Interval 0.03 to 0.11
|
0.07 percentage of cells
Interval 0.03 to 0.12
|
0.06 percentage of cells
Interval 0.03 to 0.12
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Memory B Cells-N-USA
|
0.06 percentage of cells
Interval 0.03 to 0.09
|
0.06 percentage of cells
Interval 0.02 to 0.09
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
0.06 percentage of cells
Interval 0.03 to 0.1
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
0.06 percentage of cells
Interval 0.02 to 0.11
|
0.06 percentage of cells
Interval 0.02 to 0.11
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Memory B Cells-Y-Peru
|
0.07 percentage of cells
Interval 0.03 to 0.13
|
0.14 percentage of cells
Interval 0.08 to 0.18
|
0.10 percentage of cells
Interval 0.08 to 0.14
|
0.08 percentage of cells
Interval 0.03 to 0.13
|
0.14 percentage of cells
Interval 0.08 to 0.23
|
0.04 percentage of cells
Interval 0.02 to 0.1
|
0.05 percentage of cells
Interval 0.01 to 0.11
|
0.05 percentage of cells
Interval 0.02 to 0.12
|
—
|
0.10 percentage of cells
Interval 0.06 to 0.12
|
0.08 percentage of cells
Interval 0.03 to 0.13
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Memory B Cells-Y-Total
|
0.06 percentage of cells
Interval 0.02 to 0.11
|
0.07 percentage of cells
Interval 0.04 to 0.12
|
0.08 percentage of cells
Interval 0.04 to 0.11
|
0.07 percentage of cells
Interval 0.03 to 0.11
|
0.08 percentage of cells
Interval 0.04 to 0.15
|
0.06 percentage of cells
Interval 0.03 to 0.1
|
0.06 percentage of cells
Interval 0.01 to 0.1
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
0.04 percentage of cells
Interval 0.02 to 0.06
|
0.06 percentage of cells
Interval 0.02 to 0.09
|
0.07 percentage of cells
Interval 0.03 to 0.1
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Memory B Cells-Y-USA
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
0.06 percentage of cells
Interval 0.03 to 0.11
|
0.06 percentage of cells
Interval 0.02 to 0.09
|
0.06 percentage of cells
Interval 0.03 to 0.09
|
0.07 percentage of cells
Interval 0.03 to 0.1
|
0.06 percentage of cells
Interval 0.04 to 0.09
|
0.06 percentage of cells
Interval 0.01 to 0.1
|
0.06 percentage of cells
Interval 0.02 to 0.1
|
0.04 percentage of cells
Interval 0.02 to 0.06
|
0.05 percentage of cells
Interval 0.02 to 0.08
|
0.06 percentage of cells
Interval 0.02 to 0.09
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Total B Cells-N-Peru
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Total B Cells-N-Peru
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Total B Cells-N-Total
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Total B Cells-N-USA
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Total B Cells-Y-Peru
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.02 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
—
|
0.01 percentage of cells
Interval 0.01 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Total B Cells-Y-Total
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Total B Cells-N-Total
|
0.01 percentage of cells
Interval 0.01 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
0.01 percentage of cells
Interval 0.0 to 0.03
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Total B Cells-N-USA
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Total B Cells-Y-Peru
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
0.03 percentage of cells
Interval 0.02 to 0.04
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
0.04 percentage of cells
Interval 0.02 to 0.06
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.02 percentage of cells
Interval 0.0 to 0.03
|
0.02 percentage of cells
Interval 0.01 to 0.03
|
—
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Total B Cells-Y-Total
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.02 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgA+ of Total B Cells-Y-USA
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.01 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Memory B Cells-N-Peru
|
0.79 percentage of cells
Interval 0.4 to 1.22
|
0.71 percentage of cells
Interval 0.38 to 1.21
|
0.73 percentage of cells
Interval 0.41 to 1.22
|
0.64 percentage of cells
Interval 0.37 to 1.23
|
0.68 percentage of cells
Interval 0.37 to 1.21
|
0.81 percentage of cells
Interval 0.42 to 1.23
|
0.75 percentage of cells
Interval 0.42 to 1.24
|
0.79 percentage of cells
Interval 0.41 to 1.22
|
0.72 percentage of cells
Interval 0.39 to 1.22
|
0.77 percentage of cells
Interval 0.4 to 1.22
|
0.67 percentage of cells
Interval 0.37 to 1.23
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Memory B Cells-N-Total
|
0.69 percentage of cells
Interval 0.36 to 1.21
|
0.68 percentage of cells
Interval 0.33 to 1.2
|
0.72 percentage of cells
Interval 0.36 to 1.22
|
0.63 percentage of cells
Interval 0.34 to 1.21
|
0.63 percentage of cells
Interval 0.31 to 1.2
|
0.72 percentage of cells
Interval 0.36 to 1.24
|
0.68 percentage of cells
Interval 0.35 to 1.21
|
0.69 percentage of cells
Interval 0.36 to 1.22
|
0.71 percentage of cells
Interval 0.35 to 1.23
|
0.73 percentage of cells
Interval 0.37 to 1.26
|
0.64 percentage of cells
Interval 0.36 to 1.22
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Memory B Cells-N-USA
|
0.56 percentage of cells
Interval 0.32 to 1.11
|
0.67 percentage of cells
Interval 0.25 to 1.15
|
0.69 percentage of cells
Interval 0.32 to 1.27
|
0.58 percentage of cells
Interval 0.31 to 1.06
|
0.57 percentage of cells
Interval 0.23 to 1.14
|
0.67 percentage of cells
Interval 0.32 to 1.29
|
0.56 percentage of cells
Interval 0.3 to 1.07
|
0.63 percentage of cells
Interval 0.31 to 1.23
|
0.69 percentage of cells
Interval 0.31 to 1.33
|
0.68 percentage of cells
Interval 0.31 to 1.43
|
0.61 percentage of cells
Interval 0.3 to 1.21
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Memory B Cells-Y-Peru
|
0.64 percentage of cells
Interval 0.39 to 1.2
|
1.20 percentage of cells
Interval 0.83 to 1.53
|
0.47 percentage of cells
Interval 0.39 to 0.93
|
0.81 percentage of cells
Interval 0.43 to 1.18
|
1.05 percentage of cells
Interval 0.62 to 1.23
|
0.52 percentage of cells
Interval 0.29 to 0.64
|
0.62 percentage of cells
Interval 0.35 to 1.01
|
0.62 percentage of cells
Interval 0.4 to 0.86
|
—
|
0.51 percentage of cells
Interval 0.28 to 0.62
|
0.81 percentage of cells
Interval 0.43 to 1.17
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Memory B Cells-Y-Total
|
0.66 percentage of cells
Interval 0.29 to 1.21
|
0.72 percentage of cells
Interval 0.31 to 1.53
|
0.29 percentage of cells
Interval 0.09 to 0.52
|
0.81 percentage of cells
Interval 0.29 to 1.31
|
1.01 percentage of cells
Interval 0.57 to 1.27
|
0.50 percentage of cells
Interval 0.18 to 0.86
|
0.68 percentage of cells
Interval 0.08 to 1.17
|
0.63 percentage of cells
Interval 0.24 to 1.08
|
0.29 percentage of cells
Interval 0.05 to 0.48
|
0.52 percentage of cells
Interval 0.15 to 0.97
|
0.69 percentage of cells
Interval 0.29 to 1.15
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Memory B Cells-Y-USA
|
0.68 percentage of cells
Interval 0.16 to 1.19
|
0.53 percentage of cells
Interval 0.25 to 1.28
|
0.16 percentage of cells
Interval 0.07 to 0.33
|
0.75 percentage of cells
Interval 0.13 to 1.37
|
0.97 percentage of cells
Interval 0.55 to 1.27
|
0.36 percentage of cells
Interval 0.15 to 0.97
|
0.76 percentage of cells
Interval 0.08 to 1.44
|
0.63 percentage of cells
Interval 0.16 to 1.12
|
0.29 percentage of cells
Interval 0.05 to 0.48
|
0.55 percentage of cells
Interval 0.15 to 0.97
|
0.63 percentage of cells
Interval 0.16 to 1.12
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Total B Cells-N-Peru
|
0.18 percentage of cells
Interval 0.09 to 0.25
|
0.18 percentage of cells
Interval 0.08 to 0.27
|
0.20 percentage of cells
Interval 0.09 to 0.29
|
0.19 percentage of cells
Interval 0.09 to 0.29
|
0.18 percentage of cells
Interval 0.08 to 0.26
|
0.20 percentage of cells
Interval 0.1 to 0.29
|
0.18 percentage of cells
Interval 0.08 to 0.27
|
0.19 percentage of cells
Interval 0.1 to 0.27
|
0.19 percentage of cells
Interval 0.08 to 0.27
|
0.19 percentage of cells
Interval 0.09 to 0.29
|
0.19 percentage of cells
Interval 0.09 to 0.29
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Total B Cells-N-Total
|
0.15 percentage of cells
Interval 0.08 to 0.23
|
0.14 percentage of cells
Interval 0.06 to 0.24
|
0.15 percentage of cells
Interval 0.07 to 0.24
|
0.14 percentage of cells
Interval 0.06 to 0.25
|
0.13 percentage of cells
Interval 0.06 to 0.23
|
0.15 percentage of cells
Interval 0.07 to 0.25
|
0.14 percentage of cells
Interval 0.07 to 0.23
|
0.15 percentage of cells
Interval 0.07 to 0.25
|
0.15 percentage of cells
Interval 0.07 to 0.24
|
0.16 percentage of cells
Interval 0.07 to 0.25
|
0.16 percentage of cells
Interval 0.07 to 0.25
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Total B Cells-N-USA
|
0.10 percentage of cells
Interval 0.05 to 0.14
|
0.11 percentage of cells
Interval 0.04 to 0.18
|
0.12 percentage of cells
Interval 0.05 to 0.19
|
0.11 percentage of cells
Interval 0.05 to 0.18
|
0.10 percentage of cells
Interval 0.04 to 0.17
|
0.12 percentage of cells
Interval 0.04 to 0.18
|
0.10 percentage of cells
Interval 0.05 to 0.16
|
0.11 percentage of cells
Interval 0.05 to 0.18
|
0.12 percentage of cells
Interval 0.05 to 0.19
|
0.12 percentage of cells
Interval 0.05 to 0.21
|
0.11 percentage of cells
Interval 0.05 to 0.19
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Total B Cells-Y-Peru
|
0.19 percentage of cells
Interval 0.08 to 0.31
|
0.24 percentage of cells
Interval 0.21 to 0.39
|
0.10 percentage of cells
Interval 0.08 to 0.16
|
0.19 percentage of cells
Interval 0.08 to 0.27
|
0.27 percentage of cells
Interval 0.17 to 0.32
|
0.09 percentage of cells
Interval 0.06 to 0.19
|
0.19 percentage of cells
Interval 0.08 to 0.29
|
0.14 percentage of cells
Interval 0.07 to 0.31
|
—
|
0.15 percentage of cells
Interval 0.07 to 0.18
|
0.18 percentage of cells
Interval 0.08 to 0.26
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Total B Cells-Y-Total
|
0.13 percentage of cells
Interval 0.05 to 0.25
|
0.12 percentage of cells
Interval 0.05 to 0.24
|
0.06 percentage of cells
Interval 0.01 to 0.13
|
0.13 percentage of cells
Interval 0.06 to 0.23
|
0.18 percentage of cells
Interval 0.12 to 0.28
|
0.09 percentage of cells
Interval 0.05 to 0.19
|
0.14 percentage of cells
Interval 0.01 to 0.25
|
0.11 percentage of cells
Interval 0.05 to 0.22
|
0.04 percentage of cells
Interval 0.01 to 0.11
|
0.10 percentage of cells
Interval 0.04 to 0.17
|
0.13 percentage of cells
Interval 0.06 to 0.21
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgG+ of Total B Cells-Y-USA
|
0.12 percentage of cells
Interval 0.04 to 0.21
|
0.11 percentage of cells
Interval 0.04 to 0.17
|
0.04 percentage of cells
Interval 0.0 to 0.08
|
0.11 percentage of cells
Interval 0.03 to 0.19
|
0.16 percentage of cells
Interval 0.11 to 0.24
|
0.08 percentage of cells
Interval 0.04 to 0.17
|
0.12 percentage of cells
Interval 0.01 to 0.24
|
0.11 percentage of cells
Interval 0.04 to 0.19
|
0.04 percentage of cells
Interval 0.01 to 0.11
|
0.10 percentage of cells
Interval 0.04 to 0.17
|
0.11 percentage of cells
Interval 0.04 to 0.17
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-N-Peru
|
0.12 percentage of cells
Interval 0.09 to 0.15
|
0.11 percentage of cells
Interval 0.08 to 0.15
|
0.11 percentage of cells
Interval 0.08 to 0.15
|
0.11 percentage of cells
Interval 0.08 to 0.15
|
0.12 percentage of cells
Interval 0.08 to 0.15
|
0.12 percentage of cells
Interval 0.08 to 0.15
|
0.12 percentage of cells
Interval 0.08 to 0.15
|
0.12 percentage of cells
Interval 0.08 to 0.15
|
0.12 percentage of cells
Interval 0.08 to 0.15
|
0.11 percentage of cells
Interval 0.08 to 0.15
|
0.11 percentage of cells
Interval 0.08 to 0.15
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-N-Total
|
0.11 percentage of cells
Interval 0.08 to 0.15
|
0.10 percentage of cells
Interval 0.07 to 0.14
|
0.10 percentage of cells
Interval 0.07 to 0.14
|
0.10 percentage of cells
Interval 0.08 to 0.14
|
0.10 percentage of cells
Interval 0.07 to 0.14
|
0.10 percentage of cells
Interval 0.07 to 0.15
|
0.11 percentage of cells
Interval 0.08 to 0.15
|
0.11 percentage of cells
Interval 0.08 to 0.15
|
0.10 percentage of cells
Interval 0.07 to 0.15
|
0.11 percentage of cells
Interval 0.08 to 0.15
|
0.10 percentage of cells
Interval 0.08 to 0.15
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-N-USA
|
0.10 percentage of cells
Interval 0.07 to 0.13
|
0.09 percentage of cells
Interval 0.06 to 0.13
|
0.09 percentage of cells
Interval 0.07 to 0.13
|
0.09 percentage of cells
Interval 0.07 to 0.14
|
0.09 percentage of cells
Interval 0.07 to 0.12
|
0.09 percentage of cells
Interval 0.07 to 0.14
|
0.10 percentage of cells
Interval 0.07 to 0.12
|
0.10 percentage of cells
Interval 0.07 to 0.14
|
0.09 percentage of cells
Interval 0.07 to 0.14
|
0.10 percentage of cells
Interval 0.07 to 0.15
|
0.09 percentage of cells
Interval 0.07 to 0.14
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Total B Cells-Y-USA
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.00 percentage of cells
Interval 0.0 to 0.01
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
0.01 percentage of cells
Interval 0.0 to 0.02
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ of Total B Cells-N-Peru
|
0.40 percentage of cells
Interval 0.29 to 0.52
|
0.40 percentage of cells
Interval 0.28 to 0.52
|
0.40 percentage of cells
Interval 0.28 to 0.54
|
0.40 percentage of cells
Interval 0.28 to 0.54
|
0.39 percentage of cells
Interval 0.26 to 0.54
|
0.42 percentage of cells
Interval 0.29 to 0.54
|
0.40 percentage of cells
Interval 0.28 to 0.55
|
0.40 percentage of cells
Interval 0.28 to 0.53
|
0.40 percentage of cells
Interval 0.28 to 0.54
|
0.40 percentage of cells
Interval 0.28 to 0.54
|
0.40 percentage of cells
Interval 0.27 to 0.54
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ of Total B Cells-N-Total
|
0.34 percentage of cells
Interval 0.24 to 0.48
|
0.33 percentage of cells
Interval 0.21 to 0.49
|
0.33 percentage of cells
Interval 0.22 to 0.5
|
0.33 percentage of cells
Interval 0.22 to 0.5
|
0.32 percentage of cells
Interval 0.2 to 0.49
|
0.34 percentage of cells
Interval 0.23 to 0.5
|
0.33 percentage of cells
Interval 0.22 to 0.5
|
0.35 percentage of cells
Interval 0.23 to 0.5
|
0.34 percentage of cells
Interval 0.23 to 0.5
|
0.38 percentage of cells
Interval 0.24 to 0.52
|
0.36 percentage of cells
Interval 0.23 to 0.52
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-Y-Peru
|
0.10 percentage of cells
Interval 0.07 to 0.15
|
0.16 percentage of cells
Interval 0.13 to 0.37
|
0.15 percentage of cells
Interval 0.13 to 0.22
|
0.13 percentage of cells
Interval 0.07 to 0.16
|
0.10 percentage of cells
Interval 0.08 to 0.14
|
0.10 percentage of cells
Interval 0.07 to 0.14
|
0.10 percentage of cells
Interval 0.05 to 0.13
|
0.10 percentage of cells
Interval 0.07 to 0.15
|
—
|
0.12 percentage of cells
Interval 0.06 to 0.14
|
0.13 percentage of cells
Interval 0.07 to 0.16
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ of Total B Cells-N-USA
|
0.26 percentage of cells
Interval 0.2 to 0.36
|
0.28 percentage of cells
Interval 0.18 to 0.39
|
0.28 percentage of cells
Interval 0.2 to 0.4
|
0.28 percentage of cells
Interval 0.19 to 0.43
|
0.26 percentage of cells
Interval 0.17 to 0.38
|
0.28 percentage of cells
Interval 0.19 to 0.41
|
0.26 percentage of cells
Interval 0.2 to 0.37
|
0.28 percentage of cells
Interval 0.19 to 0.42
|
0.28 percentage of cells
Interval 0.2 to 0.42
|
0.30 percentage of cells
Interval 0.21 to 0.46
|
0.28 percentage of cells
Interval 0.21 to 0.46
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-Y-Total
|
0.10 percentage of cells
Interval 0.07 to 0.14
|
0.10 percentage of cells
Interval 0.08 to 0.16
|
0.10 percentage of cells
Interval 0.07 to 0.15
|
0.10 percentage of cells
Interval 0.07 to 0.15
|
0.09 percentage of cells
Interval 0.06 to 0.14
|
0.09 percentage of cells
Interval 0.07 to 0.12
|
0.09 percentage of cells
Interval 0.06 to 0.13
|
0.08 percentage of cells
Interval 0.07 to 0.12
|
0.07 percentage of cells
Interval 0.06 to 0.1
|
0.09 percentage of cells
Interval 0.07 to 0.12
|
0.10 percentage of cells
Interval 0.07 to 0.14
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ of Total B Cells-Y-Peru
|
0.39 percentage of cells
Interval 0.25 to 0.54
|
0.65 percentage of cells
Interval 0.44 to 0.99
|
0.37 percentage of cells
Interval 0.29 to 0.49
|
0.41 percentage of cells
Interval 0.28 to 0.51
|
0.51 percentage of cells
Interval 0.36 to 0.71
|
0.29 percentage of cells
Interval 0.18 to 0.37
|
0.37 percentage of cells
Interval 0.2 to 0.51
|
0.37 percentage of cells
Interval 0.23 to 0.63
|
—
|
0.33 percentage of cells
Interval 0.24 to 0.42
|
0.41 percentage of cells
Interval 0.29 to 0.51
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ IgD+ of Total B Cells-Y-USA
|
0.09 percentage of cells
Interval 0.07 to 0.12
|
0.09 percentage of cells
Interval 0.07 to 0.12
|
0.10 percentage of cells
Interval 0.07 to 0.11
|
0.09 percentage of cells
Interval 0.06 to 0.12
|
0.08 percentage of cells
Interval 0.06 to 0.12
|
0.09 percentage of cells
Interval 0.07 to 0.11
|
0.08 percentage of cells
Interval 0.06 to 0.13
|
0.08 percentage of cells
Interval 0.07 to 0.11
|
0.07 percentage of cells
Interval 0.06 to 0.1
|
0.08 percentage of cells
Interval 0.07 to 0.11
|
0.09 percentage of cells
Interval 0.07 to 0.12
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Memory B Cells-N-Peru
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Memory B Cells-N-Total
|
0.05 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.05 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Memory B Cells-N-USA
|
0.05 percentage of cells
Interval 0.02 to 0.06
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.05 percentage of cells
Interval 0.01 to 0.08
|
0.05 percentage of cells
Interval 0.02 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.05 percentage of cells
Interval 0.01 to 0.08
|
0.05 percentage of cells
Interval 0.01 to 0.08
|
0.05 percentage of cells
Interval 0.01 to 0.08
|
0.05 percentage of cells
Interval 0.01 to 0.08
|
0.05 percentage of cells
Interval 0.02 to 0.08
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Memory B Cells-Y-Peru
|
0.04 percentage of cells
Interval 0.01 to 0.07
|
0.05 percentage of cells
Interval 0.03 to 0.11
|
0.07 percentage of cells
Interval 0.05 to 0.07
|
0.04 percentage of cells
Interval 0.02 to 0.08
|
0.05 percentage of cells
Interval 0.02 to 0.08
|
0.02 percentage of cells
Interval 0.01 to 0.04
|
0.04 percentage of cells
Interval 0.02 to 0.07
|
0.03 percentage of cells
Interval 0.02 to 0.05
|
—
|
0.04 percentage of cells
Interval 0.02 to 0.06
|
0.04 percentage of cells
Interval 0.02 to 0.07
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Memory B Cells-Y-Total
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.0 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.06
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.03 percentage of cells
Interval 0.01 to 0.06
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.03 percentage of cells
Interval 0.01 to 0.06
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.04 percentage of cells
Interval 0.01 to 0.07
|
0.04 percentage of cells
Interval 0.01 to 0.07
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ IgM+ of Memory B Cells-Y-USA
|
0.04 percentage of cells
Interval 0.01 to 0.08
|
0.04 percentage of cells
Interval 0.0 to 0.07
|
0.02 percentage of cells
Interval 0.0 to 0.05
|
0.04 percentage of cells
Interval 0.0 to 0.07
|
0.02 percentage of cells
Interval 0.0 to 0.08
|
0.03 percentage of cells
Interval 0.01 to 0.07
|
0.03 percentage of cells
Interval 0.0 to 0.08
|
0.03 percentage of cells
Interval 0.01 to 0.07
|
0.01 percentage of cells
Interval 0.0 to 0.04
|
0.04 percentage of cells
Interval 0.01 to 0.07
|
0.04 percentage of cells
Interval 0.0 to 0.07
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ of Total B Cells-Y-Total
|
0.32 percentage of cells
Interval 0.18 to 0.5
|
0.29 percentage of cells
Interval 0.21 to 0.53
|
0.26 percentage of cells
Interval 0.15 to 0.38
|
0.33 percentage of cells
Interval 0.2 to 0.44
|
0.39 percentage of cells
Interval 0.29 to 0.52
|
0.28 percentage of cells
Interval 0.17 to 0.36
|
0.33 percentage of cells
Interval 0.15 to 0.49
|
0.28 percentage of cells
Interval 0.17 to 0.41
|
0.19 percentage of cells
Interval 0.11 to 0.29
|
0.27 percentage of cells
Interval 0.17 to 0.35
|
0.30 percentage of cells
Interval 0.18 to 0.42
|
|
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
%S+ of Total B Cells-Y-USA
|
0.28 percentage of cells
Interval 0.16 to 0.42
|
0.27 percentage of cells
Interval 0.19 to 0.48
|
0.15 percentage of cells
Interval 0.13 to 0.31
|
0.28 percentage of cells
Interval 0.16 to 0.36
|
0.33 percentage of cells
Interval 0.25 to 0.46
|
0.26 percentage of cells
Interval 0.17 to 0.35
|
0.29 percentage of cells
Interval 0.15 to 0.48
|
0.25 percentage of cells
Interval 0.15 to 0.34
|
0.19 percentage of cells
Interval 0.11 to 0.29
|
0.26 percentage of cells
Interval 0.17 to 0.35
|
0.28 percentage of cells
Interval 0.17 to 0.36
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: American Population
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , overall and by region
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Marijua0 smoking - current
|
4 Participants
|
20 Participants
|
4 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Marijua0 smoking - ever
|
11 Participants
|
19 Participants
|
17 Participants
|
14 Participants
|
7 Participants
|
17 Participants
|
26 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Any targeted conditions at enrollment
|
14 Participants
|
21 Participants
|
18 Participants
|
32 Participants
|
20 Participants
|
33 Participants
|
53 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
COPD/emphysema/ asthma
|
2 Participants
|
23 Participants
|
6 Participants
|
6 Participants
|
4 Participants
|
8 Participants
|
11 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Chronic kidney disease
|
0 Participants
|
28 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Cigarette smoking - current
|
5 Participants
|
18 Participants
|
4 Participants
|
1 Participants
|
2 Participants
|
0 Participants
|
9 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Cigarette smoking - ever
|
11 Participants
|
17 Participants
|
15 Participants
|
19 Participants
|
11 Participants
|
18 Participants
|
37 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Congestive heart failure
|
0 Participants
|
24 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
3 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Currently smoke cigarettes or marijua0
|
8 Participants
|
5 Participants
|
8 Participants
|
2 Participants
|
3 Participants
|
2 Participants
|
12 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Diabetes
|
3 Participants
|
26 Participants
|
3 Participants
|
8 Participants
|
7 Participants
|
9 Participants
|
12 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Diabetes with complications
|
1 Participants
|
27 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Ever smoked cigarettes or marijua0
|
18 Participants
|
16 Participants
|
23 Participants
|
25 Participants
|
15 Participants
|
24 Participants
|
47 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
HIV
|
4 Participants
|
29 Participants
|
6 Participants
|
2 Participants
|
4 Participants
|
4 Participants
|
21 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Hypertension
|
6 Participants
|
22 Participants
|
2 Participants
|
20 Participants
|
12 Participants
|
17 Participants
|
22 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Immune system disorders
|
5 Participants
|
30 Participants
|
11 Participants
|
6 Participants
|
6 Participants
|
14 Participants
|
29 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Immune system disorders, non HIV
|
1 Participants
|
31 Participants
|
5 Participants
|
4 Participants
|
2 Participants
|
10 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Myocarditis/ pericarditis
|
0 Participants
|
25 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
Prolonged viral shedding
|
1 Participants
|
0 Participants
|
3 Participants
|
2 Participants
|
0 Participants
|
0 Participants
|
30 Participants
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Measured at Months 0Population: african Population
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , overall and by region
Outcome measures
| Measure |
Group 1A
n=79 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=17 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=129 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=26 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=73 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=24 Participants
2B: Hospitalized, \> 55
|
Group 3
n=24 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Myocarditis/ pericarditis
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
HIV
|
6 Participants
|
2 Participants
|
14 Participants
|
0 Participants
|
18 Participants
|
2 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Any targeted conditions at enrollment
|
14 Participants
|
12 Participants
|
44 Participants
|
17 Participants
|
38 Participants
|
20 Participants
|
13 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
COPD/emphysema/ asthma
|
0 Participants
|
2 Participants
|
9 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Chronic kidney disease
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Congestive heart failure
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Currently smoke cigarettes or marijua0
|
12 Participants
|
1 Participants
|
12 Participants
|
3 Participants
|
4 Participants
|
2 Participants
|
2 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Diabetes
|
4 Participants
|
3 Participants
|
11 Participants
|
6 Participants
|
15 Participants
|
10 Participants
|
4 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Diabetes with complications
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
2 Participants
|
2 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Ever smoked cigarettes or marijua0
|
20 Participants
|
2 Participants
|
27 Participants
|
6 Participants
|
10 Participants
|
4 Participants
|
6 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Hypertension
|
7 Participants
|
8 Participants
|
15 Participants
|
15 Participants
|
18 Participants
|
18 Participants
|
8 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Immune system disorders
|
6 Participants
|
2 Participants
|
15 Participants
|
0 Participants
|
18 Participants
|
3 Participants
|
3 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Immune system disorders, non HIV
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
Prolonged viral shedding
|
1 Participants
|
0 Participants
|
2 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Measured at Months 0, 2, 5Population: American Population (USA and Peru only), all available data at each visit
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA nasal sample) at Visit 1, 2, 3, overall and by region and enrollment group among America Cohort
Outcome measures
| Measure |
Group 1A
n=50 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=34 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=53 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=51 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=49 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=50 Participants
2B: Hospitalized, \> 55
|
Group 3
n=101 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F at Month 0-Peru
|
—
|
1.88 MFI
Interval 1.88 to 1.88
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F at Month 0-Total
|
2.67 MFI
Interval 2.24 to 3.1
|
1.36 MFI
Interval 0.72 to 1.62
|
0.2 MFI
Interval 0.09 to 0.28
|
0.41 MFI
Interval 0.12 to 2.02
|
1.13 MFI
Interval 0.91 to 1.36
|
0.55 MFI
Interval 0.38 to 1.86
|
0.88 MFI
Interval 0.18 to 2.26
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F at Month 0-USA
|
2.67 MFI
Interval 2.24 to 3.1
|
0.72 MFI
Interval 0.41 to 1.04
|
0.2 MFI
Interval 0.09 to 0.28
|
0.41 MFI
Interval 0.12 to 2.02
|
1.13 MFI
Interval 0.91 to 1.36
|
0.55 MFI
Interval 0.38 to 1.86
|
0.88 MFI
Interval 0.18 to 2.26
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F at Month 2-Peru
|
0.32 MFI
Interval 0.18 to 0.94
|
0.1 MFI
Interval 0.1 to 0.1
|
0.51 MFI
Interval 0.17 to 0.65
|
0.09 MFI
Interval 0.09 to 0.35
|
1.98 MFI
Interval 0.64 to 3.8
|
10.13 MFI
Interval 10.13 to 10.13
|
1.78 MFI
Interval 1.22 to 2.09
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F at Month 2-Total
|
0.46 MFI
Interval 0.2 to 1.07
|
0.1 MFI
Interval 0.09 to 0.1
|
0.56 MFI
Interval 0.17 to 0.84
|
0.75 MFI
Interval 0.18 to 2.72
|
0.67 MFI
Interval 0.51 to 3.63
|
4.8 MFI
Interval 2.47 to 7.46
|
1 MFI
Interval 0.63 to 2.19
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F at Month 2-USA
|
2.25 MFI
Interval 2.25 to 2.25
|
0.09 MFI
Interval 0.09 to 0.09
|
0.58 MFI
Interval 0.13 to 0.95
|
2.32 MFI
Interval 0.57 to 2.73
|
0.38 MFI
Interval 0.38 to 0.38
|
2.47 MFI
Interval 1.3 to 3.63
|
1 MFI
Interval 0.47 to 1.68
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F at Month 4-Peru
|
0.16 MFI
Interval 0.09 to 0.81
|
0.09 MFI
Interval 0.09 to 0.09
|
0.09 MFI
Interval 0.09 to 0.11
|
0.62 MFI
Interval 0.38 to 0.86
|
0.72 MFI
Interval 0.17 to 2.66
|
1.53 MFI
Interval 1.38 to 1.67
|
4 MFI
Interval 1.66 to 4.18
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F at Month 4-Total
|
0.16 MFI
Interval 0.09 to 0.81
|
0.09 MFI
Interval 0.09 to 0.09
|
0.12 MFI
Interval 0.09 to 0.37
|
0.89 MFI
Interval 0.22 to 1.25
|
0.72 MFI
Interval 0.17 to 2.66
|
1.46 MFI
Interval 1.22 to 1.71
|
0.74 MFI
Interval 0.5 to 4.09
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
2019-nCoV S/293F at Month 4-USA
|
—
|
—
|
0.46 MFI
Interval 0.24 to 2.21
|
0.89 MFI
Interval 0.3 to 1.41
|
—
|
1.42 MFI
Interval 1.29 to 1.55
|
0.52 MFI
Interval 0.38 to 0.69
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
229E-RBD at Month 0-Peru
|
—
|
0.3 MFI
Interval 0.3 to 0.3
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
229E-RBD at Month 0-Total
|
0.97 MFI
Interval 0.59 to 1.36
|
0.3 MFI
Interval 0.15 to 0.55
|
0.4 MFI
Interval 0.13 to 1.06
|
1.17 MFI
Interval 0.33 to 2.36
|
0.07 MFI
Interval 0.06 to 0.08
|
0.54 MFI
Interval 0.36 to 1.07
|
0.44 MFI
Interval 0.18 to 1.96
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
229E-RBD at Month 0-USA
|
0.97 MFI
Interval 0.59 to 1.36
|
0.4 MFI
Interval 0.2 to 0.6
|
0.4 MFI
Interval 0.13 to 1.06
|
1.17 MFI
Interval 0.33 to 2.36
|
0.07 MFI
Interval 0.06 to 0.08
|
0.54 MFI
Interval 0.36 to 1.07
|
0.44 MFI
Interval 0.18 to 1.96
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
229E-RBD at Month 2-Peru
|
0.5 MFI
Interval 0.44 to 1.74
|
2.75 MFI
Interval 2.75 to 2.75
|
0.69 MFI
Interval 0.35 to 1.22
|
1.16 MFI
Interval 0.67 to 5.86
|
0.58 MFI
Interval 0.41 to 0.63
|
5.04 MFI
Interval 5.04 to 5.04
|
0.24 MFI
Interval 0.18 to 0.31
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
229E-RBD at Month 2-Total
|
0.5 MFI
Interval 0.45 to 1.64
|
1.72 MFI
Interval 1.21 to 2.23
|
0.59 MFI
Interval 0.18 to 1.07
|
1.66 MFI
Interval 0.6 to 3.05
|
0.54 MFI
Interval 0.33 to 0.62
|
1 MFI
Interval 0.82 to 3.02
|
0.31 MFI
Interval 0.12 to 1.87
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
229E-RBD at Month 2-USA
|
1.64 MFI
Interval 1.64 to 1.64
|
0.7 MFI
Interval 0.7 to 0.7
|
0.49 MFI
Interval 0.13 to 1.0
|
1.66 MFI
Interval 0.67 to 2.73
|
0.28 MFI
Interval 0.28 to 0.28
|
0.82 MFI
Interval 0.74 to 0.91
|
0.59 MFI
Interval 0.11 to 2.32
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
229E-RBD at Month 4-Peru
|
0.48 MFI
Interval 0.32 to 1.17
|
2.63 MFI
Interval 2.63 to 2.63
|
0.25 MFI
Interval 0.22 to 0.57
|
1.84 MFI
Interval 1.25 to 2.43
|
0.29 MFI
Interval 0.2 to 0.38
|
6.17 MFI
Interval 3.48 to 8.86
|
0.55 MFI
Interval 0.38 to 1.57
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
229E-RBD at Month 4-Total
|
0.48 MFI
Interval 0.32 to 1.17
|
2.63 MFI
Interval 2.63 to 2.63
|
0.25 MFI
Interval 0.15 to 0.85
|
1.92 MFI
Interval 0.45 to 2.91
|
0.29 MFI
Interval 0.2 to 0.38
|
0.75 MFI
Interval 0.58 to 3.48
|
0.55 MFI
Interval 0.21 to 1.99
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
229E-RBD at Month 4-USA
|
—
|
—
|
0.37 MFI
Interval 0.09 to 0.94
|
1.92 MFI
Interval 0.24 to 2.8
|
—
|
0.45 MFI
Interval 0.32 to 0.58
|
0.72 MFI
Interval 0.21 to 2.11
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His at Month 0-Peru
|
—
|
0.7 MFI
Interval 0.7 to 0.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His at Month 0-Total
|
0.93 MFI
Interval 0.51 to 1.34
|
0.7 MFI
Interval 0.67 to 0.79
|
0.69 MFI
Interval 0.24 to 1.98
|
1.88 MFI
Interval 0.51 to 4.13
|
0.03 MFI
Interval 0.02 to 0.03
|
0.74 MFI
Interval 0.68 to 1.39
|
1.09 MFI
Interval 0.2 to 2.85
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His at Month 0-USA
|
0.93 MFI
Interval 0.51 to 1.34
|
0.77 MFI
Interval 0.71 to 0.83
|
0.69 MFI
Interval 0.24 to 1.98
|
1.88 MFI
Interval 0.51 to 4.13
|
0.03 MFI
Interval 0.02 to 0.03
|
0.74 MFI
Interval 0.68 to 1.39
|
1.09 MFI
Interval 0.2 to 2.85
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His at Month 2-Peru
|
1.36 MFI
Interval 0.58 to 3.34
|
2.8 MFI
Interval 2.8 to 2.8
|
1.51 MFI
Interval 1.39 to 2.57
|
3.32 MFI
Interval 1.71 to 6.49
|
1.55 MFI
Interval 0.37 to 2.69
|
4.34 MFI
Interval 4.34 to 4.34
|
0.67 MFI
Interval 0.5 to 1.32
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His at Month 2-Total
|
1.63 MFI
Interval 0.66 to 3.22
|
1.7 MFI
Interval 1.16 to 2.25
|
1.48 MFI
Interval 0.25 to 2.2
|
3.35 MFI
Interval 1.56 to 4.64
|
0.64 MFI
Interval 0.35 to 2.61
|
1.71 MFI
Interval 0.92 to 3.03
|
1.27 MFI
Interval 0.34 to 1.98
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His at Month 2-USA
|
1.9 MFI
Interval 1.9 to 1.9
|
0.61 MFI
Interval 0.61 to 0.61
|
0.42 MFI
Interval 0.16 to 2.04
|
3.37 MFI
Interval 1.62 to 4.52
|
0.42 MFI
Interval 0.42 to 0.42
|
0.92 MFI
Interval 0.52 to 1.32
|
1.87 MFI
Interval 0.3 to 2.93
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His at Month 4-Peru
|
1.19 MFI
Interval 0.49 to 3.09
|
2.79 MFI
Interval 2.79 to 2.79
|
2.28 MFI
Interval 1.21 to 3.57
|
1.3 MFI
Interval 0.98 to 1.63
|
0.45 MFI
Interval 0.29 to 1.95
|
3.65 MFI
Interval 2.12 to 5.17
|
0.85 MFI
Interval 0.83 to 4.43
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His at Month 4-Total
|
1.19 MFI
Interval 0.49 to 3.09
|
2.79 MFI
Interval 2.79 to 2.79
|
0.98 MFI
Interval 0.16 to 1.91
|
1.86 MFI
Interval 0.41 to 2.92
|
0.45 MFI
Interval 0.29 to 1.95
|
1.28 MFI
Interval 0.47 to 3.16
|
0.85 MFI
Interval 0.61 to 3.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-229E S1S2 ECD His at Month 4-USA
|
—
|
—
|
0.28 MFI
Interval 0.1 to 0.71
|
1.86 MFI
Interval 0.16 to 3.88
|
—
|
1.04 MFI
Interval 0.57 to 1.51
|
1.34 MFI
Interval 0.25 to 2.94
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His at Month 0-Peru
|
—
|
0.28 MFI
Interval 0.28 to 0.28
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His at Month 0-Total
|
2.26 MFI
Interval 2.09 to 2.43
|
0.28 MFI
Interval 0.19 to 0.45
|
0.12 MFI
Interval 0.07 to 1.13
|
0.66 MFI
Interval 0.36 to 2.34
|
0.44 MFI
Interval 0.3 to 0.58
|
0.81 MFI
Interval 0.19 to 2.08
|
0.87 MFI
Interval 0.27 to 3.75
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His at Month 0-USA
|
2.26 MFI
Interval 2.09 to 2.43
|
0.37 MFI
Interval 0.23 to 0.5
|
0.12 MFI
Interval 0.07 to 1.13
|
0.66 MFI
Interval 0.36 to 2.34
|
0.44 MFI
Interval 0.3 to 0.58
|
0.81 MFI
Interval 0.19 to 2.08
|
0.87 MFI
Interval 0.27 to 3.75
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His at Month 2-Peru
|
0.72 MFI
Interval 0.14 to 1.47
|
0.37 MFI
Interval 0.37 to 0.37
|
0.31 MFI
Interval 0.28 to 1.1
|
0.48 MFI
Interval 0.27 to 1.72
|
2.16 MFI
Interval 0.67 to 3.37
|
7.26 MFI
Interval 7.26 to 7.26
|
1.17 MFI
Interval 0.84 to 2.17
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His at Month 2-Total
|
0.77 MFI
Interval 0.15 to 1.61
|
0.23 MFI
Interval 0.16 to 0.3
|
0.3 MFI
Interval 0.16 to 1.21
|
2.04 MFI
Interval 0.35 to 4.5
|
1.42 MFI
Interval 0.37 to 3.21
|
2.24 MFI
Interval 1.26 to 4.75
|
1.69 MFI
Interval 0.64 to 3.11
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His at Month 2-USA
|
1.66 MFI
Interval 1.66 to 1.66
|
0.09 MFI
Interval 0.09 to 0.09
|
0.29 MFI
Interval 0.1 to 1.24
|
2.34 MFI
Interval 0.39 to 5.02
|
0.12 MFI
Interval 0.12 to 0.12
|
1.26 MFI
Interval 0.77 to 1.75
|
1.72 MFI
Interval 0.73 to 3.41
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His at Month 4-Peru
|
0.36 MFI
Interval 0.14 to 1.73
|
0.26 MFI
Interval 0.26 to 0.26
|
0.2 MFI
Interval 0.14 to 0.37
|
0.47 MFI
Interval 0.46 to 0.49
|
0.45 MFI
Interval 0.2 to 2.47
|
0.75 MFI
Interval 0.55 to 0.96
|
2.09 MFI
Interval 1.63 to 5.21
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His at Month 4-Total
|
0.36 MFI
Interval 0.14 to 1.73
|
0.26 MFI
Interval 0.26 to 0.26
|
0.2 MFI
Interval 0.14 to 0.68
|
0.5 MFI
Interval 0.44 to 0.68
|
0.45 MFI
Interval 0.2 to 2.47
|
0.75 MFI
Interval 0.3 to 1.51
|
1.95 MFI
Interval 0.95 to 3.61
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-HKU1 N5 S1S2 ECD His at Month 4-USA
|
—
|
—
|
0.39 MFI
Interval 0.14 to 1.0
|
0.51 MFI
Interval 0.44 to 0.85
|
—
|
1.38 MFI
Interval 0.78 to 1.97
|
1.33 MFI
Interval 0.37 to 2.64
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His at Month 0-Peru
|
—
|
0.05 MFI
Interval 0.05 to 0.05
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His at Month 0-Total
|
0.14 MFI
Interval 0.12 to 0.16
|
0.05 MFI
Interval 0.03 to 0.05
|
0.03 MFI
Interval 0.02 to 0.2
|
0.06 MFI
Interval 0.03 to 0.15
|
0.06 MFI
Interval 0.05 to 0.07
|
0.23 MFI
Interval 0.03 to 0.29
|
0.21 MFI
Interval 0.03 to 0.28
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His at Month 0-USA
|
0.14 MFI
Interval 0.12 to 0.16
|
0.03 MFI
Interval 0.01 to 0.04
|
0.03 MFI
Interval 0.02 to 0.2
|
0.06 MFI
Interval 0.03 to 0.15
|
0.06 MFI
Interval 0.05 to 0.07
|
0.23 MFI
Interval 0.03 to 0.29
|
0.21 MFI
Interval 0.03 to 0.28
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His at Month 2-Peru
|
0.16 MFI
Interval 0.08 to 0.39
|
0.11 MFI
Interval 0.11 to 0.11
|
0.13 MFI
Interval 0.07 to 0.26
|
0.14 MFI
Interval 0.09 to 0.72
|
0.57 MFI
Interval 0.2 to 1.04
|
0.55 MFI
Interval 0.55 to 0.55
|
0.07 MFI
Interval 0.06 to 0.33
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His at Month 2-Total
|
0.19 MFI
Interval 0.09 to 0.37
|
0.08 MFI
Interval 0.07 to 0.09
|
0.09 MFI
Interval 0.04 to 0.28
|
0.22 MFI
Interval 0.15 to 0.86
|
0.25 MFI
Interval 0.17 to 1.0
|
0.47 MFI
Interval 0.26 to 0.51
|
0.2 MFI
Interval 0.08 to 0.44
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His at Month 2-USA
|
0.23 MFI
Interval 0.23 to 0.23
|
0.05 MFI
Interval 0.05 to 0.05
|
0.08 MFI
Interval 0.02 to 0.23
|
0.27 MFI
Interval 0.15 to 0.82
|
0.15 MFI
Interval 0.15 to 0.15
|
0.26 MFI
Interval 0.15 to 0.37
|
0.21 MFI
Interval 0.11 to 0.44
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His at Month 4-Peru
|
0.09 MFI
Interval 0.05 to 0.16
|
0.08 MFI
Interval 0.08 to 0.08
|
0.11 MFI
Interval 0.05 to 0.26
|
0.18 MFI
Interval 0.16 to 0.19
|
0.24 MFI
Interval 0.12 to 0.35
|
0.17 MFI
Interval 0.1 to 0.24
|
0.15 MFI
Interval 0.06 to 0.54
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His at Month 4-Total
|
0.09 MFI
Interval 0.05 to 0.16
|
0.08 MFI
Interval 0.08 to 0.08
|
0.05 MFI
Interval 0.01 to 0.17
|
0.16 MFI
Interval 0.1 to 0.28
|
0.24 MFI
Interval 0.12 to 0.35
|
0.17 MFI
Interval 0.03 to 0.33
|
0.15 MFI
Interval 0.06 to 0.45
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-NL63 S1S2 ECD His at Month 4-USA
|
—
|
—
|
0.02 MFI
Interval 0.005 to 0.08
|
0.16 MFI
Interval 0.06 to 0.34
|
—
|
0.22 MFI
Interval 0.12 to 0.31
|
0.19 MFI
Interval 0.07 to 0.35
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His at Month 0-Peru
|
—
|
0.95 MFI
Interval 0.95 to 0.95
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His at Month 0-Total
|
4.66 MFI
Interval 3.77 to 5.54
|
0.74 MFI
Interval 0.64 to 0.85
|
0.51 MFI
Interval 0.15 to 1.98
|
1.55 MFI
Interval 0.66 to 4.23
|
1.05 MFI
Interval 0.93 to 1.16
|
1.47 MFI
Interval 0.64 to 3.63
|
2.05 MFI
Interval 0.8 to 6.71
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His at Month 0-USA
|
4.66 MFI
Interval 3.77 to 5.54
|
0.53 MFI
Interval 0.53 to 0.53
|
0.51 MFI
Interval 0.15 to 1.98
|
1.55 MFI
Interval 0.66 to 4.23
|
1.05 MFI
Interval 0.93 to 1.16
|
1.47 MFI
Interval 0.64 to 3.63
|
2.05 MFI
Interval 0.8 to 6.71
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His at Month 2-Peru
|
1.7 MFI
Interval 0.56 to 2.99
|
2.23 MFI
Interval 2.23 to 2.23
|
1.08 MFI
Interval 0.86 to 2.62
|
1.63 MFI
Interval 0.86 to 2.18
|
3.22 MFI
Interval 1.6 to 5.18
|
7.58 MFI
Interval 7.58 to 7.58
|
2.61 MFI
Interval 1.76 to 2.62
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His at Month 2-Total
|
2.07 MFI
Interval 0.65 to 4.07
|
1.34 MFI
Interval 0.89 to 1.78
|
1.06 MFI
Interval 0.48 to 2.71
|
3.02 MFI
Interval 0.74 to 5.02
|
2.84 MFI
Interval 1.14 to 4.66
|
3.2 MFI
Interval 2.05 to 5.39
|
2.99 MFI
Interval 1.06 to 6.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His at Month 2-USA
|
4.43 MFI
Interval 4.43 to 4.43
|
0.45 MFI
Interval 0.45 to 0.45
|
1.02 MFI
Interval 0.41 to 2.48
|
3.96 MFI
Interval 0.89 to 5.13
|
0.95 MFI
Interval 0.95 to 0.95
|
2.05 MFI
Interval 1.47 to 2.62
|
4.51 MFI
Interval 1.07 to 8.16
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His at Month 4-Peru
|
1 MFI
Interval 0.44 to 4.27
|
1.46 MFI
Interval 1.46 to 1.46
|
0.76 MFI
Interval 0.32 to 1.32
|
0.59 MFI
Interval 0.55 to 0.64
|
1.08 MFI
Interval 0.82 to 2.62
|
1.17 MFI
Interval 1.02 to 1.32
|
4.38 MFI
Interval 3.53 to 6.23
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His at Month 4-Total
|
1 MFI
Interval 0.44 to 4.27
|
1.46 MFI
Interval 1.46 to 1.46
|
0.76 MFI
Interval 0.3 to 1.96
|
0.77 MFI
Interval 0.59 to 1.48
|
1.08 MFI
Interval 0.82 to 2.62
|
1.17 MFI
Interval 0.79 to 2.66
|
3.53 MFI
Interval 1.53 to 5.41
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HCoV-OC43 S1S2 ECD His at Month 4-USA
|
—
|
—
|
1.23 MFI
Interval 0.3 to 3.79
|
1.18 MFI
Interval 0.77 to 1.77
|
—
|
3.4 MFI
Interval 1.99 to 4.82
|
2.24 MFI
Interval 0.5 to 4.25
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HKU1-RBD at Month 0-Peru
|
—
|
0.2 MFI
Interval 0.2 to 0.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HKU1-RBD at Month 0-Total
|
0.85 MFI
Interval 0.51 to 1.2
|
0.02 MFI
Interval 0.01 to 0.11
|
0.07 MFI
Interval 0.04 to 0.55
|
0.29 MFI
Interval 0.19 to 0.42
|
0.39 MFI
Interval 0.24 to 0.53
|
0.33 MFI
Interval 0.21 to 0.76
|
0.17 MFI
Interval 0.06 to 0.62
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HKU1-RBD at Month 0-USA
|
0.85 MFI
Interval 0.51 to 1.2
|
0.01 MFI
Interval 0.01 to 0.02
|
0.07 MFI
Interval 0.04 to 0.55
|
0.29 MFI
Interval 0.19 to 0.42
|
0.39 MFI
Interval 0.24 to 0.53
|
0.33 MFI
Interval 0.21 to 0.76
|
0.17 MFI
Interval 0.06 to 0.62
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HKU1-RBD at Month 2-Peru
|
0.28 MFI
Interval 0.07 to 0.48
|
0.24 MFI
Interval 0.24 to 0.24
|
0.11 MFI
Interval 0.04 to 0.22
|
0.09 MFI
Interval 0.05 to 0.12
|
0.31 MFI
Interval 0.12 to 0.51
|
6.99 MFI
Interval 6.99 to 6.99
|
0.51 MFI
Interval 0.28 to 1.07
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HKU1-RBD at Month 2-Total
|
0.24 MFI
Interval 0.09 to 0.48
|
0.13 MFI
Interval 0.08 to 0.18
|
0.11 MFI
Interval 0.04 to 0.43
|
0.27 MFI
Interval 0.15 to 0.51
|
0.15 MFI
Interval 0.12 to 0.5
|
0.98 MFI
Interval 0.75 to 3.98
|
0.27 MFI
Interval 0.1 to 0.69
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HKU1-RBD at Month 2-USA
|
0.16 MFI
Interval 0.16 to 0.16
|
0.03 MFI
Interval 0.03 to 0.03
|
0.11 MFI
Interval 0.04 to 0.55
|
0.46 MFI
Interval 0.19 to 0.51
|
0.15 MFI
Interval 0.15 to 0.15
|
0.75 MFI
Interval 0.64 to 0.86
|
0.27 MFI
Interval 0.13 to 0.62
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HKU1-RBD at Month 4-Peru
|
0.23 MFI
Interval 0.05 to 0.72
|
0.21 MFI
Interval 0.21 to 0.21
|
0.03 MFI
Interval 0.02 to 0.05
|
0.14 MFI
Interval 0.13 to 0.15
|
0.11 MFI
Interval 0.07 to 0.34
|
1.19 MFI
Interval 0.8 to 1.58
|
0.7 MFI
Interval 0.64 to 0.81
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HKU1-RBD at Month 4-Total
|
0.23 MFI
Interval 0.05 to 0.72
|
0.21 MFI
Interval 0.21 to 0.21
|
0.07 MFI
Interval 0.02 to 0.13
|
0.16 MFI
Interval 0.16 to 0.38
|
0.11 MFI
Interval 0.07 to 0.34
|
0.64 MFI
Interval 0.34 to 1.15
|
0.51 MFI
Interval 0.13 to 0.75
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
HKU1-RBD at Month 4-USA
|
—
|
—
|
0.14 MFI
Interval 0.08 to 0.21
|
0.32 MFI
Interval 0.16 to 0.44
|
—
|
0.51 MFI
Interval 0.33 to 0.69
|
0.27 MFI
Interval 0.09 to 0.47
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
NL63-RBD at Month 0-Peru
|
—
|
0.4 MFI
Interval 0.4 to 0.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
NL63-RBD at Month 0-Total
|
1.65 MFI
Interval 1.59 to 1.72
|
0.53 MFI
Interval 0.47 to 0.7
|
0.47 MFI
Interval 0.21 to 1.75
|
1.27 MFI
Interval 0.44 to 2.29
|
0.56 MFI
Interval 0.51 to 0.62
|
1.18 MFI
Interval 0.28 to 2.34
|
1.11 MFI
Interval 0.32 to 1.45
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
NL63-RBD at Month 0-USA
|
1.65 MFI
Interval 1.59 to 1.72
|
0.7 MFI
Interval 0.61 to 0.78
|
0.47 MFI
Interval 0.21 to 1.75
|
1.27 MFI
Interval 0.44 to 2.29
|
0.56 MFI
Interval 0.51 to 0.62
|
1.18 MFI
Interval 0.28 to 2.34
|
1.11 MFI
Interval 0.32 to 1.45
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
NL63-RBD at Month 2-Peru
|
0.67 MFI
Interval 0.45 to 3.71
|
1.78 MFI
Interval 1.78 to 1.78
|
0.76 MFI
Interval 0.44 to 2.66
|
2.11 MFI
Interval 1.27 to 5.49
|
2.22 MFI
Interval 1.44 to 3.69
|
2.67 MFI
Interval 2.67 to 2.67
|
0.31 MFI
Interval 0.23 to 0.51
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
NL63-RBD at Month 2-Total
|
0.68 MFI
Interval 0.48 to 3.2
|
1.36 MFI
Interval 1.14 to 1.57
|
0.62 MFI
Interval 0.37 to 1.49
|
1.99 MFI
Interval 1.2 to 4.25
|
2.05 MFI
Interval 1.52 to 3.26
|
1.04 MFI
Interval 0.75 to 1.85
|
0.95 MFI
Interval 0.25 to 2.09
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
NL63-RBD at Month 2-USA
|
1.66 MFI
Interval 1.66 to 1.66
|
0.93 MFI
Interval 0.93 to 0.93
|
0.42 MFI
Interval 0.21 to 1.13
|
1.87 MFI
Interval 1.38 to 3.83
|
1.8 MFI
Interval 1.8 to 1.8
|
0.75 MFI
Interval 0.61 to 0.89
|
1.1 MFI
Interval 0.54 to 3.39
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
NL63-RBD at Month 4-Peru
|
0.87 MFI
Interval 0.33 to 3.17
|
2.11 MFI
Interval 2.11 to 2.11
|
0.52 MFI
Interval 0.34 to 0.79
|
2.24 MFI
Interval 2.13 to 2.36
|
1.8 MFI
Interval 1.14 to 2.41
|
1.49 MFI
Interval 1.03 to 1.94
|
1.49 MFI
Interval 0.6 to 2.42
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
NL63-RBD at Month 4-Total
|
0.87 MFI
Interval 0.33 to 3.17
|
2.11 MFI
Interval 2.11 to 2.11
|
0.46 MFI
Interval 0.25 to 0.79
|
2.01 MFI
Interval 1.18 to 3.35
|
1.8 MFI
Interval 1.14 to 2.41
|
1.3 MFI
Interval 0.49 to 2.11
|
1.57 MFI
Interval 0.57 to 4.56
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
NL63-RBD at Month 4-USA
|
—
|
—
|
0.31 MFI
Interval 0.06 to 1.39
|
1.43 MFI
Interval 0.93 to 4.23
|
—
|
1.14 MFI
Interval 0.7 to 1.58
|
2.28 MFI
Interval 0.8 to 5.35
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
OC43-RBD at Month 0-Peru
|
—
|
0.36 MFI
Interval 0.36 to 0.36
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
OC43-RBD at Month 0-Total
|
0.86 MFI
Interval 0.71 to 1.0
|
0.17 MFI
Interval 0.08 to 0.26
|
0.2 MFI
Interval 0.03 to 0.39
|
0.19 MFI
Interval 0.15 to 0.74
|
0.52 MFI
Interval 0.37 to 0.67
|
0.46 MFI
Interval 0.36 to 0.48
|
0.2 MFI
Interval 0.11 to 0.51
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
OC43-RBD at Month 0-USA
|
0.86 MFI
Interval 0.71 to 1.0
|
0.08 MFI
Interval 0.04 to 0.13
|
0.2 MFI
Interval 0.03 to 0.39
|
0.19 MFI
Interval 0.15 to 0.74
|
0.52 MFI
Interval 0.37 to 0.67
|
0.46 MFI
Interval 0.36 to 0.48
|
0.2 MFI
Interval 0.11 to 0.51
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
OC43-RBD at Month 2-Peru
|
0.18 MFI
Interval 0.08 to 0.85
|
1.27 MFI
Interval 1.27 to 1.27
|
0.13 MFI
Interval 0.05 to 0.21
|
0.97 MFI
Interval 0.5 to 1.38
|
0.19 MFI
Interval 0.14 to 0.33
|
3.44 MFI
Interval 3.44 to 3.44
|
0.25 MFI
Interval 0.18 to 0.27
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
OC43-RBD at Month 2-Total
|
0.4 MFI
Interval 0.09 to 0.99
|
0.7 MFI
Interval 0.41 to 0.98
|
0.11 MFI
Interval 0.05 to 0.39
|
0.7 MFI
Interval 0.31 to 1.21
|
0.26 MFI
Interval 0.15 to 0.33
|
1.71 MFI
Interval 1.16 to 2.57
|
0.19 MFI
Interval 0.11 to 0.3
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
OC43-RBD at Month 2-USA
|
1.04 MFI
Interval 1.04 to 1.04
|
0.13 MFI
Interval 0.13 to 0.13
|
0.09 MFI
Interval 0.05 to 0.44
|
0.44 MFI
Interval 0.31 to 1.15
|
0.33 MFI
Interval 0.33 to 0.33
|
1.16 MFI
Interval 0.89 to 1.43
|
0.16 MFI
Interval 0.11 to 0.54
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
OC43-RBD at Month 4-Peru
|
0.12 MFI
Interval 0.08 to 0.76
|
1.09 MFI
Interval 1.09 to 1.09
|
0.06 MFI
Interval 0.02 to 0.11
|
0.25 MFI
Interval 0.2 to 0.3
|
0.1 MFI
Interval 0.06 to 0.27
|
0.65 MFI
Interval 0.6 to 0.7
|
0.44 MFI
Interval 0.38 to 0.84
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
OC43-RBD at Month 4-Total
|
0.12 MFI
Interval 0.08 to 0.76
|
1.09 MFI
Interval 1.09 to 1.09
|
0.07 MFI
Interval 0.02 to 0.15
|
0.38 MFI
Interval 0.25 to 0.53
|
0.1 MFI
Interval 0.06 to 0.27
|
0.52 MFI
Interval 0.41 to 0.6
|
0.38 MFI
Interval 0.09 to 0.64
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
OC43-RBD at Month 4-USA
|
—
|
—
|
0.09 MFI
Interval 0.03 to 2.28
|
0.42 MFI
Interval 0.38 to 0.63
|
—
|
0.33 MFI
Interval 0.25 to 0.41
|
0.15 MFI
Interval 0.07 to 0.36
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His at Month 0-Peru
|
—
|
1.64 MFI
Interval 1.64 to 1.64
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His at Month 0-Total
|
1.55 MFI
Interval 1.0 to 2.1
|
0.64 MFI
Interval 0.35 to 1.14
|
0.06 MFI
Interval 0.06 to 0.17
|
0.15 MFI
Interval 0.06 to 1.1
|
0.18 MFI
Interval 0.12 to 0.23
|
0.38 MFI
Interval 0.22 to 0.83
|
0.62 MFI
Interval 0.19 to 1.04
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His at Month 0-USA
|
1.55 MFI
Interval 1.0 to 2.1
|
0.35 MFI
Interval 0.2 to 0.49
|
0.06 MFI
Interval 0.06 to 0.17
|
0.15 MFI
Interval 0.06 to 1.1
|
0.18 MFI
Interval 0.12 to 0.23
|
0.38 MFI
Interval 0.22 to 0.83
|
0.62 MFI
Interval 0.19 to 1.04
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His at Month 2-Peru
|
0.19 MFI
Interval 0.12 to 0.49
|
0.08 MFI
Interval 0.08 to 0.08
|
0.24 MFI
Interval 0.14 to 0.6
|
0.09 MFI
Interval 0.08 to 0.46
|
0.59 MFI
Interval 0.26 to 2.59
|
9.18 MFI
Interval 9.18 to 9.18
|
0.6 MFI
Interval 0.46 to 1.51
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His at Month 2-Total
|
0.19 MFI
Interval 0.13 to 0.64
|
0.07 MFI
Interval 0.06 to 0.07
|
0.23 MFI
Interval 0.07 to 0.71
|
0.35 MFI
Interval 0.06 to 1.73
|
0.42 MFI
Interval 0.29 to 2.0
|
6.59 MFI
Interval 3.35 to 7.88
|
0.44 MFI
Interval 0.19 to 1.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His at Month 2-USA
|
1.51 MFI
Interval 1.51 to 1.51
|
0.06 MFI
Interval 0.06 to 0.06
|
0.19 MFI
Interval 0.08 to 0.78
|
0.62 MFI
Interval 0.06 to 2.02
|
0.42 MFI
Interval 0.42 to 0.42
|
3.35 MFI
Interval 1.72 to 4.97
|
0.26 MFI
Interval 0.18 to 0.96
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His at Month 4-Peru
|
0.06 MFI
Interval 0.06 to 0.29
|
0.06 MFI
Interval 0.06 to 0.06
|
0.06 MFI
Interval 0.06 to 0.08
|
0.66 MFI
Interval 0.44 to 0.87
|
0.2 MFI
Interval 0.08 to 1.51
|
1.64 MFI
Interval 1.48 to 1.79
|
1.97 MFI
Interval 1.27 to 3.36
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His at Month 4-Total
|
0.06 MFI
Interval 0.06 to 0.29
|
0.06 MFI
Interval 0.06 to 0.06
|
0.1 MFI
Interval 0.06 to 0.24
|
0.24 MFI
Interval 0.1 to 0.5
|
0.2 MFI
Interval 0.08 to 1.51
|
1.64 MFI
Interval 1.08 to 2.16
|
1.27 MFI
Interval 0.41 to 2.66
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 DB His at Month 4-USA
|
—
|
—
|
0.25 MFI
Interval 0.18 to 0.33
|
0.16 MFI
Interval 0.06 to 0.34
|
—
|
1.57 MFI
Interval 0.94 to 2.2
|
0.46 MFI
Interval 0.2 to 1.35
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His at Month 0-Peru
|
—
|
0.02 MFI
Interval 0.02 to 0.02
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His at Month 0-Total
|
1.58 MFI
Interval 1.2 to 1.96
|
0.02 MFI
Interval 0.02 to 0.02
|
0.02 MFI
Interval 0.02 to 0.02
|
0.02 MFI
Interval 0.02 to 0.39
|
0.02 MFI
Interval 0.02 to 0.02
|
0.3 MFI
Interval 0.02 to 2.95
|
0.08 MFI
Interval 0.02 to 0.64
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His at Month 0-USA
|
1.58 MFI
Interval 1.2 to 1.96
|
0.02 MFI
Interval 0.02 to 0.02
|
0.02 MFI
Interval 0.02 to 0.02
|
0.02 MFI
Interval 0.02 to 0.39
|
0.02 MFI
Interval 0.02 to 0.02
|
0.3 MFI
Interval 0.02 to 2.95
|
0.08 MFI
Interval 0.02 to 0.64
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His at Month 2-Peru
|
0.02 MFI
Interval 0.02 to 0.13
|
0.02 MFI
Interval 0.02 to 0.02
|
0.08 MFI
Interval 0.05 to 0.17
|
0.1 MFI
Interval 0.06 to 0.21
|
0.27 MFI
Interval 0.05 to 0.53
|
0.7 MFI
Interval 0.7 to 0.7
|
0.06 MFI
Interval 0.04 to 0.08
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His at Month 2-Total
|
0.06 MFI
Interval 0.02 to 0.19
|
0.02 MFI
Interval 0.02 to 0.02
|
0.1 MFI
Interval 0.02 to 0.52
|
0.02 MFI
Interval 0.02 to 0.18
|
0.4 MFI
Interval 0.08 to 0.59
|
0.7 MFI
Interval 0.4 to 1.48
|
0.44 MFI
Interval 0.03 to 0.72
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His at Month 2-USA
|
2 MFI
Interval 2.0 to 2.0
|
0.02 MFI
Interval 0.02 to 0.02
|
0.25 MFI
Interval 0.02 to 0.74
|
0.02 MFI
Interval 0.02 to 0.12
|
0.96 MFI
Interval 0.96 to 0.96
|
1.18 MFI
Interval 0.64 to 1.72
|
0.51 MFI
Interval 0.21 to 0.94
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Total
|
0.02 MFI
Interval 0.02 to 0.29
|
0.02 MFI
Interval 0.02 to 0.02
|
0.02 MFI
Interval 0.02 to 0.13
|
0.02 MFI
Interval 0.02 to 0.09
|
0.15 MFI
Interval 0.04 to 0.71
|
0.6 MFI
Interval 0.35 to 1.19
|
0.46 MFI
Interval 0.06 to 2.95
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro-293F-PPF at Month 4-USA
|
—
|
—
|
0.16 MFI
Interval 0.07 to 0.42
|
0.02 MFI
Interval 0.02 to 0.02
|
—
|
0.31 MFI
Interval 0.26 to 0.35
|
0.06 MFI
Interval 0.02 to 0.37
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.1.7-AB at Month 0-Peru
|
—
|
1.15 MFI
Interval 1.15 to 1.15
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.1.7-AB at Month 0-Total
|
4.73 MFI
Interval 2.48 to 6.98
|
0.02 MFI
Interval 0.02 to 0.59
|
0.02 MFI
Interval 0.02 to 0.14
|
0.42 MFI
Interval 0.02 to 1.39
|
2.86 MFI
Interval 1.63 to 4.08
|
0.53 MFI
Interval 0.21 to 5.3
|
0.74 MFI
Interval 0.1 to 1.93
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.1.7-AB at Month 0-USA
|
4.73 MFI
Interval 2.48 to 6.98
|
0.02 MFI
Interval 0.02 to 0.02
|
0.02 MFI
Interval 0.02 to 0.14
|
0.42 MFI
Interval 0.02 to 1.39
|
2.86 MFI
Interval 1.63 to 4.08
|
0.53 MFI
Interval 0.21 to 5.3
|
0.74 MFI
Interval 0.1 to 1.93
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.1.7-AB at Month 2-Peru
|
0.19 MFI
Interval 0.13 to 0.84
|
0.02 MFI
Interval 0.02 to 0.02
|
0.24 MFI
Interval 0.18 to 0.62
|
0.02 MFI
Interval 0.02 to 0.02
|
1.27 MFI
Interval 0.39 to 5.04
|
8.95 MFI
Interval 8.95 to 8.95
|
1.01 MFI
Interval 0.96 to 2.43
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.1.7-AB at Month 2-Total
|
0.3 MFI
Interval 0.14 to 0.99
|
0.02 MFI
Interval 0.02 to 0.02
|
0.25 MFI
Interval 0.17 to 0.78
|
0.02 MFI
Interval 0.02 to 1.31
|
0.51 MFI
Interval 0.34 to 4.04
|
0.69 MFI
Interval 0.39 to 4.82
|
0.75 MFI
Interval 0.54 to 1.01
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.1.7-AB at Month 2-USA
|
4.96 MFI
Interval 4.96 to 4.96
|
0.02 MFI
Interval 0.02 to 0.02
|
0.26 MFI
Interval 0.1 to 0.72
|
0.25 MFI
Interval 0.02 to 1.56
|
0.33 MFI
Interval 0.33 to 0.33
|
0.39 MFI
Interval 0.24 to 0.54
|
0.68 MFI
Interval 0.48 to 0.92
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.1.7-AB at Month 4-Peru
|
0.09 MFI
Interval 0.02 to 0.78
|
0.02 MFI
Interval 0.02 to 0.02
|
0.06 MFI
Interval 0.02 to 0.11
|
0.4 MFI
Interval 0.21 to 0.59
|
0.41 MFI
Interval 0.09 to 2.73
|
1.48 MFI
Interval 1.21 to 1.76
|
4.35 MFI
Interval 3.36 to 4.68
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.1.7-AB at Month 4-Total
|
0.09 MFI
Interval 0.02 to 0.78
|
0.02 MFI
Interval 0.02 to 0.02
|
0.12 MFI
Interval 0.02 to 0.54
|
0.09 MFI
Interval 0.02 to 0.43
|
0.41 MFI
Interval 0.09 to 2.73
|
0.99 MFI
Interval 0.77 to 1.29
|
0.74 MFI
Interval 0.3 to 4.51
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.1.7-AB at Month 4-USA
|
—
|
—
|
0.9 MFI
Interval 0.15 to 2.04
|
0.09 MFI
Interval 0.02 to 0.35
|
—
|
0.67 MFI
Interval 0.48 to 0.86
|
0.3 MFI
Interval 0.29 to 0.33
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.351-AB at Month 0-Peru
|
—
|
1.47 MFI
Interval 1.47 to 1.47
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.351-AB at Month 0-Total
|
0.08 MFI
Interval 0.04 to 0.12
|
0.01 MFI
Interval 0.01 to 0.74
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.21
|
0.29 MFI
Interval 0.28 to 0.29
|
0.08 MFI
Interval 0.01 to 2.0
|
0.14 MFI
Interval 0.01 to 0.49
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.351-AB at Month 0-USA
|
0.08 MFI
Interval 0.04 to 0.12
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.21
|
0.29 MFI
Interval 0.28 to 0.29
|
0.08 MFI
Interval 0.01 to 2.0
|
0.14 MFI
Interval 0.01 to 0.49
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.351-AB at Month 2-Peru
|
0.01 MFI
Interval 0.01 to 0.2
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.26
|
0.01 MFI
Interval 0.01 to 0.01
|
0.62 MFI
Interval 0.34 to 1.71
|
3.08 MFI
Interval 3.08 to 3.08
|
0.12 MFI
Interval 0.06 to 0.22
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.351-AB at Month 2-Total
|
0.03 MFI
Interval 0.01 to 0.19
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.18
|
0.01 MFI
Interval 0.01 to 0.09
|
0.53 MFI
Interval 0.18 to 1.38
|
0.51 MFI
Interval 0.26 to 1.8
|
0.13 MFI
Interval 0.01 to 0.32
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.351-AB at Month 2-USA
|
0.18 MFI
Interval 0.18 to 0.18
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.13
|
0.01 MFI
Interval 0.01 to 0.32
|
0.09 MFI
Interval 0.09 to 0.09
|
0.26 MFI
Interval 0.14 to 0.39
|
0.14 MFI
Interval 0.01 to 0.43
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.351-AB at Month 4-Peru
|
0.01 MFI
Interval 0.01 to 0.06
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.15 MFI
Interval 0.08 to 0.22
|
0.2 MFI
Interval 0.05 to 0.23
|
0.76 MFI
Interval 0.51 to 1.02
|
0.18 MFI
Interval 0.08 to 0.9
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.351-AB at Month 4-Total
|
0.01 MFI
Interval 0.01 to 0.06
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.02
|
0.01 MFI
Interval 0.01 to 0.15
|
0.2 MFI
Interval 0.05 to 0.23
|
0.31 MFI
Interval 0.24 to 0.59
|
0.09 MFI
Interval 0.01 to 0.57
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.351-AB at Month 4-USA
|
—
|
—
|
0.04 MFI
Interval 0.01 to 0.22
|
0.01 MFI
Interval 0.01 to 0.01
|
—
|
0.27 MFI
Interval 0.23 to 0.32
|
0.05 MFI
Interval 0.01 to 0.2
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.617-AB at Month 0-Peru
|
—
|
1.34 MFI
Interval 1.34 to 1.34
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.617-AB at Month 0-Total
|
0.34 MFI
Interval 0.28 to 0.41
|
0.01 MFI
Interval 0.01 to 0.67
|
0.01 MFI
Interval 0.01 to 0.01
|
0.22 MFI
Interval 0.01 to 0.38
|
0.27 MFI
Interval 0.22 to 0.33
|
0.34 MFI
Interval 0.14 to 2.73
|
0.32 MFI
Interval 0.01 to 0.51
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.617-AB at Month 0-USA
|
0.34 MFI
Interval 0.28 to 0.41
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.22 MFI
Interval 0.01 to 0.38
|
0.27 MFI
Interval 0.22 to 0.33
|
0.34 MFI
Interval 0.14 to 2.73
|
0.32 MFI
Interval 0.01 to 0.51
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.617-AB at Month 2-Peru
|
0.06 MFI
Interval 0.01 to 0.16
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.35
|
0.01 MFI
Interval 0.01 to 0.01
|
0.7 MFI
Interval 0.35 to 1.98
|
4.17 MFI
Interval 4.17 to 4.17
|
1.3 MFI
Interval 0.74 to 1.71
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.617-AB at Month 2-Total
|
0.07 MFI
Interval 0.01 to 0.29
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.26
|
0.01 MFI
Interval 0.01 to 0.16
|
0.67 MFI
Interval 0.19 to 1.57
|
0.42 MFI
Interval 0.23 to 2.3
|
0.24 MFI
Interval 0.05 to 1.11
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.617-AB at Month 2-USA
|
0.41 MFI
Interval 0.41 to 0.41
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.25
|
0.01 MFI
Interval 0.01 to 0.33
|
0.13 MFI
Interval 0.13 to 0.13
|
0.23 MFI
Interval 0.14 to 0.33
|
0.18 MFI
Interval 0.01 to 0.44
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.617-AB at Month 4-Peru
|
0.01 MFI
Interval 0.01 to 0.11
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.07 MFI
Interval 0.04 to 0.1
|
0.25 MFI
Interval 0.06 to 0.36
|
0.65 MFI
Interval 0.5 to 0.79
|
2.91 MFI
Interval 0.12 to 3.31
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.617-AB at Month 4-Total
|
0.01 MFI
Interval 0.01 to 0.11
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.28
|
0.01 MFI
Interval 0.01 to 0.01
|
0.25 MFI
Interval 0.06 to 0.36
|
0.53 MFI
Interval 0.27 to 0.76
|
0.24 MFI
Interval 0.06 to 3.11
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-B.1.617-AB at Month 4-USA
|
—
|
—
|
0.54 MFI
Interval 0.01 to 1.39
|
0.01 MFI
Interval 0.01 to 0.01
|
—
|
0.35 MFI
Interval 0.18 to 0.53
|
0.12 MFI
Interval 0.01 to 0.25
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-P.1-AB at Month 0-Peru
|
—
|
1.43 MFI
Interval 1.43 to 1.43
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-P.1-AB at Month 0-Total
|
0.6 MFI
Interval 0.51 to 0.69
|
0.04 MFI
Interval 0.04 to 0.74
|
0.04 MFI
Interval 0.04 to 0.15
|
0.45 MFI
Interval 0.06 to 0.89
|
0.94 MFI
Interval 0.66 to 1.22
|
0.91 MFI
Interval 0.3 to 3.35
|
0.53 MFI
Interval 0.06 to 1.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-P.1-AB at Month 0-USA
|
0.6 MFI
Interval 0.51 to 0.69
|
0.04 MFI
Interval 0.04 to 0.04
|
0.04 MFI
Interval 0.04 to 0.15
|
0.45 MFI
Interval 0.06 to 0.89
|
0.94 MFI
Interval 0.66 to 1.22
|
0.91 MFI
Interval 0.3 to 3.35
|
0.53 MFI
Interval 0.06 to 1.6
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-P.1-AB at Month 2-Peru
|
0.16 MFI
Interval 0.12 to 0.53
|
0.1 MFI
Interval 0.1 to 0.1
|
0.16 MFI
Interval 0.07 to 0.33
|
0.04 MFI
Interval 0.04 to 0.12
|
2.11 MFI
Interval 0.58 to 4.02
|
3.57 MFI
Interval 3.57 to 3.57
|
0.17 MFI
Interval 0.16 to 0.78
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-P.1-AB at Month 2-Total
|
0.21 MFI
Interval 0.13 to 0.62
|
0.07 MFI
Interval 0.05 to 0.08
|
0.18 MFI
Interval 0.04 to 0.49
|
0.46 MFI
Interval 0.04 to 1.64
|
0.62 MFI
Interval 0.53 to 3.88
|
1.42 MFI
Interval 0.79 to 2.49
|
0.37 MFI
Interval 0.14 to 0.87
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-P.1-AB at Month 2-USA
|
0.65 MFI
Interval 0.65 to 0.65
|
0.04 MFI
Interval 0.04 to 0.04
|
0.35 MFI
Interval 0.04 to 0.51
|
1.4 MFI
Interval 0.04 to 1.67
|
0.22 MFI
Interval 0.22 to 0.22
|
0.79 MFI
Interval 0.47 to 1.11
|
0.4 MFI
Interval 0.11 to 0.8
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-P.1-AB at Month 4-Peru
|
0.04 MFI
Interval 0.04 to 0.4
|
0.04 MFI
Interval 0.04 to 0.04
|
0.04 MFI
Interval 0.04 to 0.05
|
0.26 MFI
Interval 0.15 to 0.37
|
0.89 MFI
Interval 0.25 to 1.54
|
0.51 MFI
Interval 0.44 to 0.59
|
0.19 MFI
Interval 0.18 to 3.14
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-P.1-AB at Month 4-Total
|
0.04 MFI
Interval 0.04 to 0.4
|
0.04 MFI
Interval 0.04 to 0.04
|
0.07 MFI
Interval 0.04 to 0.43
|
0.41 MFI
Interval 0.04 to 0.76
|
0.89 MFI
Interval 0.25 to 1.54
|
0.62 MFI
Interval 0.52 to 0.93
|
0.27 MFI
Interval 0.17 to 1.88
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S-P.1-AB at Month 4-USA
|
—
|
—
|
0.57 MFI
Interval 0.23 to 2.28
|
0.41 MFI
Interval 0.04 to 1.05
|
—
|
1.15 MFI
Interval 0.86 to 1.44
|
0.28 MFI
Interval 0.1 to 0.54
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His at Month 0-Peru
|
—
|
1.08 MFI
Interval 1.08 to 1.08
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His at Month 0-Total
|
0.61 MFI
Interval 0.31 to 0.91
|
0.01 MFI
Interval 0.01 to 0.55
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.18
|
0.09 MFI
Interval 0.05 to 0.13
|
0.18 MFI
Interval 0.01 to 0.71
|
0.32 MFI
Interval 0.01 to 0.94
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His at Month 0-USA
|
0.61 MFI
Interval 0.31 to 0.91
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.18
|
0.09 MFI
Interval 0.05 to 0.13
|
0.18 MFI
Interval 0.01 to 0.71
|
0.32 MFI
Interval 0.01 to 0.94
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His at Month 2-Peru
|
0.1 MFI
Interval 0.01 to 0.21
|
0.01 MFI
Interval 0.01 to 0.01
|
0.08 MFI
Interval 0.01 to 0.29
|
0.01 MFI
Interval 0.01 to 0.01
|
0.34 MFI
Interval 0.07 to 2.42
|
7 MFI
Interval 7.0 to 7.0
|
0.35 MFI
Interval 0.22 to 1.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His at Month 2-Total
|
0.12 MFI
Interval 0.01 to 0.26
|
0.01 MFI
Interval 0.01 to 0.01
|
0.05 MFI
Interval 0.01 to 0.34
|
0.01 MFI
Interval 0.01 to 0.45
|
0.32 MFI
Interval 0.12 to 1.76
|
3.66 MFI
Interval 1.86 to 5.33
|
0.22 MFI
Interval 0.01 to 1.02
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His at Month 2-USA
|
1.16 MFI
Interval 1.16 to 1.16
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.36
|
0.01 MFI
Interval 0.01 to 0.46
|
0.32 MFI
Interval 0.32 to 0.32
|
1.86 MFI
Interval 0.97 to 2.76
|
0.08 MFI
Interval 0.01 to 1.0
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His at Month 4-Peru
|
0.01 MFI
Interval 0.01 to 0.11
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.35 MFI
Interval 0.18 to 0.52
|
0.01 MFI
Interval 0.01 to 0.63
|
1.7 MFI
Interval 1.29 to 2.1
|
1.28 MFI
Interval 0.24 to 1.52
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His at Month 4-Total
|
0.01 MFI
Interval 0.01 to 0.11
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.03
|
0.01 MFI
Interval 0.01 to 0.22
|
0.01 MFI
Interval 0.01 to 0.63
|
1.22 MFI
Interval 0.7 to 1.79
|
0.27 MFI
Interval 0.13 to 1.38
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S1 C His at Month 4-USA
|
—
|
—
|
0.04 MFI
Interval 0.01 to 0.11
|
0.01 MFI
Interval 0.01 to 0.01
|
—
|
0.84 MFI
Interval 0.49 to 1.19
|
0.14 MFI
Interval 0.01 to 0.42
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis) at Month 0-Peru
|
—
|
3.34 MFI
Interval 3.34 to 3.34
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis) at Month 0-Total
|
4.49 MFI
Interval 3.7 to 5.28
|
2.39 MFI
Interval 1.28 to 2.87
|
0.36 MFI
Interval 0.21 to 0.54
|
2.16 MFI
Interval 0.68 to 4.38
|
2.12 MFI
Interval 2.11 to 2.13
|
1.91 MFI
Interval 0.99 to 4.82
|
1.75 MFI
Interval 0.71 to 4.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis) at Month 0-USA
|
4.49 MFI
Interval 3.7 to 5.28
|
1.28 MFI
Interval 0.73 to 1.84
|
0.36 MFI
Interval 0.21 to 0.54
|
2.16 MFI
Interval 0.68 to 4.38
|
2.12 MFI
Interval 2.11 to 2.13
|
1.91 MFI
Interval 0.99 to 4.82
|
1.75 MFI
Interval 0.71 to 4.4
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis) at Month 2-Peru
|
0.62 MFI
Interval 0.32 to 1.3
|
0.18 MFI
Interval 0.18 to 0.18
|
0.89 MFI
Interval 0.29 to 1.18
|
0.39 MFI
Interval 0.28 to 0.41
|
3.18 MFI
Interval 0.99 to 6.52
|
13.71 MFI
Interval 13.71 to 13.71
|
2.4 MFI
Interval 1.82 to 3.39
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis) at Month 2-Total
|
0.88 MFI
Interval 0.35 to 1.69
|
0.18 MFI
Interval 0.18 to 0.18
|
0.99 MFI
Interval 0.28 to 1.26
|
1.53 MFI
Interval 0.4 to 3.57
|
0.99 MFI
Interval 0.96 to 6.14
|
7.53 MFI
Interval 3.87 to 10.62
|
1.6 MFI
Interval 1.24 to 2.25
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis) at Month 2-USA
|
3.85 MFI
Interval 3.85 to 3.85
|
0.17 MFI
Interval 0.17 to 0.17
|
1.09 MFI
Interval 0.3 to 1.55
|
2.76 MFI
Interval 1.21 to 4.82
|
0.57 MFI
Interval 0.57 to 0.57
|
3.87 MFI
Interval 2.05 to 5.7
|
1.54 MFI
Interval 0.94 to 1.78
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis) at Month 4-Peru
|
0.33 MFI
Interval 0.17 to 1.3
|
0.17 MFI
Interval 0.17 to 0.17
|
0.18 MFI
Interval 0.17 to 0.19
|
1.08 MFI
Interval 0.63 to 1.53
|
1.73 MFI
Interval 0.59 to 4.58
|
2.29 MFI
Interval 2.12 to 2.46
|
5.76 MFI
Interval 3.42 to 8.19
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis) at Month 4-Total
|
0.33 MFI
Interval 0.17 to 1.3
|
0.17 MFI
Interval 0.17 to 0.17
|
0.19 MFI
Interval 0.17 to 0.61
|
1.94 MFI
Interval 0.37 to 4.11
|
1.73 MFI
Interval 0.59 to 4.58
|
2.72 MFI
Interval 2.46 to 2.86
|
1.28 MFI
Interval 0.81 to 6.97
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 spike (PreS Nexelis) at Month 4-USA
|
—
|
—
|
0.76 MFI
Interval 0.39 to 3.29
|
1.94 MFI
Interval 0.56 to 6.25
|
—
|
2.92 MFI
Interval 2.86 to 2.98
|
0.81 MFI
Interval 0.6 to 1.17
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin at Month 0-Peru
|
—
|
0.1 MFI
Interval 0.1 to 0.1
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin at Month 0-Total
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.05
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.05
|
0.01 MFI
Interval 0.01 to 0.01
|
0.22 MFI
Interval 0.01 to 0.3
|
0.01 MFI
Interval 0.01 to 0.32
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin at Month 0-USA
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.05
|
0.01 MFI
Interval 0.01 to 0.01
|
0.22 MFI
Interval 0.01 to 0.3
|
0.01 MFI
Interval 0.01 to 0.32
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin at Month 2-Peru
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.07
|
2.7 MFI
Interval 2.7 to 2.7
|
0.01 MFI
Interval 0.01 to 0.06
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin at Month 2-Total
|
0.01 MFI
Interval 0.01 to 0.05
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.11
|
0.19 MFI
Interval 0.1 to 1.45
|
0.01 MFI
Interval 0.01 to 0.14
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin at Month 2-USA
|
0.06 MFI
Interval 0.06 to 0.06
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.06
|
0.12 MFI
Interval 0.12 to 0.12
|
0.1 MFI
Interval 0.05 to 0.14
|
0.01 MFI
Interval 0.01 to 0.17
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin at Month 4-Peru
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.13 MFI
Interval 0.07 to 0.19
|
0.01 MFI
Interval 0.01 to 0.27
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin at Month 4-Total
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.02
|
0.01 MFI
Interval 0.01 to 0.01
|
0.01 MFI
Interval 0.01 to 0.01
|
0.11 MFI
Interval 0.01 to 0.22
|
0.01 MFI
Interval 0.01 to 0.08
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-NTD-AVI Biotin at Month 4-USA
|
—
|
—
|
0.04 MFI
Interval 0.01 to 0.07
|
0.01 MFI
Interval 0.01 to 0.01
|
—
|
0.11 MFI
Interval 0.06 to 0.16
|
0.01 MFI
Interval 0.01 to 0.01
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His at Month 4-Peru
|
0.02 MFI
Interval 0.02 to 0.15
|
0.02 MFI
Interval 0.02 to 0.02
|
0.02 MFI
Interval 0.02 to 0.04
|
0.02 MFI
Interval 0.02 to 0.02
|
0.02 MFI
Interval 0.02 to 0.23
|
0.02 MFI
Interval 0.02 to 0.02
|
0.1 MFI
Interval 0.02 to 0.36
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His at Month 4-Total
|
0.02 MFI
Interval 0.02 to 0.15
|
0.02 MFI
Interval 0.02 to 0.02
|
0.04 MFI
Interval 0.02 to 0.12
|
0.02 MFI
Interval 0.02 to 0.02
|
0.02 MFI
Interval 0.02 to 0.23
|
0.57 MFI
Interval 0.02 to 1.73
|
0.27 MFI
Interval 0.02 to 0.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 Nucleoprotein His at Month 4-USA
|
—
|
—
|
0.13 MFI
Interval 0.05 to 0.35
|
0.02 MFI
Interval 0.02 to 0.02
|
—
|
2.35 MFI
Interval 1.73 to 2.97
|
0.4 MFI
Interval 0.09 to 1.16
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-Peru
|
—
|
0.83 MFI
Interval 0.83 to 0.83
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-Total
|
0.77 MFI
Interval 0.77 to 0.77
|
0.03 MFI
Interval 0.03 to 0.43
|
0.03 MFI
Interval 0.03 to 0.03
|
0.03 MFI
Interval 0.03 to 0.17
|
0.03 MFI
Interval 0.03 to 0.03
|
0.08 MFI
Interval 0.03 to 0.58
|
0.3 MFI
Interval 0.05 to 0.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-USA
|
0.77 MFI
Interval 0.77 to 0.77
|
0.03 MFI
Interval 0.03 to 0.03
|
0.03 MFI
Interval 0.03 to 0.03
|
0.03 MFI
Interval 0.03 to 0.17
|
0.03 MFI
Interval 0.03 to 0.03
|
0.08 MFI
Interval 0.03 to 0.58
|
0.3 MFI
Interval 0.05 to 0.5
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Peru
|
0.03 MFI
Interval 0.03 to 0.07
|
0.03 MFI
Interval 0.03 to 0.03
|
0.17 MFI
Interval 0.12 to 0.26
|
0.03 MFI
Interval 0.03 to 0.37
|
0.24 MFI
Interval 0.17 to 0.29
|
5.91 MFI
Interval 5.91 to 5.91
|
0.18 MFI
Interval 0.16 to 0.45
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Total
|
0.03 MFI
Interval 0.03 to 0.14
|
0.03 MFI
Interval 0.03 to 0.03
|
0.1 MFI
Interval 0.03 to 0.27
|
0.03 MFI
Interval 0.03 to 0.24
|
0.19 MFI
Interval 0.16 to 0.29
|
4.2 MFI
Interval 2.12 to 5.05
|
0.26 MFI
Interval 0.14 to 0.67
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-USA
|
0.36 MFI
Interval 0.36 to 0.36
|
0.03 MFI
Interval 0.03 to 0.03
|
0.05 MFI
Interval 0.03 to 0.35
|
0.03 MFI
Interval 0.03 to 0.24
|
0.16 MFI
Interval 0.16 to 0.16
|
2.12 MFI
Interval 1.07 to 3.16
|
0.33 MFI
Interval 0.09 to 0.87
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Peru
|
0.03 MFI
Interval 0.03 to 0.07
|
0.03 MFI
Interval 0.03 to 0.03
|
0.03 MFI
Interval 0.03 to 0.05
|
0.28 MFI
Interval 0.28 to 0.28
|
0.08 MFI
Interval 0.03 to 0.37
|
0.99 MFI
Interval 0.79 to 1.18
|
0.6 MFI
Interval 0.13 to 1.22
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Total
|
0.03 MFI
Interval 0.03 to 0.07
|
0.03 MFI
Interval 0.03 to 0.03
|
0.06 MFI
Interval 0.03 to 0.12
|
0.03 MFI
Interval 0.03 to 0.03
|
0.08 MFI
Interval 0.03 to 0.37
|
0.99 MFI
Interval 0.48 to 1.54
|
0.13 MFI
Interval 0.08 to 0.91
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-USA
|
—
|
—
|
0.12 MFI
Interval 0.08 to 0.19
|
0.03 MFI
Interval 0.03 to 0.03
|
—
|
1.09 MFI
Interval 0.61 to 1.57
|
0.08 MFI
Interval 0.04 to 0.21
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro-293F-PPF at Month 0-Peru
|
—
|
0.81 MFI
Interval 0.81 to 0.81
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro-293F-PPF at Month 0-Total
|
0.23 MFI
Interval 0.23 to 0.23
|
0.02 MFI
Interval 0.02 to 0.42
|
0.02 MFI
Interval 0.02 to 0.06
|
0.23 MFI
Interval 0.02 to 0.68
|
0.84 MFI
Interval 0.72 to 0.95
|
0.4 MFI
Interval 0.15 to 0.92
|
0.44 MFI
Interval 0.02 to 0.73
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro-293F-PPF at Month 0-USA
|
0.23 MFI
Interval 0.23 to 0.23
|
0.02 MFI
Interval 0.02 to 0.02
|
0.02 MFI
Interval 0.02 to 0.06
|
0.23 MFI
Interval 0.02 to 0.68
|
0.84 MFI
Interval 0.72 to 0.95
|
0.4 MFI
Interval 0.15 to 0.92
|
0.44 MFI
Interval 0.02 to 0.73
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Peru
|
0.1 MFI
Interval 0.02 to 0.25
|
0.02 MFI
Interval 0.02 to 0.02
|
0.15 MFI
Interval 0.05 to 0.59
|
0.02 MFI
Interval 0.02 to 0.02
|
0.72 MFI
Interval 0.42 to 1.44
|
7.46 MFI
Interval 7.46 to 7.46
|
0.4 MFI
Interval 0.39 to 1.08
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Total
|
0.15 MFI
Interval 0.03 to 0.47
|
0.02 MFI
Interval 0.02 to 0.02
|
0.17 MFI
Interval 0.04 to 0.64
|
0.02 MFI
Interval 0.02 to 0.65
|
0.56 MFI
Interval 0.34 to 1.25
|
0.5 MFI
Interval 0.29 to 3.98
|
0.38 MFI
Interval 0.02 to 0.87
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro-293F-PPF at Month 2-USA
|
2.38 MFI
Interval 2.38 to 2.38
|
0.02 MFI
Interval 0.02 to 0.02
|
0.19 MFI
Interval 0.05 to 0.85
|
0.02 MFI
Interval 0.02 to 0.74
|
0.31 MFI
Interval 0.31 to 0.31
|
0.29 MFI
Interval 0.19 to 0.4
|
0.15 MFI
Interval 0.02 to 0.73
|
—
|
—
|
—
|
—
|
|
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Peru
|
0.02 MFI
Interval 0.02 to 0.29
|
0.02 MFI
Interval 0.02 to 0.02
|
0.02 MFI
Interval 0.02 to 0.02
|
0.12 MFI
Interval 0.07 to 0.17
|
0.15 MFI
Interval 0.04 to 0.71
|
1.57 MFI
Interval 1.19 to 1.94
|
2.89 MFI
Interval 1.25 to 3.01
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Measured at Months 0, Month 2, Month 4, Month 12Population: Nasopharyngeal or nasal swab samples were collected at enrollment from 155 participants in the Americas cohort (Peru and USA) using the RT-RNA Panther assay, and from 320 participants in the Africa cohort (South Africa and other African countries) using the RT-RNA Fisher TaqPath assay.
This outcome measures the detection rate of viral RNA in nasopharyngeal or nasal swab samples collected at Visits 1, 2, 3, 4 using RT-PCR. Participation was optional, and not all participants provided samples. Results presented in this table include only participants from the Africa cohort (South Africa and other African countries), whose samples were tested using the RT-RNA Fisher TaqPath assay and Americas cohort (Peru and the United States), samples were tested using the RT-RNA Panther assay.
Outcome measures
| Measure |
Group 1A
n=81 Participants
1A: Asymptomatic, 18 - 55
|
Group 1B
n=36 Participants
1B: Asymptomatic, \> 55
|
Group 1C
n=122 Participants
1C: Symptomatic, 18 - 55
|
Group 1D
n=49 Participants
1D: Symptomatic, \> 55
|
Group 2A
n=83 Participants
2A: Hospitalized, 18 - 55
|
Group 2B
n=43 Participants
2B: Hospitalized, \> 55
|
Group 3
n=61 Participants
3: Clinical spectrums
|
Group 8
Clinical spectrums , age 55+
|
Group 9
HIV
|
Group 10
Hypertension
|
Group 11
Immune system disorders
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 IC at Month 0 Africa
|
5 Participants
|
6 Participants
|
17 Participants
|
3 Participants
|
11 Participants
|
3 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 N-GENE at Month 0 Africa
|
5 Participants
|
6 Participants
|
17 Participants
|
3 Participants
|
11 Participants
|
3 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 ORF1ab at Month 0 Africa
|
5 Participants
|
6 Participants
|
17 Participants
|
3 Participants
|
11 Participants
|
3 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 S-GENE at Month 0 Africa
|
5 Participants
|
6 Participants
|
17 Participants
|
3 Participants
|
11 Participants
|
3 Participants
|
5 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 IC at Month 2 Africa
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 N-GENE at Month 2 Africa
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 ORF1ab at Month 2 Africa
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 S-GENE at Month 2 Africa
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 IC at Month 4 Africa
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 N-GENE at Month 4 Africa
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 ORF1ab at Month 4 Africa
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 S-GENE at Month 4 Africa
|
0 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 IC at Month 12 Africa
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 N-GENE at Month 12 Africa
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 ORF1ab at Month 12 Africa
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
SARS-COV-2 S-GENE at Month 12 Africa
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
ORF at Month 0 America
|
0 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
1 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
ORF at Month 2 America
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
ORF at Month 4 America
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
|
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
ORF at Month 12 America
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
—
|
—
|
—
|
—
|
Adverse Events
Group 1
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Group 2
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Group 3
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Jessica Andriesen, PhD, Associate Director of HVTN SDMC Operations
Fred Hutchinson Cancer Center
Phone: 206-667-5812
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place